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ABSTRACT OF DISSERTATION

MOLECULAR AND GENOMIC APPROACHES TO UNDERSTANDING HOSTVIRUS INTERACTIONS IN SHAPING THE OUTCOME OF EQUINE ARTERITIS
VIRUS INFECTION
Equine arteritis virus (EAV) is the causal agent of equine viral arteritis, a disease of
equids. During natural outbreaks of the disease, EAV can cause abortion in pregnant mares and
persistent infection in stallions. Understanding how host cellular proteins interact with viral RNA
and viral proteins, as well as their role in viral infection, will enable better characterization of the
pathogenesis of EAV and establishment of persistent infection in stallions. Accordingly, we
hypothesized that both viral factors and host genetically related factors could influence the
outcome of EAV infection in horses. To test this hypothesis, we first combined contemporary
molecular biology techniques with dual color flow cytometric analysis to characterize the
interactions of viral structural proteins and the equine peripheral blood mononuclear cells in vitro.
Results from this study demonstrated that interactions between GP2, GP3, GP4, GP5 and M
envelope proteins of EAV play a major role in determining the CD14+ monocyte tropism while
the tropism of CD3+ T lymphocytes is determined by GP2, GP4, GP5 and M envelope proteins
but not the GP3 protein. Secondly, a genome wide association study using SNP genotyping
identified a common haplotype associated with the in vitro CD3+ T lymphocyte/resistance to
EAV infection among four breeds of horses. Subsequently, these studies were extended to
establish a possible correlation between the in vitro susceptibility of CD3+ T lymphocytes to EAV
and establishment of persistent infection in stallions. Interestingly, carrier stallions with
susceptible CD3+ T lymphocyte phenotype to EAV may represent those at higher risk of
becoming persistently infected. Finally, the precise effect of EAV on the immune system of
horses, innate and humoral immunity, was studied. Horses were shown to mount a strong
humoral antibody response to nonstructural proteins (nsps) 2, 4, 5 and 12 of EAV, whereas nsps 1,
2 and 11 suppressed the type I interferon production. The data presented in this dissertation
suggest new directions for future EAV research using genomic and proteomic approaches to
study host cell factors involved in EAV attachment and entry and establishment of persistent
infection in the stallions.

KEYWORDS: Equine arteritis virus, Equine viral arteritis, Susceptibility/resistance,
Humoral immunity, Innate immunity
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CHAPTER ONE

Literature Review

1.1. INTRODUCTION
Positive-stranded RNA viruses constitute the largest virus group and comprise a
wide variety of pathogens of plants and animals. Positive-stranded RNA viruses that
consist of linear, single-stranded genomes of mRNA polarity can initiate viral gene
expression immediately after genome uncoating in infected cells. These viruses replicate
in the cytoplasm of infected cells. RNA viruses have evolved having extremely diverse
genomes and replicative mechanisms due to presumably low fidelity of their RNA
synthesis [1,2]. Among RNA viruses, nidoviruses are considered the most genetically
complex group with relatively large genomes. The complex feature of nidoviral RNA
replication and transcription involving numerous virus-encoded proteins with enzymatic
activities is a unique feature of the members of the order Nidovirales [3,4,5,6]. In
particular, generation of a nested set of subgenomic (sg) mRNAs is the hallmark of their
genome expression from which the name Nidovirales (the Latin word nidus means “nest”)
is derived. Nidovirus infections are often associated with severe diseases such as human
severe acute respiratory syndrome (SARS), feline infectious peritonitis, infectious
bronchitis of chickens, porcine reproductive and respiratory syndrome (PRRS) and
yellow head disease of prawns. Recently, efforts to understand nidovirus replication and
transcription have been facilitated by development of reverse genetic systems for many
coronaviruses and arteriviruses. Another important goal is to understand the mechanisms
of virus entry, assembly and egress from infected cells which involves studies
concentrated on interactions between viral and host cellular proteins. Most recently, the
host-virus interaction has become one of the most focused areas of nidovirus research.
The host’s innate immune response is critical in controlling infections and effectively
inhibiting spread of the virus in the early phase of infection. Thus, viruses have evolved
mechanisms to counteract the innate immune response in order to survive in the host.

1

Nidoviruses have also developed mechanisms to suppress type I interferon induction and
signaling, the details of which are still to be determined. Unraveling such mechanisms
will enable development of antiviral drugs and therapeutics to combat devastating
diseases caused by some nidoviruses.

2

Table 1.1. Order Nidovirales
Order

Family
Arteriviridae

3

Nidovirales
Coronaviridae

Roniviridae

Subfamily

Genus

Species
Equine arteritis virus
Lactate dehydrogenase-elevating virus
Arterivirus
Porcine reproductive and respiratory syndrome virus
Simian hemorrhagic fever virus
Alphacoronavirus 1
Human coronavirus 229E
Human coronavirus NL63
Miniopterus bat coronavirus 1
Alphacoronavirus
Miniopterus bat coronavirus HKU8
Porcine epidemic diarrhea virus
Rhinolophus bat coronavirus HKU2
Scotophilus bat coronavirus 512
Coronavirinae
Betacoronavirus 1
Human coronavirus HKU1
Murine coronavirus
Betacoronavirus
Pipistrellus bat coronavirus HKU5
Rousettus bat coronavirus HKU9
Severe acute respiratory syndrome-related coronavirus
Tylonycteris bat coronavirus HKU4
Avian coronavirus
Gammacoronavirus
Beluga whale coronavirus SW1
Bafinivirus
White bream virus
Bovine torovirus
Torovirinae
Equine torovirus
Torovirus
Human torovirus
Porcine torovirus
Okavirus
Gill-associated virus

1.2. ORDER NIDOVIRALES
The order Nidovirales is comprised of the families Coronaviridae, Arteriviridae,
and Roniviridae [7,8,9] (Table 1.1). The family Arteriviridae is comprised of the single
genus Arterivirus. Recently, the family Coronaviridae has been reorganized and now
consists of two subfamilies, Coronavirinae and Torovirinae.

The subfamily

Coronavirinae is subdivided into three genera, Alphacoronavirus, Betacoronavirus and
Gammacoronavirus; and Torovirinae is subdivided into two genera, Bafinivirus and
Torovirus. The family Roniviridae has a single genus Okavirus. Although nidoviruses
are significantly different in virion morphology, genome length and host specificity, they
belong to the same order based on similarities in their genome organization, gene
expression mechanisms, and in sharing common ancestry of the key replicase gene
[10,11,12,13].
Nidoviruses infect a wide range of hosts, including invertebrates, avian, human
and many other mammalian species [14]. Porcine reproductive and respiratory syndrome
virus (PRRSV), a member of the Arteriviridae family, is associated with significant
economic losses in the swine industry [15]. Coronaviruses (CoV) are well-known agents
of respiratory, enteric, and neurologic disease in humans and domestic animals
(alphacoronaviruses and betacoronaviruses: mammals; gammacoronaviruses: avian
species) and are the only nidovirus group that has been reported to cause disease in
humans (http://www.ictvonline.org/virusTaxonomy.asp?version=2009). In 2003, SARS
emerged from China as a potentially fatal and untreatable human respiratory disease
which was caused by a previously unknown CoV strain [16,17,18,19]. Discovery of
SARS-CoV triggered a search for the reservoir species. After extensive investigative
studies over a number of years certain species of bats were inflicted as reservoir hosts of
the virus. This finding led to the discovery of many novel bat coronaviruses [20]. In
2008, a highly divergent coronavirus was identified from a deceased captive beluga
whale and grouped as a gammacoronavirus [21]. The ronivirus yellow head virus (YHV)
infects black tiger shrimp causing high mortality and resulting in severe economic losses
for shrimp farms [22]. Except for SARS-CoV, which infects a broad range of mammals,
the majority of nidoviruses have restricted host specificity, infecting one or a narrow
range of closely related species. In 2011, the first insect-associated nidovirus, tentatively
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named Cavally virus (CAVV), was reported in association with the tropical rainforest. It
shares genetic features in common with members of the order Nidovirales [23]. These
findings indicate that the virus has evolved and resultant genomic changes have likely
facilitated cross-species transmission.
Nidoviruses are enveloped, positive-sense, single-stranded RNA viruses and
include mammalian, avian and invertebrate viruses [14].

Arterivirus particles are

spherical with smaller envelope projections. In contrast, virions of coronaviruses and
toroviruses are spherical and disk-shaped, respectively, that contain tubular helical
nucleocapsids with large surface projections on the envelope formed by membranespanning viral proteins. Bafinivirus and ronivirus particles are rod-shaped and contain
tubular nucleocapsids with helical symmetry (Figure 1.1) [14].

Figure 1.1. Schematic diagram of order Nidovirales. The tree represents known
members of order Nidovirales based on the virion architecture representative of five main
nidovirus genera: arterivirus, coronavirus, torovirus, bafinivirus and okavirus. Schematic
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representations and electron micrograph pictures were adapted from Enjuanes et al. [24]
and Snijder et al. [14] with permission.

The size and the number of genes encoded in the genome vary considerably
among families of the order Nidovirales. Members of the Arteriviridae family have
smaller genomes (12.7-15.7 kb) compared to other nidoviruses.

In contrast, the

Coronaviridae and Roniviridae families possess the largest RNA genomes (26.2-31.3 kb)
[8]. Despite the wide genome size differences, sequence analysis has shown that all
nidoviruses share a similar genomic organization (Figure 1.2.).

Figure 1.2. Comparison of genome organization of representative nidoviruses. The
genomic RNA of representative viruses of the families Arteriviridae, Coronaviridae and
Roniviridae are shown to the same scale. The open reading frames (ORFs) encoding
replicase proteins and viral structural proteins are depicted. The ribosomal frame shift
(RFS) of the ORF1a/1b and the 3’ poly A tail (An) are indicated. The newly identified
ORF5a in arteriviruses is depicted with a red box. EAV, equine arteritis virus; SARSCoV, severe acute respiratory syndrome coronavirus; EToV, equine torovirus; GAV, gillassociated virus. Modified figure from Nidoviruses book chapter [5] with permission.
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Arteriviruses have 9 to 12 open reading frames (ORFs), coronaviruses encode 9 to
14 ORFs, toroviruses have six ORFs and roniviruses have only four ORFs. The genome
carries a 5’-capped structure and a 3’-polyadenylated (poly A) tail. It also contains
untranslated regions (UTR) at the 5’- and 3’-ends of the genome. At the 5’-proximal
two-thirds to three-quarters of the genome, the nonstructural proteins (nsps) are encoded
by the two largest ORFs, ORF1a and ORF1b connected by a -1 ribosomal frameshift site
(RFS) [25]. The translation of genomic RNA starts at the start codon of ORF1a resulting
in the production of a polyprotein, pp1a. In some cases, specific RNA signals promote
ribosomal frameshifting at a -1 RFS or “slippery” sequence between ORF1a and ORF1b
which results in the C-terminal extension of pp1a with the ORF1b-encoded polypeptide,
pp1ab. The pp1a and pp1ab are co- and post-translationally processed by two to four
virus-encoded proteases to produce 13-16 nsps [26].

These products of the large

replicase protein, possibly with other viral and cellular proteins, assemble into a
replication/transcription complex (RTC) bound to modified intracellular membranes.
The different groups of nidoviruses encode different sets of structural proteins that result
in distinctive virion morphology for each group. The genes encoding viral structural
proteins and, in the case of coronaviruses, “accessory or niche-specific” proteins are
located at the remaining 3’-proximal thirds of the genome downstream of the replicase
gene. The structural and accessory proteins are expressed from a 3’ co-terminal nested
set of sg mRNAs [27,28,29,30].

1.3. FAMILY ARTERIVIRIDAE
EAV was first isolated in 1953, LDV in 1960 and SHFV in 1968; the porcine
arterivirus, PRRSV, was not isolated until the late 1980s [15]. Initially, equine arteritis
virus (EAV) was classified as a non-arthropod-borne togavirus along with pestiviruses
and rubiviruses, lactate dehydrogenase-elevating virus (LDV), simian hemorrhagic fever
virus (SHFV), and cell fusion virus [31]. Although structural proteins of LDV and EAV
differed from those of togaviruses, EAV, LDV and SHFV were assigned to a new genus
Arterivirus within the family Togaviridae [32] in 1984.

Subsequently, molecular

characterization studies have shown that genomic organization and replication strategy of
EAV resemble those of corona- and toroviruses suggesting that it is evolutionally related
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to the coronavirus-like superfamily [10,33].

In 1996, the family Arteriviridae was

established comprising four viruses: EAV, PRRSV, SHFV and LDV of mice [7,34].
Arterivirus particles are spherical with a diameter of 40 to 60 nm. The buoyant density of
arteriviruses is 1.13 to 1.17 g/cm3 in sucrose, and their sedimentation coefficient ranges
from 214S to 230S [35,36,37,38]. The icosahedral core, 25 to 35 nm in diameter, is
surrounded by a relatively smooth envelope that lacks large projections.
The natural host range of arteriviruses is highly restricted. Arterivirus infection
can vary from acute symptomatic or asymptomatic infection, abortion or lethal
hemorrhagic fever and persistent infection. Interestingly, all four arteriviruses have the
ability to give rise to long-term persistent infection in their respective hosts. The severity
of disease can vary greatly and seems to be influenced by the strain of the virus, the
condition and age of the infected animal and various environmental factors.
Macrophages appear to be the primary target cell for all arteriviruses [15].
PRRSV was first recognized in the United States in 1987 and independently in
Germany in 1990,; it was identified as the cause of a “mystery swine disease” [39,40].
At present, PRRSV is globally disseminated. The early PRRSV isolates from North
America and Europe, PRRSV-NA and PRRSV-EU, were genetically distinct from each
other with the genotypes sharing only ~63% nucleotide homology [41,42]. Since its
initial discovery, the virus has continued to evolve. A new strain of PRRSV has been
identified in the US [43,44], and a highly virulent strain has appeared in China [45,46,47]
which subsequently spread to neighboring countries [48,49]. PRRSV is transmitted
primarily via the respiratory route; however, venereal transmission is an important
secondary route of spread of PRRSV, as well as for EAV, due to constant shedding of
virus in semen of infected males.
The natural host of LDV is the house mouse, Mus musculus domesticus [50].
LDV is characterized by an increased level of lactate dehydrogenase in the blood of
infected mice, hence the derivation for the name of the virus [51]. The virus infects a
renewable subpopulation of macrophages and is able to escape immune surveillance [15].
Although most cases of persistent infection caused by LDV are asymptomatic,
neurovirulent LDV variants can cause fatal age-dependent poliomyelitis in certain inbred
mouse strains [52].
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SHFV was isolated after devastating outbreaks of hemorrhagic fever in colonies
of captive macaque monkeys [53,54]. The virus causes an asymptomatic persistent
infection among several different species of African monkeys and remains endemic in
affected populations.

Different strains of SHFV vary considerably in their cellular

tropism, virulence and immunogenicity based on infection studies in African monkeys.
Transmission of SHFV from African to Asian monkeys results in hemorrhagic fever with
a high case-fatality rate. Vascular damage and disseminated intravascular coagulation are
principal to the pathogenesis of simian hemorrhagic fever (SHF) [55].
The size of the arterivirus replicase gene, in particular ORF1a, varies widely
among arteriviruses, encoding between 1,727 amino acids (aa) in EAV and 2,500 aa in
PRRSV, while the ORF1b region is more conserved. Seven to ten small genes encoding
structural proteins are located downstream of the replicase gene and most of them have
both 5’- and 3’- terminal sequence regions overlapping with neighboring genes. With the
exception of SHFV, the organization of structural proteins is generally well conserved in
the arterivirus genome except for. Downstream of the SHFV replicase gene are three
additional ORFs, comprising about 1.6 kb, which may have arisen from the duplication of
ORFs 2 to 4.

1.4. EQUINE ARTERITIS VIRUS
EAV, the causative agent of equine viral arteritis (EVA), is the prototype virus of
the family Arteriviridae. The virion of EAV is spherical with a diameter of 40 to 60 nm.
The isometric core particle (25 to 35 nm in diameter) is surrounded by a relatively
smooth envelope that lacks large projections. EAV genome is encapsidated by the
nucleocapsid (N) protein (14 kDa) encoded by ORF7 which forms an icosahedral core
structure (Figure 1.1) [10,34,56].

The lipid bilayer that surrounds the nucleocapsid

contains six envelope proteins (E, GP2, GP3, GP4, GP5 and M) encoded by ORFs 2a, 2b,
3-6, respectively, that are located at the 3’ proximal quarter of the genome
[34,56,57,58,59].
EAV is stable at -70°C for years without significant loss of infectivity. Virus
infectivity is lost within six months at room temperature, and after a month at 37°C [60].
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It has been reported that tissue culture fluid containing the experimentally derived
virulent Bucyrus strain (VBS) of EAV survived≥75 days at 4°C, 2~3 days at 37°C, and
20~30 min at 56°C [61]. Lyophilized virus is highly stable at -20°C and moderately
stable at 4°C [62].

1.4.1. Genome properties and organization
EAV genome length varies between 12,704 to 12,731 bp among different strains
[7,34,63]. The EAV genome includes a 5’ leader sequence and at least nine ORFs [10,64]
(Figure 1.3). The two most 5’-proximal ORFs (1a and 1b) occupy approximately threequarters of the genome and encode two replicase polyproteins (pp1a and pp1ab). The
two precursor proteins are extensively processed after translation into at least 13 nsps
(nsp1-12, including nsp7 α/β) by three viral proteases (nsp1, nsp2 and nsp4) [34,65,66].
The structural proteins of EAV are expressed from a 3’-coterminal nested set of sg
mRNAs and not from the genomic RNA. Three of the minor envelope proteins (GP2,
GP3 and GP4) form a heterotrimer in the EAV particle. The two major envelope proteins
(M and GP5) form a disulfide-linked heterodimer in the EAV virion [59,67,68]. The
GP5 protein expresses the known major neutralization determinants of EAV
[69,70,71,72,73,74,75]. Although there is considerable variation in the sequence of the
GP5 protein of field strains of the virus, there is only one known major serotype of EAV
and all strains evaluated thus far are neutralized by polyclonal equine antiserum raised
against the Bucyrus strain of EAV [76,77]. However, field strains differ both in their
neutralization and virulence phenotypes and not all strains are neutralized to the same
degree [63,74,78,79,80].
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Figure 1.3. The genome organization and polycistronic nature of EAV genome. The
leader sequence and leader TRS (transcription regulating sequence) located at the 5’-end
of genome are indicated as a purple circle and a yellow box, respectively. Translation of
E and GP2 genes occurs by leaky scanning of the 5’-proximal end of sg mRNA2 [58].
The red square indicates the newly identified open reading frame, ORF5a and the protein
is likely to be expressed from the same sg mRNA [81]; see chapter 7.

1.5. EQUINE ARTERITIS VIRUS LIFE CYCLE
Enveloped viruses typically have surface molecules that bind to cell surface
receptors which mediate the process of cell attachment and membrane fusion with the
host cell membrane. While receptors for EAV have not yet been identified, it has been
suggested that EAV is taken up via clathrin-dependent endocytosis and is delivered to
acidic endosomal compartments [82]. Following entry and release into the cytosol, the
plus-stranded RNA genome is uncoated and translated into two replicase polyproteins
(pp1a and pp1ab) from which at least 13 nsps are released by autoproteolytic processing
mediated by the virus proteases [66,83]. The nsps assemble into a membrane-bound
RTC [84,85,86,87]. The RTC generates minus-stranded RNA genomes that are used as
templates for genome replication and subgenomic mRNA transcription.
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The

subgenomic mRNAs are translated into the viral structural proteins.

The newly

synthesized genome is encapsidated into the N proteins forming the nucleocapsid (NC),
which becomes enveloped by budding through the ER-Golgi intermediate compartment
(ERGIC) that contains membranes with viral envelope proteins. Newly formed virions
mature in the golgi complex during their exocytic pathway and are ultimately released
from infected cells (Figure 1.4).

Figure 1.4. Schematic overview of EAV life cycle. ER: endoplasmic reticulum;
ERGIC: ER-Golgi intermediate compartment; NC: nucleocapsid. Red square represents
newly identified ORF5a protein.
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1.5.1. Genome replication and transcription
The EAV genome is an RNA polycistronic molecule with a 5’ cap and 3’ poly A
structure [34]. The 5’ UTR (leader), comprising approximately 208 nucleotides (nt),
functions as a template for the host translation machinery and as a protective element
against degradation by exonucleases [88].

Among nidoviruses, replication and

transcription are processed through different minus-strand intermediates: a full-length
minus-strand template is used for replication, while subgenome-sized minus strands
produced during a process of discontinuous RNA synthesis are used to synthesize sg
mRNAs [89,90,91,92]. The initiation of full-length minus-strand RNA (or anti-genome)
synthesis, which is also used as template for new genome RNA replication, occurs after
recognition of RNA signals near the 3’ end of the viral genome by the RNA-dependent
RNA polymerase (RdRp) complex [93].

For production of new genomic RNA,

recognition of signals present close to the 3’ end of the anti-genome must be used [4,94].
During viral RNA synthesis, more plus strands are produced than minus-strand RNAs
[95]. There are two widely considered but conflicting models of arterivirus transcription:
leader-primed transcription and discontinuous extension of minus-strand RNA synthesis
(Figure 1.5). In both models, the TRS elements play a critical role. The TRSs are short
and conserved sequence elements (5’-UCAAC-3’) that determine a base-pairing
interaction between positive and nascent minus-strand RNA and are essential for leaderto-body joining [92,96,97]. In the “leader-primed transcription model”, transcription is
initiated from the 3’ end of the minus-strand genome to produce a leader primer from
which the 3’-terminal leader TRS base pairs with the anti-TRS in the minus-strand
genome. The leader transcript is extended to complete the sg mRNA. This model
proposes that the discontinuous step occurs during the plus-strand synthesis and the body
TRS complementary to the minus-strand genome acts as promoter for transcription
[27,29,30]. On the other hand, according to the nidovirus transcription model proposed
by Sawicki and Sawicki [90] which is the widely accepted model, sg mRNAs are
produced by a discontinuous transcription mechanism controlled by the transcription
regulation sequence (TRS). The EAV sg mRNAs contain a common 5’ sequence of 208
nt, called “leader”, identical to the 5’ end of viral genomic RNA [34]. The leader TRS is
located in a hairpin loop structure at the 3’ end of the leader [98] and the body TRSs are
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present upstream of every structural protein gene [28,99]. The EAV genome contains
multiple UCAAC sequences that could be transcriptionally silent. For example, the
RNA3 uses three alternative leader-body junction sites, TRSs 3.1, 3.2, and 3.3 among
which TRSs 3.1 and 3.3 are noncanonical junction sites. There are two UCAAC boxes
upstream of ORF4, -5 and -7 whereas three UCAAC sequences are found upstream of
ORF2 and -2b [100]. However, only a single TRS has been identified as an active site
for each of these sg mRNAs. Moreover, a number of 5’ UCAAC 3’ sequences were also
identified in the replicase gene [99]. The TRSs are thought to regulate transcription of
the genome template and to serve as signals for either attenuation or termination of
minus-strand RNA synthesis in all nidoviruses, thus producing subgenome-sized minus
strands that are utilized later as templates for sg mRNA synthesis [95]. Minus-strand
RNA synthesis, initiated at the 3’-end of the viral genome, is attenuated at one of the
body TRS regions [89,91]. Subsequently, the nascent minus strand carrying the body
TRS complement at its 3’ end is translocated to the 5’ end of the genomic template. In
EAV, the genomic leader TRS serves as a base-pairing target for the 3’ end of the nascent
minus strand that is facilitated by its presence in the loop of an RNA hairpin. When
minus-strand synthesis resumes, nascent strands are extended with the complement of the
genomic leader sequence, yielding a nested set of subgenome-length minus-strand
templates that are used for the subsequent synthesis of the various sg mRNAs.

If

attenuation does not occur, minus-strand RNA synthesis proceeds to yield a full-length
complement of the genome, the intermediate required for its replication. During the
discontinuous transcription mechanism, the TRS at the 3’ end of the leader transcript base
pairs with the complement of the body TRS in the negative-stranded template allowing
extension of the complement of the genomic leader sequence in the nascent negative
strand [90]. The resulting sg negative-stranded RNA serves as template for the synthesis
of the corresponding sg mRNA. With the exception of the last one, each sg mRNA, is
structurally polycistronic, although they are functionally monocistronic. With some
exceptions, only the 5’-proximal ORF is translated from each sg mRNA; therefore, the
number of sg mRNA produced is proportional to the number of ORFs located
downstream of ORF1b.
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Figure 1.5. Illustration of two transcription models in nidoviruses: “leader-primed
transcription” [27,29,30] and “discontinuous extension of minus-strand RNA” [90]
models. (A) The “leader-primed transcription” proposes that the discontinuous step of
viral sg mRNA synthesis occurs during the plus-strand synthesis. After transcription of a
leader primer (+L) from the 3’ end of minus-strand full-length genome, the leader TRS in
this primer joins to the anti-body TRS in the minus-strand genome and is extended to
generate sg mRNA. (B) The alternative model, “discontinuous extension of minus-strand
RNA model” proposes that sg-length negative strand is produced that functions as a
template for generation of sg mRNA. The anti-body TRS may serve as a “jump” signal
of the nascent minus strand to leader TRS located at the 5’-end of the plus-strand fulllength genome. After the anti-leader (-L) is added to the nascent minus strand, the sglength minus strand functions as template for transcription. The later model has gained
stronger experimental support from biochemical and genetic studies. Modified from
Pasternak et al. (2006) [89] with permission.
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1.5.2. EAV replication/transcription complex
Formation of paired membranes and double-membrane vesicles (DMVs) at 3-6 h
post-infection is a typical feature of arterivirus replication [101,102,103,104,105].
Frequently, RTCs of positive-strand RNA viruses are found to be associated with
modified intracellular membranes.

The transmembrane nsps are incorporated into

cellular organelles, particularly the ER, where early viral RNA synthesis occurs and
results in increased expression of replicase proteins. Interaction of accumulated nsps
with membranes results in membrane pairing and vesiculation [84]. It is supposed that
formation of DMVs is based on interactions between luminal domains of transmembrane
proteins of either virus and/or cellular origin to bring opposite membranes together. In
nidovirus-infected cells, newly synthesized viral RNA and many replicase subunits were
found in the perinuclear region together with a large number of DMVs [84,106,107].
Immunoelectron microscopy revealed that viral nsps that are part of RTC and nascent
viral RNA are associated with DMVs [84,107,108,109]. Therefore, DMVs are presumed
to carry the enzyme complex responsible for virus replication and sg mRNA synthesis.
Expression of EAV nsp2-3 is critical in inducing formation of DMVs [84,85]. Among
the EAV replicase subunits, the nsp2, nsp3, and nsp5 encode a considerably large portion
of hydrophobic regions that are presumed to have a structural function by inducing DMV
formation [85] and anchoring the RTC to the membrane [86,110,111]. More recently,
isolated RTC contained replicase subunits that were involved in DMV formation (nsp2
and nsp3) or viral replication (nsp9 and nsp10) and were cosedimented with newly
synthesized viral RNA in a heavy membrane fraction [112] which confirmed their
association with DMV and their essential role in RTC function.

1.6. NONSTRUCTURAL PROTEINS OF EAV
The replicase gene, ORF1a and ORF1b, occupies 75% of the 5’ end of the EAV
genome,. Translation of genomic RNA results in two large polyproteins, 187-kDa pp1a
(1728 aa) and 345-kDa pp1ab (3175 aa). Expression of pp1ab occurs through a -1
ribosomal frameshift mechanism in the overlapping region of ORF1a and ORF1b [10].
The polyproteins undergo an extensive proteolytic processing by three virus-encoded
proteases (nsp1, nsp2, and nsp4) resulting in 13 nsps [66,113] (Figure 1.6; Table 1.2).
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The mature nsps are involved in the formation of a membrane-anchored RTC that directs
viral genome replication and synthesis of a nested set of sg mRNAs [89,91].

The

structural proteins are expressed from sg mRNAs whose genes are located downstream of
the replicase gene. The ORF1a encodes two papain-like cysteine protease domains
(“accessory proteases” located in nsp1 and nsp2) and a chymotrypsin-like serine protease
(“main protease”) in nsp4. The ORF1a protein is cleaved at seven sites resulting in eight
cleaved end products, nsp1 to nsp8, plus a number of processing intermediates
[110,111,114]. The ORF1b is processed into four major end products by nsp4 protease,
including RNA-dependent RNA polymerase and NTPase/RNA Hel domains essential for
viral RNA replication and mRNA transcription [10,11]. Immunofluorescence studies
have shown that the ORF1b-encoded replicase subunits are localized in the perinuclear
region of the EAV-infected cells suggesting that they may be associated with intracellular
membranous compartments [87], most likely the ER.

Figure 1.6. Schematic representation of EAV replicase polyproteins. The numbers
of nsps are indicated above corresponding nsps. The predicted PCPβ and CP cleavage
sites are indicated by black arrows. The 3CLSP cleavage sites are indicated by open
arrowheads. The genes encoding structural proteins are depicted in grey. PCP, papainlike cysteine protease; CP, cysteine protease; 3CLSP, 3chymotrypsin-like serine protease;
ZF, predicted zinc finger; C/H, cysteine/histidine-rich clusters; TM, predicted
transmembrane domains; P, protease domain; Z, zinc-binding domain; N, NendoU.
Figure modified from Nidoviruses book chapter [26] with permission.
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Table 1.2. Nonstructural proteins of EAV.
ORF

Nucleotide
position (bp)a

Protein

Protein
Predicted
length (aa)
M.W. (kDa)
1a polyprotein
1728
190
ORF1a
225-5399 (5175)
ORF1b
5405-9751 (4347)
1ab polyprotein
3176
349.3
ORF1ab
225-9751 (9527)
Nonstructural
nsp1
260
28.6
225-1004 (780)
proteins
nsp2
571
61.4
1005-2717 (1713)
nsp3
233
25
2718-3416 (699)
nsp4
204
21
3417-4028 (612)
nsp5
162
18.1
4029-4514 (486)
nsp6
22
2.3
4515-4580 (66)
nsp7
225
25.2
4581-5255 (675)
nsp8
50
5.5
5256-5405 (150)
nsp9
693
76.8
5256-7333 (2078)
nsp10
467
50.5
7334-8734 (1401)
nsp11
219
24.2
8735-9391 (657)
nsp12
119
12.5
9392-9748 (357)
a
The nucleotide positions are based on the sequence of the experimentally derived EAV
VBS strain (GenBank accession number: DQ846750).

1.6.1. Nsp1
The 29-kDa nsp1 (260 aa) is the first viral protein expressed and is the most Nterminal replicase cleavage product produced. It contains an “accessory protease” which
is not involved directly in proteolytic processing of RdRp and helicase. Three domains
have been identified in the nsp1 region: predicted zinc finger (ZF) domain, papain-like
cysteine protease (PCP) α and PCPβ. The predicted ZF domain present near the N
terminus of nsp1 contains four Cys and His residues [26]. ZFs found in many cellular
transcription factors are involved in protein-nucleic acid and protein-protein interactions
[115]. The nsp1 is released from the replicase polyprotein by the autocatalytic activity of
PCPβ, which is responsible for cleavage of nsp1/2, located in its C-terminal domain
[110,116]. The cleavage and release of nsp1 from the replicase polyprotein was found to
be essential for viral RNA synthesis [117]. In EAV, the PCPα is functionally inactive
due to its loss of an active Cys site during virus evolution [118]. However, PCPα may
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possess RNA-binding and/or protein-binding activities (along with PCPβ), serving as a
platform for the ZF during transcription. Therefore, the structural integrity of nsp1 is
essential since all three domains are required for trans-activation of sg RNA synthesis
[119]. It has been reported that nsp1 is essential for sg RNA transcription but dispensable
for genome replication [119]. The nsp1 not only plays a crucial role in processing of
replicase polyprotein and production of sg mRNA but it is also important for virion
biogenesis [119] [117]. Nsp1 is the only EAV replicase subunit that localizes both in the
nucleus and cytoplasm where it associates with modified cytoplasmic membranes of the
replication complex [84,120]. During the early stages of infection, nsp1 is primarily
located in the nucleus while its cytoplasmic localization, especially in the perinuclear
region, becomes evident later in infection [120].

1.6.2. Nsp2
The 61-kDa nsp2 serves as a cofactor in the processing of the downstream part of
the polyprotein directed by the nsp4 protease [85]. The nsp2 contains two hydrophobic
regions around aa 450 and 490 and a main hydrophobic region between aa 520 and 640,
large enough to span the lipid bilayer several times. However, the exact topology of this
protein needs further characterization [85]. The N-terminal domain of nsp2 contains
cysteine protease activity responsible for cleavage of the nsp2/3 site [121]. Therefore,
nsp2 is released from the polyprotein by internal cysteine autoprotease activity [110]. In
the major processing pathway, the mature nsp2 acts as cofactor for the processing of the
nsp4/5 site by the nsp4 serine protease (SP). The nsp2 interacts strongly with nsp3 or
nsp3- containing precursors (e.g. nsp3-8), a property that may be required for processing
the nsp4/5 site by the nsp4 SP (Figure 1.7). When there is no interaction between nsp2
and nsp3-8, its internal site nsp4/5 cannot be cleaved and further processing of the
replicase subunits occurs via the minor processing pathway (Figure 1.7).

1.6.3. Nsp3
The 22-kDa nsp3 is highly hydrophobic and is presumed to be a tetra-spanning
transmembrane molecule [122].

It contains four conserved cysteine residues in the

predicted first luminal domain (aa 853 to 902) that are likely to be involved in membrane
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pairing and DMV formation [122]. Due to the multiple spanning nature of the protein,
nsp3 is considered to play a key role in the interaction between the EAV RTC and host
cell membranes. Site-directed mutagenesis studies have shown that mutation of nsp3
impairs the interaction of the protein with the ER, disrupts the formation of DMVs,
affects replicase polyprotein processing and inhibits viral RNA synthesis [85,122]. It is
possible that the N-terminal domain (aa 833 to 993) of nsp3 could function as a signal
sequence for membrane insertion of nsp2/3 polyprotein before its cleavage by nsp2 [122].
However, the mechanism of interaction between nsp3 and the membranes or with other
replicase subunits involved in DMV formation remains poorly understood.

1.6.4. Nsp4
The 33-kDa nsp4 contains chymotrypsin-like SP activity at the N-terminal
domain. As the protease name indicates, the main catalytic residue of this C-like protease
in arteriviruses is Ser. Nsp4 is the “main protease” which controls the production of the
viral RNA-dependent RNA polymerase and RNA helicase [66,123]. It is responsible for
processing the polypeptides (nsp3-8 and nsp3-12) that remain after nsp1 and nsp2 have
been autocatalytically released from pp1a and pp1ab [65,110,111,114,116,121]. The
nsp4 SP cleaves at five sites in the ORF1a protein [114] and three sites in the ORF1b
protein [111]. The nsp4 SP processes the C-terminal half of the ORF1a (nsp3-8) protein
via two alternative pathways (Figure 1.7).

In the major processing pathway, nsp2

associates with nsp3-8 (96 kDa) as a cofactor which triggers nsp4 SP to cleave the
majority of nsp3-8 precursors at the nsp4/5 site resulting in nsp3-4 (50 kDa) and nsp5-8
(44 kDa) intermediates. Subsequently, the nsp5-8 is cleaved at the nsp7/8 site while the
nsp5/6 and nsp6/7 are inaccessible to the protease [111].

In the minor processing

pathway, the nsp4/5 site remains intact while the nsp5/6 and nsp6/7 sites are cleaved
(Figure 1.7) [111].
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Figure 1.7. Proteolytic processing of EAV replicase polyprotein pp1a through the
major and minor pathways. The proteases involved in processing are depicted in a
black box with “P”.

The PCPβ and CP cleavage sites are indicated with black

arrowheads. The 3CLSP nsp4 cleavage site is indicated by open arrowheads. PCP,
papain-like cysteine protease; CP, cysteine protease; 3CLSP, 3chymotrypsin-like serine
protease; TM, predicted transmembrane domains. Figure modified from Nidoviruses
book chapter [26] with permission.
1.6.5. Nsp5, nsp6, nsp7α/β and nsp8
The processing intermediate nsp5/6/7/8 is a result of cleavage of the nsp4/5
junction upon association of nsp2 as a cofactor with nsp3-8. In the major pathway,
nsp3/4 and nsp7/8 junctions are cleaved, but not the nsp5/6 and nsp6/7; therefore, cleaved
nsp6 and 7 are not generated. In the minor pathway, nsp4/5 is not cleaved; instead, nsp4
cleaves the nsp3/4, nsp5/6, nsp6/7, and nsp7/8 junctions of the nsp3-8 intermediate
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producing cleaved nsp6 and nsp7 [111]. Fully processed nsp5, nsp6, nsp7, and nsp8 are
approximately 41, 3, 25, and 5.5 kDa, respectively [110].
The nsp5 contains a significant portion of the highly hydrophobic domain
suggesting a role in the membrane association of the EAV replication complex [86,110].
Moreover, the presence of hydrophobic nsp5 in the N-terminus of processing
intermediates, like nsp5-8, nsp5-7 and even larger intermediates such as nsp5-12,
supports its probably association with the intracellular membrane [86].
Little is known about the nsp6 and nsp8 proteins [110]. Currently, there are no
references to either protein in the literature.
An internal cleavage site (nsp7α/β) has been identified in mature nsp7 which is
cleaved by nsp4 protease and produces nsp7α (123 aa; ~13.5 kDa) and nsp7β fragments
corresponding to the N- and C-terminal regions of nsp7, respectively [113].

Most

recently, the solution structure of nsp7α, the most conserved region of nsp7, has been
determined by Nuclear Magnetic Resonance (NMR) [124]. The nsp7α contains four
hydrophobic regions needed for correct folding of the proteins; it has a unique
conformation consisting of three α-helices packed against a mixed β-sheet [124].
Although this study did not reach a definite conclusion about the function of nsp7, it
confirmed that nsp7α is critical for arterivirus RNA synthesis [124].
1.6.6. Nsp9
The 80-kDa EAV nsp9 (aa 1678 to 2370 of pp1ab) contains the RdRp domain
which functions as the catalytic subunit of the viral RTC and directs viral RNA synthesis
in conjunction with other viral proteins and host cellular proteins. The EAV nsp9/RdRp
initiates RNA synthesis by a de novo mechanism involving homopolymeric templates in
a template-specific manner. Increased intracellular concentration of Zn2+ can block the
initial step of viral RNA replication carried out by nsp9/RdRp [125].

1.6.7. Nsp10
The 51-kDa EAV nsp10 contains a predicted zinc-binding domain (ZBD) in its Nterminus and the nucleoside triphosphate-binding/helicase (Hel) motif in its C-terminal
domain [10,11,126]. The nsp10 is the most conserved replicase subunit of the viral RNA
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synthesis machinery [127,128,129]. The nsp10 has ATPase and nucleic acid duplexunwinding activities that require the presence of 5’ single-stranded regions indicating 5’3’ polarity of the reaction [130]. The ZBD region, especially the 13 conserved Cys and
His residues that are most likely to be associated with zinc binding, is critical for ATPase
and duplex-unwinding activities of the C-proximal helicase domain [10,11,126,131].
Reverse genetic studies have shown that mutation of conserved Cys/His residues in ZBD
disrupted interactions between the ZF and enzymatic domains, thus completely blocking
viral RNA synthesis and virion biogenesis [126,131].

Taken together, the nsp10-

associated ZF domain has multiple functions specifically involved in viral RNA
replication, sg mRNA transcription and virion biogenesis [126].

1.6.8. Nsp11
The 26-kDa nsp11 is considered as a multifunctional protein with a crucial role in
viral RNA synthesis. The nsp11 contains a highly conserved endoribonuclease (NendoU;
nidoviral-endonuclease specific for U) domain which is not present in other RNA viruses
and is therefore considered a unique genetic marker of the order Nidovirales [132,133].
The NendoU possesses pyrimidine (uridylates in particular)-specific endoribonuclease
activity independent of divalent cations (e.g. Mn2+) in vitro [134]. Studies using reverse
genetics have shown the importance of NendoU activity for viral RNA synthesis
[132,134].

However, identification of substrate and molecular characterization of

NendoU still remain unclear.

1.6.9. Nsp12
Little is known about the 12-kDa nsp12 of arteriviruses. There are no current
references available in the literature.

1.7. STRUCTURAL PROTEINS OF EAV
The ORFs encoding the structural proteins of EAV are located downstream of
ORF1a and 1b that encode viral replicase proteins. The ORF2a, 2b and 3 through 7 are
expressed from a 3’ co-terminal nested set of subgenomic mRNAs.

The viral RNA

genome is packaged by the N protein, encoded by ORF7, into an icosahedral core
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surrounded by a lipid-containing envelope with small surface projections [135,136]. Six
viral proteins, encoded by ORF2 to 6, have been identified in the EAV envelope (Table
1.3.) [57,58,137]. The envelope (E) protein is the third most abundant protein in the viral
membrane and is encoded by ORF2a. The GP2b, GP3, and GP4 proteins, encoded by
ORF2b, -3 and -4 respectively, are minor envelope glycoproteins that exist in equimolar
amounts in virus particles [57,137].

The minor envelope proteins are covalently

associated and form a heterotrimeric complex on the surface of the virion.

The

nonglycosylated membrane protein M and glycosylated GP5 protein are the major
envelope proteins and are the most abundant envelope proteins. These major envelope
proteins are presented as disulfide-linked heterodimers in virus particles [67]. Wieringa
et al. [59] has shown that the major envelope proteins (GP5 and M) and the N protein are
essential for EAV particle formation.

In contrast, neither E protein nor the minor

envelope proteins are required for production of viral particles since absence of either of
these proteins did not inhibit incorporation of viral genomic RNA or change buoyant
density or microscopic appearance of the virus [59]. In contrast, all major and minor
structural proteins are required for production of infectious progeny virus as has been
shown by individually knocking out the expression of each structural protein separately
[59].
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Table 1.3. Structural proteins of EAV.
ORF

Nucleotide position

Protein

Protein length

Predicted M.W.

(aa)

(kDa)

(bp)*
ORF2a

9751-9954 (204)

E

67

7.4

ORF2b

9824-10507 (684)

GP2

227

25.0

ORF3

10306-10797 (492)

GP3

163

17.9

ORF4

10700-11158 (459)

GP4

142

15.6

ORF5a

11112-11291 (180)

ORF5a

59

6.5

ORF5

11146-11913 (768)

GP5

255

28.0

ORF6

11901-12389 (489)

M

162

17.8

ORF7

12313-12645 (333)

N

110

12.1

* The nucleotide positions are based on the sequence of experimentally derived EAV
VBS strain (GenBank accession number: DQ846750).

1.7.1. Minor envelope proteins
E protein
The EAV E protein is a small 8 kDa (67 aa) protein encoded by ORF2a [58].
ORF2a and ORF2b are both expressed from a bicistronic mRNA2. The E protein lacks
N-linked oligosaccharide side chains and its single cysteine residue does not form
intermolecular disulfide bonds. E protein is stable, highly hydrophobic and is predicted
to be an integral membrane protein with an uncleaved signal-anchor sequence in the
central part of the molecule (Figure 1.8). The E protein could be either a type III integral
membrane protein or it may span the lipid bilayer twice with both termini located in the
cytoplcasmic face of the membrane [58]. It contains a conserved site for myristoylation
in the N-terminal domain followed by a phosphorylation site for casein kinase II [138].
The E protein is found in intermediate amounts in infected cells [58]. E protein along
with GP2 protein is essential for production of infectious progeny virus [58]. Data
suggest that the E protein is noncovalently associated with the GP2, GP3 and GP4
trimeric complex. In the absence of the minor envelope protein complex, the amount of
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E protein in viral particles is diminished by 60 to 80 %. Similarly, the absence of E
protein completely blocks the incorporation of the minor envelope proteins (GP2, GP3
and GP4) into viral particles [59].

GP2
The GP2 protein is a 25 kDa minor envelope protein encoded by ORF2b (Figure
1.8). GP2 is a type I membrane glycoprotein with a single N-glycosylation site at
position 155 (Asn-155) [139].

It has three amino-terminal (extracellular) cysteine

residues likely to be important for dimerization and protein function and one in its
transmembrane anchor domain [139]. The Cys-102 is responsible for the cystine bridge
with the GP4 protein while Cys-48 and Cys-137 form an intramolecular disulfide bond
[140]. The GP2 protein occurs in several distinct conformations, as four monomers as a
result of different disulfide-bonded structures and as a disulfide-linked dimer [139].
However, only the dimeric form of GP2, which is associated with GP3 and GP4 proteins
as a heterotrimeric complex, is assembled into viral particles and the GP2 monomers are
retained in the endoplasmic reticulum of infected cells [139]. GP2 is abundant in EAVinfected cells, but is expressed in low amounts in viral particles. It has been shown that
GP2 protein is not essential for viral RNA replication and transcription [58,141].
Sequence comparison analysis indicated that the GP2 protein is highly conserved
between EAV isolates [142].

GP3
The GP3 is encoded by ORF3 and is a membrane-associated protein of 36 to 42
kDa with six potential N-glycosylation sites, Asn-28, Asn-29, Asn-49, Asn-96, Asn-106
and Asn-118 [137,143]. The membrane topology of GP3 proteins has still not been
clearly demonstrated. The protein could be either a class II protein, anchored into the
lipid bilayer by its uncleaved amino-terminal signal sequence, or a class IV protein,
possibly embedded by both sides of the hydrophobic terminal domains (Figure 1.8)
[137,143]. While the GP3 protein has two putative N-myristoylation sites and three
casein kinase II phosphorylation motifs, it is unclear whether there are active sites. Little
is known about the function of this protein; however, inactivation of ORF3 expression
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inhibited the production of infectious virus particles indicating that GP3 protein has an
essential role in the viral replication cycle.

GP4
The GP4 protein, encoded by ORF4, is a typical class I integral membrane
glycoprotein with amino-terminal signal sequence and its predicted carboxy-terminal
hydrophobic membrane anchor (Figure 1.8) [137].

Three of the four predicted N-

glycosylation sites (Asn-33, Asn-55, Asn-65 and Asn-90) are functional and produce a
fully glycosylated protein with a molecular mass of 28 kDa [137]. However, Wieringa et
al. [137] reported that N-glycosylation of the GP4 protein is an inefficient process and
only a few portions of the protein acquire N-linked glycans in EAV-infected cells.
Moreover, only the fully glycosylated form of GP4 is found in virus particles, which
indicates that a small fraction of the ORF4 products produced in EAV-infected cells are
incorporated into virus particles [137]. The function of GP4, as well as the GP3 protein,
is not well characterized, but both are essential in the viral replication cycle.

Figure 1.8. Predicted membrane topology of minor envelope proteins: E, GP2, GP3
and GP4 proteins. Two alternative predictions of E protein and GP3 membrane
topology are shown.

Putative N-glycosylation sites are indicated in yellow with

corresponding amino acid positions.
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GP2/GP3/GP4 heterotrimeric complex
The GP2, GP3 and GP4 proteins are incorporated into virions as a covalently
associated heterotrimeric complex and lack of one of the components blocks the
successful incorporation of the other minor envelope proteins [59]. After the release of
virus particles from infected cells, GP3 becomes disulfide-linked to the GP2/GP4
heterodimers which results in a 66-kDa complex consisting of covalently bound GP2,
GP3 and GP4 [144].

Due to this post-assembly modification, both GP2/GP4

heterodimers and GP2/GP3/GP4 heterotrimers are detected in EAV particles [144]. The
cystine bridges play essential roles in the formation and stabilization of the trimeric
complex.

The cysteine residues at positions 48 and 137 (Cys-48 and Cys-137,

respectively) of GP2 are linked by an intrachain disulfide bond while the cysteine residue
at position 102 (Cys-102) of GP2 forms an intermolecular cystine bridge with one of the
cysteines of the GP4 protein [140]. The covalent association of GP3 with the GP2/GP4
heterodimer likely occurs through the GP4 protein; however, the precise cysteine residue
forming the intermolecular disulfide bond between GP4 and GP3 has not yet been
determined (Figure 1.9). Similarly, the cysteine residue of GP4 that interacts with Cys102 of GP2 has not been identified. The GP2/GP3/GP4/E heterotrimeric complex is most
likely involved in the virus entry process into the cell based on the observation that it is
not required for EAV virus particle formation, but is essential for production of infectious
progeny virus.
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Figure 1.9.

Two predicted models of GP2-GP3-GP4 heterotrimer.

The two

alternative models differ in membrane topology of GP3 that is currently not determined.
The GP3 protein may be either a class II membrane protein (A) or a class IV membrane
protein (B).

The intermolecular cystine bridges are depicted arbitrarily with disulfide

bonds (S-S) since the Cys positions have not yet been determined. N-glycosylation sites
are indicated in orange with corresponding amino acid positions.

Modified from

Wieringa et al. [144] with permission.

A novel structural protein GP5a
A detailed computational analysis revealed an additional ORF which overlaps the
5’ end of ORF5, named ORF5a, that is conserved in all arterivirus species [81]. The
ORF5a protein is 59 aa long and is likely to be expressed from the same subgenomic
mRNA (sg mRNA5) as the GP5 protein, possibly involving leaky ribosomal scanning.
The ORF5a protein is predicted to be a type III membrane protein with a short (5-12 aa)
amino terminal domain into the lumen, a central signal-transmembrane sequence and a
carboxy-terminal domain into the cytosol (Figures 1.10 and 1.11) [81]. The function of
this protein is yet to be characterized, but studies using reverse genetics suggested that
this novel protein may be the eighth structural protein of arteriviruses and is important for
arterivirus infection [81].
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Figure 1.10.

Amino acid sequences of ORF5a protein of five representative

arterivirus sequences. The ORF5a is predicted to be a type III membrane protein and
the predicted transmembrane domain is indicated in yellow. The lengths, variable among
species, of amino-, caryboxy-terminal and signal-anchor/transmembrane domains are
indicated. Figure adapted from Firth et al. (2011) with permission [81].

Figure 1.11. Predicted membrane topology of ORF5a protein. The ORF5a protein is
predicted to be a class III membrane protein with the carboxy-terminal domain in the
cytosol and the amino-terminal domain in the lumen.
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1.7.2. Major envelope proteins
GP5
The 30- to 42-kDa GP5 protein is encoded by ORF5 and contains one or two
potential N-glycosylation sites (Asn-56 and Asn-81).

It is known that most of the

laboratory adapted EAV strains contain only the N-linked sugar moiety at position Asn56 [74,145,146]. A third potential N-glycosylation site at aa 73 (Asn-73) was observed
in five EAV isolates from clinical specimens obtained from the 2006-2007 EVA
occurrence in the USA [63]. GP5 is one of the most abundant proteins in the EAV
particle. The GP5 protein is a type IV integral membrane protein with triple-membrane
spanning domains from aa 116 to 181 (Figure 1.12) [57]. The ectodomain of GP5 is 95
aa long and contains an N-terminal signal sequence that is cleaved [68]. The smear
appearance of the GP5 protein after analysis by denaturing SDS-PAGE, is due to the
addition of poly-N-acetyllactosamine during its transport through the secretory pathway
[57,67]. However, the function of poly-N-acetyllactosamine modification of the GP5
protein is unclear. The GP5/M forms a disulfide-linked heterodimer in the virus particle
[67]. Proper posttranslational modification and folding of the GP5 protein occurs only in
the presence of the M protein suggesting that the latter may act as its essential scaffold
protein [73]. Studies using EAV chimeras have shown that replacement of the GP5
ectodomain with that of different arterivirus species did not alter the cell tropism of EAV,
indicating that GP5 is not involved in receptor binding [147].
Equine neutralizing antibodies and monoclonal antibodies against EAV bind to
the N-terminal hydrophilic ectodomain (aa 19 to 115) of GP5 [74,145,148,149,150].
Four distinct neutralization determinants of the virus have been identified: aa 49 (site A),
61 (site B), 67 to 90 (site C) and 99 to 106 (site D) [74,145,148,149,151,152]. Except for
site A located in the C1 region, these sites are located in the V1 variable region (aa 61-121)
within the second half of the N-terminal ectodomain of GP5. Site D expresses several
overlapping linear epitopes [145,151] in the protein that may possibly interact with three
other sites to form conformational epitopes [74].
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The membrane (M) protein
The 16-kDa M protein is encoded by ORF6. The M protein is the most highly
conserved envelope protein of arteriviruses [57].

The M protein has three internal

membrane-spanning segments and a short amino terminus exposed at the viral surface
(10 to 18 aa long) and its carboxy terminus (approximately 72 aa long) is buried within
the virus interior (Figure 1.12) [34,57]. It lacks N-glycosylation sites and contains five
methionines and one cysteine. The M protein forms a disulfide-linked heterodimer with
the GP5 protein in the virus particle [67]. The M protein also forms covalently linked
homodimers, but only the GP5/M heterodimers are incorporated into virus particles. It is
possibly involved in virus budding.

Figure 1.12. Predicted structure of GP5 and M heterodimer. The neutralization sites
A (aa 49), B (aa 61), C (aa 67-90) and D (aa 99-106) are shown. The predicted Nglycosylation sites (Asn-56 and Asn-81) are depicted with orange circle. The green circle
represents the N-glycosylation site (Asn-73) found in isolates of a recent EVA outbreak.
The GP5 and M proteins are covalently linked by a disulfide bond (S-S) formed between
Cys-34 in the GP5 protein and Cys-8 in the M protein. Modified from Balasuriya et al.
[76] with permission.
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GP5/M heterodimeric complex
The GP5 and M proteins form a disulfide-linked heterodimer and occur in
equimolar amounts in the virion (Figure 1.12). These proteins associate with each other
with different kinetics and efficiencies in infected cells. Newly synthesized GP5 proteins
rapidly interact with M protein, while newly produced M proteins are incorporated
slowly into the heterodimer. Presence of a high concentration of M protein in the ER is a
prerequisite for efficient recruitment of GP5 protein into the GP5/M heterodimeric
complex [67]. The interaction between the two major envelope proteins is determined by
the formation of the disulfide bridge between the cysteine residue at position 8 (Cys-8) of
M and Cys-34 of GP5 since abolition of either cysteine residue completely inhibited
heterodimerization of the two proteins [68].
The GP5/M heterodimeric complex is essential for EAV assembly where the
interaction between nucleocapsid and viral envelope is most likely to be mediated by the
disulfide-bonded GP5/M heterodimers since the minor envelope proteins are not required
for generation of virus particles. Covalent association of the GP5 and M proteins is
indispensable for the production of infectious arteriviruses [68,153].

In addition,

expression of both GP5 and M proteins as a heterodimer is required for induction of
neutralizing antibodies [154].

Nonetheless, peptides derived from just the GP5

ectodomain were also able to induce neutralizing antibodies to EAV in horses [148,155].

The nucleocapsid (N) protein
The 14-kDa (110 aa) N protein, encoded by ORF7, is the most abundant viral
protein in EAV-infected cells. The N protein is synthesized in the cytoplasm of EAVinfected cells and possibly binds to envelope protein domains exposed to the cytoplasm
during the budding process. Most of the N protein localizes in the cytoplasm of infected
cells, while a small fraction resides in the nucleus where it seems to accumulate in
nucleoli. This suggests a possible post-translational modification of some molecules of N
protein, such as phosphorylation.

An important function of the N protein is the

packaging of the viral genome into a putative icosahedral core. The N-terminal domain
(aa 1-47) of the N protein, the least conserved region, is thought to interact with the viral
genomic RNA during nucleocapsid assembly [120]. The C-terminal (aa 49-110) of the
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EAV N protein forms a dimer consisting of a β-sheet that is capped and flanked by αhelices. In the crystal structure, the N protein forms a dimer-dimer, in other words a
tetramer, organized via a quasi-twofold axis [156]. The N protein comprises more than
30% of the protein molecules in an EAV particle.

1.8. GENETIC VARIATION AND MOLECULAR EPIDEMIOLOGY OF EAV
Although only one major serotype of EAV has been recognized to date [157],
there is considerable antigenic variation among EAV field strains. Genomic variation
among field strains of EAV has been demonstrated [142,158,159,160,161,162] by
comparative sequence analysis of ORFs 2 to 7. ORF5 was found to be a main target due
to the variable regions within ORF5; it is valuable for tracing the origin of EAV strains
[80,142,146,158,159,163,164,165,166,167,168]. Phylogenetic analyses based on M and
N protein genes confirmed EAV strain variation [159]. Distinct geographic groups of
EAV isolates from Europe and the USA were separated based on sequence analysis of the
M protein gene [161].

Comprehensive phylogenetic analyses have identified two

phylogenetic groups: Group I consists of viruses isolated mainly in North America and
Group II consists mainly of viruses isolated in Europe [146,158,164,166,169].

In

addition, several subgroups have been identified within each group. However, American
lineage viruses were isolated in Europe and vice versa indicating interchange of viruses
between the two continents, which is thought to have resulted mainly as an outcome of
the movement of carrier stallions and/or shipment of virus-infective semen.

The

nucleotide identity between North American and European isolates of EAV is about 85%
[158,164]. However, a genetically very diverse strain of EAV has been isolated from the
semen of a donkey in South Africa which has been reported to have nucleotide identity of
only 60-70% compared to sequences of EAV strains isolated from North American and
European horses and donkeys [170].
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1.9. EQUINE VIRAL ARTERITIS

1.9.1. Seroprevalence, world distribution and modes of transmission
EAV, the causative agent of EVA is distributed throughout the world
[171,172,173,174,175,176], but the seroprevalence of EAV infection varies between
countries and horses of various breeds and ages.

There is a marked difference in

seroprevalence of EAV infection between Standardbred and Thoroughbred horses in
countries in which this has been studied. EAV is endemic among adult Standardbred
horses in the United States, (seroprevalence of 78 to 84%), whereas only 0 to 5% of
Thoroughbred horses are seropositive [177]. Antibodies against EAV have been found in
horses, donkeys and mules in South Africa [176,178,179,180] but not in free-ranging or
captive zebra species in southern Africa [181,182]. EAV-specific neutralizing antibodies
were detected in 51 zebras (24%) of the Burchell’s zebra population in the Serengeti
National Park [183]. There is only one report of the detection of EAV nucleic acid from
aborted alpaca fetal tissue by reverse-transcription polymerase chain reaction (RT-PCR)
and neutralization antibodies were found in a high percentage of its cohorts [184].
Transmission of EAV between horses occurs primarily via either the respiratory
or venereal route [77,185,186,187,188,189]. Respiratory transmission of EAV occurs by
dispersal of infectious respiratory tract secretions from acutely infected horses. This is
the most important and primary route of dissemination of EAV during outbreaks [187].
High titers of EAV are present in respiratory secretions for some 7 to 14 days during the
acute phase of infection [177,187]. Similarly, the virus may be detected in the buffy coat
for up to 28 days after exposure with some strains of EAV [177,190]. The second most
important mode of transmission of EAV is venereal, from acutely or chronically infected
stallions. Venereal transmission of EAV occurs during natural breeding or by artificial
insemination with infective semen from persistently infected stallions [188,189].
Persistently infected stallions shed virus solely by the venereal route and up to 85 to 100%
of seronegative mares bred to long-term carrier stallions seroconvert within 28 days after
breeding. Persistence of virus in semen of carrier stallions does not appear to cause any
short- or long-term virus-related fertility problems [177,188].

Persistently infected

stallions are the primary natural reservoir of EAV; they disseminate and perpetuate the
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virus in equine populations. Recent study by Broaddus et al. (2011) demonstrated that
there could also be a risk of EAV transmission resulting from in vivo embryo transfer
from a donor mare inseminated with EAV infective semen [191]. Dissemination of EAV
by indirect contact through contaminated fomites (e.g. personnel, vehicles, twitches,
apparel and shanks) is believed to play a minor role; however, its significance varies
between outbreaks [77,192,193]. Other sources of EAV can be an infected teaser stallion
or nurse mare [77]. It has recently been reported that exposure of pregnant mares to EAV
very late in gestation can result in transplacental transmission of the virus and congenital
infection of the fetus [194].

1.9.2. Clinical signs
Equine viral arteritis is a contagious infectious disease of equids caused by EAV.
The virus was first isolated during an outbreak of abortion and respiratory illness on a
Standardbred breeding farm near Bucyrus, Ohio in 1953 [185,195]. The disease was
named after the distinctive vascular lesions present in acutely infected horses [196].
Many years earlier, EVA was commonly referred to as “epizootic cellulitis-pinkeye” or
as “equine influenza” [197,198]. EAV is present in equine populations in many countries
throughout the world [77,177,199,200]. The outcome of EAV infection in horses ranges
from subclinical infection to an influenza-like illness in adult horses, abortion in pregnant
mares, and interstitial pneumonia or pneumoenteritis in young foals [77,194,201,202,203].
Development of clinical signs depend on a variety of factors including strain of virus,
challenge dose, route of infection, age and physical condition of the horse(s) and
environmental conditions [77,204]. The incubation period can range from 3 to 14 days
(usually 6 to 8 days following venereal exposure) followed by development of pyrexia of
up to 41°C (39-41°C) which may persist for 2 to 9 days. In addition to pyrexia, typical
cases of the disease may exhibit all or any combination of the following signs: depression,
anorexia, nasal and/or ocular discharge, conjunctivitis, rhinitis, leukopenia, periorbital or
supraorbital edema, edema of the limbs, edema involving the scrotum and prepuce of the
stallion and mammary glands of the mare, urticaria around the head, sides of neck and/or
body, and abortion of pregnant mares [77,192,195,204,205,206]. The most consistent
clinical features of EVA are pyrexia and leukopenia. Regardless of clinical severity,
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most naturally infected horses recover spontaneously from EVA. However, the virus can
cause a rapidly progressive pneumoenteric syndrome and severe fulminating interstitial
pneumonia in neonatal foals [194,207] and foals up to a few months of age [208].
Abortion in pregnant mares may occur late in the acute phase or early in the convalescent
phase of EAV infection [77,195,209,210]. Abortions have been documented anywhere
from 3 to over 10 months of gestation following natural or experimental infection
[77,210,211]. It has been shown that it is safe to vaccinate healthy pregnant mares up to
3 months before foaling and during the immediate postpartum period with a commercial
modified live virus vaccine (MLV, ARVAC®, Pfizer Animal Health) but not during the
last 2 months of gestation due to an increased risk of abortion [212]. In natural outbreaks
of EVA, abortion rates have varied from less than 10% to between 50 to 60% [77].
Although mortality is very low in natural outbreaks of EVA, experimental inoculation
with the experimentally derived EAV VBS strain can cause up to 60% case-fatality in
adult horses [77,213].

1.9.3. Persistent infection
Persistence of virus in the semen of infected stallions is a unique feature of EAV
infection. Frequency of the carrier state can vary from less than 25% to 65% in stallions
exposed to EAV via the respiratory route [188,190,214,215]. The virus appears to be
restricted to the male reproductive tract and is localized mainly in the ampulla of the vas
deferens [77].

Not withstanding high neutralizing antibody titers in serum, carrier

stallions continuously shed infectious virus in their semen. The virus is associated with
the sperm-rich and not the pre-ejaculatory fluid fraction of semen. Duration of virus
persistence can vary; carrier stallions can stop shedding virus in their semen weeks to
years after infection with no evidence of reversion to a shedding status later. However,
the mechanism of spontaneous viral clearance in persistently infected stallions has not yet
been identified [77]. Many outbreaks are initiated following venereal transmission of
infection to a susceptible mare by a carrier stallion. Subsequent spread of virus to
seronegative cohorts occurs via the respiratory transmission route [78,79]. The carrier
stallion is mainly responsible for maintenance and dissemination of EAV in the equine
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population; thus, they are clearly central to the epidemiology of EAV infection
[78,79,216].
Although the detailed mechanism of establishment of the carrier state in stallions
is still unidentified, Little et al. [217] have reported that shedding of EAV in the semen of
persistently infected stallions is testosterone-dependent [217,218]. Surgical castration of
carrier stallions resulted in either viral clearance or significant reduction of virus
shedding in their semen [218] has been convincing. The effects of testosterone on
reproductive tissues, such as immunosuppressive activities or maintenance of susceptible
host cell population, that could maintain EAV persistence have also been considered
[219,220]. Other studies have related persistence to the interaction between the host
immune response and EAV in the reproductive tract [190,221,222]. It was suggested that
high levels of circulating testosterone is essential for long-term persistence but not for
viral replication or persistence of intermediate duration [223]. Experimental infection of
prepubertal and peripubertal colts with EAV have shown that the virus can replicate in
the male reproductive tract for a variable period of time (intermediate duration) even in
the absence of circulating concentration of testosterone similar to those of sexually
mature stallions after clinical recovery [223]. However, none of the prepubertal colts
maintained long-term virus persistence comparable to that of experimentally or naturally
infected stallions [223]. Therefore, long-term persistent EAV infection does not occur
either in colts exposed to the virus before the onset of puberty or mares, geldings or
fetuses [177,189,218].
It is assumed that virus persists by continuously re-infecting susceptible tissues in
the reproductive tract together with constant evolution of antigenic variants of the virus
[79,80,164].

In contrast to the relative genetic stability of EAV during infection

associated with respiratory transmission, significant evolution and genetic heterogeneity
of EAV quasispecies occur during persistent infection of individual carrier stallions
[78,79,80]. Sequence analyses of EAV isolated from semen of carrier stallions have
demonstrated that there is a significant evolution of EAV quasispecies during long-term
persistence that results in emergence of novel variants with divergent phenotypes
responsible for major EVA outbreaks [79,80,224].

High rates of nonsynonymous

changes occur in regions of GP3 and GP5 proteins [80,164] indicating that these viral
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proteins are under strong selective pressure during establishment and maintenance of
persistent EAV infection [74,80]. Particularly, amino acid changes in the GP5 protein
that occur during persistent infection of stallions are found to be restricted to the critical
V1 neutralization region [74,224]. It has also been observed that development of clinical
signs of EVA was more common in susceptible mares bred to certain carrier stallions
than others [189]. Thus, genetic variation of EAV during persistent infection results in
both altered neutralization phenotype and emergence of variants of variable virulence
phenotypes [80,164].
Persistent infection of cell cultures has been reported previously for numerous
viruses

including

certain

[101,225,226,227,228,229,230,231,232,233,234,235].

nidoviruses

Since there is no information

available about host and viral factors, other than testosterone, involved in establishment
and maintenance of persistent EAV infection, Zhang et al. [236] developed an in vitro
model system in an attempt to elucidate the mechanism of EAV persistence. This study
showed that viral determinants are also critical in mediating persistent infection of EAV
in vitro.

Reverse genetic studies using an EAV infectious cDNA clone clearly

demonstrated that amino acid changes in the structural proteins were responsible for the
persistence in HeLa cells, indicating a multigenic effect on EAV persistence [236]. This
in vitro model system could serve as a suitable method to determine viral and/or host
factors involved in EAV persistence as well as possibly help to define the mechanisms of
EAV persistence in vivo.

1.9.4. Pathogenesis
Most of the information on the pathology and pathogenesis of EVA is derived
from experimental studies in horses inoculated with the experimentally derived Bucyrus
strain of EAV [187,195,210,213,237,238,239].

The most frequently observed gross

necropsy findings in horses inoculated with the Bucyrus strain of EAV are edema,
congestion, and hemorrhage in subcutaneous tissues, lymph nodes, and viscera of the
thoracic and abdominal cavities [195,206,213,239]. There is considerable variation in the
quantitative distribution of EAV between experimental studies, which may reflect
differences in the route of infection, virus dose, strain of virus, and quality of the
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specimens and cell culture systems used for virus isolation. Apart from its incidental
recovery from buffy coat cells [240,241], and with the possible exception of the
reproductive tract of stallions and colts, EAV is not generally isolated after 28 days
following infection.
The exact mechanism of EVA pathogenesis remains to be determined.

The

vascular lesions are likely caused by the direct effect of viral replication on vascular
endothelium. EAV replicates in pulmonary macrophages and endothelial cells following
respiratory infection and rapidly spreads first to the draining lymph nodes and then
systematically by a cell-associated viremia [51,187,213,242]. Although endothelial cells
and macrophages are the principal sites of virus replication, selected epithelia,
mesothelium, and smooth muscle cells of the tunica media of smaller arteries, venules,
and the myometrium may also be infected [76,242]. Increased vascular permeability and
leukocyte infiltration resulting from generation of chemotactic factors leads to
hemorrhage and edema around affected vessels [238]. The clinical manifestations of
EVA likely reflect endothelial cell injury and increased vascular permeability; however,
the relative roles and importance of direct virus-mediated endothelial cell injury and
virus-induced vasoactive and inflammatory cytokines in the pathogenesis of EAVinduced vascular injury have not yet been clearly defined [76].
The pathogenesis of EAV-induced abortion is still controversial. Fetuses aborted
after natural or experimental infection with EAV frequently do not show any gross or
histopathological lesions [195,206,210,243,244]. Fetuses are usually partially autolyzed
at the time of expulsion and may have increased peritoneal and pleural fluid, and
petechial hemorrhages in the mucosal linings of the respiratory and digestive tracts and
on the serosal lining of peritoneal and pleural cavities [195,206,210]. The placenta
typically is grossly unremarkable and expelled with the fetus. Doll et al.[210] concluded
that fetal expulsion is the result of a lethal fetal infection and not maternal factors such as
fever, toxemia, or debilitation. However, Jones et al.[245] suggested that abortions result
from an impaired uterine and placental blood supply due to systemic vascular necrosis in
the mare. Coignoul and Cheville [243] also suggested that abortion may result from
myometritis of the mare rather than fetal infection with the virus, based upon light and
electron microscopic studies of tissues from the genital tracts, placentae and fetuses of
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mares experimentally infected with experimentally derived Bucyrus strain of EAV. In
contrast, MacLachlan et al., [213] suggested that abortion likely results from direct
infection of the fetus by EAV.

Fetal stress and subsequent activation of the fetal

hypothalamic-pituitary axis due to viral infection of the developing fetus likely contribute
significantly to the pathogenesis of EAV-induced abortion.

1.10. IMMUNE RESPONSE TO EAV INFECTION
The immune response to viruses can be considered under two categories. The
innate immune response, the first line of defense, plays an important role in the detection
of invading pathogens and in limiting their spread. The second category is the adaptive
immune response, the second line of defense, is responsible for total clearance of
pathogens. While the innate immunity is activated immediately, the adaptive immunity
takes longer to develop. While antibodies are clearly important in preventing reinfection
with viruses, removal of virus-infected cells during acute infection typically is mediated
by the cellular arm of the immune system.

1.10.1. Innate immune response
Natural EAV infection of horses primarily occurs via either the respiratory tract
following exposure to infective secretions/excretions or the reproductive tract following
venereal exposure [77,246]. Thus, it is the innate immune response of the mucosal lining
of the respiratory and genital tracts that constitutes the first line of defense that EAV
encounters in cases of natural exposure. There are few detailed studies that describe the
innate immune response of horses to EAV or other viruses, thus information pertaining to
innate antiviral immunity is largely derived from the study of other viruses of order
Nidovirales.
The innate immune response is the first line of the host’s defense against a virus infection;
it also plays an important role in activation of the adaptive immune response. Type I
IFNs (IFN-α and IFN-β) are major players in the innate immune response and are
expressed in response to most intracellular infectious agents, especially viruses [247].
They induce expression of genes encoding antiviral proteins and also function as an
important link between innate and adaptive immune responses.

41

There is mounting

evidence that PRRSV circumvents the host innate response, resulting from inadequate
induction of type I IFNs [248,249,250]. As a consequence, there is a delayed production
of IFN-γ, cellular immunity and neutralizing antibodies [76,251], and in consequence,
delayed viral clearance [250,252,253]. Additionally, it has been shown that PRRSV
infection of alveolar macrophages fails to elicit any significant expression of genes
encoding proinflammatory cytokines, including TNF-α [254,255].

Furthermore, the

sensitivity and induction of IFN-α in porcine alveolar macrophages (PAMs) differ
significantly among different strains of PRRSV [256]. Some of the North American
PRRSV strains strongly down regulate the induction of IFN-α in PAMs [256].
Viral components are recognized by specific host pathogen recognition receptors
(PRRs) that trigger the activation of IRF3, NF-kB and AP-1, three regulators of IFN-β
expression. IFN-β is responsible for the induction of interferon stimulated genes (ISGs)
that encode antiviral effectors important in limiting viral spread and in establishing an
antiviral state in the infected cells as well in the neighboring non-infected cells.
In previous studies, it has been shown that EAV infects alveolar macrophages
(AMΦ) after respiratory infection of horses, but recent in vitro studies using cultured
equine AMΦ confirmed that although these cells were susceptible to infection, they were
refractory to productive replication of EAV [257]. In contrast, productive replication
occurred following EAV infection of cultured blood-derived equine macrophages (BMΦ)
[257]. EAV infection of both equine AMΦ and BMΦ resulted in increased transcription
of genes encoding proinflammatory mediators, including IL-1β, IL-6, IL-8 and TNF-α,
with the release of substantial quantities of TNF-α into the culture medium [257].
Furthermore, virulent and avirulent strains of EAV induced different quantities of TNF-α
and other proinflammatory cytokines (IL-1β, IL-6, IL-8), and the magnitude of the
cytokine response of equine AMΦ and BMΦ to EAV infection reflected the virulence of
the infecting virus strain [257]. These studies clearly show that cytokine mediators are
produced by EAV infected equine cells and, presumably, these play an important role in
determining the nature and severity of the outcome of infection. However, a more
specific and detailed investigation into innate and adaptive immune responses to EAV
has not been carried out.
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1.10.2. Humoral immune response
The humoral immune response to EAV is characterized by the development of
both complement-fixing (CF) and virus-specific neutralizing (VN) antibodies [157,258].
The CF antibodies appear between 1-2 weeks and peak 2-3 weeks after EAV infection in
adult horses and ponies [157].

Interestingly, avirulent strains of EAV (e.g. MLV)

stimulate a stronger CF antibody response than that elicited by virulent strains, such as
the VBS of EAV [157]. The mechanism of EAV neutralization by specific antisera is not
clear.

Several in vitro studies indicate that neutralization of EAV is complement-

dependent [259,260,261,262]. These studies have shown that EAV neutralizing activity
of horse, hamster, guinea pig and rabbit antisera was decreased following heat
inactivation, and restored by addition of fresh complement. Homologous complement
appeared to be more efficient in neutralizing the sensitized virus than heterologous
complement [157,263]. Complement dependent EAV neutralizing antibody activity is
associated with the IgG fraction of late antiserum, but not with early antisera or their IgM
and IgG fractions [261].

The requirement of complement for efficient virus

neutralization is also dependent on the virus strain [176,263].
EAV infection in horses induces long-lasting immunity that protects against
reinfection with all strains of the virus [76,196,264,265,266]. Appearance of neutralizing
antibodies (7-14 days post infection) coincides with the disappearance of virus from the
circulation of infected horses [240,267]. However, virus does persist in the reproductive
tract of the carrier stallion for a variable period despite the presence of high titers of VN
antibodies in serum [77]. The humoral immune response to structural EAV proteins in
naturally or experimentally infected horses varies widely with the infecting EAV strain,
the interval after infection, and the individual horse [150,221,268]. The variation in the
antibody response to EAV structural proteins was also observed in horses immunized
with the modified live EAV vaccine [221,268]. Vaccination of horses with either live
attenuated virus strains or inactivated virus vaccines also induce long-term VN antibodies
in horses [266,269,270]. In addition, horses immunized with recombinant GP5 protein
(residues 55 to 98) or synthetic oligopeptides (residues 75 to 97) also developed
neutralizing antibodies to EAV [148]. Foals acquire EAV-specific antibodies from the
colostrum of seropositive (immune) dams and these antibody levels decrease with time.
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Furthermore, passively acquired antibodies protect young foals that received colostrum
from EAV seropositive mares against EAV infection confirming the importance of
antibodies in protection against the disease [271,272]. However, VN antibodies are not
detected in sera from foals prior to nursing suggesting that the passive immunity does not
occur through the placenta in utero [271]. The maternally acquired antibody titer is high
at 1 week of age and declines until no longer detectable after 2-6 months. The mean
biological half-life of maternal antibodies in serum from foals was 32 days [272]. Foals
that received colostrum should be vaccinated after maternal antibodies disappear since
these antibodies in their serum are able to neutralize the vaccine virus [271]. The time to
implement vaccination of foals is dependent on the duration of passively acquired
immunity to EAV [272].
The humoral immune response to EAV is mainly directed to the major envelope
proteins, GP5, M and N proteins [148,221,268,273,274,275,276].

Early studies on

characterization of antigenicity and function of viral proteins using monoclonal
antibodies (MAbs) have identified that neutralization determinants of EAV are located in
the GP5 protein [149,151,152]. Different neutralization abilities of MAbs suggested that
while they recognize different epitopes, they all recognized the GP5 protein. To induce
neutralizing antibodies in mice, co-expression of GP5 and M in eukaryotic cells is
required [73]. In contrast, non-neutralizing MAbs were directed to either the GP5 or N
protein [74,145,149,151,152,273,277,278]. Initially, Balasuriya et al. [151] identified a
critical neutralizing epitope present between residues 99 to 104 using MAbs,
neutralization-resistant mutants and recombinant proteins of individual viral proteins.
Amino acid mutations within this region were found in neutralization-resistant mutants
[151,152]. Similarly, Chirnside et al. identified a linear epitope between residues 55 and
98 of the GP5 protein using the expression vector pGEX system [148]. Additionally,
Glaser et al. [145] recognized that resistance to VN is associated with mutations around
positions 99 and 100 based on testing different EAV isolates.

Taken together, the

dominant neutralizing domain was recognized as between aa residues 75 and 104 within
the GP5 protein [145].

The study conducted by Balasuriya et al. [74] further

characterized at least four potential neutralization sites on the N-terminal hydrophilic
ectodomain of the GP5 protein, including aa 49 (site A), 61 (site B), 67-90 (site C), and
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99-106 (site D). Most of the neutralization epitopes, except for aa 49, are located in the
variable region V1 (aa 61-121) of the GP5 protein [74]. Studies using MAbs and reverse
genetics have shown that aa changes at aa 61 (site B) and 67-90 (site C) of the GP5
protein influence the expression of conformational neutralizing epitopes and similar
changes could also be responsible for antigenic variation among EAV field strains
[69,74].

Therefore, it is likely that aa changes in the GP5 N-terminal ectodomain,

especially if they occur during persistent infection in carrier stallions, contribute to the
emergence of EAV strains with different neutralization phenotypes [69].

Besides

neutralizing antibodies recognizing GP5 protein, horses also produce non-neutralizing
anti-GP5 antibodies in response to EAV infection or immunization with an inactivated
whole-virus vaccine [274,279].
Non-neutralizing antibodies which recognized N and M proteins [221,268,279]
were detected as early as 14 days post-infection (dpi) and lasted at least 145 days in
sequential sera from horses experimentally infected with EAV [276]. The M protein is
the most consistently recognized among the EAV structural proteins by convalescent sera
from EAV-infected horses [221,268] while response to the N and GP5 proteins was
variable. The GP2 protein was poorly recognized by equine antisera [268]. The Cterminal domain of the M protein (aa 88-162) contains linear epitopes and is recognized
by all EAV-specific horse antisera [280]. The ORF7 encoding the N protein is highly
conserved among strains [159]. The portion between aa 1-69 of the N protein has been
identified as the most immunoreactive region. Sera from persistently infected stallions
consistently recognized GP5, N and M proteins [268]. In contrast, most convalescent
sera from mares, geldings and stallions that did not become carriers after exposure to
EAV recognized the carboxy-terminal region of the M protein [268].
Until now, characterization of the humoral immune response to EAV has been
mainly focused on the structural proteins of EAV. The nonstructural proteins of EAV are
the first viral proteins synthesized in cells infected with EAV and are essential to the viral
replication cycle. Based on their expression levels and immunogenicity, it is reasonable
to think that antibodies to nsps are generated during early infection. However, little is
known about the equine humoral immune response to the nonstructural proteins. In
response to this need, chapter 9 of the dissertation is focused on determining the humoral
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immune response of EAV-infected horses to each of the nsps encoded by the ORF1a and
ORF1b region of the viral genome.

1.10.3. Cell mediated immune response
Both innate and adaptive immunological responses are mediated by leukocytes,
and among these cells, lymphocytes are the pivotal population [281]. Castillo-Olivares et
al. [282] described EAV-specific cytotoxic T-lymphocyte (CTL) responses using
peripheral blood mononuclear cells (PBMCs) from convalescent EAV-infected
(experimental) ponies. The data showed that cytotoxicity induced by EAV-stimulated
PBMCs was virus-specific, genetically-restricted, and mediated by CD8+ T cells, and that
EAV-specific CTL precursors persist for at least 1 year after infection in ponies [282].
Other than this study, there are no comprehensive studies that describe either the innate
or cell-mediated immune (CMI) response to the MLV vaccine or to any other strains of
EAV in horses.
In contrast to EAV, CMI responses to two other arteriviruses (PRRSV and LDV)
have been characterized in detail [15,76,250,283,284]. PRRSV-specific T cell responses
(both CD4+ and CD8+) in infected pigs occur between 4 and 12 weeks after infection and
it is suggested that the unglycosylated M envelope protein may be an important target of
the CMI response [283,284].
The murine arterivirus LDV causes lifelong persistent infection in mice and
evades both humoral and cell mediated immune responses. The virus escapes the
neutralizing antibodies by generating neutralizing-escape variants. Furthermore, during
the acute phase of LDV infection, mice mount a strong CTL immune response that
disappears within 30 days [285]. It has been suggested that this may be due to the clonal
deletion (exhaustion) of LDV-specific CD8+ T cells in the thymus as well as inhibition of
IL-4 with suppression of helper T cells [15].
In summary, it has been clearly shown that PRRSV and LDV have their own
mechanisms to evade the host immune response, but nothing is known about immune
evasion by EAV in horses.
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1.11. DIAGNOSIS OF EQUINE VIRAL ARTERITIS

1.11.1. Virus isolation
EAV infects a wide variety of cell types. The virus can be propagated in a number of
continuous cell lines such as baby hamster kidney (BHK-21), African green monkey
kidney (Vero and BSC-1), rhesus monkey kidney (LLC-MK2), rabbit kidney (RK-13 and
LLC-RK1), equine ovary cells (EO), hamster lung (HmLu), and canine hepatitis virustransformed hamster tumor cells (HS and HT-7) [60,103,145,261,265,286,287,288,289].
The cytopathic effect (CPE) and virus titer can vary significantly among cell lines. The
CPE in EAV infected cells is usually characterized by rounding, vacuolation, increased
optical density, refraction and detachment from culture vessels [60,61,290,291].
The presence of EAV in body fluid, tissue samples, blood, semen and placenta
can usually detected by virus isolation in cell culture. The most appropriate specimens
for virus isolation from live animals are nasopharyngeal swabs, conjuctival swabs and
citrated or EDTA blood samples for separation of buffy coat cells. Isolation of EAV is
currently performed using a high passage RK-13 cell line. Virus isolation (VI) is the
current gold standard test, approved by World Organization for Animal Health (OIE), for
the detection of EAV in semen from stallions and is the prescribed test for international
trade [292].

1.11.2. Molecular diagnostics
Rapid and highly specific diagnostic systems for detection and characterization of
EAV in diagnostic specimens are critical to ensure proper management of infected
animals and to provide effective control measures of the disease. The modern nucleic
acid-based tests are widely available to test clinical specimens for many infectious
disease agents. The molecular diagnostic tests are often more sensitive, faster and less
expensive. A number of sensitive standard RT-PCR, RT-nested PCR and real-time RTPCR based assays have been developed for the detection of EAV nucleic acid in tissue
culture fluid, nasal secretions and semen [293,294,295,296,297,298,299,300]. Initially,
published primer sets were specific to the 3’ end of ORF1b of the viral polymerase gene
[293,294,297,298]. However, more conserved regions of the viral genome were also

47

used as targets. Comparative nucleotide and amino acid sequence analysis of ORF7
(encoding N protein) deduced the aa sequences of ORF7 which are highly conserved and
less likely to be the subject of antigenic variation. Therefore, both TaqMan®-based
[299,300] and TaqMan® minor-groove-binding (MGB) group-based [301] real-time RTPCR have been developed targeting ORF7 of the EAV genome. These assays have been
compared and validated using a large number of equine semen and tissue culture fluid
(TCF) samples. Lu et al. [302] compared specificity and sensitivity of two TaqMan®based RT-PCR assays, described by Balasuriya et al. (T1) [299] and Westcott et al. (T2)
[300]. Both T1 and T2 assays showed high sensitivities, 100% and 95.2%, respectively,
for detecting EAV RNA in TCF. However, these assay were less sensitive, 93.4% and
42.6%, respectively, than the OIE-prescribed VI test (gold standard) for detection of
EAV RNA in semen. In an attempt to increase the diagnostic sensitivities of the T1 and
T2 assays for testing semen samples, Miszczak et al. [303] used three different one-step
real-time RT-PCR reagents in combination with two different magnetic bead-based RNA
extraction methods to test 409 semen samples. The study determined that under strictly
defined conditions with respect to the nucleic acid extraction method and testing reagents,
the T1 assay provides sensitivity equal to or slightly higher than virus isolation for the
detection of EAV in semen. Taken altogether, the real-time RT-PCR can reliably detect
EAV nucleic acid when the reagents for nucleic acid extraction and amplification
methods are optimized.

Therefore, this assay has the potential to provide a faster,

convenient and more economical test for detection of EAV nucleic acid in TCF and
equine semen and be an alternative to VI.

1.11.3. Serological diagnosis
The virus neutralization test (VNT) is considered the “gold standard” for
detection and determination of antibodies to EAV [292]. Currently, the VNT is the only
validated test accepted for international trade. Although, the VNT is highly sensitive and
accurate, it has several disadvantages: it is expensive, labor-intensive and timeconsuming to perform. In addition, results can vary among laboratories when adequate
attention is not paid to standardization of both test reagents and procedure. Moreover,
serum cytotoxicity caused by anti-cellular antibodies directed against RK-13 cells can to
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the inexperienced, be mistaken for viral CPE and can give rise to difficulties in test
interpretation at lower serum dilutions. Also, the VNT cannot differentiate the antibody
response of vaccinated from naturally infected horses. To overcome these disadvantages,
several enzyme-linked immunoassays (ELISA) have been described using whole virions,
recombinant GP5, M and/or N proteins expressed from bacterial- or baculovirus systems
with ovalbumin-conjugated synthetic oligopeptides of GP5 protein as antigen
[150,221,254,274,275,304,305,306]. Given the importance of the GP5 protein to virus
neutralization, it was the logical target as an antigenic protein for development of
serological diagnostic assays. An ELISA using a recombinant fusion protein expressing
GP5 55-98 had a sensitivity and specificity of 99.6% and 90.1%, respectively [274]. An
ELISA based on a cocktail of recombinant GP5, M and N proteins expressed in
baculoviruses had 100% specificity and 92.3% sensitivity when tested with sera from
naturally or experimentally infected horses.

However, the test was not reliable in

detecting antibodies in sera of vaccinated horses [221].

A blocking ELISA using

partially purified EAV and MAb against the GP5 protein with 99.4% sensitivity and 97.7%
specificity was developed [254]. Another ELISA based on GP5 protein, the ovalbuminconjugated synthetic peptide containing amino acids 81-106 of GP5 (GL-OVA) had a
sensitivity and specificity of 96.7% and 95.6%, respectively [150]. Due to the conserved
nature of the nucleotide sequence of M and N proteins among different EAV strains and
isolates, they are considered appropriate candidates for diagnostic purposes as well [159].
Jeronimo and Archambault (2002) demonstrated that the carboxy terminus of the M
protein (aa 88-162) is consistently recognized by EAV-specific horse sera, thus
suggesting this region be used as the antigen for serology tests such as ELISA [280].
However, none of the above mentioned assays were sensitive and specific enough to
replace the current VNT. Currently, there is a commercially available ELISA, Ingezim
Arteritis ELISA (Ingenasa, Madrid, Spain); however, sensitivity and specificity of the
assay was considerably lower compared to VNT making this commercially available
ELISA unsuitable for screening of samples [307]. As discussed in chapter 8, a new
immunological assay to detect antibodies to EAV in horses was developed using the
microsphere assay system.

This particle array using microspheres (microbeads)

incorporates three well-developed technologies: bioassays, solution-phase microspheres
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and flow cytometry. The microsphere immunoassay (MIA) has several advantages over
traditional ELISAs: accuracy, high sensitivity and specificity, reproducibility, highthroughput sample analysis and multiplex capability. In our study, the assay was based
on recombinant structural proteins with putative antigenic regions.

Among tested

recombinant structural proteins, either full-length or partial, GP555-98 MIA showed the
highest sensitivity and specificity of 92.6% and 92.9%, respectively. Currently, we are in
the process of maximizing the sensitivity of this assay by incorporating a cocktail of
recombinant EAV proteins including structural and nonstructural proteins. Hopefully,
the new strategy will improve the sensitivity and specificity of the assay and it can be
used as a reliable serological diagnostic test to detect antibodies to EAV.

1.12. PREVENTION AND TREATMENT OF EQUINE VIRAL ARTERITIS

1.12.1. Vaccine
The development of a safe and effective vaccine against an infectious disease is
always of paramount importance in preventing a disease outbreak and minimizing
economic losses. The modified live virus (MLV) vaccine against EVA was developed
many years ago following serial passage (P266) of the experimentally derived Bucyrus
strain of EAV in horse kidney (HK), rabbit kidney (RK) and equine dermal (ED) cells
[62,308]. This attenuated strain of virus did not show any reversion to virulence after
five consecutive passages in horses [264,267]. Experimental vaccination studies have
been performed to ensure the safety of the vaccine for use in stallions [309,310].
However, vaccination of pregnant mares is not recommended especially in the last
trimester of pregnancy. The commercial modified live virus vaccine, ARVAC® (passage
history HK-131, RK-111 and ED-24), and the strains of earlier passage history were
shown to be effective for protection against disease [264,266,267,309]. Vaccination
studies using the MLV showed that a single dose of vaccine stimulates only low,
transient levels of VN antibodies; however, additional doses boost antibody levels with
titers maintained for at least 9-12 months [193,310,311]. Similarly, formalin-inactivated
virus vaccine without adjuvant was shown to induce high titers of VN antibodies after
repeated doses [269,270,312,313].

The modified live virus vaccine, ARVAC® is
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currently in use in North America, while the adjuvanted killed virus vaccine,
ARTERVAC®, is approved for use in several European countries.
Current serological tests cannot discriminate between naturally infected and
vaccinated horses. Therefore, an effort was undertaken to develop vaccines that might
make such discrimination possible e.g. sub-unit vaccine.
DNA vaccination using GP5 and N proteins of EAV has been tested using mice
[314]. The highest VN antibodies were induced when animals were vaccinated with
plasmid DNA encoding ORF5 [314]. Later, a DNA vaccine expressing ORFs 2, 5, and 7
in combination with equine interleukin-2 was tested in horses [315]. After the initial
immunization, three boosters were administered at two-week intervals. All vaccinated
horses developed high VN antibody titers regardless of age and VN antibodies were still
detectable over a year later [315]. The N-terminal ectodomain (aa 18-122) of GP5
expressed in bacterial cells induced higher neutralizing antibody titers compared to other
GP5 polypeptides in ponies [155].
Balasuriya et al. [154] explored the possibility of using alphavirus replicon
particles (VRP) co-expressing GP5/M as a vaccine and of inducing protective immunity
in horses. Previously, they established that VRP expressing GP5/M heterodimer can
induce neutralizing antibodies in mice. This study showed that the VRP system could be
used as a strategy for developing a vaccine against EAV and other viral pathogens.

1.12.2. Antivirals
Antiviral potentials of phosphorodiamidate morpholino oligomers (PMOs)
directed against EAV have been studied [316,317]. PMOs are single-stranded DNA
analogues [318], usually 20-25 bases in length, water-soluble and nuclease-resistant [319].
PMOs can base pair with a complementary RNA target sequence and form a steric
blockade to interfere with gene expression, particularly with translation of the genome
[319,320]. Peptide-conjugation to the PMO (P-PMO) greatly improves delivery of PMO
into cells [321]. The 5’ UTR of the EAV genome was found to contain the most sensitive
targets for inhibition with P-PMOs [317]. Treatment with an antisense P-PMO targeting
the EAV 5’-terminus at a concentration of 5-10 µM eliminated the virus from persistently
infected HeLa cells [316]. However, the efficacy of P-PMO against EAV in vivo remains

51

to be evaluated. Moreover, several carbohydrate-binding agents such as plant and nonplant lectins have been shown to have antiviral activities against nidoviruses [322]. It has
also been reported that EAV could not be propagated in 100 U/ml recombinant equine
IFN-γ when 100 TCID50 of infectious virus was inoculated into horse cells [323].
Furthermore, horse cells transfected with small interfering RNA (siRNAs) targeting the
ORF1ab prior to infection with EAV drastically reduced virus titers in cell culture [324].
Although the antiviral effects shown in vitro are promising, in vivo application of the
above mentioned antiviral agents may be limited due to the large body weight of horses
and the costs involved.

1.13. RECENT ADVANCES IN EAV RESEARCH AND FUTURE DIRECTIONS

1.13.1. Reverse genetics
The naked genome of a positive-strand RNA virus is infectious: it serves as an
mRNA for translation of viral replicase, thus, infection starts by a simple transfection of
the genome into the host cell. Construction of full-length cDNA clones has greatly
enhanced our understanding of RNA virus replication and gene expression by
manipulating the genetic information. They can serve as potential tools for fundamental
studies of virus replication and pathogenesis.
To date, the first two cDNA clones of the original Bucyrus strain were derived
from a highly cell culture adapted strain [325,326] and one of these clones, pEAV030
(GenBank accession number: Y07862) was found to be attenuated in horses [327]. The
third clone was derived from a horse adapted, experimentally derived VBS strain of EAV
[328]. The recombinant virus generated from this infectious cDNA clone (rVBS) causes
severe disease in experimentally infected horses [328]. Recently, a full-length cDNA
clone of MLV has been constructed [329]. Infectious RNAs can be produced in vitro
from full-length EAV cDNA clones using T7 RNA polymerase.
Availabililty of EAV cDNA clones have greatly increased our knowledge of
molecular characterization of genetic expression and replication of EAV using reverse
genetics technology. Balasuriya et al. (2004) employed an infectious cDNA clone and
reverse genetics technology to generate a panel of chimeric and mutant viruses by means
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of site-directed mutagenesis and to characterize neutralization determinants of EAV [69].
However, manipulation of the genome of arteriviruses is complicated due to the compact
and overlapping gene arrangement. de Vries et al. (2000) investigated the importance of
the overlapping gene organization in the virus life-cycle by constructing a series of
mutant full-length cDNA clones in which EAV ORFs 4/5 or ORFs 5/6 or ORFs 4/5/6
were separated [325]. RNA transcribed from each of these plasmids was infectious,
indicating that the overlapping gene arrangement is not crucial for viability of the virus.
The fact that small changes in the spacing between ORFs 4/5 and ORFs 5/6 mutant
viruses have only a limited effect on virus yields, was a big advantage for generation of
recombinant chimeric viruses between virulent and attenuated strains of EAV. Genes
encoding structural and nonstructural proteins are often interchanged between strains of
EAV of differing virulence and are used to study virulence determinants, mechanisms of
pathogenesis and persistent infection [236,330,331].

Assessment of viral proteins

involved in T lymphocyte tropism is described in this dissertation (chapter 2).
EAV cDNA clones have also been used as a vector for heterologous gene
expression, such as enhanced green fluorescence protein (eGFP) [332].

The infectious

recombinant EAV expressing GFP (EAV-GFP2) from its replicase had similar growth
characteristics to those of the wild-type virus. The recombinant virus EAV-GFP2 is a
convenient tool for basic and applied research. The same approach, namely insertion of a
foreign gene in the arterivirus replicase gene for intracellular expression, could be used
for vaccine development.
It is clear that infectious clones and reverse genetics are valuable and powerful
tools that can increase our understanding of many aspects of the viral infection process
and life cycle, as well as virulence. Specifically, it offers possibilities for exploring
vaccine production as well as vector development.

1.14. HOST-VIRUS INTERACTION AND GENOMIC STUDIES
Viruses constantly adapt to and modulate the host environment to their advantage
during replication and propagation. Therefore, virus interaction with host target cells is
complex and it is possible that almost every step of the virus infection cycle may rely on
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the recruitment of cellular proteins and basic machineries by viral proteins. Moreover, as
a virus that induces persistent infection, EAV could have developed strategies to
overcome the antiviral activity of the host factors, possibly through its own set of viral
proteins by modulating the cellular environment. Therefore, dissecting the molecular
interaction between the host and EAV is key to understanding the pathogenesis of EAV
and to develop strategies to control EAV replication.
For initial host cell attachment and entry, the virus uses attachment factors and
cellular receptors as yet to be identified for EAV. Subsequently, EAV penetrates into the
cell by a clathrin-dependent endocytosis and low pH is required in the endocytic
compartments [82].

Similarly, PRRSV also utilizes a low pH-dependent endocytic

pathway to enter cells, most likely clathrin-dependent endocytosis [333]. It is not clear
whether there are other means of entry for EAV; however, the clathrin-mediated pathway
is the only mechanism of EAV entry that has been reported so far. Still remaining to be
identified are the factors required for fusion of endosomal membrane and viral envelope
and the subsequent uncoating step that are both essential steps for releasing the viral
genome into the cytoplasm. Following uncoating, the genome is translated and following
proteolytic processing of the replicase polyprotein, viral RNAs are synthesized and are
used as templates for genome replication.

In addition, transcription of subgenomic

mRNAs that encode the structural proteins occurs. Arteriviruses acquire their envelope
by budding preformed nucleocapsids into the smooth endoplasmic reticulum and/or the
Golgi complex [101,102,136]. After budding, virions accumulate in intracellular vesicles
which are transported to the plasma membrane for release of progeny virus. However,
our knowledge about viral proteins that interact with the cytoplasmic molecules during
this process is very limited.
In addition to regulating cellular factors to support efficient replication of the
virus itself, viruses have also evolved with a view to counteracting the host innate and
adaptive immune responses. In the last several years, it has been increasingly clear that
viruses have evolved multiple strategies to escape the IFN system, which is the first line
of defense to virus infection. They either inhibit IFN synthesis, bind and inactivate
secreted IFN molecules, block IFN-activated signaling, or disturb the action of IFNinduced antiviral proteins.
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With the advent of genomic tools, it became possible to study virus-host
interactions at the molecular level. Many new methodologies have been developed in
genomic and proteomic fields of research to identify host molecules that closely interact
during the virus life cycle. Thus, the “genomics revolution” offers high-throughput tools
to study the complex virus-host interaction. Microarray technology has been extended
inter alia to genotyping of the host (SNP analysis). Therefore, genetic and genomic
technologies offer ample opportunities to discover the mechanisms of virus infections
and virus interaction with the host, which will have great implications for vaccine
development and drug design.
Over the past few years, autoimmune disease and human infectious diseases have
been investigated extensively in genome-wide association studies (GWAS). Researchers
have used a variety of approaches to investigate how the genes identified in GWAS relate
to disease pathogenesis. Studies revealed links between disease developments to regions
of the host genome that are involved in host-virus interactions. The field of interaction
between EAV with host factors is discussed in chapter 3. We believe that some of host
factors found during the study directly or indirectly interact with EAV to influence its
replication.

1.15. SCOPE AND OUTLINE OF DISSERTATION

A virus is a small infectious agent that can replicate only inside of living cells of
organisms; in other words, it depends solely on the host/cellular machinery to make new
products. Therefore, successful infection depends on the interaction between the host and
virus that are complex and multifactorial. At the molecular level, interactions that occur
between cellular and viral gene products determine host susceptibility to infection. The
series of events that occur during viral infection in a host may result in a disease that is
the outcome of the effects of virus replication in the host and the host defense system.
Thus, elucidating the genetic and functional roles that viral proteins play during
productive viral infection as well as studying the host immune response to combat the
viral infection are critical to preventing and treating viral diseases.
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The objective of this study was to characterize the virus-host interactions in EAV
infection by combining contemporary molecular biology techniques and host genomic
analysis using GWAS. The interaction between the virus and the host is important for
viral replication, virulence and pathogenesis. The availability of full-length infectious
cDNA clones and reverse genetic systems greatly facilitates the functional analysis of
viral proteins in relation to cellular tropism and the immune response. The interactions of
viral structural proteins that determine the host cell tropism is discussed first, and
possible genetic and host cell factors that determine susceptibility/resistance of equine
PBMCs to EAV infection are then addressed. The recent availability of the equine
genome sequence and development of genome-wide screening technologies offer
unparalleled

opportunities

to

identify

variants

associated

with

increased

susceptibility/resistance to infectious disease agents such as EAV. Understanding how
cellular proteins interact with viral RNA or viral proteins, as well as their role in viral
infection, will allow for better characterization of the mechanisms of EAV pathogenesis
and persistent infection in stallions.

Furthermore, the findings from this study should

allow the design of novel antiviral agents based on these interactions and appropriate
preventive measures.
Chapter 1, literature review, provides a broad perspective on the molecular
biology of EAV and EVA in horses.
Chapter 2 investigates the altered tropism of EAV VBS during extensive cell
culture passage that resulted in the modified live virus vaccine strain for equine CD3+ T
lymphocytes and CD14+ monocytes. Evaluation of chimeric viruses demonstrates that
cellular tropism in PBMCs is determined by the amino acid sequence of viral envelope
proteins. Combined interactions of both major (GP5 and M) and minor (GP2, GP3 and
GP4) envelope proteins of the EAV VBS are needed for efficient infection of CD3+ T
lymphocytes (predominantly CD4+ T lymphocytes) and CD14+ monocytes.
Chapter 3 describes the identification of a distinct phenotypic trait that can be
used as a marker to divide equine populations, regardless of breed, into susceptible and
resistant groups based on dual color flow cytometric analysis of CD3+ T cells infected
with EAV.

The GWAS demonstrates the putative candidate genes associated with

susceptibility/resistance of CD3+ T lymphocytes to EAV are located on horse
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chromosome 11. Biological pathways analysis reveals several cellular genes within this
region encoding proteins associated with virus attachment and entry, cytoskeletal
organization and NFκB pathways that may be associated with the trait responsible for the
in vitro susceptibility/resistance of CD3+ T lymphocytes to EAV infection. The data
presented in this study demonstrate a strong association of certain genetic markers with
de facto proof that the trait is under genetic control.
Chapter 4 addresses whether the differences in the susceptibility or resistance of
CD3+ T cells in vitro correlate with development and severity of clinical signs in vivo.
Horses were divided into two groups based on their in vitro CD3+ T cell susceptible or
resistant phenotype and challenged with the recombinant EAV VBS. The data show that
there was a significant difference between the two groups of horses in terms of cytokine
mRNA expression and increased clinical signs in horses possessing the in vitro CD3+ T
cell resistant phenotype. Thus, there was an inverse correlation between the in vitro
susceptibility or resistance phenotype of CD3+ T lymphocytes and the variable
clinical/cytokine expression responses observed in horses following infection with EAV.
This study provides further insight into the variation in clinical signs seen among horses
after infection with virulent strains of EAV.
Chapter 5 establishes a correlation between susceptibility of CD3+ T lymphocytes
to EAV infection and establishment of persistent infection in stallions. The data suggest
that carrier stallions that have the phenotype of susceptible CD3+ T lymphocytes to EAV
infection may represent those at higher risk of becoming persistently infected compared
to stallions that do not possess this phenotype. The in vitro assay described is currently
the most precise method for determining the phenotype. Findings from this study will
allow us to develop diagnostic tools to predict possible carrier stallions of EAV and
prevent further spread of the virus.
Chapter 6 investigates the effect of EAV on type I IFN production and signaling.
IFN-β mRNA level in equine endothelial cells (EECs) infected with EAV VBS strain was
not increased compared to that in mock-infected cells; whereas Sendai virus infection
strongly induced production of IFN-β mRNA. Protein levels determined by IFN bioassay
provided additional confirmation of this finding. Among 12 nonstructural proteins, nsp1
exhibited the strongest inhibitory effect, namely the ability to inhibit both IFN synthesis
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and signaling. Based on these findings, we propose that failure to induce type I IFN in
infected cells may allow the virus to subvert the equine innate immune response, and
nsp1 may play a critical role in inducing this effect.
Chapter 7 addresses discovery of a novel short coding sequence in the 3’proximal end of the EAV genome, named ORF5a. Its biological significance in the EAV
life cycle was investigated using EAV reverse genetics systems. The effect of ORF5a
knockout mutant was independently confirmed using two molecular clones, the
pEAV515 and pEAVrVBS of the EAV VBS. This study suggest that the ORF5a protein
may be the eighth structural protein of EAV, although further studies are needed to obtain
more detailed information into its yet unknown function.
Chapter 8 describes development and validation of an MIA to detect equine
antibodies to the major structural proteins of EAV. Of the eight recombinant proteins,
the partial GP555-98 protein showed the highest concordance with the VNT.

The

sensitivity and specificity of the MIA were 92.6% and 92.9%, respectively. The GP555-98
MIA and VNT test outcomes correlated significantly (r =0.84; p-value <0.0001).
Although the GP555-98 MIA is less sensitive than the standard VNT, it has the potential to
provide a rapid, convenient and more economical test for screening equine sera for the
presence of antibodies to EAV with the VNT used as a confirmatory assay.
Chapter 9 describes evaluation of the humoral immune response of horses to each
of the nonstructural proteins (nsps) of EAV by ORFs 1a and 1b of the viral genome. To
characterize the humoral immune response to EAV nsps, serum samples from horses that
were

seropositive

to

EAV

were

reacted

with

recombinant

proteins

in

immunoprecipitation assays. The data showed that nsp2, nsp5 and nsp12 were the most
immunogenic proteins of the nsps. Information from this study will be used in ongoing
efforts to develop improved methods for the serologic diagnosis of EAV infection in
horses.

Copyright © Yun Young Go 2011
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CHAPTER TWO

Complex Interactions Between the Major and Minor Envelope Proteins of Equine
Arteritis Virus Determine its Tropism for Equine CD3+ T Lymphocytes and CD14+
Monocytes
J. Virol. 2010, 84(10): 4898-911
Reprinted with permission

2.1. SUMMARY
Extensive cell culture passage of the virulent Bucyrus (VB) strain of equine
arteritis virus (EAV) to produce the modified live virus (MLV) vaccine strain has altered
its tropism for equine CD3+ T lymphocytes and CD14+ monocytes. The VB strain
primarily infects CD14+ monocytes and a small subpopulation of CD3+ T lymphocytes
(predominantly CD4+ T) as determined by dual-color flow cytometry. In contrast, the
MLV vaccine strain has significantly reduced ability to infect CD14+ monocytes and has
lost its capability to infect CD3+ T lymphocytes. Using a panel of five recombinant
chimeric viruses, we demonstrated that interactions between GP2, GP3, GP4, GP5 and M
envelope proteins play a major role in determining the CD14+ monocyte tropism while
the tropism of CD3+ T lymphocytes is determined by GP2, GP4, GP5 and M envelope
proteins but not the GP3 protein.

The data clearly suggest that there are intricate

interactions among these envelope proteins that affect binding of EAV to different cell
receptors on CD3+ T lymphocytes and CD14+ monocytes. This study shows for the first
time that CD3+ T lymphocytes may play an important role in the pathogenesis of equine
viral arteritis when horses are infected with the virulent strains of EAV.
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2.2. INTRODUCTION
Equine arteritis virus (EAV) is a small enveloped virus with a positive-sense,
single-stranded RNA genome of 12.7 kb that belongs to the family Arteriviridae (genus
Arterivirus, order Nidovirales), which also includes porcine reproductive and respiratory
syndrome virus, simian hemorrhagic fever virus, and lactate dehydrogenase-elevating
virus of mice [7,34]. The EAV genome includes nine known functional open reading
frames [58]. Open reading frames (ORFs) 1a and 1b encode two replicase polyproteins
(pp1a and pp1ab) that are post-translationally processed by three ORF1a-encoded
proteinases (nsp1, 2, and 4) to yield at least 13 nonstructural proteins (nsp1-12, including
nsp 7α and 7β [34,66,113], and the remaining seven ORFs (2a, 2b and 3-7) encode
structural proteins of the virus. These include four minor envelope proteins (E, GP2,
GP3, and GP4 encoded by ORFs 2a, 2b, 3 and 4, respectively), two major envelope
proteins (GP5 and M encoded by ORFs 5 and 6) and the highly conserved nucleocapsid
protein (N encoded by ORF7) [93]. The two major envelope proteins GP5 and M form a
disulfide-linked heterodimer [67,68] and the three minor envelope proteins GP2, GP3 and
GP4 form a covalently associated heterotrimeric complex in the virion [140,144]. By
independently knocking out the expression of each structural protein, it was shown that
all major and minor structural proteins are required for the production of infectious
progeny virus [141].
EAV is the causative agent of equine viral arteritis (EVA) [185,195].
Geographically and temporally different strains of EAV vary in the severity of the
clinical disease they induce and in their abortigenic potential [77,78,216,224]. While
most EAV infections are asymptomatic, some infected horses can exhibit clinical
manifestations such as an influenza-like illness, abortion in pregnant mares, and
pneumonia or pneumoenteritis in neonatal foals [77,194,202,203,208,244,334,335].
Following experimental infection of horses by the respiratory route, the virus initially
replicates in both macrophages and endothelial cells in the lung [187,237]. EAV is then
transported to the draining lymph nodes, where it replicates and is released into the blood
and lymphatic system for transportation throughout the body. The virus infects the
smaller blood vessels, especially the arterioles, causing a panvasculitis [187,213,242]. A
number of studies have demonstrated that different strains of EAV vary significantly in
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their pathogenicity, with very different clinical outcomes upon experimental inoculation of
horses [154,240,327,328,334]. The horse-adapted Bucyrus (VB) strain of EAV is highly
velogenic and causes severe clinical disease with a case-fatality rate of 50-60% under
experimental conditions [213,239]. Horses inoculated with virulent strains of EAV (e.g. VB
and recombinant VB [rVBS] strains, and KY84) develop severe lymphopenia with a high
titered viremia (6x103-1x105 pfu/ml) [154,213,244,328]. In contrast, horses inoculated with
the attenuated modified live virus (MLV) vaccine strain, or other avirulent strains of EAV
(e.g. 030H and CA95G) [224,327] develop a mild, transient lymphopenia with only a very
low-titer viremia ( ≤1x101 pfu/ml) [61,62,264,265,267,336].
The modified live virus (MLV) vaccine (ARVAC®, Fort Dodge Animal Health)
that is in current use in the United States and Canada [61,264,265,267,336], was developed
by serial passage of the VB strain of EAV in primary horse kidney cells (HK131 passages),
primary rabbit kidney cells (RK111 passages) and equine dermis cells (ED24 passages)
which resulted in attenuation of the virus [62]. Previously, it has been shown that the VB
strain was fully attenuated for horses by 116th passages in primary horse kidney cells
(EAV HK116) [265,267,291]. Subsequently, EAV HK116 virus was further passaged in
HK cells for additional 15 times (HK131) and in two other cell lines (RK111 and ED24)
to obtain the MLV vaccine virus (HK131, RK111, ED24) used in this study. There are
23 additional amino acid substitutions that accumulated in GP2, GP3, GP4, GP5 and M
envelope proteins during cell culture passage of the HK116 virus to generate the current
MLV strain (ARVAC®; Table 2.1) which may have contributed to further attenuation of
the vaccine strain of EAV and increased the safety of the vaccine for horses. Recently,
using reverse genetics we showed that a chimeric virus containing the nonstructural
proteins of VB virus and the structural proteins of HK116 (rVBS/HK116 S) [331] strain
has an attenuated phenotype in horses.

The data showed that critical amino acid

substitutions in structural protein genes of HK116 virus were responsible for attenuation
of the VB strain.
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Table 2.1. Comparative amino acid analysis of rVBS, HK116 and rMLV envelope proteins
Amino acid difference
Position rVBS HK116 rMLV
ORF2a (9751-9954)
E (67)
ORF2b (9824-10507)
GP2 (227)
62
Tyr
Tyr
His
92
Ile
Thr
Thr
158
Gly
Gly
Glu
223
Arg
Pro
Pro
ORF3 (10306-10797)
GP3
80
Leu
Leu
Val
(rVBS and HK116: 163;
123
Leu
Leu
Ser
rMLV 168)
160
Cys
Cys
Tyr
164
Stop
Stop
Gln
165
Phe
166
Tyr
167
Leu
168
His
169
Stop
ORF4 (10700-11158)
GP4 (152)
4
Tyr
Tyr
Ser
ORF5 (11146-11913)
GP5 (255)
69
Leu
Leu
Pro
72
Gln
Gln
Lys
81
Asn
Asp
Asp
100
Ser
Gly
Gly
104
Asn
Gly
Gly
106
Met
Met
Val
170
Ala
Ala
Ser
214
Gly
Gly
Glu
ORF6 (11901-12389)
M (162)
38
Leu
Leu
Ser
49
Phe
Phe
Leu
71
Val
Val
Ala
81
Met
Thr
Thr
122
Ile
Val
Val
150
Phe
Phe
Cys
154
Ala
Thr
Met
Note: Amino acid substitutions located in predicted ectodomain on each protein are
ORF

Protein (aa length)

indicated in bold. All potential N-glycosylation sites are conserved in GP2 (aa 155), GP3
(aa. 28, 29, 49,96, 106, 118) and GP4 (aa. 33, 55, 90).

To enhance fundamental understanding of the pathobiology of EAV infections it is
important to identify those peripheral blood mononuclear cells (PBMCs) that are most
closely associated with the virus during vascular transport and how genetic changes
associated with an attenuated phenotype alter the dynamics of virus/host-cell relationships in
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blood. Thus, we hypothesized that VB and MLV strains differ in their ability to infect
PBMCs and that the altered tropism of the attenuated MLV strain of EAV in PBMCs is
associated with amino acid changes in the viral proteins. To test this hypothesis we used
three previously described recombinant viruses (rVBS [328], rVBS/HK116 S [331] and
rMLV [329]), as well as four newly generated chimeric viruses (rVBS/MLV S, rMLV/VBS
S, rMLV/VBS 234 and rMLV/VBS 56) and infected ex vivo preparations of PBMCs
collected from horses. The data suggested that the difference in cellular tropism and
virulence phenotype of VB and MLV strains is associated with the collective interactions of
both major (GP5 and M) and minor (GP2, GP3 and GP4) envelope proteins of EAV.
Furthermore, this study also demonstrated that CD3+ T lymphocyte tropism is primarily
determined by amino acid substitutions in the GP2, GP4, GP5 and M envelope proteins but
not the GP3 minor envelope protein.

However, the macrophage tropism is mainly

determined by intricate interactions among GP2, GP3, GP4, GP5 and M envelope proteins
of the virus.

2.3. MATERIALS AND METHODS
Cell lines
Equine pulmonary artery endothelial cells (EECs) were maintained in Dulbecco’s
modified essential medium (Mediatech, Herndon, VA) with sodium pyruvate, 10% fetal
bovine

serum

(Hyclone

Laboratories,

Inc.,

Logan,

UT),

100U/ml

of

penicillin/streptomycin and 200mM L-glutamine [154,213,328]. The rabbit kidney cells
(RK-13, ATCC CCL-37; American Type Culture Collection, Manassas, VA) were grown
in Eagle’s minimum essential medium with 10% ferritin supplemented bovine calf serum
(Hyclone Laboratories, Inc., Logan, UT) and 100U/ml of penicillin/streptomycin (Gibco,
Carlsbad, CA).

Horses
A total of 10 horses of different breeds (Thoroughbreds, n=4; Standardbreds, n=2;
mixed breeds, n=4) were used in this study. The horses were maintained on pasture at the
Department of Veterinary Science’s Maine Chance Farm, Lexington, KY. All horses
were confirmed seronegative for EAV neutralizing antibodies using previously described
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protocols [337]. The horses were clinically evaluated prior to collection of blood samples
for isolation of peripheral blood mononuclear cells. Furthermore, complete blood counts
and differential counts were performed to establish that all animals had normal blood cell
values. Blood samples were collected according to a protocol approved by Institutional
Animal Care and Use Committee at University of Kentucky, Lexington, KY.

Antibodies
To determine the phenotype of EAV infected mononuclear cells, the following
monoclonal antibodies (MAbs) directed against different cell-type-specific surface
molecules were used in this study: anti-equine CD3+ T lymphocytes (UC F6G; kindly
provided by Dr. Jeff Stott, University of California at Davis; [338], anti-equine CD4+ T
lymphocytes and anti-equine CD8+ T lymphocytes (CVS4 and CVS8, respectively;
Serotec, Raleigh, NC; [339,340]. A MAb specific for human CD14 (Alexis Biochemicals,
Lausen, Switzerland) that cross-reacts with equine CD14 [341] was used to identify
equine monocytes and R-phycoerythrin (R-PE) conjugated anti-human CD21 (B-ly4; BD
Pharmingen, San Jose, CA) previously shown to cross-react with equine B cells was used
[342]. R-phycoerythrin (R-PE)-conjugated F(ab’)2 fragment of goat anti-mouse IgG1
(Southern Biotech, Birmingham, AL) was used as a secondary antibody.
To detect EAV antigens in infected cells, MAbs against EAV nonstructural
protein-1 (nsp1; MAb 12A4) and nucleocapsid protein (N; Mab 3E2) were used
[213,306]. Mouse ascitic fluid containing MAbs 12A4 and 3E2 were purified using a
Melon™ Gel IgG Spin Purification Kit (Pierce, Rockford, IL). Purified IgG was directly
conjugated to Alexa Fluor® 488 (Invitrogen, Carlsbad, CA) following manufacturer’s
instructions. Briefly, purified IgG from MAbs 12A4 and 3E2 were diluted with PBS to a
concentration of 2 mg/ml and 1 M sodium bicarbonate (pH 8.3) was added.
Subsequently, diluted IgG solution was incubated with Alexa Fluor® 488 reactive dye for
1 h at room temperature in the dark with slow stirring. The reaction mixture was loaded
onto a fine size exclusion purification resin column for separation of labeled antibodies
from unincorporated dye.

Fractions of Alexa Fluor® 488 labeled antibodies were

collected and stored at 4°C. To detect nonspecific binding, mouse IgG1 (MOPC; Sigma,
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St. Louis, MO) and Alexa Fluor® 488 conjugated mouse IgG1 isotype controls (Invitrogen,
Carlsbad, CA) were used.

Viruses
Two strains of EAV, the virulent Bucyrus (VB) strain (ATCC VR-796; [185,195]
and the modified live virus (MLV) vaccine strain (ARVAC®, Fort Dodge Laboratories,
Fort Dodge, IA, [62,309], were used for in vitro study of identifying the EAV target cell
population in PBMCs. Each virus was propagated once in EECs to prepare high titered
working stocks as previously described [343,344]. Briefly, EECs infected with each
virus were frozen at -80°C when 90-100% cytopathic effect (CPE) was observed. Cell
lysates were clarified by centrifugation (500 ×g) at 4°C for 15 min, followed by
ultracentrifugation (Beckman Coulter, Miami, FL) at 121,600 ×g through a 20% sucrose
cushion in NET buffer (150 mM NaCl, 5 mM EDTA, and 50 mM Tris-HCl, pH 7.5) at
4°C for 4 h to pellet the virus. Purified preparations of each strain of EAV were
resuspended in phosphate buffered saline (PBS; pH 7.4) and frozen at -80°C. Virus
stocks were titrated by standard plaque assay in RK-13 cells and titers were expressed as
PFU/ml [291].

Construction of chimeric cDNA clones of EAV and recovery of recombinant viruses
Infectious cDNA clones of the virulent VB strain of EAV and modified live virus
(MLV) vaccine strain of EAV (pEAVrVBS and pEAVrMLV, respectively) were recently
constructed in our laboratory [328,329]. The in vitro and in vivo characterization of these
viruses showed that they are phenotypically indistinguishable to that of their respective
wild-type parental viruses. Five chimeric infectious cDNA clones, pEAVrVBS/HK116 S,
pEAVrVBS/MLV S, pEAVrMLV/VBS S, pEAVrMLV/VBS 234 and pEAVrMLV/VBS
56 were constructed by using standard molecular biological techniques [236,328,331].
The recombinant chimeric infectious cDNA clone pEAVrVBS/HK116 S was generated
by substituting the genes (ORFs 2a to 7) encoding the structural proteins of pEAVrVBS
by the corresponding genes from the HK116 virus [331]. The recombinant chimeric
infectious cDNA clone pEAVrVBS/MLV S was constructed by replacing the structural
protein genes (ORFs 2a to 7) of the infectious cDNA clone pEAVrVBS [328], which was

65

derived from the VB strain of EAV, with the corresponding genes of pEAVrMLV clone
[329]. A similar approach was used to construct the recombinant infectious cDNA clones
pEAVrMLV/VBS S where the structural protein genes (ORFs 2a to 7) of the infectious
cDNA clone pEAVrMLV were substituted with the corresponding genes of the
pEAVrVBS clone; the pEAVrMLV/VBS 234 clone in which the minor envelope protein
genes (ORFs 2a to 4) of the rMLV were replaced with the corresponding genes of
pEAVrVBS; and the rMLV/VBS 56 clone in which the major envelope protein genes
(ORFs 5 and 6) of the pEAVrMLV were replaced with the corresponding genes of
pEAVrVBS.
The recombinant viruses, rVBS, rMLV, rVBS/HK116 S, rVBS/MLV S,
rMLV/VBS S, rMLV/VBS 234 and rMLV/VBS 56, were generated by in vitro
transcription of infectious viral RNAs from XhoI-linearized full-length infectious cDNA
clones and electroporated into EECs following previously described protocols [328].
Virus particles were harvested from cell culture supernatant at 48 to 72 h after
electroporation when cytopathic effect (CPE) was evident, clarified of cell debris by
centrifugation, and stored at -80°C in single-use aliquots (passage 0 [P0]). Recombinant
viruses (P0) harvested from transfected EECs were used to prepare high titered working
stocks by passing one more time in EECs (P1) as described above and purified viruses
were used for in vitro infection studies.

Comparative amino acid sequence analysis and membrane topology prediction of
EAV envelope proteins
The published sequences of rVBS, rMLV, HK116 were downloaded from the
GenBank

database

(http://www.ncbi.nlm.nih.gov/

Genbank/index.html;

accession

numbers DQ846751 [328], EU586275 [329], and EU586274 [331], respectively). ORFs
2a, 2b, 3, 4, 5 and 6 were translated into amino acid sequences and aligned with the
Vector NTI Advance™ 11 software (Invitrogen, Carlsbad, CA). Prediction of membrane
topology for viral envelope proteins was performed using four most commonly used
topology

prediction

methods

available

(http://www.psipred.net/psiform.html)

on

the

[345,346],

(http://www.cbs.dtu.dk/services/TMHMM/)
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[347],

Internet:

PSIPRED
TMHMM
TMPred

(http://www.ch.embnet.org/software/TMPRED_form.html),

TOPPRED

(http://www.bioweb.pasteur.fr/seqanal/interfaces/toppred.html) [348]. All user-adjustable
parameters were left at their default values.

Preparation of peripheral blood mononuclear cell (PBMC) cultures
Blood (150-200ml) was collected aseptically from each of 10 horses using
vacutainer tubes containing 15% EDTA solution (Kendall Healthcare, Mansfield, MA).
Peripheral blood mononuclear cells (PBMC) were isolated from the buffy coat fraction
by centrifugation through Ficoll-Paque Plus™ (Amersham Biosciences, Piscataway, NJ)
at 500 ×g for 30 min at 25°C. The PBMC layer was collected, washed twice with PBS
(pH 7.4) by centrifuging at 100 ×g for 10 min to eliminate the platelets. The cells were
resuspended in complete RPMI (c-RPMI) 1640 medium (Gibco, Carlsbad, CA)
supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories,
Logan, UT), 2 mM glutamine, 100U/ml penicillin/streptomycin and 55 µM 2mercaptoethanol and counted using a Vicell Counter-XR (Beckman Coulter, Miami, FL).
The adherent and non-adherent cell populations were separated by plating out the PBMCs
in 100 mm tissue culture dishes (Corning, Corning, NY).

Briefly, the cells were

incubated at 37°C for 4 h to allow adherent cells to attach, and after incubation, the
unattached cells were removed, centrifuged and resuspended to be counted and plated out
as a non-adherent cell population in 100 mm tissue culture dishes containing 5ml of cRPMI medium. The adherent cells were washed twice with PBS to remove remaining
non-adherent cells and replaced with 5 ml of fresh c-RPMI medium. Both adherent and
non-adherent cells were incubated at 37°C until infected with EAV.

Sorting of lymphocytes and monocytes
Positive selection of five different cell populations (CD3+, CD4+, CD8+, CD21+
and CD14+ cells) was performed using aseptically obtained horse blood and a MoFlo Cell
Sorter (Dako Cytomation, Glostrup, Denmark). Briefly, 5 × 107 PBMCs were incubated
with specific MAbs against equine CD3, CD4 or CD8 for T lymphocytes and human
CD14 that cross-react with equine monocytes. Equine B lymphocytes were sorted by
two-way sorting using R-PE conjugated anti-human CD21 antibody that cross react with
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equine B lymphocytes on cells already incubated with anti-equine CD8 MAb.

All

antibodies were incubated on ice in sorting buffer (1% FBS in Hanks’ Balanced Salt
Solution, pH 7.4; Gibco, Carlsbad, CA) for 20 min. After incubation with primary
antibody, cells were washed and stained with goat anti-mouse IgG1-R-PE (Southern
Biotechnology Inc., Birmingham, AL) or goat anti-mouse IgG-FITC (Caltag Laboratories,
Burlingame, CA) on ice for 20 min.

In vitro infection of lymphocytes and monocytes
Cultures of lymphocytes and monocytes were infected with either wild-type (VBS
and MLV) or recombinant viruses (rVBS, rMLV, rVBS/HK116 S, rVBS/MLV S,
rMLV/VBS S, rMLV/VBS 234 and rMLV/VBS 56) of EAV at an m.o.i. of 2. As
negative controls, mock infected lymphocytes and monocytes were cultured under
identical conditions.

Dual-color immunofluorescence staining and flow cytometry
For two color immunofluorescence staining of wild-type or recombinant virus
infected cells, lymphocytes (1×106 cells) were incubated on ice for 30 min with MAbs
specific for equine CD3+, CD4+ or CD8+ T cells and R-PE conjugated anti-human CD21
antibody for B cells. Blood-derived monocytes (1×106 cells) were stained with antihuman CD14 monoclonal antibody. After washing, cells were incubated with secondary
R-PE-conjugated goat anti-mouse IgG1 (Southern Biotech, Birmingham, AL) for 30 min
on ice. After washing to remove unbound secondary antibody, cells were fixed with 4%
paraformaldehyde and then washed once in PBS-saponin buffer (PBS [pH 7.4]
supplemented with 1% FBS, 0.1% saponin and 0.1% sodium azide).

Intracellular

staining for EAV antigen was performed using an Alexa Fluor® 488 conjugated anti-EAV
nsp1 MAb 12A4 or anti-EAV N MAb 3E2 in PBS-saponin buffer and incubated on ice
for 30 min. After incubation, washed cells were resuspended in PBS containing 0.5%
paraformaldehyde for two-color cytometric acquisition using a FACSCalibur (Becton
Dickinson, San Jose, CA). Lymphocytes and monocytes were gated and selected based
on forward and side-scatter parameters of analysis. Cells were evaluated by a two-color
plot of anti-EAV antigen (FL-1) vs. cell surface antigen (FL-2), and the percentage of
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CD3+, CD4+, CD8+, CD21+ or CD14+ and EAV antigen positive cells was determined by
CellQuest™ quadrant statistics.

Results were expressed as the percentage of

lymphocytes or monocytes infected with EAV, after subtraction of the non-specific
staining of mock-infected cells.
Virus growth curve and quantitative EAV real-time TaqMan® RT-PCR assay
Sorted CD3+, CD4+, CD8+ T lymphocytes, CD21+ B lymphocytes and CD14+
monocytes were infected with VB or MLV strains of EAV at an m.o.i. of 2. Tissue
culture supernatants were collected at 0, 1, 6, 12, 18, 24, 36, 48, 60 and 72 hpi for onestep growth curve and quantitative EAV real-time TaqMan® RT-PCR assays. For onestep growth curve analysis, virus titers in tissue culture supernatants were determined
according to the method of Reed and Muench [349], and expressed as 50% tissue culture
infective dose (TCID50)/50 μl.

To detect EAV nucleic acids, a one-tube real-time

TaqMan® RT-PCR assay was performed using the TaqMan® One-Step RT-PCR Master
Mix (Applied Biosystems, Foster City, CA) in an Applied Biosystems 7500 Fast RealTime PCR System according to a previously published protocol [299,302]. The copy
numbers of EAV molecules were determined by absolute quantification with an IVT
ORF7 RNA standard curve as described previously [299,302].

Statistical analysis
The student’s t-test was used to establish significant difference among infected
lymphocyte subpopulations and monocytes between group A and B horses. Statistical
analysis was performed using Sigma Plot 11 (Systat Inc., Richmond, CA).

Nucleotide sequence accession numbers
The nucleotide sequences of the rVBS/HK116 S, rVBS/MLV S, rMLV/VBS S,
rMLV/VBS 56 and rMLV/VBS 234 were deposited in GenBank under the accession
numbers GU732202, GU732201, GU732200, GU732199 and GU732198, respectively.
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2.4. RESULTS
Differences in susceptibility of equine peripheral blood mononuclear cells (PBMCs)
to infection with virulent and attenuated strains of EAV
To investigate the susceptibility of equine PBMCs to virulent and attenuated
strains of EAV, PBMCs collected from ten randomly selected horses were infected either
with the VB or MLV strains of the virus. Dual fluorescent antibody staining of PBMC
cultures was performed using a panel of leukocyte differentiation antigen-specific
monoclonal antibodies (MAbs) specific for pan CD3+ T lymphocytes, CD4+ helper T
lymphocytes, CD8+ cytotoxic T lymphocytes and CD21+ B lymphocytes, as well as a
MAb specific for the EAV nsp1. Dual immunofluorescence labeling with CD3 specific
MAb and antibody against EAV nsp1 indicated that CD3+ T lymphocytes recovered from
six of the ten tested horses could be infected with the VB strain of EAV (Figure 2.1 A).
At 12 hpi, the mean percentage of CD3+ T lymphocytes double-labeled with cell surface
antibody and MAb to EAV nsp1 antigen was 0.5% (± 0.02). The mean percentage of
double-labeled CD3+ T lymphocytes increased to 5.5% (± 1.0) by 24 hpi. The EAV nsp1
antigen expression peaked with a mean percentage of 6.6% (± 0.8) of double-labeled
CD3+ T cells at 36 hpi and decreased to 4% (± 0.4) at 48 hpi. Interestingly, none of the
CD3+ T lymphocytes from the remaining four horses were infected with the VB strain of
EAV (Figure 2.1 B). Based on the phenotype of CD3+ T lymphocyte subpopulations to
in vitro infection with VB strain of EAV, the ten horses could be divided into susceptible
(Group A; 6/10) and resistant (Group B; 4/10) groups. Contrary to infection with the VB
strain, T lymphocytes from none of the 10 donor horses were susceptible to infection
with the MLV vaccine strain of EAV (Figures 2.1 A and B).
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Figure 2.1. Differences in susceptibility of CD3+ T lymphocytes to infection with VB
and MLV strains of EAV. Dual color immunofluorescence flow cytometric analysis
was performed at various hours post-infection (hpi). (A) Values represent the mean
percentage of infected CD3+ T cells (± S.E.M) with VB (black circles) and MLV (white
circles) for 6 horses with T lymphocytes susceptible to EAV VB infection (Group A).
Percentages of infected cells at the indicated times (data points on the curve) were
determined by using dot plots derived from dual fluorescence flow cytometric analyses of
cells (representative dot plots of VB infection, insets a through d; MLV infection, insets e
through h). (B) Values represent the mean percentage of infected CD3+ T cells (± S.E.M)
with VB (black circles) and MLV (white circles) for 4 horses with T lymphocytes
resistant to EAV VB infection (Group B) as determined by using dot plots derived from
dual fluorescence flow cytometric analyses of cells (representative dot plots of VB
infection, insets a through d; MLV infection, insets e through h).
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In an attempt to define the T lymphocyte subpopulation susceptible to VB
infection, lymphocytes from Group A horses were infected with the VB strain and were
stained with either CD4 or CD8 specific MAb and antibody to EAV nsp1. Similar to
CD3+ T lymphocytes, the mean percentage of double-labeled CD4+ T cells increased to
4.4% (± 0.8) by 24 hpi.

The EAV nsp1 antigen expression peaked at 36 h after

inoculation with a mean percentage of 5% (± 0.7) of double-labeled CD4+ T cells which
decreased subsequently to 2.8% (± 0.3) at 48 hpi (Figure 2.2 A). The mean percentage of
double-labeled CD8+ T cells ranged from 0.03 to 1.1% ([± 0.03 to 0.2]; Figure 2.2 B)
through to the completion of the experiment. These findings indicated that the majority
of CD3+ T lymphocytes infected with the VB strain were CD4+ T lymphocytes rather
than CD8+ T lymphocytes. Not surprisingly, in a similar experiment neither CD4+ nor
CD8+ T lymphocytes from the four horses in group B could be infected with the VB
strain of EAV (data not shown). EAV nsp1 antigen expression was not detected in the
CD21+ B lymphocyte cultures from either group A or B horses inoculated with either the
VB or MLV vaccine strains (Figure 2.2 C) indicating that B lymphocytes are not
susceptible to EAV infection. In summary, viral antigen could be detected primarily in
CD4+ T lymphocyte subpopulations from Group A horses infected with VB strain of
EAV.

These data showed that only CD4+ T lymphocytes from some horses are

susceptible to infection with the VB strain but none of them are susceptible to infection
with MLV strain indicating that attenuation of the VB strain has altered its cellular
tropism.
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Figure 2.2. Susceptibility differences between CD4+ and CD8+ T lymphocytes and
CD21+ B lymphocytes to infection with VB and MLV strains of EAV. Dual color
immunofluorescence flow cytometric analysis was performed at various time p.i. Values
represent the mean percentage of (A) infected CD4+ T cells, (B) infected CD8+ T cells
and (C) infected CD21+ B cells (± S.E.M) with VB (black circles) and MLV (white
circles) strains of EAV. Percentages of infected cells at the indicated times (data points
on the curve) were determined by using dot plots derived from dual fluorescence flow
cytometric analyses of cells (representative dot plots of VB infection, insets a through d;
MLV infection, insets e through h).
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To investigate whether monocytes are equally susceptible to infection with VB
and MLV strains of EAV, dual immunofluorescence staining was performed using MAbs
specific for CD14+ monocytes and MAb specific for the EAV nsp1. Using the adherent
cells obtained from PBMCs derived from two of each group of horses, the percentage of
CD14+ monocytes ranged from 60 to 75% depending on the preparation. Double-labeled
flow cytometric analysis showed that monocytes from all of the tested horses could be
infected with VB and MLV strains of EAV (Figure 2.3).

Figure 2.3. Infection of monocytes with the VB and MLV strains of EAV. (A and B)
Dual color immunofluorescence flow cytometric analysis was performed at various time
p.i. Values represent the mean percentage of infected monocytes (± S.E.M) with VB
(black circles) and MLV (white circles) for (A) 2 horses with T lymphocytes susceptible
to EAV VB infection (Group A) and (B) 2 horses with T lymphocytes resistant to EAV
VB infection (Group B). Percentages of infected cells at the indicated times (data points
on the curve) were determined by using dot plots derived from dual fluorescence flow
cytometric analyses of cells (representative dot plots of VB infection, insets a through d;
MLV infection, insets e through h).
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However, the mean percentage of MLV infected cells was significantly lower and
remained near the lower limit of detection throughout the experimental time course
compared to those detected in VB infected monocytes (Figures 2.3 A and B) from both
group of horses. In the case of cultures infected with the VB strain, the maximum mean
percentage of cells expressing EAV nsp1 antigen in monocytes from Group A horses
(n=2) was approximately 31.8% (± 7.2) at 12 hpi, after which it had declined sharply by
(1.8 ± 0.2%) 48 hpi (Figure 3A; Group A). Similar patterns were noted for monocytes
purified from the Group B horses (n=2; Figure 2.3 B; Group B). However, the overall
mean percentage of cells expressing EAV antigen was significantly lower in monocytes
from the Group B horses (14.3% ± 7.3 at 12 hpi and 11.3% ± 4.7 at 24 hpi) compared to
monocytes from the susceptible horses (Group A) at 12 and 24 hpi (Figures 2.3 A and B).
The mean percentage of infected monocytes in MLV inoculated cultures was minimal at
12 hpi after which it gradually increased. Although similar patterns of infection were
shown for cells derived from horses in groups A and B, the mean percentage of infected
cells in the case of the former was significantly higher than in the case of the latter
(Figures 2.3 A and B). Furthermore, these findings confirm that not only T lymphocytes
but also monocytes differ in their susceptibility to infection with VB and MLV strains of
EAV.
Expression of the structural proteins of EAV in PBMCs infected with virulent and
attenuated strains of EAV
One of the key findings of this study is the susceptibility of CD3+ T
(predominantly CD4+ T) lymphocytes of Group A horses to VB infection as determined
by the expression of the nsp1 protein. To investigate whether viral structural protein
genes are also expressed in infected cultures, two-color flow cytometric analysis was
performed using MAbs specific for cell surface markers and MAb specific for the EAV
nucleocapsid (N) protein. When T lymphocytes isolated from horses in Group A were
infected with the VB strain, both nsp1 and N protein expression were detected in CD3+,
CD4+ and CD8+ T lymphocytes (Figure 2.4, panels a through c [nsp1] and panels d
through f [N]).
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Figure 2.4. Detection of EAV nucleocapsid (N) protein expression in T lymphocytes
infected with the VB strain. The CD3+, CD4+ and CD8+ T lymphocytes from Group A
horses infected with VB and MLV strains of EAV were examined by dual-color
immunofluorescence flow cytometric analysis using MAbs against EAV nsp1 (MAb
12A4) and N (MAb 3E2) proteins and MAbs for cell specific cell surface antigens at 24
hpi. (Panels a through c) Lymphocytes infected with VB strain were stained with antiEAV nsp1 AF488 MAb and one of the specific antibodies for T lymphocytes including
MAbs to CD3, CD4, and CD8, respectively. (Panels d through f) Dot plots derived from
same cultures stained with anti-EAV N AF488 MAb and specific antibodies for CD3+,
CD4+ and CD8+ T lymphocytes, respectively. (Panels g through i) Lymphocytes infected
with MLV strain were stained with anti-EAV nsp1 MAb and specific antibodies for T
lymphocytes including MAbs to CD3, CD4, and CD8, respectively. (Panels j through l)
Dot plots derived from same cultures stained with anti-EAV N AF488 MAb and specific
antibodies for CD3+, CD4+ and CD8+ T lymphocytes, respectively.

In contrast, CD3+, CD4+ and CD8+ T lymphocytes were completely refractory to
infection with the MLV strain since neither nsp1 nor N protein expression could be
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observed in inoculated cultures (Figure 2.4, panels g through i [nsp1] and panels j
through l [N]). The data indicated that a virus replication cycle, at least up to expression
of structural proteins, occurred in VB infected T lymphocytes but not in MLV infected T
lymphocytes of Group A horses. However, release of progeny virus particles could not
be detected in VB inoculated cultures of sorted CD3+, CD4+ and CD8+ T lymphocytes
from any of tested horses based on virus one step growth curve and quantitative real-time
RT-PCR (qrRT-PCR) results (data not shown). Furthermore, we also investigated the
expression of N protein in monocytes infected with the VB and MLV strains of EAV
(Figure 2.5.A.). In contrast to T lymphocytes, expression of both nsp1 and N protein
were detected in monocytes infected with VB and MLV strains. Not surprisingly, the
percentage of monocytes expressing nsp1 and N proteins was significantly greater in VB
infected cultures (24.8% ± 4.4 and 18.3% ± 1.8, respectively [panels a and b]) compared
to the corresponding percentage of cultures infected with the MLV strain (5.5% ± 1.9 and
3.7% ± 1.8, respectively; Figure 2.5 A [panels c and d]). Additionally, viral titers and
viral nucleic acid copy numbers from sorted CD14+ monocytes inoculated with VB and
MLV strains of EAV confirmed the findings from double-staining flow cytometric
analysis (Figures 2.5.B and 2.5.C, respectively). In monocyte cultures inoculated with
the VB strain, viral titers increased gradually by 18 hpi reaching a maximum titer of
approximately 105 TCID50/50 µl at 36 hpi. After reaching this peak level, titers gradually
declined to 104 TCID50/50 µl by the final sample collection time at 72 hpi. Although,
productive viral replication also occurred in MLV inoculated monocytes, viral titers were
lower than those detected in VB inoculated cells (Figure 2.5.B). Interestingly, while
MLV titers remained low until 48 hpi, they showed a significant increase by 72 hpi. The
trends in the viral growth curves were similar to those observed in nucleic acid copy
numbers quantified by qrRT-PCR (Figure 2.5.C). Monocytes infected with the VB strain
had increased viral nucleic acid copy numbers from 18 hpi reaching a maximum after 48
hpi in both groups of horses. In contrast to VB infected monocytes, viral nucleic acid
copy numbers in monocytes infected with the MLV strain remained low throughout the
time course of the experiment, though they had started to increase at 72 hpi which was
consistent with the viral growth curve results (Figure 2.5.C). These data confirmed that
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the MLV strain replicates slower and to lower titers in monocytes compared to the VB
strain of EAV in Group A horses.

Figure 2.5. Replication of VB and MLV strains of EAV in blood-derived monocytes
of Group A horses. (A) The CD14+ monocytes infected with VB and MLV strains of
EAV were examined by dual-color immunofluorescence flow cytometric analysis using
MAbs against EAV nsp1 (12A4) and N (3E2) proteins and MAbs for cell specific cell
surface antigens at 24 hpi. (Panels a, b) Monocytes infected with VB strain were stained
with anti-EAV nsp1 MAb (panel a) or N MAb (panel b) and a specific antibody to cell
surface antigen, CD14 MAb. (Panels c, d) Monocytes infected with MLV strain were
stained with anti-EAV nsp1 MAb (panel c) or N MAb (panel d) and a specific antibody
to cell surface antigen, CD14. (B) Replication of VB (black circles) and MLV (white
circles) strains in purified monocytes. Tissue culture fluids were collected at indicated
times and viral titers were determined as log10 50% tissue culture infective dose
(TCID50)/50µl. Values shown are the mean viral titers ± S.E.M. (C) Quantification of
viral RNA copy number in cell culture fluid from purified monocytes infected with VB
(black bars) and MLV (white bars) strains using qrRT-PCR. Results are expressed as
mean (± S.E.M) values.
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Infection of CD3+ T lymphocytes and CD14+ monocytes with EAV recombinant
chimeric viruses
A marked disparity in the ability of VB and MLV strains to infect subpopulations
of susceptible CD3+ T lymphocytes and monocytes (Group A horses) suggested that there
is a clear difference in cellular tropism between the two strains. In our preliminary
studies, the recombinant viruses, rVBS and rMLV, had similar growth kinetics in equine
endothelial cells (EECs; data not shown) and an equivalent capacity for lymphocyte
infectivity as confirmed by flow cytometry analysis (Figure 2.6; panels a through d
[rVBS] and i through l [rMLV]) when compared to their respective wild-type parental
viruses, VB and MLV. To identify the viral proteins responsible for the differential
cellular tropism between VB and MLV, we attempted to assess the impact of amino acid
changes accumulated during cell culture passage of HK116 strain, which is fully
attenuated for horses as compared to the VB strain. Therefore, we used the previously
described rVBS/HK116 S chimeric virus [331] containing the structural proteins of EAV
HK116 virus in backbone of rVBS genome to infect PBMCs from Group A horses.
When susceptible T lymphocytes were inoculated with chimeric rVBS/HK116 S, the
number of T lymphocytes expressing EAV nsp1 antigen decreased significantly
compared to rVBS (2.3% to 0.2%; Figure 2.6; panels e through g). In contrast, the
percentage of infected monocytes was comparable to that using the rVBS virus indicating
that the tropism of the HK116 strain had changed for lymphocytes but not for monocytes
following 116 passages in primary horse kidney cells (Figure 2.6; panel h). In summary,
these data showed that amino acid substitutions in the structural protein genes of HK116
strain changed CD3+ T lymphocyte tropism of the virus without any significant effect on
its CD14+ monocyte tropism.
In an attempt to further identify the specific viral proteins responsible for the
differential tropism among VB, HK116 and MLV strains in equine PBMCs, we generated
a new panel of four recombinant chimeric viruses using the infectious cDNA clones of
the VB and MLV strains (rVBS and rMLV, respectively).

The panel consisted of

reciprocal chimeric viruses containing interchanged structural and nonstructural protein
genes of the VB and MLV strains (Figure 2.6). When susceptible lymphocytes and
monocytes were infected with rVBS/MLV S and rMLV/VBS S viruses, rVBS/MLV S
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did not infect any CD3+ T lymphocytes and only replicated in CD14+ monocytes at a very
low level which was identical to that observed in rMLV infection (Figure 2.6; panels m
through p).

In contrast, the rMLV/VBS S infected and replicated in both CD3+ T

lymphocytes and CD14+ monocytes similar to rVBS but there was a reduction in viral
protein expression in lymphocytes compared with that observed in cells infected with
rVBS virus (Figure 2.6; panels q through t). These results suggest that the structural
proteins of the VB strain are responsible for determining its tropism for lymphocytes and
monocytes. Furthermore, comparison of dual-color flow cytometric data of PBMCs
infected with rVBS/HK116 S and rVBS/MLV S showed significant differences in CD14+
monocyte infectivity, indicating that amino acid substitutions that occurred during further
cell culture passage of HK116 may have contributed to the change in monocyte tropism.
Taken together, the data suggest that viral tropism for CD3+ T lymphocyte and CD14+
monocyte was altered by amino acid changes in structural proteins of EAV.
To further investigate the role of minor and major envelope proteins of EAV in
cellular tropism, additional recombinant viruses, rMLV/VBS 234 and rMLV/VBS 56,
were generated with the MLV infectious cDNA clone as the viral backbone and used for
in vitro infection of susceptible lymphocytes and monocytes. Recombinant rMLV/VBS
234 virus contained the genome sequence identical to that of the rMLV virus except for
ORFs 2a, 2b, 3 and 4 (encoding for E, GP2, GP3 and GP4 minor envelope proteins) that
were replaced by the corresponding regions of the rVBS virus. In the case of rMLV/VBS
56 virus, whose ORFs 5 and 6 (encoding for GP5 and M major envelope proteins) were
replaced with the corresponding genes of rVBS in the rMLV backbone (Figure 2.6). In
contrast to expectations, neither rMLV/VBS 234 nor rMLV/VBS 56 chimeras were able
to infect T lymphocytes (Figure 2.6; panels u through w [rMLV/VBS 234] and panels y
through z’ [rMLV/VBS 56]). However, comparisons in monocytes showed that while the
percentage of cells infected with rMLV/VBS 56 virus was similar to that of rMLV and
rVBS/MLV S viruses, infection rates for rMLV/VBS 234 virus were significantly lower
(Figure 2.6; panels z’’ and x, respectively). Therefore, the higher relative fluorescence
intensity values observed in monocytes with rMLV/VBS 56 (Figure 2.6; panel z’’)
compared to rMLV/VBS 234 (Figure 2.6; panel x) suggest GP5 and M amino acid
sequences may play a more critical role than those of E, GP2, GP3 and GP4 in facilitating
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monocyte infections.

Taken together, these data demonstrate the minor envelope

glycoproteins as well as the two major envelope proteins play a critical role in
determining monocyte tropism.

Figure 2.6. Infection of lymphocytes and monocytes with recombinant EAV. The
genome of the infectious full-length cDNA clone of rVBS (red boxes) and the genome of
rMLV clone (blue boxes) are depicted. The genes encoding structural proteins of EAV
HK116 virus are shown in green. The four chimeric viruses containing nonstructural and
structural protein genes of either rVBS, or rMLV virus are also depicted. L, leader; An,
poly A. The CD3+, CD4+ and CD8+ T lymphocytes and CD14+ monocytes infected with
recombinant viruses rVBS (panels a through d), rVBS/HK116 S (panels e through h),
rMLV (panels i through l), rVBS/MLV S (panels m through p), rMLV/VBS S (panels q
through t), rMLV/VBS 234 (panels u through x) and rMLV/VBS 56 (panels y through z’’)
were examined by dual-color immunofluorescence flow cytometric analysis using MAbs
against EAV nsp1 (12A4) and MAbs for cell specific cell surface antigens at 24 hpi.
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Comparative amino acid sequence analysis of GP2, GP3, GP4, GP5 and M proteins
of rVBS, HK116 and rMLV viruses
The reverse genetic studies using recombinant chimeric viruses clearly indicated
that collective interactions among all EAV envelope proteins are required for efficient
infection of susceptible subpopulations of CD3+ T lymphocytes and CD14+ monocytes,
and these interactions were disabled or altered by the amino acid changes which had
occurred during extensive serial passage of the VB strain resulting in the HK116 and
MLV vaccine strains of EAV. Accordingly, the nucleotide sequences of ORFs 2 to 6
from VB, HK116 and MLV strains have been translated, aligned and analyzed in the
context of the predicted topography of each viral structural protein.

The E minor

envelope protein encoded by ORF2a was conserved (100% identity) among VB, HK116
and MLV strains and therefore it is almost certainly not responsible for the differences in
tropism among the three EAV strains (Table 2.1). When compared to the VB strain, the
GP2, GP4, GP5 and M envelope proteins of HK116 strain had several amino acid
substitutions (2, 1, 3 and 3 substitutions respectively; Table 2.1). With the exception of
amino acid substitutions in the M protein and one amino acid substitution in the GP2
protein (223R>P) of HK116 virus, all the amino acid changes were located in the
ectodomain of these proteins (Table 2.1 and Figure 2.7). Interestingly, in contrast to GP2,
GP4, GP5 and M envelope proteins, the amino acids of the GP3 protein of HK116 strain
were identical to the parental VB strain.

The data indicated that loss of CD3+ T

lymphocyte tropism of HK116 virus is primarily due to substitutions involving the GP2,
GP4, GP5 and M envelope proteins rather than the GP3 minor envelope protein.
However, further cell culture passage of this HK116 strain resulted in numerous other
non-synonymous amino acid substitutions in ORFs 2b, 3-6 (Table 2.1, Figure 2.7). All of
these substitutions appear to be non-conservative and therefore are likely to affect
secondary and tertiary structure, which may change the interactions between these
envelope proteins (Figure 2.7). Analysis of ORF3 demonstrated a U
→C substitution at
position 10,795 in rMLV resulting in the removal of the normal stop codon present in
rVBS and HK116 and permitting the addition of five amino acids to the carboxylterminus of GP3.
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Figure 2.7. Predicted membrane topology of minor (GP2, GP3 and GP4) and major
(GP5 and M) EAV envelope proteins.

Amino acid substitutions occurred during

extensive cell culture passage of the VB strain of EAV resulting in the HK116 and MLV
strain of the virus are indicated. A predicted model for the disulfide-bonded structure of
covalently linked minor envelope proteins GP2, GP3 and GP4 proteins is depicted based
on previous experimental studies [137,139,140,143,144]. The major envelope GP5 and
M proteins are covalently linked by a disulfide bond (S-S) formed between Cys-8 in the
M protein and the Cys-34 in the GP5 protein [68].

Furthermore, there are three other non-synonymous nucleotide substitutions
between rMLV and rVBS (as well as the intermediate HK116 strain) in ORF3 of which
leucine to serine at amino acid position 123 and cysteine to tyrosine at position 160
appear to be non-conservative (Table 2.1, Figure 2.7). In common with ORF3, all four
non-synonymous nucleotide substitutions in ORF4 are predicted to occur in the
ectodomain of GP4, a trend also observed in ORF5 where six of the eight nonsynonymous substitutions occur within the same predicted domain for GP5 (Table 2.1,
Figure 2.7). Therefore, it appears as if most of the variation in amino acid content
between the structural proteins of rVBS and rMLV occurs in those regions that could
interact directly with host-cell receptor molecules. An exception to this is in ORF6
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where all seven non-synonymous nucleotide substitutions between rMLV and rVBS are
predicted to occur in the endodomain or transmembrane-spanning domain of the M
protein.

During extensive cell culture passage, the second putative N-linked

glycosylation site at amino acid position 81 (81N>D) in GP5 was lost leaving the GP5 of
MLV with only the conserved putative N-linked glycosylation site at amino acid position
56. Taken together, these data clearly demonstrate that the failure of MLV to infect
CD3+ T lymphocytes was determined by the amino acid changes in the GP2, GP4, GP5
and M proteins but not the GP3 protein. In contrast, the reduced monocyte tropism of the
MLV strain appears to be due to the amino acid changes in the GP3 protein. However,
additional amino acid substitutions in GP2, GP4, GP5 and M protein may also have
contributed to the altered monocyte tropism. Since the nucleocapsid protein (N) encoded
by ORF7 is not exposed on the virus surface, it is unlikely that this protein has
contributed to the change in cellular tropism of EAV. Therefore, it is more likely that
tropism of CD3+ T lymphocytes and CD14+ monocytes was altered due to the changes in
major and minor envelope proteins of EAV.

2.5. DISCUSSION
In contrast to attenuated strains of EAV, highly pathogenic strains are highly
cell-associated with PBMCs and cause high titered viremia [154,213,328]. However,
until now the interaction between EAV and PBMCs has not been fully characterized and
the specific cell types infected with EAV were not identified. Therefore, the primary
objective of this study was to unequivocally establish which components of the PBMC
population were susceptible to EAV infection and then identify the viral proteins
responsible for infection of these cells. Based on dual-color flow cytometric analysis and
conventional viral titration assay along with qrRT-PCR on infected cell culture fluids, we
demonstrated that the predominant host cell type susceptible to virulent VB strain of
EAV are CD14+ cells of the monocyte/macrophage lineage. Furthermore, under ex-vivo
culture conditions these cells were permissive for complete productive replication of the
VB strain. Although this is an important finding, it is perhaps not surprising in view of
the fact EAV antigens have been found in alveolar macrophages in infected horses
[76,257]

and

that

all

other

members
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of

the

Arteriviridae

family

are

monocyte/macrophage tropic [51]. However, the finding that the VB strain can infect
CD3+ T lymphocytes (predominantly CD4+ T cells) of some but not all horses is the first
report of a member of this virus family being associated with T lymphocytes.
Surprisingly, there was a clear difference in the horse population based on the
susceptibility of their CD3+ T lymphocytes and CD14+ monocytes with in vitro VB
infection. As a result, horses were categorized as Group A in which almost one third of
monocytes along with CD3+ T lymphocyte (mainly CD4+ T cells) subpopulations were
susceptible to infection with the virulent EAV strain or as Group B in which monocyte
susceptibility was only half of that observed in Group A horses and all CD3+ T
lymphocyte subpopulations were resistant to EAV infection. Based on this finding, we
assumed that horse’s genetic background may play a significant role in determining the
clinical outcome of primary infection with EAV as reported in other species [350,351].
Efforts are underway in our laboratory to investigate if there is a genetic basis for the
differences between horses in the susceptibility of their monocytes and CD3+ T lymphocytes
to VB infection by analyzing possible associations with single nucleotide polymorphisms
(SNP). Furthermore, an in vivo study is planned in which Group A and B horses are
infected with rVBS to establish the relationship between PBMCs susceptibility and the
severity of clinical illness or EVA, respectively.
Expression of nsp1 and N proteins in CD3+ T lymphocytes demonstrated the VB
strain undergoes initial replication steps such as binding/entry, uncoating and translation
of nonstructural and structural proteins. However, production of progeny virus was not
evident in sorted CD3+, CD4+ and CD8+ T lymphocytes from any of the tested horses
based on the virus one-step growth curve results or qrRT-PCR results despite synthesis of
the full complement of viral proteins. This indicates that the number of progeny virions
generated is either below the limit of detection, a possible reflection of the relatively
small numbers of T lymphocytes infected (about 5%), or there is a blockage at a later
stage in viral assembly and/or release. It remains to be determined if these cells represent
“dead-end” hosts or if they are fully permissive. In contrast to the VB strain, expression
of MLV nsp1 or N could not be detected in CD3+ T lymphocytes from any tested horses
demonstrating that the amino acid substitutions that occurred during the attenuation process
of the VB strain prevented entry and replication of MLV strain in these cells. In addition,
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the number of CD14+ monocytes expressing viral nsp1 or N proteins following infection
with the attenuated MLV strain was significantly less than observed with VB virus.
Data derived from this study suggested that the amino acid substitutions in major
and minor envelope proteins that occurred during cell culture passage of the VB strain
contributed to the altered tropism of MLV virus for CD3+ T lymphocytes and CD14+
monocytes. In an attempt to identify the viral proteins associated with infection of T
lymphocytes and greater numbers of monocytes, we generated a panel of recombinant
chimeric viruses in which the structural and nonstructural protein genes of the parental
rVBS were replaced with corresponding genes of the rMLV strain. In vitro evaluation of
rMLV/VBS S chimeric virus demonstrated conclusively that cell tropism was determined
by envelope proteins of the virus. The role of the viral envelope proteins in CD3+ T
lymphocyte and macrophage tropism was further defined by using recombinant chimeric
viruses in which sequences encoding the minor envelope glycoproteins (GP2, GP3 and
GP4) or major envelope proteins (GP5 and M) of the MLV strain were replaced with the
corresponding genes of rVBS in an rMLV backbone (designated rMLV/VBS 234 and
rMLV/VBS 56, respectively).

Recombinant chimeric viruses derived from these

infectious cDNA clones were unable to infect T lymphocytes and numbers of monocytes
expressing nsp1 were either lower (rMLV/VBS 234) or equivalent (rMLV/VBS 56) to
those observed when these cells were infected with parental rMLV. For the first time
evidence is presented suggesting that infection of T lymphocytes along with the ability to
infect relatively large numbers of monocytes is dependent on cooperative interactions
between five out of the six envelope proteins of EAV (GP2, GP3, GP4, GP5 and M).
This, in turn, suggests that the infection process of these cell types is complex, possibly
involving multiple receptor and/or receptor accessory molecules. Furthermore, the data
also indicated that during extensive sequential cell culture passage, viral envelope protein
genes have coevolved resulting in a synergistic effect on cellular tropism. Interestingly,
based on findings with the rVBS/HK116 S chimeric virus, the GP3 protein is not
associated with altered tropism for CD3+ T lymphocytes. Substitutions in the other two
minor envelope glycoproteins (GP2 and GP4) and the two major envelope proteins (GP5
and M), however, play a critical role in changing the tropism for these cells. The dualcolor flow cytometry data clearly demonstrated that the HK116 strain was significantly
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different from both VB and MLV strains. By 116th passages of the VB strain in primary
HK cells, the virus lost its permissiveness for CD3+ T lymphocytes but its ability to infect
CD14+ monocytes remained similar to the parental VB strain.

Further cell culture

passage of HK116 virus in different cell lines (HK15, RK111 and ED24) to obtain the
MLV strain, resulted in significant reduction in its ability to infect macrophages (27% to
5%; Fig. 6; panels h and l, respectively). However, it is important to note that the
attenuated phenotype of EAV HK116 for horses correlates with the loss of
permissiveness for T lymphocytes while the ability to infect monocytes remains similar
to that of the parental VB strain. This suggests that either directly or indirectly tropism
for T lymphocytes has a significant role in the pathogenesis of VB infections in vivo.
Therefore, the susceptibility of CD3+ T lymphocytes to virulent and avirulent field strains
of EAV and their role in the pathogenesis of EVA warrants further in-depth investigation.
Interestingly, based on comparative amino acid sequence and predicted
membrane topology of the envelope proteins, the majority of the amino acid variations
between VB and MLV viruses, as well as HK116, are located within the predicted
ectodomain of each envelope protein, except for the M protein, in which the changes are
in the transmembrane and cytoplasmic domains (Figure 2.7). It is known that GP5 and M
exist in the virion as a heterodimer while the minor envelope proteins (GP2, GP3 and
GP4) occur in particles as heterotrimeric complexes constituting a virion-exposed
structure that is predicted to mediate binding of the virion to the primary receptor [144].
Formation of the heterotrimeric minor envelope complex is dependent on intramolecular
cysteine bonding with GP2 and GP3 being linked via interactions with GP4 [140]. The
existence of these complexes coupled with the fact that most of the amino acid
substitutions appear to be non-conservative, suggest that the cell tropism of MLV and VB
strains is determined by conformational differences in structural envelope proteins that
are manifested at the tertiary and quaternary levels.

Therefore, the amino acid

substitutions located within the various ectodomains may have direct and indirect effects
on interactions with host cells as well as associations between the viral structural proteins.
Consistent with our findings, a recent published study on porcine reproductive and
respiratory syndrome virus has shown that inter-glycoprotein interactions are critical for
mediating interactions with the receptor responsible for virus entry into host cells [352].
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Specifically, it has been demonstrated strong interaction between GP4 and GP5, as well
as weak interactions among other minor envelope proteins resulting in the formation of
multiprotein complex. Furthermore, in a previous study we have also demonstrated that
change in cellular tropism and establishment of persistent infection in HeLa cells by VB
strain of EAV was associated with amino acid substitutions in the envelope proteins
[236]. Reverse genetic studies further confirmed that substitutions in the minor envelope
proteins E and GP2 or GP3 and GP4 alone were unable to change cellular tropism and
establishment of persistent infection in HeLa cells but recombinant viruses with
combined substitutions in the E, GP2, GP3 and GP4 as well as a single amino acid
substitution in the GP5 were able to alter cellular tropism of VB strain of EAV and favor
establishment of persistent infection in HeLa cells. Nevertheless, the situation is further
complicated by the fact so little is known about the EAV receptor and whether this is
restricted to a single molecule or if the virus can use multiple alternatives but potentially
cell-type specific molecules.
In summary, for the first time we demonstrate that extensive cell culture passage
of the VB strain of EAV to produce the MLV vaccine strain has altered its cellular
tropism for equine PBMCs. Evaluation of chimeric viruses demonstrated that cellular
tropism in PBMCs is determined by the amino acid sequence of viral envelope proteins.
Specifically the data suggest that the GP2, GP4, GP5 and M envelope proteins play a
critical role in CD3+ T lymphocyte tropism while three minor envelope proteins (GP2,
GP3 and GP4) as well as the GP5 and M major envelope proteins determine the CD14+
monocyte tropism of EAV.
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CHAPTER THREE

Genome-Wide Association Study Identifies a Common Haplotype in Horses
Associated with CD3+ T Cell Susceptibility to Equine Arteritis Virus Infection
J. Virol. 2011, 85 (24):13174-84
Reprinted with permission

3.1. SUMMARY
Equine viral arteritis (EVA) is a reproductive and respiratory disease of horses
caused by equine arteritis virus (EAV), the prototype virus of the family Arteriviridae.
Recently, we have shown that horses could be divided into susceptible and resistant
groups based on an in vitro assay using dual color flow cytometric analysis of CD3+ T
cells infected with EAV. We hypothesized that the differences in in vitro susceptibility of
CD3+ T lymphocytes to EAV infection may have a genetic basis. To investigate the
possible hereditary basis for this trait, we conducted a genome-wide association study
(GWAS) using the Illumina Equine SNP50 chip to compare susceptible and resistant
phenotypes. Initial testing with Thoroughbred horses (n= 37) implicated an association
between a region of equine chromosome 11 (ECA11) and the CD3+ T cell
susceptibility/resistant trait. The results were extended and confirmed by retesting 267
horses (Thoroughbred [n=94], American Saddlebred [n=60], Quarter Horse [n=53] and
Standardbred [n=60]) for additional SNPs in this region, leading to the identification of a
common, genetically dominant haplotype associated with the susceptible phenotype in
the region ECA11: 49572804-49643932. The presence of a common haplotype indicates
that the trait occurred in a common ancestor for all four breeds suggesting that it may be
segregating among other modern horse breeds. Biological pathways analysis revealed
several cellular genes within this region encoding proteins associated with virus
attachment and entry, cytoskeletal organization and NFκB pathways that may be
associated with the trait responsible for the in vitro susceptibility/resistance of CD3+ T
lymphocytes to EAV infection. The data presented in this study demonstrated a strong
association of genetic markers with de facto proof that the trait is under genetic control.
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To our knowledge, this is the first GWAS of an equine infectious disease and the first
GWAS of EVA.
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3.2. INTRODUCTION
Equine arteritis virus (EAV) is a small enveloped virus with a positive-sense,
single-stranded RNA genome of 12.7 kb that belongs to the family Arteriviridae (genus
Arterivirus, order Nidovirales) [7,34]. EAV is the causal agent of equine viral arteritis
(EVA), a disease of equids. The vast majority of EAV infections are inapparent or
subclinical [77,353].

However, some acutely infected horses may develop any

combination of the following clinical signs: pyrexia, depression, anorexia, dependent
edema (scrotum, ventral trunk, and limbs), conjunctivitis, lacrimation and swelling
around the eyes (periorbital or supraorbital edema), respiratory distress, urticaria, and
leukopenia [77,353].

During natural outbreaks of the disease, the virus can cause

abortion in pregnant mares with abortion rates varying from 10 to 71%, depending on the
virus strain [77,353]. Following EAV infection, a variable proportion of stallions (3070%) can become persistently infected and continuously shed the virus in their semen
[77,190]. The mechanism of persistence of EAV in the male reproductive tract is not
clear.

However, studies have established that persistence of EAV in stallions is

testosterone-dependent [217,218]. Moreover, the prevalence of EAV infection differs
markedly among different breeds of horses, strengthening the assumption of genetic
influence on susceptibility to infection [77]. The seroprevalence of EAV infection of
horses varies between countries and among horses of different breeds and ages, with
marked disparity between the prevalence of infection among Standardbred (STB) and
Thoroughbred (TB) horses [175]. EAV infection is considered endemic in STB horses
but not in TBs in the U.S, with 77.5% to 84.3% of all STBs but only up to 5.4% of TBs
being seropositive to the virus [175,354,355,356]. Furthermore, the seroprevalence of
EAV infection among Warmblood stallions is also very high in a number of European
countries, as about 55 to 93% of Austrian Warmblood stallions are positive for antibodies
to EAV [357]. Although many of these differences are likely attributable to circulating
virus strains and environmental or management conditions, inherent genetic differences
may also play a significant role in determining clinical outcome and influence severity of
disease following exposure to EAV.
In a recent study using dual color flow cytometry, we demonstrated that the EAV
VBS can infect a small population of CD3+ T lymphocytes in vitro from some but not all
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horses [330].

The data suggested that the CD3+ T lymphocyte subpopulation of

individual horses varied in their susceptibility to in vitro EAV VBS infection and they
could be divided into susceptible and resistant groups [330]. The CD3+ T lymphocyte
susceptible/resistant phenotypes were not associated with age, prior exposure to EAV or
presence of antibodies to EAV but appeared to show an association with breed in
preliminary studies. Therefore, we hypothesized that susceptibility/resistance of equine
CD3+ T lymphocytes to EAV reflects genetic differences between horses in their
response to infection with the virus. The primary objective of this study was to identify
chromosomal regions and candidate genes associated with susceptibility/resistance of
CD3+ T lymphocytes to EAV infection in horses by using a genome-wide association
study (GWAS). Genetic factors contribute to host susceptibility and progression of
disease, but the genes responsible for disease development are largely unknown. Until
now, there was no evidence to indicate what role genetic factors play in determining the
susceptibility to and outcome of EAV infection in horses. Availability of the equine
genome sequence and development of genome wide screening technologies offer
unparalleled

opportunities

to

identify

variants

associated

with

increased

susceptibility/resistance to infectious disease agents such as EAV [358]. In this study, we
describe the identification of a distinct phenotypic trait that can be used as a marker to
divide equine populations, regardless of breed, into susceptible and resistant groups based
on an in vitro assay system. Using GWAS in combination with biological pathways
analysis, we have identified for the first time several cellular genes that may be
associated

with

the

trait

responsible

for

in

vitro

CD3+

T

lymphocyte

susceptibility/resistance to EAV infection.

3.3. MATERIALS AND METHODS
Virus and antibodies
The virulent Bucyrus strain of EAV (EAV VBS; ATCC VR-796, American Type
Culture Collection, Manassas, VA) was used for in vitro infection of equine PBMCs as
previously described [330]. The monoclonal antibody (MAb) to equine CD3 surface
molecule, UC F6G, was kindly provided by Jeff Stott, University of California, Davis.
The R-PE conjugated F(ab’)2 fragment of goat anti-mouse IgG1 (Southern Biotech,
92

Birmingham, AL) was used as the secondary antibody.

To detect EAV antigen in

infected cells, Alexa Fluor 488-labeled MAb against nonstructural protein 1 (nsp1; MAb
12A4) was used [306,330].

Horses
A total of 310 horses of different breeds, ASB (n=60), STB (n=60), TB (n=137),
and QH (n=53) were used in the study.

Phenotypic trait
The susceptible or resistant phenotype of each animal was defined by dual color
flow cytometric analysis of in vitro EAV infected CD3+ T lymphocytes as described
previously [330]. The horses were classified into susceptible or resistant groups based on
their CD3+ T lymphocyte susceptible/resistant phenotype to in vitro EAV infection.

DNA extraction
Genomic DNA (gDNA) was obtained from PBMCs of each animal using
Puregene whole blood extraction kit (Qiagen, Valencia, CA) following the
manufacturer’s instructions.

DNA quality and concentration was assessed using

Nanodrop® (Thermo Scientific, Wilmington, DE) at absorbance ratio OD260nm/280nm.

Genotyping and quality control
Samples were genotyped using EquineSNP50 Genotyping BeadChip (Illumina,
San Diego, CA) at the core facility for the Mayo Clinic in Rochester, MN. This array
contains 59,355 SNPs derived from the EquCab2.0 SNP database of the horse genome
(http://www.broadinstitute.org/mammals/horse) with an average probe spacing of 43.2 kb
between adjacent variants. For the initial GWAS analysis (N=37), DNA samples from 16
TB horses known to be susceptible and 21 TB horses known to be resistant for the in
vitro EAV infectivity trait were used for the EquineSNP50 Genotyping BeadChip
(Illumina Inc, San Diego, CA; Figure 3.1).
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Figure 3.1. Schematic representation of the study design. Horses were phenotyped
first and grouped into susceptible or resistant phenotype based on their CD3+ T cell
infectivity to EAV. To identify the region associated with EAV susceptible/resistant
phenotype, gDNA from 37 TB horses was isolated and analyzed using Illumina
EquineSNP50.

Results from the initial study were confirmed by genotyping 267

additional horses, including TBs tested with Illumina Equine SNP50, with
MassARRAY® system technologies. TB, Thoroughbreds; STB, Standardbreds; ASB,
American Saddlebreds; QH, Quarter horses.

Subsequently, additional SNPs from the region (Table 3.1) were selected using
the

Broad

Institute

Equine

SNP

database

(http://www.broadinstitute.org/ftp/distribution/horse_snp_release/v2/) for further testing
along with some of the original SNPs.

The second SNP assay was conducted at

Geneseek, Inc (Lincoln, NE) using the Sequenom MassARRAY® system (Sequenom
Inc., San Diego, CA; http://www.sequenom.com). Horses tested in this second assay
included a second population of TB horses (n=57) as well as horses of several different
breeds (60 ASB horses, 60 STB horses, 53 QH) plus the 37 TB horses tested in the
original Illumina assay.
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Table 3.1. ECA11 SNPs selected for the MassARRAY® system
SNP
BIEC2-157847
BIEC2-157867a
BIEC2-157892
BIEC2-157899b
BIEC2-165951b
BIEC2-165967b
BIEC2-157944
BIEC2-157945
BIEC2-165988
BIEC2-157947
BIEC2-165991
BIEC2-165992
BIEC2-157953b
BIEC2-165997
BIEC2-165998
BIEC2-165999
BIEC2-166001
BIEC2-166003
BIEC2-166005
BIEC2-166006
BIEC2-166009
BIEC2-166011
BIEC2-166013b
BIEC2-166014b
BIEC2-166015
BIEC2-166016
BIEC2-166018
BIEC2-166020
BIEC2-166021
BIEC2-166027

Position on
ECA11 (bp)
49389493
49424839
49446386
49459247
49473877
49475165
49509504
49514091
49529433
49529680
49533085
49537432
49541824
49545584
49549767
49558533
49564266
49569444
49572804
49580531
49584513
49589952
49594275
49604594
49613954
49621050
49627471
49634340
49637772
49643932

SNP
BIEC2-166028b
BIEC2-166029
BIEC2-157989
BIEC2-166033
BIEC2-166034
BIEC2-166036
BIEC2-166040
BIEC2-157998
BIEC2-166042b
BIEC2-158000
BIEC2-166044
BIEC2-166047
BIEC2-166049
BIEC2-166050
BIEC2-166052b
BIEC2-166056
BIEC2-166060
BIEC2-166065
BIEC2-166066
BIEC2-158024b
BIEC2-166449
BIEC2-158587
BIEC2-159231

Position on
ECA11 (bp)
49649380
49660962
49663560
49665617
49676359
49682023
49684089
49684299
49688617
49691181
49693957
49696679
49700501
49707607
49711761
49716340
49724419
49729958
49747467
49757978
50863263
51188148
52379156

Data analyses
Data from both assays were analyzed using the Golden Helix SNP & Variation
Suite 7 (Bozeman, MT). Of the 59,355 SNPs, 53,747 had call rates above 95%. The rest
were excluded from the analyses. Filtering for minor allele frequencies (removing SNPs
with minor allele frequencies below 55%) and genotyping (excluding SNPs with
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genotypes involving less than 90% of the horses) 42,506 SNPs were evaluated. Data
from both studies were evaluated using the association (chi-square) in the additive model
and linkage disequilibrium.

Gene ontology clustering and pathway analysis
Unsupervised analysis was performed using Ingenuity Pathways Analysis (IPA)
tool (Ingenuity Systems Inc., Redwood City, CA) to investigate biological and molecular
networks associated with genes identified within the selected region. The IPA builds
networks relevant to queried genes based on their functional annotation and known
molecular interaction which data are supported by peer-reviewed scientific publications
and stored in Ingenuity Pathways Knowledge Base (IPKB).

A list of interactions

between genes identified in the GWAS (‘focus genes’) and all other genes stored in the
IPKB was obtained with a maximum network size of 35 genes. Networks of direct or
indirect interactions among genes are displayed graphically. In addition, IPA computes a
score for each network, the –log (p-value), which indicates the likelihood of the ‘focus
genes’ in a network from IPKB being found together due to random chance.

To

investigate the molecular and biological functions, genes identified within the region
were categorized using the PANTHER classification system (www.pantherdb.org). In
addition to above mentioned database analyses, functional information was also obtained
from a literature search.

3.4. RESULTS
Phenotype analysis based on in vitro susceptibility of CD3+ T lymphocytes to EAV
infection
Horses from four different breeds TB, American Saddlebred (ASB), STB and
Quarter Horse (QH), a total of 310 horses, were randomly selected from farms in central
Kentucky for this study. In an attempt to define the CD3+ T lymphocyte susceptible or
resistant phenotype, blood was collected from each horse and peripheral blood
mononuclear cells (PBMCs) were isolated. PBMCs were infected with EAV VBS and
subsequently subjected to dual-color flow cytometric analysis to identify horses with the
CD3+ T lymphocyte-susceptible or -resistant phenotype to EAV infection. Cells from
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horses with a CD3+ T lymphocyte susceptible phenotype were stained with antibodies to
both CD3+ T lymphocyte surface molecule and intracellular EAV antigen (nonstructural
protein 1 [nsp1]). In contrast, cells from horses with a CD3+ T lymphocyte resistant
phenotype were stained with antibody to CD3+ T lymphocyte surface molecule but not to
intracellular EAV antigen.

Consistent with previously reported results, horses were

divided into two distinct groups, CD3+ T cell susceptible or resistant. Of the 310 horses,
167 horses had the CD3+ T lymphocyte susceptible phenotype and 143 horses had the
CD3+ T lymphocyte resistant phenotype. Subsequently, data were analyzed by individual
horse breed. In the susceptible phenotype group, there was no significant difference in
the percentage of the EAV infected CD3+ T lymphocyte subpopulation, regardless of
breed. The percentage of the CD3+ T cell subpopulation susceptible to EAV was 4.0% ±
0.95 in TB, 5.4% ± 0.4 in STB, 7.2% ± 0.6 in ASB and 3.9% ± 0.4 in QH (Figure 3.2.A).
The results confirm that determination of the EAV susceptible/resistant CD3+ T
cell phenotype is consistent in horses, regardless of breed. Interestingly, there was a clear
difference in prevalence of the susceptibility/resistance phenotype among breeds.
Ninety-five percent of STBs tested in this study were of the susceptible phenotype (57
out of 60). Similarly, 53 out of 60 ASBs had the CD3+ T lymphocyte susceptible
phenotype (~90%). The lowest prevalence of the susceptible phenotype was in TB, 32
out of 137 (23%), and QHs had both phenotypes evenly distributed with approximately
50% prevalence of each phenotype (Figure 3.2.B).
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Figure 3.2. Effect of breeds on prevalence of T cell susceptible/resistant phenotype.
(A) Representative dot plots from flow cytometry analysis for each breed are shown. The
mean percentage of CD3+ T cells with intracellular EAV nsp1 antigen is indicated in the
right upper quadrant for susceptible phenotype. (B) The percentage of susceptible (black)
and resistant (white) phenotype for each breed is indicated in a bar graph.
Seroprevalence of each breed (red) is indicated below the bar representing phenotypic
prevalence where available. TB, Thoroughbreds (n=137); STB, Standardbreds (n=60);
ASB, American saddlebreds (n=60); QH, Quarter horses (n=53).

Genome-wide association study (GWAS)
To investigate the possibility of genetic influence on susceptibility/resistance of
CD3+ T lymphocyte to in vitro infection to EAV, we applied the GWAS to identify the
genetic element(s) associated with this phenotypic trait. In order to simplify the process
of defining any genetic differences between positive and negative groups, we initially
focused on TB horses since they have less diversity for genetic markers than most other
breeds of horses. A group of 80 TB yearlings, serologically negative for EAV were
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tested for the phenotype described above. Only 16 out of 80 TB yearlings had the CD3+
T lymphocyte susceptible phenotype. Thus, 37 horses were selected for the GWAS
including 16 with the susceptible phenotype and 21 with the resistant phenotype. DNA
from these horses (Illumina TBs) was genotyped for single nucleotide polymorphisms
(SNPs) using the EquineSNP50 BeadChip (Illumina Inc., San Diego, CA). Using the
option for association studies, the distribution of SNPs was compared between the
susceptible horses and the resistant horses. The results from this study are represented
graphically in a Manhattan plot (Figure 3.3) showing the P-values when comparing the
distribution of markers for susceptible and resistant horses for each SNP. The values
from a region of ECA11 showed a distinctive peak.

Figure 3.3. Manhattan plot. The distribution of probability values (-log10 transformed)
for the 42,506 SNPs investigated using the 37 Thoroughbred horses (16 susceptibles and
21 resistants) is depicted. Genomic positions are indicated by chromosome with different
colors.

The 10 highest associations that were found included 7 SNPs in one region on
ECA11 (Table 3.2). The single highest association was found for SNP marker BIEC2157867 from ECA11 which had a statistical significance of P=7.42 × 10-8 (uncorrected)
and P=0.003 using the Bonferroni correction for the number of assays. None of the other
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markers achieved statistical significance when factoring the correction to the probability
value.

Table 3.2. Results from the GWAS using the Illumina Equine SNP50 Beadchip
SNP#

Chromosome

Position

Uncorrected P-Value

BIEC2_157867

11

49424839

7.42 × 10-8

BIEC2_409206

18

24674961

2.00 × 10-5

BIEC2_158932

11

51677777

5.42 × 10-5

BIEC2_409219

18

24736336

9.69 × 10-5

BIEC2_159231

11

52379156

2.90 × 10-4

BIEC2_158587

11

51188148

3.06 × 10-4

BIEC2_158588

11

51188190

3.06 × 10-4

BIEC2_157160

11

48595739

3.63 × 10-4

BIEC2_157720

11

49039853

3.98 × 10-4

BIEC2_1046042

8

40043641

4.47 × 10-4

Representation of 10 highest associations found using the Ilumina Equine SNP50
BeadChip based on 37 Thoroughbreds exhibiting the in vitro infection phenotype (N=16
susceptible) and the in vitro resistance phenotype (N=21 resistant)

Study validation and haplotype analysis
To confirm and extend the results from this initial study, additional SNPs were
selected from the EquCab2.0 SNP database (Table 3.2) along with some of the original
SNPs for the region on ECA11 and tested using the Sequenom MassARRAY® system
(Sequenom Inc., San Diego, CA). The Illumina TB horses served as controls, being
tested in both SNP assays, and had identical results for the 12 SNPs in common in the
two assays. Table 3.3 provides the results from comparing the distribution of SNPs
among susceptible and resistant horses for all horses (combined), TB horses alone, QH
alone, ASB horses alone and STB horses alone.

The SNP showing the strongest

association in the Illumina study, BIEC2-157867 had a significant and slightly higher P-
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value of 5.84 × 10-5 for this new set of TB horses. The most significant value was found
for BIEC2-166050 with the combined set of horses (P=1.77 × 10-22). For the group of
TB horses, the most significant P-value was for BIEC2-166057 (P=4.96 × 10-7). All
breeds except STB showed statistically significant associations for the trait with SNPs in
this region.
Next, linkage disequilibrium (LD) among the SNPs in this region was
investigated and compared to the distribution of cases and controls in the different
populations. A haplotype defined by 8 SNPs, BIEC2- 166005, 166006, 166009, 166011,
166015, 166018, 166021 and 166027, spanning 71 kb from ECA11: 49572804-49643932
had the highest association across all breeds. The SNP BIEC2-166016 did not contribute
to definition of the haplotype and was therefore not included in the haplotype definition.
The haplotype associated with the susceptibility phenotype was defined by the presence
of nucleotides GGGGAGGT at those 8 SNP sites.

Figure 3.4 shows a schematic

representation of LD for the haplotype among all groups of horses tested. The schematic
representations are similar for all groups except the STB, in which this haplotype is
almost completely fixed in the breed.
Figure 3.5 provides the frequencies for this haplotype among susceptible and
resistant horses as well as the statistical significance for the differences in each group. In
each breed, including STB, this haplotype was associated with susceptible horses. The
haplotype was also present among the resistant horses but at a much lower frequency.
Among the 13 TB cases, all but one horse were heterozygous for the haplotype,
possessing one copy of the haplotype; the remaining susceptible TBs did not possess the
haplotype (data not shown). Among the 44 resistant TB horses, 8 horses possessed one
copy of the haplotype while two horses were homozygotes (data not shown). Similar
results were found for the distribution of the haplotype in other breeds.
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Table 3.3. P-values of case and control groups for the combined set and for the individual breed of horses

10
2

BIEC2-SNP#
166050
166027
166011
165991
166065
166015
166021
166009
166047
166018
157944
166001
157867a
157847
165999
165997
166056

Position
49707607
49643932
49589952
49533085
49729958
49613954
49637772
49584513
49696679
49627471
49509504
49564266
49424839
49389493
49558533
49545584
49716340

P-Combined
1.73×10-22
1.49×10-21
1.17×10-19
1.70×10-19
3.44×10-19
4.99×10-19
5.97×10-19
6.30×10-19
3.23×10-18
6.03×10-18
5.75×10-17
3.10×10-13
1.12×10-9
3.60×10-9
5.45×10-9
2.28×10-5
6.52×10-5

P-TB
6.11×10-4
4.96 ×10-7
1.46×10-4
7.64×10-5
7.02×10-5
2.74×10-4
1.87×10-4
1.87×10-4
7.02×10-5
3.72×10-4
5.78×10-4
2.69×10-3
5.84×10-5
0.01
0.10
0.26
3.93×10-3

P- QH
3.00×10-3
1.62×10-3
1.07×10-3
6.26×10-4
9.40×10-4
9.40×10-4
9.40×10-4
9.40×10-4
9.40×10-4
1.64×10-3
3.02×10-3
0.01
0.50
0.17
0.18
0.23
0.07

P-ASB
6.18×10-11
1.24×10-5
1.74×10-6
2.00×10-4
9.48×10-5
4.11×10-5
4.11×10-5
3.24×10-5
9.48×10-5
4.11×10-5
2.00×10-4
3.89×10-4
1.66×10-5
2.97×10-6
0.10
0.69
0.02

P-STB
n/a
0.61
n/a
0.72
n/a
n/a
n/a
n/a
0.61
n/a
0.56
0.44
0.48
0.93
0.34
0.80
0.46

a

The most highly associated SNP in the initial assay.
n/a represents no variation observed between resistant and susceptible.

NOTE: The table shows SNPs in ECA 11 with the lowest 17 P-values of combined set of horses (N=267) and the individual groups of Thoroughbred (TB, N=57),
Quarter Horse (QH, N=53), American Saddlebred (ASB, N=60) and Standardbred (STB, N=60).

Figure 3.4. Linkage disequilibrium (LD) plots. The shown region represents the
strongest association with the EVA susceptibility haplotype from ECA11:4957280449643932. The haplotype block is highlighted with black line.

103

Figure 3.5. Frequency of the GGGGAGGT haplotype found for selected SNPs in
ECA11: 49572804-49643932. The frequency represented by each section of the pie
chart is shown on the pie chart in white. Data are represented for all horses together (All)
and for the individual breeds (Thoroughbred, American Saddlebred, Quarterhorse and
Standardbred).

The statistical significance for the frequency differences of the

GGGGAGGT haplotype between susceptible and resistant horses is shown to the left of
each set of pie charts (P”GGGGAGGT”).
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Gene network analysis
The EAV-associated haplotype is located in a block with strong LD expanding
~71 kb. This LD block includes five genes: SPAG7, ENO3, PFN1, CHRNE and MINK1.
For the purpose of analyzing possible functional relationship among genes using the
Ingenuity Pathway Analysis (IPA, Ingenuity Systems) and the PANTHER classification
system, we have included those genes in high LD and genes located outside of this
particular LD block (500 kb upstream and downstream of the most significantly
associated gene, KIF1C). Unsupervised IPA analysis retrieved three top networks that
were merged into a single interaction network (Figure 3.6.A). The network contained 22
genes showing significant correlation with networks implicated in cell morphology and
cellular movement. Similarly, genes categorized by biological functions were mostly
involved in cellular movement (P=1.2 × 10-5), cell death (P=1.45 × 10-3), cell morphology
(P=1.45 × 10-3), cellular assembly and organization (P=1.45 × 10-3) and cellular function
and maintenance (P= 1.45 × 10-3). We also classified the genes from the region by their
molecular function and biological process categories using the PANTHER classification
database.

The enriched molecular function categories included binding, catalytic

activities and receptors suggesting these genes might mediate viral-cellular interaction
and facilitate viral entry (Figure 3.6.B). Furthermore, there was a predominance of genes
regulating metabolic and cellular processes as well as cell communication and immune
responses (Figure 3.6.C; Table 3.4).
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Figure 3.6. Pathway analysis. (A) Three top networks retrieved using unsupervised
IPA analysis were merged into a single interaction network.

Red nodes represent

molecules encoded by genes found in the region of ECA11; white nodes are genes
identified by IPA with direct or indirect interactions with genes of ECA11. The blue
nodes represent molecules/complexes identified by IPA involved in canonical pathways.
Classification of candidate molecules based on their (B) molecular functions and (C)
biological processes.

3.5. DISCUSSION
The data presented in this study demonstrate a very strong association of genetic
markers with the susceptible phenotype described for in vitro infection of CD3+ T
lymphocytes with EAV. Association of genetic markers with a trait is de facto proof that
the trait is under genetic control. To our knowledge, this is the first GWAS of an equine
infectious disease and the first GWAS of EVA. We have developed an easy and reliable
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in vitro assay based on dual color flow cytometry to phenotype an equine population.
The data presented in this study clearly demonstrated that there was a genetic difference
within and among the horse populations based on the susceptibility of their CD3+ T
lymphocytes to in vitro infection with the EAV VBS of EAV. The in vitro assay
described is currently the most precise method for determining the phenotype. However,
it is expensive, time consuming and cumbersome to run on a routine or large-scale basis.
The association of the ECA11 haplotype with the phenotype will allow us to use the
molecular test in large-scale studies to determine the impact of this phenotype on the
consequences of infection.
Interestingly, distinct phenotypic prevalence of each breed found in this study was
similar to EAV seroprevalence that has been reported previously (Figure 3.2.B) [175,356].
Similar distribution in both seroprevalence and CD3+ T lymphocyte susceptible trait
strengthened our hypothesis that genetic factors might play a role in determining the
CD3+ T lymphocyte susceptibility/resistance of horses to EAV infection. The haplotype
associated with the trait was distributed among horses in a manner characteristic for that
harboring a gene with a dominant mode of action. However, the association of the trait
with the genetic markers was imperfect since several susceptible horses were found
without the implicated genetic markers implicated for susceptibility and, conversely,
some resistant horses were found with susceptibility markers. However, this is not
surprising since the 53 SNPs under study represented a very small proportion from the
three million bp long region and the chances of having selected the SNP defining the
actual mutation defy expectations. Although additional work is needed to investigate
candidate genes and re-sequencing of candidate regions, it is clear that a gene or genes
within the region of ECA11: 49572804-49643932 plays a major role in determining the
CD3+ T lymphocyte susceptibility phenotype.

In a parallel study, we have

experimentally inoculated both groups of horses and assessed the severity of clinical
disease, virus shedding, and production of proinflammatory/immunomodulatory
cytokines in PBMCs using real-time quantitative RT-PCR (Go et al., in revision). The
data showed that there was a significant difference between the two groups of horses in
terms of cytokine mRNA expression and increased clinical signs in horses possessing the
in vitro CD3+ T cell resistant phenotype. Thus, there was a clear correlation between the
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in vitro susceptibility or resistance phenotype of CD3+ T lymphocytes and the different
clinical/cytokine expression responses observed in horses following infection with EAV.
Therefore, further studies on genes located in ECA11 will enhance our understanding of
the pathogenesis of EAV infection, variation in susceptibility to establishment of the
carrier state in stallions, and hopefully, lead to identification of putative EAV cell
receptor(s).
The association of the haplotype with CD3+ T lymphocyte susceptibility in all
four breeds is remarkable. This implies that the trait first appeared in a common ancestor
of these breeds. Although these horses are products of four different breed registries,
they are known to have common ancestors within the last 100 years [359]. The use of the
four breeds together also produced the strongest associations for the trait using both the
haplotype and individual SNPs (Table 3.3). This was a product of the wide differences
among the selected horse breeds for the susceptibility/resistance trait. The choice of TB
horses for the initial stage of the study was fortuitous since the susceptibility/resistance
trait is highly polymorphic among TB horses. Had the initial study been conducted
among STBs, the association would not have been uncovered because almost all STBs
have the susceptibility phenotype. Indeed, STBs appear almost fixed for the genes and
the trait. Therefore, the results of this study suggest that preliminary studies of such traits
might best be conducted using pools of different horse breeds when that trait is
manifested across breed lines.
Furthermore, we have identified for first time a significant number of candidate
genes that might be associated with CD3+ T lymphocyte susceptibility to EAV infection
and these genes may also play a major role in pathogenesis and persistent infection in the
stallion. We used IPA in an unsupervised manner, allowing identification of gene-gene
relationships without a priori assumptions. This analysis linked 22 of 28 genes to other
nodes in a highly significant network (Figure 3.6.A). These genes might be functionally
interrelated and may play a direct or indirect role in susceptibility to EAV infection and
pathogenesis of EVA. In relation to virus life cycle and host response to virus infections,
these genes can be broadly classified into several categories based on molecular functions
and biological processes (Figure 3.6.B and 3.6.C; Table 3.4). The proteins encoded by
these genes are involved in virus attachment and entry pathway (putative cellular
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receptors for viral entry, molecules associated with cytoskeleton and endocytosis),
various transcription factors, cell-signaling molecules and molecules associated with
inflammatory response, innate and adaptive immunity.

Interestingly, some of these

proteins that are already identified, have been associated with other virus infections
(Table 3.4), may contribute to the pathogenesis of EVA as well.
We found several proteins, such as CHRNE, CXCL16, RABEP1, ARRB2, and
PELP1 that may be involved in EAV attachment and entry into the cell. Although, the
cellular receptor for EAV is not yet known, it is plausible that some of these molecules
(e.g. CHRNE, CXCL16 and PELP1) may act as putative EAV receptor(s) or if not
directly, serve as essential component(s) in viral attachment and entry process. The
CXCL16 belongs to the macrophage scavenger receptor family which is the receptor
family in which the porcine reproductive and respiratory syndrome virus receptor and
human hepatitis C virus, CD168 and SR-BI, respectively, belong [360]. Recently, it has
been demonstrated that EAV is taken up via clathrin-dependent endocytosis and is
delivered to acidic endosomal compartments during entry into the cell [82].

Thus,

proteins involved in the endocytic pathway may also play a critical role in the resistance
or susceptibility of cells to EAV. ARRB2 encodes β-arrestin-2, a multifunctional adaptor
protein, which is involved in desensitization and endocytosis of cell surface receptors in
clathrin-coated pits [361,362,363]. Similarly, RABEP1 is indirectly involved in receptor
internalization and endosome fusion, besides its function of interacting with proteins
involved in endoplasmic reticulum (ER) to Golgi transport [364]. Interestingly, both
ASGPR1 and ASGPR2, well-studied endocytic recycling receptor molecules, are located
in the same chromosome approximately 800 kb downstream of RABEP1, making them
attractive receptor candidates in line with clathrin-dependent endocytosis [82].
In relation to the viral life cycle, intracellular trafficking of molecules, cell
movements, cell-to-cell communication as well as cell-substrate adhesion pattern and cell
polarization are critical in virus infection in cells and spreading processes. All these
processes can be modified by viral infections, contributing to the pathogenesis and
disease progression.

It has become apparent that numerous viruses interact with

cytoskeletal components at various stages of their life cycle disrupting or remodeling
cytoskeletal networks to their own advantage. Some viruses can directly or indirectly
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hijack cytoskeletal cell component organization to their own advantage often altering cell
behavior and cell fate. In EAV infected cells, cytopathic effect (CPE) is characterized by
rounding, vacuolation, increased optical density, refraction and detachment from the
supporting surface indicating viral modulations of the actin cytoskeleton [60,61,290,291].
In the region of interest identified in this study, several genes have been classified as
involved in cellular movement function such as ARRB2, PLD2 and PFN1 and are known
to be involved in actin cytoskeleton reorganization (Figure 3.7) [365]. In addition, some
molecules such as KIF1C, PELP1, DERL2 are important in cellular trafficking. Derlins,
including DERL1 and DERL2, are ER membrane proteins involved in the degradation of
proteins that misfold in the ER [366,367,368,369,370]. KIF1C, a member of the kinesin
superfamily, is involved in retrograde vesicle transport from the Golgi-apparatus to the
ER [371]. It has been suggested that KIF1C associates with the 14-3-3 protein which
regulates cytokinesis and cell cycle arrest due to DNA damage.
Interestingly, our network analysis also included some genes encoding proteins
associated with apoptosis and modulating innate and adaptive immune responses to virus
infections (Figure 3.7).
These proteins such as ARRB2 are known to modulate chemotatic responses and
granule release as well as contribute to anti-apoptotic signaling [372,373,374,375]. In
recent years, ARRB2 has been increasingly implicated in modulation of nuclear factor
kappa B (NFκB) signaling and interacting with I kappa B alpha (IκBα) and
extracellularly-regulated kinases 1 and 2 (ERK1/2) activation by acting as
scaffold/adaptor proteins for G protein coupled receptor activation of MAP kinases,
respectively, suggesting that ARRB2 is a regulator of innate immune activation and
inflammatory gene expression besides its importance as a key component in actin
cytoskeleton

modulation

[373,376,377,378,379,380,381,382,383,384,385].

Phosphatidylcholine-specific phospholipase D (PLD2) produces phosphatidic acid, an
intracellular signaling lipid involved in vesicular trafficking and regulation of
cytoskeletal organization. PLD2 is also involved in downstream activation of MAPK and
cell signaling primarily associated with leukocyte chemotaxis [386]. Furthermore, some
genes in the region were associated with the host inflammatory response and innate
immunity. CXCL16, also a member of the CXC chemokine family, is expressed as a

110

soluble form and a transmembrane protein that induces chemotaxis of activated T cells
into a site of inflammation [387,388,389]. While the transmembrane form may have
receptor activity, the soluble CXCL16 induces inflammatory responses [388,390]. The
nucleotide binding and oligomerization, leucine-rich repeat (NLR) family of proteins
senses microbial infections and activates the inflammasome, a multiprotein complex
critical for activation of caspase-1 and production of proinflammatory cytokines,
particularly interleukin (IL)-1β and IL-18 [391]. The NUP88, belongs to nucleoporin
proteins [NUPs] essential for the exchange of macromolecules across the nuclear
envelope [392]. NUP88 promotes nuclear retention of NFκB and is required for proper
nuclear accumulation of key animal and plant immune regulators such as Rel-like
transcription factors [393,394]. Thus, depletion of NUP88 in mammalian cells prevents
NFκB-dependent target gene expression. Although EAV replicates in the cytoplasm, the
EAV nsp1 and N proteins are targeted to the nucleus. In particular, the N protein
possibly shuttles between cytoplasm and nucleus and may be engaged in cytoplasmic
virus assembly [120]. Thus, NUP88 may play an important role in EAV assembly and
cells that are deficient or have an abnormal form of this protein may not be able to
produce infectious virus particles.
Finally, the network analysis showed (Figure 3.7) that many molecules encoded
by genes found in ECA11 are directly or indirectly related in the ERK1/2 and NFkB
signaling pathways.

During EAV infection there is increased production of

proinflammatory cytokines such as IL-1, IL-6, IL-8 and tumor necrosis factor alpha
(TNF-α) [257]. Some viruses ensure their survival by blocking the host anti-infective
apoptotic mechanisms with a variety of viral proteins that modulate various stages of the
death-signaling pathways.

The transcription factor NFkB is activated following

stimulation with, for example, the proinflammatory cytokines, TNF-α and IL-1. Many
viral proteins disrupt the innate immune responses mediated by NFkB by nullifying
signaling cascades that activate NFkB. In this respect, activation of NFkB was shown to
facilitate some viral infections by promoting viral replication and preventing virusinduced apoptosis, thus priming the host cell for infection.

EAV may utilize such

mechanisms to evade the equine immune response and establish persistent infection in
the cells of the reproductive tract of the stallion. However, further studies are needed to
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investigate potential mechanisms that involve the roles of proteins encoded by genes
located in this region of ECA11 in the virus life cycle and host response to EAV infection,
as well as to identify the mechanism of establishment of persistent infection in some but
not all stallions infected with the virus. The findings from this study can help to develop
working hypotheses to decipher novel mechanisms of viral immune evasion,
establishment of persistent infection and viral pathogenesis.

Figure 3.7. Subcellular location of candidate genes and EAV life cycle. The function
and subcellular location of candidate molecules were manually curated based on
PANTHER, IPA and published literature search. Subsequently, molecules were mapped
along with stages of EAV life cycle at the position most likely to interact with virus life
cycle. Green circles, molecules encoded by genes located in the haplotype block; red
circles, putative molecules encoded by genes found within 500 kb upstream and
downstream of the haplotype block; blue circles, molecules in the vicinity interacting
with genes located in the region retrieved in the network analysis; black circles, viral
proteins.
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Table 3.4. List of genes located in the vicinity of the highest associated haplotype block
Gene symbol§

NCBI gene ID

Description

Known molecular function

Virus

CHRNE

100146223

Similar to nicotinic acetylcholine
receptor epsilon

Acetylcholine receptor activity, ligandgated ion channel activity

HIV-1

ARRB2

100072892

Similar to beta-arrestin 2

Receptor internalization. Endocytosis

HIV-1

PELP1

100072897

Similar to proline, glutamic acid
and leucine rich protein 1

Estrogen receptor coactivator.
Receptor activity

RABEP1

100072805

RAB GTPase binding effector
protein 1

Endocytic pathway. Fusion of early
endosome and regulation of recycling
vesicle formation

CXCL16*

100061442

Similar to SR-PSOX

Scavenger receptor family. NKT cell
and MØ activation

HIV, SARS-CoV,
KSHV

Murine
polyomavirus

Receptor Activity

Intracellular Vesicle Trafficking
DERL2

100061027

Derlin-2 (Der1-like protein 2)

Removal of misfolded protein from ER

KIF1C

100072836

Kinesin family member 1C

Vesicle transport, redistribution of
Golgi membrane. Microtubule motor
activity

SPAG7

100061215

Similar to Sperm associated
antigen 7

Nucleic acid binding, cytoskeleton

Human parvovirus
B19

PFN1

100061295

Similar to profilin 1

Actin polymerization. Cytoskeletal
signaling pathway

RSV

NLR family, pyrin containing
domain 1

Regulation of inflammatory response.
Induction of apoptosis

KSHV/HHV8,
Myxoma virus,
HIV-1

Actin and
Cytoskeleton

Innate and Adaptive Immunity

NLRP1

DHX33

100072797

DEAH (Asp-Glu-Ala-His) box
polypeptide 33

Putative RNA helicase

HIV-1

NUP88

100061117

Nucleoporin 88kDa

Innate immunity, nuclear export

Hepatitis C and B
virus

PSMB6

100072870

Proteasome subunit beta type-6
precursor

Peptidase activity. Involved in antigen
presentation by MHCI

ALOX12

100072916

Similar to 12-lipoxygenase

Oxidoreductase activity. MØ
activation. B cell mediated immunity

CXCL16¶

100061442

Similar to SR-PSOX

Scavenger receptor family. NKT cell
and MØ activation

Transcription Factors
RPAIN

100061089

RPA interacting protein

Nuclear transporter of RPA

ZFP3

100061153

Zinc finger protein 3 homolog

DNA binding. Transcription factor
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HIV, SARS-CoV,
KSHV

CAMTA2

100072844

Similar to Calmodulin-binding
transcription activator 2

Transcriptional coactivator. DNA
binding

MED11

100072890

Similar to HSPC296

Component of pol II transcription
machinery. Transcription initiation
complex stabilization

ENO3

100061187

Hypothetical protein
LOC100061187

Lyase activity

MINK1

100061370

Misshapen-like kinase

SAPK/JNK signal pathway. Kinase
activity

PLD2

100072863

Similar to Phospholipase D2

ERK1/2 signaling pathway. Hydrolase
activity

100060987

MIND kinetochore complex
component

Chromosome segregation

Transmembrane protein C17orf87

Transmembrane protein

Hypothetical protein

-

Hypothetical protein

-

Measles virus

Enzyme Activity

Others
MIS12
C17orf87
L11_049426896

100072818

L11_049471914
INCA1

100072840

Similar to HSD45

Regulation of cell proliferation.
Spermatogenesis

GLTPD2

100072874

Glycolipid transfer protein
domain-containing protein 2

Lipid transport

VMO1

100072878

Vitelline membrane outer layer
protein 1 homolog precursor

-

TM4SF5

100072881

Transmembrane 4 L6 family
member 5

-

ZMYND15

100061402

Zinc finger MYND domaincontaining protein 15

-

Hypothetical protein

-

L11_049822588

114

HIV-1

CHAPTER FOUR
Assessment of correlation between in vitro CD3+ T cell susceptibility to EAV
infection and clinical outcome following experimental infection
Vet Micro. 2011 (accepted for publication)

4.1. SUMMARY
In a recent study, we demonstrated that the experimentally derived EAV VBS
could infect in vitro a small population of CD3+ T lymphocytes from some but not all
horses. In a subsequent genome-wide association study, we demonstrated the putative
candidate genes associated with susceptibility/resistance of CD3+ T lymphocytes to EAV
are located on horse chromosome 11. In this present study, horses were divided into two
groups based on their in vitro CD3+ T cell susceptible or resistant phenotype and
challenged with recombinant EAV VBS.

Following experimental inoculation, both

groups of horses were assessed for severity of clinical outcome, virus shedding, as well as
production of proinflammatory and immunomodulatory cytokines in peripheral blood
mononuclear cells using real-time quantitative RT-PCR. The data showed that there was
a significant difference between the two groups of horses in terms of cytokine mRNA
expression and an increase in clinical signs in horses possessing the in vitro CD3+ T cell
resistant phenotype. A correlation was found between the in vitro susceptibility or
resistance phenotype of CD3+ T lymphocytes and the different clinical/cytokine
expression responses observed in horses following infection with EAV. This is the first
study to provide direct evidence for a correlation between variation in host genotype and
phenotypic differences in terms of the extent of viral replication, nature and severity of
clinical signs and cytokine gene expression caused by infection with virulent EAV.
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4.2. INTRODUCTION
Equine arteritis virus (EAV) is a small enveloped virus with a positive-sense,
single-stranded RNA genome of 12.7 kb that belongs to the family Arteriviridae (genus
Arterivirus, order Nidovirales) [7,34]. EAV is the causal agent of equine viral arteritis
(EVA) in equids. The vast majority of EAV infections are inapparent or subclinical
[76,77,395]. However, some acutely infected horses may develop any combination of the
following clinical signs: pyrexia, depression, anorexia, dependent edema (scrotum,
ventral trunk, and limbs), conjunctivitis, lacrimation and swelling around the eyes
(periorbital or supraorbital edema), respiratory distress, urticaria, and lymphopenia
[77,353]. In natural outbreaks of the disease, the virus can cause abortion in pregnant
mares with abortion rates varying from 10 to 71%, depending on the virus strain and
other factors [77,353]. Following EAV infection, a variable proportion of stallions (3070%) can become persistently infected and continuously shed the virus in their semen
[77,190]. The mechanism of persistence of EAV in the male reproductive tract is not
clear. However, studies have established that persistence of EAV in the stallion is
testosterone-dependent [217,218].
The clinical signs observed in natural cases of EVA vary considerably between
outbreaks and among individual horses. While many of these differences are almost
certainly attributable to the virus strain, it is also likely that environmental or
management conditions and host factors such as age, immune status and nutritional state
play a significant role in determining clinical outcome following exposure to EAV. In
addition, it is probable that host genetics may be particularly important although there are
no reports linking individual horse genotypes with either susceptibility to EAV or the
clinical consequences of infection. However, there are very significant differences in the
seroprevalence among different breeds. For example, EAV infections are considered
endemic in Standardbred (STB) horses but not in Thoroughbred (TB) horses in the U.S,
with 77.5% to 84.3% of all STBs but only up to 5.4% of TBs testing seropositive for this
virus [355].

Furthermore, the seroprevalence of EAV infection among Warmblood

stallions is also very high in many European countries with 55 to 93% of all Austrian
Warmblood stallions possessing antibodies against to this virus. Although management
practices could explain some of these dramatic differences (Timoney and McCollum,
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1993), it is also possible that certain horse breeds are inherently more susceptible to
infection with this virus than others.
In a recent study, we demonstrated that the EAV VBS could infect in vitro CD3+
T lymphocytes from some but not all horses [330]. The data suggested that the CD3+ T
lymphocyte subpopulation of individual horses varied in their susceptibility to in vitro
EAV infection. Furthermore, a comprehensive single nucleotide polymorphism analysis
using Equine SNP50 Genotype Bead Chip (Ilumina, San Diego, CA) and Sequenom
MassARRAY® system (Sequenom Inc., San Diego, CA) has shown that genes associated
with susceptibility/resistance of CD3+ T lymphocytes to EAV infection are located on
horse chromosome 11 (Go et al., unpublished). As a result of this clearly defined genetic
basis, we hypothesized that in vitro susceptibility of CD3+ T lymphocytes to EAV
infection may correlate with the clinical responsiveness of horses to challenge with
virulent strains of EAV. To test this hypothesis, we conducted an in vivo study by
exposing horses possessing either susceptible or resistant CD3+ T lymphocytes with
recombinant viruses derived from the virulent Bucyrus strain (rVBS) of EAV. Following
infection, the two horse groups were monitored for clinical signs, duration plus
magnitude of virus shedding, and production of proinflammatory/immunomodulatory
cytokines at the mRNA level.

4.3. MATERIALS AND METHODS
Cells and viruses
Equine pulmonary artery endothelial cells (EECs) were maintained in Dulbecco’s
modified essential medium (Mediatech, Herndon, VA) with sodium pyruvate, 10% fetal
bovine serum (Hyclone Laboratories, Inc., Logan, UT), 100U/μg per ml of
penicillin/streptomycin and 200mM L-glutamine [142]. The high-passage rabbit kidney
cells (RK-13; passage 399-409) were grown in Eagle’s minimum essential medium
(EMEM) with 10% ferritin supplemented bovine calf serum (Hyclone Laboratories, Inc.,
Logan, UT) and 100U/μg per ml of penicillin/streptomycin (Gibco, Carlsbad, CA). The
EAV VBS (ATCC VR-796; American Type Culture Collection, Manassas, VA) was used
for in vitro infection of equine peripheral blood mononuclear cells (PBMCs) as
previously described [330]. The rVBS which has been shown to have similar growth
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kinetics in EECs and equivalent capacity for lymphocyte infectivity, was used for
experimental inoculation of horses [328,330].

Furthermore, the in vivo virulence

phenotype of this virus has been previously demonstrated by experimental inoculation of
horses [328]. Both viruses were propagated in EECs and tissue culture supernatants were
stored at -80°C. Virus titers were determined by plaque assay in high passage RK-13
cells as previously described [291]. The experimental challenge studies were carried out
in accordance with an IACUC approved protocol.

Horses
In order to divide horses into two groups based on the in vitro susceptibility
phenotype of their CD3+ T lymphocytes to the EAV VBS, a large number of horses
(n=62) were first screened by dual-color flow cytometry as previously described [330].
A total of 8 mares were selected, 4 in Group A (susceptible) and 4 in Group B (resistant),
for use in this study (Table 4.1). All horses were confirmed seronegative for EAV
neutralizing antibodies using a previously described protocol [337].

Table 4.1. Horses used in the study.
Group

A

B

Horse ID

Breed

Gender

Age

E7

TBX

F

7

F23

Mix

F

6

F84

TB

G

10

G13

TBX

F

5

F19

Mix

F

6

F64

TB

F

8

F83

TB

F

7

E9

TBX

F

7
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Antibodies
The equine CD3+ T lymphocyte monoclonal antibody (MAb) UC F6G was kindly
provided by Dr. Jeff Stott, University of California, Davis. The R-PE conjugated F(ab’)2
fragment of goat anti-mouse IgG1 (Southern Biotech, Birmingham, AL) was used as the
secondary antibody. To detect EAV antigen in infected cells, the Alexa Fluor 488labeled MAb against EAV nonstructural protein 1 (nsp1; MAb 12A4) was used [306,330].

Dual-color flow cytometry analysis of PBMCs
The susceptibility of CD3+ T lymphocytes to EAV was determined using dualcolor flow cytometry analysis. Dual fluorescent antibody staining of PBMC cultures was
performed using anti-equine CD3 monoclonal antibody (MAb) specific for CD3+ T
lymphocytes as well as an MAb specific for the EAV nsp1 as previously described [330].
Double-stained PBMCs were analyzed using a FACSCalibur (Becton Dickinson, San
Jose, CA). The percentage of CD3 surface antigen and intracellular EAV antigen positive
lymphocytes were determined by CellQuest™ quadrant statistics (Becton Dickinson, San
Jose, CA).

Experimental infection of horses
Horses (Groups A [susceptible; n=4] and B [resistant; n=4]) used in the study
were transferred to an experimental facility one week prior to challenge for
acclimatization purposes. Pre-inoculation blood samples and PAXGENE® RNA tubes
(PreAnalyticX, Valencia, CA) were collected to determine base-line values for complete
and differential blood counts and cytokine gene expression in peripheral blood from both
groups of horses. All horses were clinically evaluated prior to experimental inoculation
with the virus. Both groups of horses were inoculated intranasally with 3 × 106 pfu of the
EAV rVBS in 4.0 ml of EMEM using a fenestrated catheter inserted into the area of the
posterior nares and the nasopharynx. Horses were monitored for the appearance of
clinical signs (cough, nasal discharge, anorexia, depression, edema and urticaria) twice
daily (AM and PM) for the first two weeks after inoculation and then once daily for two
additional weeks (Figure 4.1).
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Figure 4.1. Schematic representation of study design and timeline for experimental
EAV inoculation and sample collections.

Serum, blood for PBMC isolation and

PAXGENE® blood samples were collected prior and post challenge on the indicated days.
However, PAXGENE® tubes for cytokine mRNA analysis were collected up to 21 DPI,
whereas other samples were collected up to 42 DPI.

Clinical examinations and

nasopharyngeal swab collections were also performed on the same days up to 42 DPI.
Representative dot plots of dual-color immunofluorescence flow cytometry data of CD3+
T lymphoctyes are shown for each group with percentage (%) of infected cells indicated
on the right hand corner. X-axis of the plot represents relative fluorescence intensity
(RFI) of cells stained with EAV nsp1 AF488-conjugated antibody and Y-axis represents
the RFI of cells stained with antibody to CD3 surface molecule of equine T lymphocytes.

Blood samples were collected at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 days
post-inoculation (DPI) for complete blood cell counts. Approximately 3 ml of whole
blood was collected on 0, 2, 4, 6, 8, 10, 12, 14 and 21 DPI into PAXGENE® blood RNA
tubes (PreAnalyticX, Valencia, CA) for total RNA extraction from peripheral blood [396].
The tubes were equilibrated at room temperature for several hours and then stored at -
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20°C until processed. Blood samples were collected every other day during the first two
weeks after virus challenge for immediate PBMC isolation and subsequent staining of
CD3+ T cells infected with EAV as described above. Nasal swabs were collected at 0, 2,
4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 DPI using sterile rayon swabs (1/2” x 1”) with
plastic shafts (16”). After collection, the rayon tip of each swab was cut off into 7 ml of
virus transport medium (Hank’s balanced salt solution with penicillin, streptomycin,
gentamicin sulfate and amphotericin B; all from Life Technologies, Carlsbad, CA).
Subsequently in the laboratory, individual nasal swabs in transport medium were
transferred to the barrel of a 12 ml disposable syringe and expressed through a 0.45 µm
syringe filter (Millipore, Billerica, MA). Nasal swab elutes/filtrates were stored at -80°C
until tested. The serum neutralizing antibody response to EAV was determined in each
horse at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 DPI following previously described
protocols [337].

Virus isolation
Virus isolation was attempted from PBMCs and nasal swabs as previously
described [328,331]. Briefly, confluent monolayers of RK-13 cells in 6-well plates were
inoculated with serial 10-fold dilutions (100-105 in duplicate) and overlaid with RK-13
growth medium containing 0.75% carboxymethylcellulose. The cells were incubated at
37°C in the presence of 5% CO2 for 5 days and plaques were visualized by staining
monolayers with a solution of buffered formalin-crystal violet. A second passage was
performed 4 days after the initial passage.

Microneutralization assay
Neutralizing antibody titers of the test sera were determined as described by
Senne et al. [292,337]. Briefly, serial two-fold dilutions of each sample from 1:4 to
1:512 were made in EMEM (Invitrogen, Carlsbad, CA) containing 10% guinea pig
complement (Rockland Immunochemicals, Gilbertsville, PA). Each serum sample was
tested in duplicate in 96-well plates. An equal volume of virus dilution containing an
estimated 200 TCID50 of the modified live virus vaccine strain of EAV (ARVAC®, Pfizer
Animal Health, New York, NY) was added to each well, except serum and cell controls.
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The plates were shaken to ensure mixing of the well contents and then incubated for 1h at
37°C. A suspension of high passage (P399 to P409) RK-13 cells was added to each well
in a volume double that of the serum-virus mixtures and the plates were incubated in 5%
CO2 for 72 h at 37°C until viral cytopathic effect had fully developed in the virus control
wells. Antibody titers were recorded as the reciprocal of the highest serum dilution that
provided at least 50% protection of the RK-13 cell monolayer.

Proinflammatory and immunomodulatory cytokine mRNA expression in peripheral
blood mononuclear cells after experimental inoculation of EAV
The frozen PAXGENE® blood RNA tubes (PreAnalyticX, Valencia, CA) were
thawed and total RNA was extracted using the PAXGENE blood RNA extraction kit
(Qiagen, Valencia, CA) with an automated QIAcube (Qiagen, Valencia, CA) following
the manufacturer’s protocol. The RNA concentration was assessed at OD260nm and purity
was verified by the OD260/OD280 ratio using NanoDrop (Thermo Scientific, Wilmington,
DE). The reverse transcription reaction was performed with 0.5 μg of total RNA using
random hexamer primers and MultiScribe™ reverse transcriptase enzyme (High Capacity
cDNA Reverse Transcription kit with RNase inhibitor [Applied Biosystems, Foster City,
CA]) according to the manufacturer’s instructions. The reactions were incubated at 25°C
for 10 min, 37°C for 120 min and 85°C for 5 min. The cDNA samples were stored at 20°C until further analysis by quantitative RT-PCR (qRT-PCR).

Cytokine mRNA

expression was measured using equine specific intron-spanning primers/probe sets,
except for IFN-α which does not possess introns (Table 4.2)[397,398,399,400,401,402].
Briefly, PCR amplification was carried out using a 10μl reaction mixture containing 4.5
μl of diluted cDNA (1:1 dilution with nuclease-free water), 0.5 μl of 20X assay mix for
the primers/probe set of interest (Applied Biosystems, Foster City, CA) and 5 μl of
TaqMan® Gene Expression Master Mix (Applied Biosystems, Foster City, CA). Samples
were incubated in duplicate wells at 95°C for 10 min followed by 40 cycles at 95°C for
15 s and 60°C for 60 s using an Applied Biosystems 7500 Fast Real-Time PCR System.
For each sample, cDNA corresponding to the β-glucuronidase (β-GUS) gene was
amplified and used as an endogenous control for relative quantification of sample cDNA.
All PCR efficiency values were determined using LinReg [403]. Results were expressed
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as relative quantification (RQ) calculated as 2 -ΔΔCt where ΔΔCt = [(Avg. gene of interest
Ct – Avg. β-GUS Ct)

sample

– (Avg. gene of interest Ct – Avg. β-GUS Ct) calibrator] [404].

The calibrator was calculated from the mean ΔCt of pre-inoculation samples of each horse.
Validation of reference genes as internal controls
To determine the effect of the experimental treatment on the expression of
candidate internal control genes, four reference genes, β-glucuronidase (β-GUS), equine
β-2- microglobulin, β-actin and equine GAPDH were evaluated. PBMC samples were
prepared and infected as described previously. The relative amounts of reference genes
cDNA were determined by TaqMan real-time quantitative PCR. The relative amounts of
the endogenous controls were calculated using the 2-ΔC’T equation where ΔC’T = CT,Time xCT,Time 0 [404].

Statistical analysis
Two-way repeated measures-analysis of variance (ANOVA) (Holm-Sidak method)
was used to determine differences in body temperature, absolute lymphocyte counts,
virus titers from PBMCs and nasopharyngeal swabs and cytokine gene expression within
Group A and B horses. Significant differences were determined at the level of p <0.05.
Statistical analysis was performed using SigmaPlot® 11 (Systat Inc., Richmond, CA).
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Table 4.2. PCR primers and TaqMan® MGB probes specific for equine cytokines
Primersb and probec
Cytokine Namea
IL-1β [400,401]
EQIL-1B-JN2F
EQIL-1B-JN2R
EQIL-1B-JN2M2
IL-6 [400,401]
EQIL-6-IL6F
EQIL-6-IL6R
EQIL-6-IL6M2
IL-8
EQIL-8IS-JN1F
EQIL-8IS-JN1R
EQIL-8IS-JN1M2
IL-10 [397]
EQIL10IS-JN2F
EQIL10IS-JN2F
EQIL10IS-JN2M2
TNF-α [400,401]
EQTNFAIS-JN2F
EQTNFAIS-JN2R
EQTNFAIS-JN2M1
IFN-αd
EqIL-IFN-α F
EqIL-IFN-α R
EqIL-IFN-α Pro
IFN-γ [398]
EQIFNGIS-JN3F
EQIFNGIS-JN3R
EQIFNGIS-JN3M1
β-GUS [398,399,402]
GUS-GUSF
GUS-GUSR
GUS-GUSM2
a

Sequences (5'-3')
CCGACACCAGTGACATGATGA
ATCCTCCTCAAAGAACAGGTCAT
ATTGCCGCTGCAGTAAG
GGATGCTTCCAATCTGGGTTCAA
TCCGAAAGACCAGTGGTGATTTT
ATCAGGCAGGTCTCCTG
GCCGTCTTCCTGCTTTCTG
CCGAAGCTCTGCAGTAATTCTTG
CAACCGCAGCTTCAC
AGGACCAGCTGGACAACATG
GGTAAAACTGGATCATCTCCGAC
CCAGGTAACCCTTAAAGTC
TTACCGAATGCCTTCCAGTCAAT
GGGCTACAGGCTTGTCACTT
CCAGACACTCAGATCAT
TGACCTGCCTCACACCCATA
TTGTCCCAGGAGCATCAAGAC
CCTGGGCAACACAAG
AGCAGCACCAGCAAGCT
TTTGCGCTGGACCTTCAGA
ATTCAGATTCCGGTAAATGA
GCTCATCTGGAACTTTGCTGATT
CTGACGAGTGAAGATCCCCTTTT
CTCTCTGCGGTGACTGG

References are indicated in parenthesis
F-forward primer; R-reverse primer
c
Pro-Minor groove binding (MGB™) probe labeled with 5’ FAM (6-carboxyfluorescein) reporter dye and 3’ non-fluorescent quencher dye (NFQ)
d
New primers and probe were designed and validated for this study
b

4.4. RESULTS
In vitro CD3+ T lymphocyte susceptible phenotype of horses
As a prerequisite to the in vivo infection experiments, PBMCs from horses under
consideration for inclusion in the study were subjected to a phenotypic analysis to
determine their CD3+ T cell susceptibility following in vitro infection with EAV. Based
on their T cell phenotype, horses were divided into two distinct groups. Of 62 horses
screened, 4 horses with CD3+ T cells that could be infected (susceptible) with EAV VBS
were selected and included in Group A and 4 other horses with CD3+ T cells resistant to
EAV VBS infection were included in Group B. Dot plots of flow cytometric analysis
showing infectivity of CD3+ T cells are shown in Figure 4.2 for each horse included in
the study. The percentage of the CD3+ T cell subpopulation susceptible to EAV ranged
from 2.3% to 10.3% in Group A horses (Figure 4.2). After assessing the phenotype,
horses were challenged intranasally with the EAV rVBS.
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Figure 4.2. Phenotypic analysis of horses used to identify two experimental groups
in the study. Horses were divided into Groups A and B based on their susceptibility of
CD3+ T

lymphocytes

to

infection

with

the

EAV

VBS

using

dual-color

immunofluorescence flow cytometric analysis. Dot plot of VBS infection is shown for
each horse used in the study. X-axis of the plot represents relative fluorescence intensity
(RFI) of cells stained with EAV nsp1 AF488-conjugated antibody and Y-axis represents
the RFI of cells stained with antibody to CD3 surface molecule of equine T lymphocytes.
Horse ID and percentage (%) of infected CD3+ T lymphocytes are identified on the right
hand corner of each dot plot.
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Clinical disease and virus shedding
Following experimental infection with EAV rVBS, febrile responses were
observed in all horses from both groups starting at 3 DPI and persisting (5-6 days) until 8
or 9 DPI (Figure 4.3.A). However, there was a consistent trend toward higher body
temperatures in Group B horses from 3-8 DPI that culminated in statistically significant
increases (p <0.05) in febrile responses compared to all Group A horses at 7 and 9 DPI.
The febrile response was also delayed in Group A horses with the peak temperature on 8
DPI which occurred on 7 DPI in Group B. In addition to febrile responses, other clinical
signs commonly associated with exposure to EAV were more pronounced in Group B
horses. Three out of 4 members of this group had continuous serous nasal discharge
lasting 3 to 4 days, with one horse (E9) having particularly severe respiratory distress
with labored breathing (respiratory rate >30/min) for 2 days. All Group B horses had
congestion coupled with petechial hemorrhages on oral mucous membranes (Figure 4.4.A)
from 7-8 DPI and 3 out of 4 of these animals developed mild to moderate hind leg edema,
restricted to the fetlocks (Figure 4.4.B).

In contrast, a serous nasal discharge was

encountered (present for 4 days at 6-9 DPI) in only one horse in Group A (F84).
Furthermore, petechial hemorrhages on oral mucous membranes were not seen in any
Group A horse, and only one member of this group (F84) developed hind leg edema
which was mild compared with that seen in Group B subjects. However, one Group A
mare (F23) developed skin eruptions (hives) on the body (Figure 4.4.C), while another
mare (E7) in the same group had mild mammary gland edema (Figure 4.4.D) that lasted
for more than 10 days. Horses in both groups developed severe lymphopenia between 48 DPI (Figure 4.3.B) and although this appeared to be more pronounced in Group B
horses between 4-8 DPI, this trend was not confirmed by subsequent statistical analysis.
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Figure 4.3. The body temperatures, peripheral blood lymphocyte counts, and virus
titers in nasal secretions and blood.

Rectal temperature (A), peripheral blood

lymphocyte counts (B), virus isolation from peripheral blood mononuclear cells (C) and
nasal secretions (D) of both groups of horses inoculated with EAV rVBS. The mean and
standard deviation are shown in all panels. Days when horses developed maximum
clinical outcomes are boxed in yellow.
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Figure 4.4.

Representative examples of clinical signs following experimental

inoculation of EAV rVBS. (A) Petechial hemorrhages, (B) limb edema, (C) hives and
(D) mammary edema.

Horses from both groups had detectable viremia levels from 4-10 DPI with peak
titers occurring at 8 DPI (Figure 4.3.C). As might be predicted from the clear differences
in clinical signs, viral titers in PBMCs were statistically significantly higher in Group B
compared to Group A horses at 6 and 8 DPI (p <0.05). Although these results appeared
to be contradicted by amounts of virus detected in nasal secretions (Figure 4.3.D), the
differences between the groups were due entirely to a single horse (F84) in Group A that
had a 55-fold higher virus titer in nasal swab material on day 6 post-inoculation
compared to the other members of its cohort. This subject was the only Group A
recipient to present with a prolonged nasal discharge and interestingly, compared with the
other group members, had the lowest percentage of EAV susceptible CD3+ T
lymphocytes (2.3%; Figure 4.2). As a result of this one “super-shedder”, the viral titers
present in nasal swab material were not statistically different between the two groups.
Attempts to detect EAV infected CD3+ T cells in peripheral blood analogous to those
observed following in vitro infection of PBMCs were conducted using dual-color flow
cytometry with antibodies to CD3 surface molecule and EAV nsp1 protein (intracellular
staining).

Unfortunately, CD3+ T lymphocytes expressing intracellular EAV nsp1
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antigen were not detected in any of the horses (either group) during the first 2 weeks of
acute infection.
Humoral responses following inoculation with the EAV rVBS were identical between the
horses of both groups with serum neutralizing antibody titers being detectable at 8 DPI
and increasing to≥1:512 by 10 DPI (Figure

4.5).

The appearance of neutralizing

antibodies in peripheral blood was directly correlated with significant decreases in
viremia and virus shedding in nasal secretions coupled with a return to normal clinical
values.

Figure 4.5.

Serum neutralizing antibody responses in both groups of horses

inoculated with EAV rVBS. The mean and standard deviation of reciprocal antibody
titers are shown.

Proinflammatory and immunomodulatory cytokine gene expression in peripheral
blood
There were significant differences between Group A and B horses in the level
and/or kinetics of cytokine mRNA expression as determined by qRT-PCR analysis
(Figure 4.6).

Although increased amounts of IL-1β mRNA were observed in all

experimental subjects following infection with EAV rVBS, the kinetics were
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significantly different between the two groups. In Group A horses, IL-1β mRNA reached
maximal levels just 2 days after infection, whereas peak amounts were not observed in
Group B horses until 6 DPI (Figure 4.6.A). A very similar kinetic distribution was
observed for IL-6 with maximum mRNA levels seen at 2 DPI for Group A horses
compared with 4 DPI for Group B (Figure 4.6.B) recipients. Although the kinetics of IL8 and IFN-γ mRNA expression were broadly similar between groups, with a correlation
between maximal levels and peak viral burdens, significantly higher amounts (p <0.05) of
mRNAs encoding these cytokines were produced in Group B horses (Figures 4.6 C, F).
Of the panel of cytokines investigated, only TNF-α mRNA levels appeared to be similar
between Group A and B horses both in terms of the time and the duration of increased
expression levels (Figure 4.6.D). Although increases in overall TNF-α mRNA amounts
appeared to be higher in Group B horses consistent with their more severe clinical signs,
this difference was not confirmed statistically. Somewhat surprisingly, EAV infection did
not stimulate significant increases in IFN-α expression in any of the Group A recipients.
In contrast, there was substantial induction of IFN-α mRNA synthesis in Group B horses
(Figure 4.6.E). Just as with IFN-α mRNA, EAV infection did not stimulate IL-10 gene
expression in any of the Group A horses, whereas expression of this gene was upregulated in the Group B experimental subjects. In all Group B horses, there were
significant (p <0.05) increases in IL-10 mRNA levels at 4 and 8 DPI compared with preinfection amounts and the equivalent Group A post-infection time-points (Figure 4.6.G).
In summary, with the exception of TNF-α, there were significant differences between the
two groups of horses in expression of both proinflammatory (IL-1β, IL-6 and IL-8) and
immunomodulatory (IFN-α, IFN-γ, and IL-10) cytokines indicating that they may
influence the clinical outcome along with innate and cellular immune response to EAV.
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Figure

4.6.

Relative

quantification

(RQ)

of

proinflammatory

and

immunomodulatory cytokine mRNA expression in Group A and Group B horses.
Mean (±SE) mRNA expression of proinflammatory cytokines (A) IL-1β, (B) IL-6, (C)
IL-8, (D) TNF-α and mean mRNA expression of immunomodulatory cytokines (E) IFNα, (F) IFN-γ and (G) IL-10. Statistically significant difference (p <0.05) between Group
A and B horses is indicated with an asterisk (*).
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4.5. DISCUSSION
Previous work in our laboratory using an in vitro dual-color flow cytometry assay
demonstrated that horses could be grouped into two populations based on the
susceptibility of CD3+ T lymphocyte subpopulations to infection with EAV [330].
Although progeny virions were not detected [330] suggesting infection of CD3+ T
lymphocytes is not fully permissive, it was hypothesized that the presence of virus
specific structural and/or non-structural proteins could modify functional characteristics
of these cells. Therefore, the objective of this study was to determine if the differences in
the susceptibility or resistance of CD3+ T cells in vitro correlate with clinical outcome to
exposure in vivo. These studies were conducted using viruses derived from a virulent
infectious EAV cDNA clone to minimize, as far as possible, the effects of variation
occurring within the viral population or quasispecies [328]. To our knowledge, there
have been no published reports demonstrating an association between clinical outcome
following exposure to EAV and specific host factors. The results described here clearly
demonstrate that while other environmental and/or host factors are likely to be important
as exemplified by the atypical prolonged nasal discharge coupled with high-titer
respiratory tract virus shedding seen in the Group A horse (F84), there is a correlation
between clinical response to EAV infection in vivo and the susceptibility of CD3+ T
lymphocytes in vitro. Horses with the CD3+ T lymphocyte resistant phenotype (Group B)
had higher febrile responses, possessed higher titers of virus in blood, were the only
experimental subjects to have petechial hemorrhages on oral mucous membranes and
were more likely to suffer hind leg edema or develop serous nasal discharges than horses
with the CD3+ T lymphocyte (Group A) susceptible phenotype. However, the overall
duration of clinical signs and development of humoral immune responses associated with
viral clearance were indistinguishable between horses in these two groups.
In addition to clinical signs, there were significant differences between Group A and
Group B horses in proinflammatory cytokine gene expression. At present, the regulatory
mechanisms controlling these very different cytokine mRNA expression profiles in these
two groups of horses are unknown. However, production of TNF-α, IL-1β and IL-8 by
macrophages has been shown to contribute to the pathogenesis of EVA [257] by
enhancing macrophage activation and exerting profound effects on endothelial cells
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leading to increased vascular permeability with subsequent tissue edema producing
clinical signs that are characteristic of severe EVA. Furthermore, IL-6 may contribute to
the overall severity of disease by stimulating prostaglandin E2 (PGE2) synthesis leading
to increases in febrile responsiveness. Therefore, by comparison with horses in Group A,
subjects in Group B have higher levels of mRNA encoding IL-1β, IL-6, IL-8 and
possibly TNF-α, all inflammatory cytokines with the potential to augment the
pathogenicity of EAV at times when viral burdens attain their highest levels. At present,
it is not known if the early (2 DPI) short pulse of increased IL-1β and IL-6 expression
seen in Group A horses that is predicted to stimulate for example, the synthesis of acutephase proteins, has any limiting effects on EAV replication.
Significant differences between Group A and Group B horses following infection
with the EAV rVBS were also seen in IFN-α mRNA levels and in expression of the
immunomodulatory cytokines IFN-γ and IL-10. The failure to mount a strong IFN-α
induction could affect both innate and adaptive immune responses in Group A horses.
Specifically, reduced IFN-α production could lead to slow dendritic cell maturation,
antigen-specific CD8+ T cell maturation, as well as slow IFN-γ and other cytokine
production. Furthermore, EAV infection did not stimulate IL-10 expression compared to
pre-infection levels in any Group A horse. In contrast, significant increases in IL-10
mRNA amounts, compared with both pre-infection levels and equivalent time-points for
Group A animals, were observed in all group B horses at 4 and 8 DPI (Figure 4.6.G). IL10 was originally considered as a cytokine that modulates the balance of Th1/Th2
response, in favor of the Th2-type response [405]. It inhibits macrophage activation and
antigen presentation, thereby inhibiting T cell function. The IL-10 secreted by regulatory
T (Treg) cells reduces T-cell-mediated immune inflammation by inhibiting cytokine
production (IL-1, IL-6, IL-12, TNF-α and the chemokine IL-8) in macrophages and Th1
cells (IFN-γ) [406]. As a result, IL-10 can limit and eventually terminate inflammatory
responses caused by infectious agents [333]. Therefore, it is likely that IL-10 expression
is up-regulated in Group B but not in Group A subjects because of the higher levels
and/or different kinetics of inflammatory cytokine expression observed in horses with
CD3+ T lymphocytes that are resistant to infection with EAV. Although increased EAVinduced IFN-γ expression was present in PBMCs from some Group A horses,
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significantly higher levels of mRNA encoding this cytokine were observed at 8 DPI in
Group B horses. Together, these results demonstrate that EAV induces very different
cytokine expression profiles in Group A and Group B horses.

At present, the

mechanism(s) underlying these differences is not known, although the possibility exists
that it may be a direct effect caused by EAV infecting and then modifying the functional
and/or regulatory properties of specific T-lymphocyte subsets within the CD3+ T
lymphocyte population. The fact that nsp1 expressing CD3+ T lymphocytes were not
found in peripheral blood samples from EAV infected Group A horses is perhaps not
surprising considering the blood volume of a typical horse is approximately 45 L. In
addition, it is very likely that most infected T cells will be present within the tissue sites
supporting active viral replication rather than in general circulation.
Unfortunately, the small subpopulation(s) of CD3+ T lymphocytes that are
susceptible to infection with EAV in PBMCs of Group A horses is unknown at present.
During in vitro infection experiments with PBMCs harvested from more than 400 horses,
the percentage of infected CD3+ T lymphocytes ranged from 2.3 to 20%, depending on
the individual animal (data not shown). Previously, we have reported that the majority of
CD3+ T lymphocytes infected with EAV are CD4+ rather than CD8+ T cells [330].
Regulatory T cells are a subset of CD4+ T cells with natural immune-suppressive activity
[407].

In this respect, we hypothesize that the small subpopulation of CD3+ T

lymphocytes infected with EAV could be Treg lymphocytes. Unfortunately, there are no
commercial or published antibodies specific for equine Treg cells, such as the antibodies
available to the Foxp3 and CD25 Treg markers of other species. However, it may be
possible to purify dual labeled nsp1/CD3+ expressing T cells by flow cytometry and
characterize them by PCR analysis using primers for transcription factors that are specific
for the different T helper cell types (Horohov, personal communication).
Although infection coupled with disruption to the functional properties of specific
T-cell subsets might account for all of the observed differences between Group A and B
horses following infection with EAV, this could also be just one manifestation of a more
general mechanism affecting a range of cell types. In this alternative broad-spectrum
model, variation in genotype between Group A and B horses is predicted to induce direct
effects in numerous cell-types that fundamentally alter the way in which horses respond
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following exposure to EAV in terms of permissiveness for viral replication, clinical
responses and cytokine production. Unfortunately, we cannot distinguish between these
two alternatives at the present time. The genome-wide analysis reported above has
shown the susceptibility or resistance of CD3+ T lymphocytes to infection with EAV is
associated with a genetically dominant haplotype on horse chromosome 11 in the region
ECA11: 49572804-49643932 (Go et al. unpublished data).

There are a number of

candidate genes within this region that could influence EAV replication or host responses
to this virus and that are actively associated with immune (innate and adaptive) and
inflammatory responses. As an example, in addition to a role in the chemotatic response,
ARRB2, encoded by β-arrestin-2, is believed to control NFκB signaling by interacting
with IκBα. Furthermore, this protein may also modulate MAP kinase activity. Another
example is the gene encoding the nucleoporin protein (NUP88) that promotes retention of
NFκB in the nucleus and is required for the transport of key immune regulators such as
the Rel-like transcription factors. Although considerable additional effort is required to
fully characterize the structural gene or regulatory sequences involved, there is a very
clear genetic correlation between both the susceptibility or resistance of CD3+ T
lymphocytes in vitro and the different clinical/cytokine expression responses observed in
Group A compared to Group B horses following infection with EAV.

It is hoped

identifying the role of host factors encoded by genes within ECA11: 49572804-49643932
will advance our understanding of the molecular interactions between EAV and its host.
In summary, our findings demonstrate that clinical signs and viremia burdens are
more severe in horses with CD3+ T lymphocytes that are resistant (Group B) compared
with those that are susceptible (Group A) to EAV infection in an in vitro experimental
system.

Furthermore, these separate groups within the horse population have

significantly different cytokine expression profiles following exposure to EAV. At this
stage, it is not clear whether higher viremia levels cause these differences or if they are
the result of genetically programmed intrinsic responses that for example, in Group B
horses may actually promote viral replication and facilitate more severe clinical disease.
Although genetic variability is frequently predicted to account for some of the disparities
in virus-induced clinical signs observed between individuals, this is the first study to
provide direct evidence for a correlation between variation in the genotype of horses and
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phenotypic differences in terms of the extent of viral replication, severity of disease and
cytokine gene expression caused by exposure to EAV.

Although the nucleotide

sequences located in ECA11: 49572804-49643932 involved in this phenomenon have yet
to be determined, this study provides inroads for explaining at least some of the variation
in clinical signs seen among horses after infection with a virulent strain of EAV. It is
anticipated that future genetic characterization experiments will increase our
understanding of the pathogenesis of EAV, plus contribute towards identification of
molecules involved in controlling innate and/or adaptive immune responses.
Furthermore, such studies may enable the mechanisms associated with the ability of EAV
to persist within certain stallion populations to be elucidated leading to effective
treatments or the option to preventive measures to prevent establishment of the carrier
state in particular those at higher risk.
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CHAPTER FIVE
In vitro susceptibility of CD3+ T lymphocytes to EAV infection reflects genetic
predisposition of stallions at risk of becoming carriers

5.1. SUMMARY
Following equine arteritis virus (EAV) infection, a variable proportion of stallions
(30-70%) can become persistently infected and continuously shed the virus in their semen.
Carrier stallions are the natural reservoir of EAV and ensure the virus is maintained in
equine populations between breeding seasons by continuously shedding the virus in their
semen. Recent studies in our laboratory have shown that an in vitro assay based on dual
color flow cytometry analysis of CD3+ T cells could be used to divide the horses into
susceptible and resistant groups. In this study, we have extended these previous studies
and established a possible correlation between susceptibility of CD3+ T lymphocytes to
EAV infection and establishment of persistent infection in stallions.

The data showed

that carrier stallions that have the susceptible CD3+ T lymphocyte phenotype to EAV
infection may represent those at higher risk of becoming persistently infected compared
to stallions that do not possess this phenotype.
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5.2. RESULTS AND DISCUSSION
Equine arteritis virus (EAV) is a small enveloped virus with a positive-sense,
single-stranded RNA genome that belongs to the family Arteriviridae (genus Arterivirus,
order Nidovirales) [7,34]. EAV is the causal agent of equine viral arteritis (EVA) which
is a respiratory and reproductive disease of horses and other equid species [76,77]. The
vast majority of EAV infections are inapparent or subclinical [76,77,395] in nature, but
occasional outbreaks occur which are characterized by influenza-like signs in adult
horses, abortion and pneumonia in young foals [77,353]. Following EAV infection, a
variable proportion of stallions (30-70%) can become persistently infected and
continuously shed the virus in their semen [77,190]. Carrier stallions are the natural
reservoir of EAV; they ensure the virus is maintained in equine populations between
breeding seasons [77,189]. The continued growth in international trade of horses and
semen has served as a significant means of dissemination of EAV strains around the
world [77,78,188,189,356,408]. Therefore, identification of carrier stallions is of critical
epidemiological importance in the prevention and control of EAV infection
[76,77,199,354,408]. The mechanism of persistence of EAV in the male reproductive
tract is not clear. Studies have established that persistence of EAV in the stallion is
testosterone-dependent [217,218].

Although multiple factors may contribute to

development of the carrier state, host genetic variation is assumed to explain the
individual differences in occurrence of the carrier state as well as virus clearance because
such variations exist even after exposure to the same virus. Moreover, the prevalence of
EAV infection varies markedly among different breeds of horses strengthening the
assumption of genetic influence [77]. Recently, we demonstrated differences in in vitro
susceptibility of CD3+ T lymphocytes to EAV infection that have a strong association of
genetic markers with de facto proof that the trait is under genetic control by conducting a
genome-wide association study (GWAS; Go et al., in press [chapter 3]). The objective of
current study is to establish a correlation between susceptibility of CD3+ T lymphocytes
to EAV infection and establishment of persistent infection in stallions. We were fortunate
to find stallions that became EAV carriers after natural exposure and stallions that did not
became carriers after exposure to EAV (seroconverted by natural exposure and not by
vaccination against EVA). To ensure carrier status, isolation of EAV from equine semen
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samples was attempted in high passage (P399-409) rabbit kidney-13 (RK-13) cell lines
according to the OIE described protocol [292]. Subsequently, PBMCs were collected
from carrier (n=7) and non-carrier (n=7) stallions. The susceptible or resistant phenotype
of each animal was defined by dual color flow cytometric analysis of in vitro EAV
infected CD3+ T lymphocytes as described previously [330]. Briefly, 1 × 106 PBMCs
isolated from peripheral blood by centrifugation through Ficoll-Paque Plus (Amersham
Biosciences, Piscataway, NJ) were infected with the virulent Bucyrus strain (ATCC VR796) of EAV at an m.o.i of 2. Subsequently, infected PBMCs were incubated with
monoclonal antibody (MAb) specific for equine CD3+ T cells and with secondary R-PEconjugated goat anti-mouse IgG1 (Southern Biotech, Birmingham, AL). Intracellular
staining for EAV antigen was performed using Alexa Fluor 488-conjugated anti-EAV
nps1 (12A4) MAb. Two-color cytometric acquisition was done using a FACScalibur and
data was analyzed by CellQuest software (Becton Dickinson, San Jose, CA). Results
were expressed as the percentage of CD3+ T lymphocytes infected with EAV after
subtraction of cells stained with mouse IgG1 (MOPC; Sigma, St. Louis, MO) isotype
control antibody. Interestingly, CD3+ T lymphocytes from all EAV carrier stallions were
susceptible to in vitro EAV infection (Figure 5.1.A).

The percentage of CD3+ T

lymphocytes susceptible to EAV infection ranged from 4% to 17% among carrier
stallions. In contrast, none of the EAV non-carrier stallions had the CD3+ T lymphocyte
susceptible phenotype (Figure 5.1.B). The data suggested that carrier stallions that have
the susceptible CD3+ T lymphocyte phenotype to EAV infection represent those at higher
risk of becoming persistently infected compared to stallions that do not possess this
phenotype.
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Figure 5.1. Dual-color immunofluorescence flow cytometry analysis of carrier and
seropositive non-carrier stallions. (A) Carrier status was confirmed by isolating EAV
from semen. (B)Non-carrier stallions are seropositive horses with antibodies specific to
EAV after natural exposure to EAV and not due to vaccination. Cells double stained with
anti-CD3 and anti-nsp1 (12A4) MAbs are shown in the upper right quadrant of each dot
plot.

Previously, we have identified a dominant haplotype associated with the
susceptible phenotype in a region of equine chromosome 11 (ECA11): 4957280449643932 by testing four horse breeds (Thoroughbred, Saddlebred, Strandardbred and
Quarter horses). The presence of the common haplotype suggested that the trait occurred
in a common ancestor of all four breeds that might have segregated among modern horse
breeds (discussed in detail in chapter 3 of the dissertation; Go et al., in press).

To

evaluate whether the same haplotype is associated with carrier and non-carrier status,
ECA11: 49572804-49643932 region of stallions included in the study was genotyped
using Sequenom MassARRAY® system (Sequenom Inc., San Diego, CA). Briefly,
genomic DNA (gDNA) was isolated from PBMCs of each animal using Puregene whole
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blood extraction kit (Qiagen, Valencia, CA) following the manufacturer’s instructions.
DNA from these horses was genotyped for single nucleotide polymorphisms (SNPs)
using the EquineSNP50 BeadChip (Illumina, San Diego, CA). Using the option for
association studies, the distribution of SNPs was compared between carrier and noncarrier stallions. The SNP data (Table 5.1) showed that five out of seven carrier stallions
with the CD3+ T lymphocyte susceptible phenotype had the “GGAGGT” haplotype
previously reported to be highly associated with the trait (Go et al., in press [chapter 3]).
Unfortunately, the association of the trait with the genetic markers was imperfect since
two carrier stallions (CB and I050) were found without the “GGAGGT” haplotype
implicated for susceptibility. This emphasizes once again the limitation of low coverage
SNPs available for equine and results could be inaccurate. The possibility that the
“GGAGGT” haplotype associated with CD3+ T lymphocyte susceptibility is not
conserved in all horse breeds, such as Dutch Warmblood and Rocky Mountain Paint,
cannot be excluded (Table 5.1).
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Table 5.1. Haplotype of carrier and non-carrier stallions for selected SNPs in ECA11:
49572804-49643932
Phenotype

Status

Horse ID

HAP1

HAP2

Breed

Positive

EAV shedder

CB

CACATC

GGAGGC

Dutch Warmblood

Positive

EAV shedder

G83

CACATC

GGAGGT

QH

Positive

EAV shedder

H069

GGAGGT

GGAGGC

Paint

Positive

EAV shedder

I050

GGAGGC

GGAGGC

Rocky Mountain Paint

Positive

EAV shedder

I070

GGAGGT

GGAGGC

TWH

Positive

EAV shedder

#18

GGAGGT

GGAGGT

STB

Positive

EAV shedder

NM-MR

GGAGGT

GGAGGC

QH

Negative

Non-shedder

I062

GGAGGC

GGAGGC

Rocky Mountain X

Negative

Non-shedder

NM-T

TB

Negative

Non-shedder

NM-SR

QH

Negative

Non-shedder

NM-CC

QH

Negative

Non-shedder

NM-D

TB

Negative

Non-shedder

NC-R

GGAGGC

GGAGGC

Dutch Warmblood

Negative

Non-shedder

CA-W

GGAGGT

GGAGGC

Hanoverian

NOTE: The positive and negative phenotype refers to in vitro CD3+ T lymphocyte
susceptibility and resistance, respectively. The haplotype “GGAGGT” associated with
CD3+ T cell susceptibility is highlighted in yellow as described elsewhere (Go et al., in
press [chapter 3]). Each haplotype is highlighted with a different color.
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Larger numbers of carrier and non-carrier stallions (naturally exposed) are needed
to draw definite conclusions about the link between CD3+ T cell susceptibility to EAV
infection and the genetic traits of horses at risk to become carrier stallions after exposure
to EAV. However, it is a challenge to find a large number of such stallions, especially
the non-carrier stallions that have seroconverted due to natural exposure to the virus.
Ultimately, results from this study are being confirmed in an in vivo study with
experimental infection of stallions with susceptible and resistant CD3+ T lymphocyte
phenotypes with EAV to see whether stallions with CD3+ T lymphocytes are at higher
risk of establishing carrier status compared to those with the resistant phenotype.
The data presented in this study clearly demonstrated that there is a genetic
difference between stallions that become carriers after exposure to EAV and those that
are able to clear the virus, non-carrier stallions.

The trait could be determined by

assessing the susceptibility of their CD3+ T lymphocytes to in vitro VBS EAV infection
which is likely to be the most precise method. However, it is expensive, time consuming
and cumbersome to run on a routine or large-scale basis.

This study provides the

possibility of development of a genetic test to identify stallions that are predisposed to
persistent infection.

It would allow us to develop new and improved prevention

strategies in horses.

Eventually, findings from this study will allow us to develop

diagnostic tools to predict possible carrier stallions of EAV and prevent further spreading
of the virus.

Copyright © Yun Young Go 2011
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CHAPTER SIX
Equine arteritis virus does not induce type I interferon α/β production in equine
endothelial cells: Identification of nonstructural protein 1 as a main interferon
antagonist

6.1. SUMMARY
The primary objective of this study was to investigate the effect of equine arteritis
virus (EAV) on type I IFN production. Equine endothelial cells (EECs) were infected
with virulent Bucyrus strain (VBS) of EAV at a multiplicity of infection (m.o.i) of 5 and
type I IFN (IFN-α/β) expression at mRNA and protein levels were measured by real-time
RT-PCR and IFN bioassay using vesicular stomatitis virus expressing the green
fluorescence protein (VSV-GFP), respectively.

Sendai virus (SeV), a well-known

inducer of type I IFN, was used as the positive control for type I IFN induction. IFN-α
and IFN-β mRNA levels in EECs infected with EAV VBS were not increased compared
to those in mock-infected cells, whereas SeV infection strongly induced production of
IFN-α and IFN-β mRNA in the same type of cells at both 3 and 6 h.p.i. Protein levels
determined by IFN bioassay provided additional confirmation of this finding.
Subsequently, the potential of each of the 12 nonstructural proteins (nsps) of EAV to
antagonize type I IFN production was determined by IFN-β promoter luciferase reporter
system. The results demonstrated that nsps 1, 2 and 11 had the capability to inhibit type I
IFN activity. Of these three nsps, nsp1 exhibited the strongest inhibitory effect by
inhibiting IFN synthesis. Collectively, these data demonstrated that failure to induce type
I IFN in EAV infected cells may allow the virus to subvert the equine innate immune
response. EAV nsp1 may play a critical role in producing this effect.

145

6.2. INTRODUCTION
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA),
a respiratory and reproductive disease of horses [77]. EAV is a small enveloped virus
with a positive-sense, single-stranded RNA genome of ~12.7 kb which belongs to the
family Arteriviridae (genus Arterivirus, order Nidovirales), which also includes porcine
reproductive and respiratory syndrome virus, simian hemorrhagic fever virus, and lactate
dehydrogenase-elevating virus of mice [7,34]. The EAV genome includes nine known
functional open reading frames (ORFs 1a, 1b, 2-7) [34,56]. ORFs 1a and 1b are located
in the 5’-proximal three-quarters of the genome and are translated to produce replicase
polyproteins pp1a and pp1ab (1,727 and 3,175 amino acids, respectively), with the latter
being a C-terminally extended version of the former [141]. ORF 1b translation depends
on a -1 ribosomal frameshift just before termination of ORF 1a translation [10]. The two
replicase precursor polyproteins are cleaved by three different ORF 1a-encoded proteinases
yielding at least 13 end products named nonstructural protein (nsp) 1 to 12 (including a
recently described nsp7α and 7β) [113]). The three EAV proteinase domains are located in
nsp1, nsp2 and nsp4 [34,66]. The remaining eight ORFs (2a, 2b and 3, 4, 5a, 5b and 6-7)
are located in the 3’ quarter of the genome and encode the structural proteins (GP2, E,
GP3, GP4, ORF5a protein, GP5, M and N, respectively) of the virus [57,58,81,137].
The type I interferon (IFN-α/β) is a key component of the host innate immune
response to viral infection. Recognition of pathogen-associated molecular pattern (PAMPs)
in double-stranded RNA (ds RNA) by intracellular receptors, such as retinoic acid inducible
gene I protein (RIG-I) and melanoma differentiation-associated gene product (MDA5) [409]
activates protein signaling cascades that result in activation of antiviral transcription factors
such as interferon regulatory factor-3 (IRF-3), nuclear factor-кB (NF-кB) and activating
protein 1 (AP1) [410]. The IFN-β promoter contains four positive regulatory domains
(PRDs), including the binding site for three different transcription factors, IRF-3 (PRDs I
and III), NF-κB (PRDII) and AP1 (PRD IV). Activation of these transcription factors
triggers the formation of enhanceosomes in the cell nucleus and induces the expression of
IFN-α/β . [410,411].
Many viruses have evolved strategies to counteract key elements of the IFN
response and prevent development of an antiviral environment in the host. The innate
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immune response to EAV infection is poorly characterized. Recently, it had been shown
that porcine reproductive and respiratory syndrome virus (PRRSV), a close relative of
EAV antagonizes type I IFN production in infected cells [412,413,414,415,416,417].
Based on this finding, we hypothesized that EAV infection may also down regulate type I
IFN response in infected cells and that the nsps of the virus may play an important role in
subverting the host innate immune response. To test this hypothesis, we investigated the
ability of EAV to modulate type I IFN response in infected cells. Specifically, we
investigated the mechanisms used by EAV to inhibit type I IFN production in infected
cells and the possible role of EAV nsps as modulators of the innate immune response.

6.3. MATERIALS AND METHODS
Virus and cells
Equine pulmonary artery endothelial cells (EECs), baby hamster kidney 21
(BHK-21 [ATCC CCL-10]) and HEK293T cells (kindly provided by Dr. Ying Fang,
South Dakota State University, Brookings, SD) were maintained in Dulbecco’s modified
essential medium (Mediatech, Herndon, VA) with sodium pyruvate, 10% fetal bovine
serum (FBS; HyClone Laboratories, Inc., Logan, UT), 100 U/μg per ml penicillin
streptomycin, and 200 mM L-glutamine. HeLa (ATCC CCL-2) and MDBK (ATCC
CCL-22) cells were grown in Eagle’s minimum essential medium with 10% ferritinsupplemented bovine calf serum (Hyclone Laboratories, Inc., Logan, UT) and 100 U/ μg
per ml penicillin/streptomycin (Gibco, Carlsbad, CA).

The experimentally derived

virulent Bucyrus strain (VBS) of EAV was propagated once in EECs to prepare high
titered working stocks for the present study as previously described [343,344]. Sendai
virus (SeV; Cantell strain) was purchased from American Type Culture Collection
(ATCC VR-907; Manassas, VA), propagated once in embryonated chicken eggs to
prepare the working virus stock. The virus titer was determined by hemagglutination
inhibition assay using chicken red blood cells as described previously [418]. Vesicular
stomatitis virus expressing green fluorescent protein (VSV-GFP; [419]) was kindly
provided by Dr. Adolfo Garcia-Sastre (Mt. Sinai School of Medicine, New York, NY).
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Plasmids
The construction of plasmids for expression of recombinant EAV nsp1 to nsp12
in mammalian cells has been previously described [420]. Briefly, the coding regions of
each of the twelve nsps were PCR-amplified from the EAV rVBS full-length infectious
cDNA clone [328] and cloned into the pCAGGS eukaryotic expression vector [421]. The
nsp5, nsp6, nsp10 and nsp12 were constructed as C-terminal FLAG-tagged fusion protein.
Expression of recombinant EAV nsps was performed in BHK-21 cells transfected with
individual plasmids containing nsp1 to nsp12 coding regions using Fugene HD (Promega,
Madison, WI) according to manufacturer’s instructions.
recombinant

protein

was

confirmed

by

The authenticity of each

immunofluorescence

and

Western

immunoblotting assays. Reporter plasmids expressing the firefly luciferase under the
control of either the IFN-β promoter (p125-Luc) or an artificial promoter containing three
IRF3 binding sites (p55-CIB-Luc) were kindly provided by Dr. Takashi Fujita [422].
The pNF-кB-Luc or pISRE-Luc reporter plasmids expressing the firefly luciferase under
the control of a promoter with NF-кB-response element or the interferon-stimulated
response element (ISRE) was purchased from Stratagene (La Jolla, CA). The pRL-SV40
plasmid that expresses a Renilla luciferase under the control of a simian virus (SV40)
promoter was purchased from Promega (Madison, WI). The pEFneo-RIG-I, pEFneoMDA5, and pEFneo-IKKε were kindly provided by Dr. Bin Gotoh [423]. The pcDNA3TRIF was purchased from Addgene (Cambridge, MA). Construction of pCAGGS-IRF3
plasmid was described previously [415].

Antibodies
To detect EAV antigens in infected cells, MAbs against EAV nonstructural
protein-1 (nsp1; MAb 12A4) and nucleocapsid protein (N; Mab 3E2) were used
[213,306]. Protein-specific polyclonal rabbit antisera recognizing EAV nsp2 [110], nsp3
(rabbit 98.E3, [84]), nsp4 (a 1:1 mix of anti-nsp4M and anti-nsp4C; [110]), nsp7-8 [110],
and nsp10 [87] have been previously described. In addition, antisera against nsp9 and
nsp11 were raised by immunizing rabbits with purified full-length recombinant proteins
expressed in E.coli (J.C. Zevenhoven, D. D. Nedialkova and E. J. Snijder, unpublished
data).

Commercially available anti-FLAG (Agilent Technologies, Santa Clara, CA)
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monoclonal

antibody

was

used

to

detect

FLAG-tagged

fusion

immunofluorescence and Western immunoblotting analyses.

proteins

in

Rabbit polyclonal

antibodies for human IRF3 (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-β-actin
(Cell Signaling, Danvers, MA) and monoclonal antibodies for human NF-кB p65 (Santa
Cruz Biotechnology) were used. Phosphorylation-specific rabbit polyclonal antibodies
for phospho-IRF3 (Ser398; Upstate Millipore, Billerica, MA), and phospho-NF-кB p65
(Ser276; Santa Cruz Biotechnology) were used for immunofluorescence and Western
immunoblotting analyses.

RNA extraction and quantitative real time RT-PCR
Total RNA was extracted using MagMAX™-96 Total RNA Isolation kit (Ambion,
Austin, TX) according to the manufacturer’s recommendations in a MagMAX™
Express-96 magnetic particle processor (Applied Biosystems, Foster City, CA). RNA
from each culture was treated with DNase to remove any contaminating genomic DNA
(gDNA). The RNA concentration was assessed at OD260nm and purity was verified by the
OD260/OD280 ratio using NanoDrop (Thermo Scientific, Wilmington, DE). The reverse
transcription reaction was performed with 1 μg of total RNA using RT random primers
and a MultiScribe™ reverse transcriptase (High Capacity cDNA Reverse Transcription
kit with RNase inhibitor [Applied Biosystems, Foster City, CA]) according to the
manufacturer’s instructions. The following IFN-β primers and probe set were used:
EqIL-IFN-βF:

5’-AATGGCCCTCCTGCTGTGT-3’,

CCGAAGCAAGTCATAGTTCACAGA-3’

and

EqIL-IFN-βR:

EqIL-IFN-β

probe

5’FAM-

CTCCACCACGGCTC -NFQ for PCR amplification using an Applied Biosystems 7500
Fast Real-Time PCR System.

For each sample, cDNA corresponding to the β-

glucuronidase (β-GUS) gene was amplified and used as an endogenous control for
relative quantification of a sample cDNA. All PCR efficiency values were determined
using LinReg. The relative concentration of target gene mRNA was equal to 2

-ΔΔCt

where ΔΔCt = [(Avg. gene of interest Ct – Avg. β-GUS Ct) sample – (Avg. gene of interest
Ct – Avg. β-GUS Ct) calibrator]. The calibrator was calculated from the mean ΔCt of mockinfected samples for each individual gene.
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Interferon bioassay
The interferon bioassay was performed using VSV-GFP as previously described
[416,424]. Briefly, EEC’s were either infected with EAV or SeV alone or dual infected
with both EAV/SeV at an m.o.i of 5 and incubated for 24 h at 37°C. Culture supernatants
were collected and virus in the supernatants was inactivated by ultraviolet (UV)irradiation for 30 min. Two-fold dilutions of supernatants were made in DMEM and
used in IFN bioassays. MDBK cells were grown in 96-well plates to 70% confluency
and incubated with two-fold dilutions of each of the supernatants. After 24 h incubation
at 37°C, cells were infected with VSV-GFP at an m.o.i. of 0.1 and further incubated at
the same temperature for 16 h.

Cells were fixed with 4% paraformaldehyde and

expression of green fluorescence protein was examined under an inverted fluorescence
microscope.

Confocal microscopy
HEK293 T cells grown on coverslips were transfected with plasmids as indicated
previously, washed with PBS and fixed with 4% paraformaldehyde in phosphate-buffered
saline (PBS; pH7.4) for 30 min at RT. After washing three times with PBS (pH 7.4)
containing 10mM glycine (glycine/PBS), cells were permeabilized with 0.2% Triton X100 in PBS (pH 7.4) for 10 min. The coverslips were incubated with the appropriate
primary monoclonal or polyclonal antibody in PBS containing 5% fetal bovine serum
(FBS) for 1 h at RT. After three 10mM glycine/PBS washes, coverslips were incubated
with FITC-conjugated or DyLight 549-conjugated goat anti-mouse or anti-rabbit
antibody (Southern Biotech, Birmingham, AL and KPL, Gaithersburg, MD, respectively)
for 1 h at RT. Coverslips were washed and mounted in 4’, 6’-diamidino-2-phenylindole
(DAPI) containing aqueous mounting medium (Vector Laboratories, Burlingame, CA)
and observed under an inverted fluorescence microscope.

Cell transfection and luciferase reporter assay
HEK293T cells were seeded in 24-well plates and transfected with various
combinations of plasmid DNA: the pEFneo-RIG-I, pEFneoMDA5, pEFneo-IKKε,
pcDNA3-TRIF, or pCAGGS-IRF3 was mixed with a plasmid encoding the EAV protein
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(or empty pCAGGS), luciferase reporter plasmid and SV40-RL.

Transfection was

performed using HD-FuGENE6 transfection reagent following the manufacturer’s
instruction (Promega, Madison, WI). For the Sendai virus or IFN stimulation, HEK293T
cells were transfected with a plasmid encoding the EAV proteins (or empty pCAGGS,
pCAGGS-NS1), reporter plasmids and pSV40- RL. At 20 h post-transfection, cells were
infected with Sendai virus at 5000 HA unit/0.5 ml/ well for 12-16 h, or induced by
treatment with 2000 IU/0.5 ml/ well of IFN-α or IFN-β for 16 h. Cells were harvested at
the indicated time points. Cell lysates were prepared and subjected to reporter gene assay
using the dual luciferase reporter system (Promega, Madison, WI) according to
manufacturer’s instruction. Firefly and Renilla luciferase activities were measured in a
luminometer (Berthold Technologies, Oak Ridge, TN). Values for each sample were
normalized using the Renilla luciferase values.

6.4. RESULTS
Suppression of type I interferon production by EAV
To investigate the effect of EAV on type I IFN production, IFN-β mRNA
expression was analyzed using quantitative real time RT-PCR.

Equine pulmonary

endothelial cells (EECs) were mock-infected or infected with EAV VBS at an m.o.i of 5
for 8 h, followed by infection with SeV for 3 or 6 hpi. Sendai virus (SeV) was used as a
positive control for type I IFN induction and mock-infected cells were used as a negative
control. As shown in Figure 6.1.A, IFN-β mRNA was barely detected in cells infected
with EAV alone, whereas SeV infection induced a strong expression, approximately 190200 fold, of IFN-β mRNA in the same cells. Moreover, SeV-induced IFN-β mRNA
expression, at both 3 and 6 hpi, was significantly suppressed in cells previously infected
with EAV. In parallel with the quantitative measurement for IFN-β mRNA, suppression
of IFN production by EAV was confirmed by IFN bioassay using VSV expressing the
green fluorescence protein (VSV-GFP; Figure 6.1.B). VSV is IFN sensitive and presence
of IFN-α/β blocks VSV replication. EECs were mock-infected, either infected with EAV
or SeV alone, or dual infected with both EAV/SeV. Subsequently, MDBK cells were
incubated with two-fold serial dilutions of virus inactivated cell culture supernatant fluid
for 24 h followed by infection with VSV-GFP at an m.o.i. of 0.1 for 18 h. The VSV
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infectivity was determined by monitoring the levels of GFP expression. As shown in
Figure 6.1.B, VSV-GFP replicated normally in cell culture supernatant from mockinfected cells while VSV replication was effectively inhibited in supernatant from SeVinfected cells up to a dilution of 1:32. In contrast, VSV replication was not inhibited in
cell culture supernatant from cells infected with EAV alone. Consistent with quantitative
RT-PCR results, SeV-induced type I IFN production was significantly inhibited by EAV
exposure since VSV-GFP replication was detected at a lower sample dilution compared
to that of culture supernatant from SeV-infected cells. Together, the data suggest that
EAV has an intrinsic ability to prevent induction of IFN in infected cells and suppress
IFN production in SeV-infected cells.

Figure 6.1. Inhibition of type I IFN production after EAV infection. A. EECs were
mock-infected or infected with EAV VBS at an m.o.i. of 5 for 8 or 12 h. Subsequently,
cells were infected with Sendai virus (SeV; 100 HAU/ml) for 3 h. Total RNA was
isolated and real time RT-PCR was performed for the detection of equine IFN-β. The
average IFN-β copy numbers ± standard error of the mean (SEM) from three independent
experiments is shown. B. VSV bioassay for IFN production. EECs were mock-infected
or infected with EAV VBS at an m.o.i. of 1 for 24 h. SeV was used as an IFN stimulator.
Cell culture supernatants were collected and UV-irradiated for 30 min prior to use in the
assay. MDBK cells were grown in 96-well plates and incubated with 2-fold dilution
series of the supernant up to 1/32. After 24 h incubation, cells were infected with VSV-
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GFP at an m.o.i. of 0.1, and 18 h after infection, GFP expression was assessed by
fluorescence microscopy. Each dilution was tested in duplicate.

The EAV nsp1, nsp2 and nsp11 exhibited strong inhibition of IFN-β promoter
activation
To investigate the role of EAV viral proteins as IFN antagonists, we focused on
the nonstructural proteins of EAV. The 12 nonstructural proteins derived from an
infectious cDNA clone of virulent Bucyrus strain of EAV were cloned individually into a
pCAGGS mammalian expression vector. The expression and authenticity of recombinant
proteins from the plasmids were verified by immunofluorescence and Western blot using
protein-specific rabbit antisera (nsp1-4, nsp7-9 and nsp11) or anti-FLAG antibody (nsp5,
nsp6, nsp10, and nsp12; data not shown). To determine the nsp(s) that has an effect on
IFN-β activation, we used an IFN-β promoter-luciferase reporter plasmid (p125-Luc) that
expresses the firefly luciferase under the control of the IFN-β promoter. HEK293T cells
were co-transfected with individual nsp-expressing pCAGGS plasmid, p125-Luc, and a
Renilla luciferase expression plasmid (pRL-SV40) to normalize expression levels of
samples. As a positive control, swine influenza virus NS1 (sw-ns1) gene was used to cotransfect the cells with the reporter plasmid; this has been widely reported to inhibit IFNβ promoter induction. Twenty-four hours after transfection, cells were infected with SeV
to induce luciferase production. As shown in Figure 6.2.A, the expression of sw-ns1
significantly inhibited luciferase expression. In contrast, a strong reporter signal was
observed in cells transfected with empty pCAGGS plasmid after infection with SeV.
IFN-β promoter activation by SeV infection was suppressed to various degrees by
expression of several EAV nsps, among which nsp1, nsp2 and nsp11 showed the
strongest inhibition of IFN-β promoter-driven luciferase expression. In particular, nsp1
exhibited the strongest inhibitory effect, followed by nsp11 and nsp2. These results
suggested that several EAV nsps are capable of suppressing IFN-β promoter activation of
which nsp1 had the strongest inhibitory effect, indicating that it may play a major role as
a type I IFN antagonist. The nsps expression from plasmids was confirmed by IFA
(Figure 6.2.B)
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Figure 6.2. EAV nonstructural proteins (nsps) involved in suppression of IFNpromoter activation. A. HEK293T cells were co-transfected with p125-Luc, pRL-SV40
and pCAGGS expressing nsps or pCAGGS empty vector for 24 h. Cells were harvested
and measured for firefly and Renilla luciferase activities. Relative luciferase activity is
defined as a ratio of firefly luciferase reporter activity to Renilla luciferase activity. Each
data point shown represents a mean value ± standard error of the mean (SEM) from three
experiments.

B. Expression of nsps in transfected cells detected by indirect

immunofluorescence assay.

HEK293T cells were transfected with each EAV nsp and

fixed at 24 h post-transfection. Cells were stained with EAV protein-specific rabbit
antisera or anti-FLAG monoclonal antibody. DyLight 549-conjugated goat anti-rabbit
antibody was used as secondary antibody.

EAV nsp1 interferes with IRF3- and NF-κB-mediated IFN-β activation
Since the nsp1 of EAV showed the highest type IFN antagonistic activity, it was
decided to further investigate its effect on the specific signaling pathway(s) using AP-1-,
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NF-κB- and IRF-3-driven luciferase reporter systems. Cells were co-transfected with
control plasmids or with plasmids expressing the EAV nsp1 protein, the plasmid pRLSV40 and a plasmid containing a firefly luciferase gene under the control of a promoter
(pAP-1-Luc) or containing two NF-кB binding sites (pNF-κB-Luc) or with three IRF3
binding sites (p55-CIB-Luc) (Figure 6.3). In cells expressing EAV nsp1 and sw-ns1
proteins (positive control), the level of IRF3-dependent luciferase expression upon SeV
stimulation was significantly reduced compared to that of the control plasmid (empty
pCAGGS vector). Similarly, NF-κB-dependent luciferase expression was blocked in
cells expressing EAV nsp1. In contrast, EAV nsp1 did not affect the AP-1-dependent
reporter gene expression after SeV stimulation, whereas sw-ns1 strongly inhibited
luciferase expression under control of the promoter containing the AP-1 binding site.
Based on these findings, it would appear that EAV nsp1 suppresses IFN-β transcription
by interfering with IRF-3 and NF-κB activity but not AP-1 activity.

Figure 6.3. EAV nsp1 inhibits both IRF-3 and NF-κB pathways but not AP-1.
HEK293T cells were co-transfected with (A) AP-1-Luc, (B) NF-κB-Luc and (C) p55CIB-Luc, which contains three IRF-3 binding sites, a plasmid that constitutively
expresses Renilla luciferase, and plasmids expressing EAV nsps or the indicated control
plasmids. Cells were infected with Sendai virus (SeV) 24 hpi. Cells were harvested and
analyzed for firefly and Renilla luciferase. Data were normalized using the Renilla
luciferase values. Data are averages ± standard deviation for three experiments.
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EAV nsp1 blocked expression of IRF3-dependent reporter genes
We further investigated specific steps that EAV nsp1 could possibly block the
IRF-3 signaling pathway. The ability of IRF-3 to activate its DNA binding site was
examined using a plasmid construct containing a firefly luciferase gene under the control
of a promoter with three IRF-3 binding sites (pCIB-55-Luc). First, we investigated
whether the nsp1 was interfering with the mitochondrial antiviral signaling (MAVS)
complex activity. Since MDA5 or RIG-1 is associated with the MAVS complex, cells
were co-transfected with a plasmid expressing MDA5, RIG-1 or MAVS protein, a
plasmid expressing EAV nsp1, the plasmid pRL-SV40 and the p55-CIB-Luc reporter
plasmid.

As shown in Figure 6.4.A-C, IRF-3-dependent luciferase expression was

suppressed in the presence of EAV nsp1. These results suggested that EAV nsp1 might
inhibit the MAVS-mediated IFN-β induction or downstream portion of the signaling
pathway. Therefore, we further tested the effect of EAV nsp1 on TRIF- and IKKεmediated IFN-β induction and the results showed that nsp1 had the ability to suppress
TBK1 and IKKε mediated reporter gene expression (Figure 6.4.D-E).

Similarly,

overexpression of IRF3 itself did not activate transcription of the reporter plasmid either
(Figure 6.4.F) suggesting that nsp1 blocked the IRF-3. The data suggest that EAV nsp1
might block processes downstream of IRF-3 activation, possibly in the nucleus.
Furthermore, we studied the activation of IRF-3 in EAV nsp1 transfected cells by
Western blot analysis. Neither expression of EAV nsp1 nor control plasmid increased
levels of phosphorylated IRF-3 (pIRF-3) in cells in the absence of SeV stimulus. In
contrast, infection of SeV induced phosphorylation of IRF-3 (pIRF-3) to a similar level in
cells transfected with EAV nsp1 and the control plasmid. Total levels of IRF-3 were
unaltered by expression of nsp1 and the control plasmid or SeV infection (data not
shown). Together with the luciferase assay data, these results suggest that the EAV nsp1
has the ability to block induction of IFN-β at a point downstream of activation of IRF-3,
since nsp1 expression inhibits the activation of the IFN-β promoter but does not block the
activation of IRF-3.
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Figure 6.4. EAV nsp1 inhibits the IRF-3 signaling pathway. Suppression of (A) RIGI (B) MDA-5 (C) IRF-3 (D) MAVS (E) TRIF and (F) IKKε induced IRF-3 dependent
reporter gene expression by EAV nsp1 in HEK293T cells. (A-F) Cells cultured in 24well plates were co-transfected with plasmid pEFneo-RIG-I, pEFneo-MDA-5, pEGFPN1-MAVS, pcDNA3-TRIF, pEFneo-IKKε, or pCAGGS-IRF3 along with a plCAGGS
expressing nsp1 protein or pCAGGS empty vector, pRL-SV40 and a luciferase reporter
plasmid, p55-CIB-Luc for 24 h. Cells were harvested and measured for firefly and
Renilla luciferase activities. Relative luciferase activity is defined as a ratio of firefly
luciferase reporter activity to Renilla luciferase activity. Mean value ± SEM from three
experiments is shown.
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EAV nsp1 blocked expression of NF-κB-dependent reporter genes
Next, we investigated the ability of EAV nsp1 to inhibit NF-κB mediated
transcription. In the presence of EAV nsp1, NF-κB-dependent reporter gene expression
was strongly inhibited (Figure 6.5.A) following stimulation with TNF-α, a potent inducer
of the NF-κB signaling,. Subsequently, the effect of EAV nsp1 on the MAVS complex,
TRIF and IKKε mediated IFN-β induction was evaluated. Interestingly, overexpression
of any of these proteins induced activation of NF-κB-dependent reporter gene expression
(Figure 6.5.B-D). Similarly, overexpression of p65, a subunit of the NF-κB complex,
itself had no effect on activation of transcription from the NF-κB-driven reporter plasmid
(Figure 6.5.E). These data suggested that EAV nsp1 likely blocks processes downstream
of the activation of NF-κB complex, possibly somewhere in the nucleus.

Figure 6.5. EAV nsp1 inhibits the NF-κB signaling pathway. Suppression of (A)
TNF-α (B) MAVS (C) TRIF (D) p65 subunit of NF-κB and (E) IKKε induced NF-κBdependent reporter gene expression by EAV nsp1 in HEK293T cells. (A) Cells cultured
in 24-well plates were co-transfected with pNF-κB-Luc, pRL-SV40, and pCAGGS
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expressing nsp1 or pCAGGS empty vector for 24 h and subsequently stimulated with
TNF-α (20 ng/ml) for 6 h. (B-E) Cells were co-transfected with plasmid pEGFP-N1MAVS, pcDNA3-TRIF, pEGFP-N1-p65 or pEFneo-IKKε along with a pCAGGS
expressing nsp1 protein or pCAGGS empty vector, pRL-SV40 and a luciferase reporter
plasmid, pNF-κB-Luc for 24 h. Cells were harvested and measured for firefly and Renilla
luciferase activities. Relative luciferase activity is defined as a ratio of firefly luciferase
reporter activity to Renilla luciferase activity.

Mean value ± SEM from three

experiments is shown.

EAV nsp1 expression blocked the nuclear accumulation of IRF-3 and NF-κB
The mechanism by which EAV nsp1 can reduce IRF-3 and NF-κB-dependent
gene expression was examined by assessing the nuclear localization of IRF-3 and p65,
respectively, in cells expressing EAV nsp1 by confocal microscopy (Figure 6.6). In
mock-infected cells, IRF-3 was localized primarily to the cytoplasm. On the other hand,
SeV infection stimulated IRF-3 nuclear translocation in a large number of cells.
However, IRF-3 remained in the cytoplasm of cells expressing EAV nsp1 after SeV
infection, while IRF-3 was occasionally observed in the nucleus of cells that did not
express nsp1. Similarly, NF-κB remained in the cytoplasm of most of the unstimulated
cells, whereas TNF-α stimulation induced p65 nuclear accumulation in most cells.

In

cells expressing EAV nsp1, TNF-α stimulation did not induce complete p65 nuclear
translocation since p65 was found in both nucleus and cytoplasm, indicating that EAV
nsp1 partially blocks p65 nuclear translocation. Taken together, it appears that IFN-β
transcription activation is blocked through inhibition of both IRF-3 and NF-κB nuclear
accumulation.
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Figure 6.6. Effect of EAV nsp1 in IRF-3 and NF-κB nuclear translocation. (A)
HEK293T cells were transfected with EAV nsp1 for 24 h and then infected with Sendai
SeV for 6 h. Cells were fixed and stained with Alexa 488 conjugated-anti-EAV nsp1
(12A4) MAb and rabbit anti-IRF3 antibody. (B) HEK293T cells were co-transfected
with EAV nsp1 and p65-RFP for 24 h and then stimulated with TNF- α (10 ng/ml) for 2 h.
Cells were fixed and stained with anti-EAV nsp1 (12A4) MAb. FITC-conjugated goat
anti-mouse was used as a secondary antibody. Cell nuclei were stained with DAPI.

6.5. DISCUSSION
Viruses use different mechanisms to inhibit interferon response in order to evade
the host innate immune response. Synthesis and secretion of type I IFN, such as IFN-α
and IFN-β with antiviral, anti-proliferative and immunomodulatory functions, are critical
aspects of the antiviral immune response [410,425,426]. Thus, many viral proteins that
antagonize multiple components of the interferon pathways have been identified. In
addition, many viruses encode more than one protein capable of inhibiting the interferon
response which act synergistically to ensure complete blocking of interferon activity.
Highly pathogenic viruses, such as Ebola, Nipah and SARS-CoV, encode multiple viral
proteins capable of inhibiting interferon activity, suggesting important roles for these
proteins in pathogenesis and disease outcome [427].

In this study, we investigated

whether EAV has the ability to interfere with the host’s innate immune response, in
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particular, type I IFN production. We showed that EAV infection of equine endothelial
cells significantly inhibited type I IFN production at both mRNA and protein levels,
whereas infection with SeV stimulated type I IFN production significantly. Furthermore,
EAV infection significantly inhibited SeV-induced type I IFN production as well. Based
on reporter-gene experiments, three EAV nonstructural proteins, nsp1, nsp2 and nsp11
strongly inhibited activation of the IFN-β promoter indicating that they modulate type I
IFN activity. Among these proteins, expression of nsp1 had the strongest inhibitory
effect on IFN-β-responsive promoter activation. Similar to our findings, previous studies
on PRRSV also demonstrated that nsp1α, nsp1β, nsp2, nsp4 and nsp11 of PRRSV play a
role in type I IFN antagonism and inhibit activation of IFN-β promoter [414,415]. The
two N-terminal PRRSV replicase cleavage products, nsp1α and nsp1β have the ability to
inhibit both IFN synthesis and signaling, while nsp1α strongly inhibits IFN synthesis only.
Specifically, nsp1β strongly inhibited IRF-3 dependent gene induction in the signaling
pathway leading to IFN-β synthesis. In addition to these nsps, the nuceocapsid protein of
PRRSV also inhibits type I IFN production [83,424].
Further examination revealed that EAV nsp1 inhibited two key transcription
factors that activate the IFN-β promoter, IRF-3 and NF-κB, but not AP-1. EAV nsp1
expression strongly inhibited IRF-3- and NF-κB-dependent gene induction in the
signaling pathway that leads to IFN-β synthesis. Both IRF-3 and NF-κB activation are
regulated by MAVS which functions downstream of RIG-I and MDA5 and upstream of
the IKK complex and TBK1/IFF-I [428,429,430,431].

Among the various factors

involved in type I IFN production, IRF-3 plays a critical role. IRF-3 is expressed in most
cell types and resides in the cytoplasm in an inactive form. When stimulated, IRF-3
becomes phosphorylated and undergoes conformational changes, leading to dimerization
with the exposed nuclear localization signal. In the nucleus, IRF-3 recruits co-activator
CBP/p300 and forms a complex to bind IRF-3 responsive elements (PRD I/III) of the
IFN-β promoter [410]. In addition to IRF-3, NF-κB is also a critical regulator of host
innate and adaptive immunity.

It plays an important role in the regulation of cell

proliferation as well as cell survival. Through evolution, viruses can either activate or
inhibit the NF-κB pathway in order to survive in host cells.

Viruses such as African

swine fever virus and influenza A virus block NF-κB activation to counter the host innate
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immune response [432,433]. In contrast, viruses such as hepatitis C virus, reovirus and
herpes simplex virus have developed mechanisms to directly activate NF-κB to support
production of progeny viruses and intracellular spreading [434,435,436]. Overexpression
of components of the pathway by which IRF-3 and NF-κB are activated in response to
SeV infection and TNF-α, respectively, showed that EAV nsp1 acts downstream of all
tested steps in both signaling pathways. Therefore, we postulated that EAV nsp1 may
have an effect on nuclear accumulation of these transcription factors or formation of the
transcription enhanceosome on the IFN-β promoter inside the nucleus.

Our results

showed that nsp1 inhibits nuclear accumulation of both IRF-3 and NF-κB. Furthermore,
both IRF-3- and NF-κB-dependent gene expressions were blocked by EAV nsp1.
Interestingly, IRF-3 and p65 activation by SeV and TNF-α, respectively, were not
affected, but their nuclear accumulation was inhibited. However, the exact mechanism
that EAV nsp1 uses to inhibit IRF-3 and NF-κB nuclear accumulation is unclear at this
time. It is possible that EAV nsp1 mediates the sequestration of these activated proteins
in the cytoplasm and affects enhanceosome assembly in the cell nucleus. Recent studies
have shown that PRRSV nsp1 modulates type I IFN response by blocking dsRNA–
induced IRF-3 and IFN promoter activities, but IRF-3 phosphorylation and its nuclear
translocation occur normally in the presence of the nsp1. It has been reported that
PRRSV nsp1 blocks the IRF-3 activation by degrading the CREB (cyclic AMP response
element binding)-binding protein (CBP) and subsequently inhibiting formation of
enhanceosomes in the nucleus [416].
In summary, EAV proteins with interferon antagonistic activity have been
identified for first time in this study. Our data indicated that several EAV replicase
proteins including nsp1, nsp2 and nsp11 have IFN antagonistic activity and regulate the
host innate immune response. Among these proteins, nsp1 may play a key role as
interferon antagonist by inhibiting nuclear accumulation of activated IRF-3 and NF-κB.
However, further studies are needed to map the exact step(s) at which EAV nsp1 protein
acts on the IFN induction pathway.

Copyright © Yun Young Go 2011
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CHAPTER SEVEN

A newly discovered ORF5a protein is critical for virus production in equine arteritis
virus
This work was included in Firth et al. J. Gen. Virol. 2011, 92: 1097-1106
Reprinted with permission

7.1. INTRODUCTION
The members of the family Arteriviridae (order Nidovirales) include equine
arteritis virus (EAV), lactate dehydrogenase elevating virus (LDV) of mice, porcine
respiratory and reproductive syndrome virus (PRRSV) and simian hemorrhagic fever
virus (SHFV). The arterivirus genome consists of a positive-sense, single-stranded RNA
molecule.

The genome organization and expression strategy of arteriviruses share

similarities with those of coronaviruses and it is presumed that their key replicative
enzymes have a common ancestry [7,8,9]. Therefore, arteriviruses and coronaviruses
were united in the order Nidovirales, which was recently expanded by addition of
roniviruses, toroviruses and bafiniviruses [8]. The arterivirus genome consists of at least
nine known open reading frames (ORFs). The 5’-proximal ORFs 1a and 1b encode the
non-structural polyproteins, pp1a and pp1ab precursors, that are processed into at least 13
mature non-structural proteins [66,83]. The 3’-proximal end of the genome contains
overlapping ORFs 2 to 7 that are expressed via synthesis of a set of subgenomic mRNAs
[89,91]. These ORFs encode seven structural proteins: the nucleocapsid (N) protein and
six envelope proteins, the glycoproteins (GP) GP2, GP3, GP4 and GP5, and the nonglycosylated envelope (E) and membrane (M) proteins [34,93].

The genome

organization of the EAV ORFs2-7 region is extremely compact, where the termini of the
ORFs are overlapping with neighboring genes and with transcription-regulatory
sequences (TRS) located upstream of each ORF for sg mRNA synthesis [89,91]. The
compact EAV genome organization is a result of the strong selective pressure that RNA
virus genomes are under to encode the maximum amount of information into a limited
sequence space. Therefore, overlapping coding sequences can be easily found in RNA
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viruses, although they can be difficult to detect when they are short. A recent in-depth
comparative computational analysis revealed conservation of an additional AUG-initiated
ORF in the arteriviruses, termed ORF5a, which overlaps the 5’ end of ORF5 [81]. The
newly identified ORF5a protein, conserved in all arteriviruses, was first detected in a
comparative alignment of PRRSV-NA sequences.

A similar ORF5a was found in

PRRSV-EU as well as in LDV, SHFV and EAV. The new coding sequence has 51 or 46
codons in PRRSV-NA, 43 codons in PRRSV-EU, 47 codons in LDV, 64 codons in
SHFV and 59 codons in EAV. The pattern of substitutions across sequence alignments
indicated that ORF5a is subject to functional constraints at the amino acid level, while an
analysis of substitutions at synonymous sites in ORF5 revealed a greatly reduced
frequency of substitutions in the portion of ORF5 that is overlapped by ORF5a. The
ORF5a protein and GP5 are likely expressed from the same subgenomic mRNA, via a
translation initiation mechanism involving leaky scanning. The objective of this study
was to confirm the biological relevance of ORF5a in the EAV life cycle using the EAV
reverse genetics systems. The effect of ORF5a knockout mutant was independently
confirmed using two molecular clones, the pEAV515 and pEAVrVBS of the virulent
Bucyrus strain (VBS) of EAV. In addition to BHK-21 cells, natural host cells, equine
pulmonary artery endothelial cells (EECs), were included in the study.

7.2. MATERIALS AND METHODS
Cells
Equine pulmonary artery endothelial cells (EECs) [343] were maintained in
Dulbecco’s modified essential medium (DMEM, Mediatech, Herndon, VA) with sodium
pyruvate, 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT), 100U/μg per
ml of penicillin/streptomycin and 200mM L-glutamine [154,213,328]. The baby hamster
kidney cells (BHK-21; ATCC CCL10; American Type Culture Collection, Manassas, VA)
were grown in Eagle’s minimum essential medium with 10% ferritin supplemented
bovine calf serum (Hyclone Laboratories, Inc., Logan, UT) and 100U/ μg per ml of
penicillin/streptomycin (Gibco, Carlsbad, CA).
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Infectious cDNA clones
The ORFX2b mutant viruses were constructed by introducing site-specific
mutations into two EAV infectious cDNA clones. Specifically, the pEAV515 clone was
derived from a cell culture adapted attenuated strain of EAV (pEAV030; [64]) and the
pEAVrVBS clone was derived from the EAV VBS [328].

Generation of EAV515/ORFX2b and rVBS/ORFX2b mutant viruses
Briefly, a shuttle vector (pM92128[rVBS]ORFX2b) containing a BamHI (9,150)XhoI (12,726) fragment of the pEAVrVBS infectious cDNA clone was used to mutate the
putative ORFX2b [328]. Site-specific nucleotide substitutions were introduced into the
start (UAU > UAC) and stop (UGG >UAG) codons of the ORFX2b in the
pM92128[rVBS]ORFX2b shuttle vector using a standard site-directed mutagenesis
protocol described by Landt et al. [437].

The engineered mutations in the

pM92128[rVBS]ORFX2b shuttle vector were confirmed by sequence analysis and
subsequently, the BamHI-XhoI fragment was transferred back into the full-length
pEAVrVBS infectious cDNA clone using BamHI and XhoI restriction sites and
confirmed by sequencing.
Run-off RNA transcripts were generated in vitro as previously described from
each mutant infectious cDNA clones (pEAV515/ORFX2b and prVBS/ORFX2b), as well
as their respective parental infectious cDNA clones (pEAV515 and prVBS) following
linearization with restriction enzyme XhoI [64,327]. Briefly, 3 µg of each plasmid DNA
were digested with XhoI and purified by standard phenol-chloroform extraction and
ethanol precipitation procedures, and dissolved in nuclease-free water. The in vitro
transcription reactions were performed in 50 µl reactions by adding 2 µg of each XhoIlinearized plasmid DNA, rNTP (10mM each), 1mg/ml BSA, 100mM DTT, 5X T7
transcription buffer, 10mM cap analog (New England Biolabs, Ipswich, MA), RNAguard
RNase inhibitor and T7 polymerase (Promega, Madison, WI). The transcription reactions
were incubated at 37°C for 3 h. The in vitro transcribed RNA was stored at -80°C until
further use. Each of the full-length capped RNA transcripts were transfected into either
BHK-21 cells or EECs by electroporation as previously described [327].

Briefly,

subconfluent monolayers of BHK-21 and EEC cells were trypsinized, washed, and
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resuspended in ice-cold phosphate-buffered saline (PBS; pH 7.4) at a concentration of
1×107 cells. Freshly thawed 50 µl (80 µg) aliquots of each IVT RNA were placed into
cuvettes (0.4 cm, electrode gap; BioRad, Hercules, CA) and 600 µl of 5×106 of BHK-21
or 1×107 of EEC cells were added. Two pulses of 850 V, infinite ohms (pulse controller),
and 25-mF capacitance were given with a Gene Pulser II electroporator unit (BioRad,
Hercules, CA).

After electroporation was complete, cells were set aside at room

temperature for a 10 minute “recovery period”. Subsequently, the BHK-21 and EEC
cells were resuspended in 10 ml of appropriate complete cell culture medium and seeded
into T-25cm2 tissue culture flasks (Corning, Corning, NY), and incubated at 37°C in a 5%
CO2 incubator for 48-120 h until 90-100% cytopathic effect (CPE) was observed. Cell
culture supernatant was harvested at 18, 24, 48, 72, 96 and 120 h post-transfection and
centrifuged at 1,600 ×g for 10 min at 4°C. The supernatant was stored at –80°C in
single-use aliquots.

Virus titrations and plaque morphology
Virus titers and the plaque morphology of the recombinant viruses were
determined by plaque assays. Briefly, confluent monolayers of EECs and BHK-21 cells
in 6-well culture plates were infected with 10-fold serial dilutions of recombinant
EAV515, EAV515/ORFX2b, rVBS and rVBS/ORFX2b viruses in duplicates. Following
a 1 h incubation, 0.75% CMC (caboxymethyl cellulose)-DMEM was added to each well
and cells were incubated at 37°C for 96 h (McCollum, 1962). Plaques were stained with
1% crystal violet solution containing 1% formaldehyde at 96 h post-infection and titers
were expressed as PFU/ml.

7.3. RESULTS
Using reverse genetics systems, mutants from two molecular clones, pEAV515
and pEAVrVBS, were generated with ORF5a-inactivating nucleotide substitutions. The
pEAV515 is a derivative of pEAV030 which was based on an EAV isolate that was
extensively adapted to cell culture (over 300 passages) [64]. Recombinant EAV derived
from this clone causes very mild clinical signs upon experimental infection of horses
[327]. In contrast, pEAVrVBS derived from EAV VBS, can cause severe disease in
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horses [328]. In both mutants, the ORF5a translation initiation codon (AUG to ACG: U11113C) was mutated and a premature termination codon was introduced at the 6th
codon of ORF5a (G-11128A) (Figure 7.1). The introduced mutations were carefully
designed to be translationally silent with the overlapping GP4 coding sequence.

Figure 7.1. Schematic representation of ORF5a expression in EAV. Translated
ORF5a (blue) is overlapping with both ORFs encoding GP4 (purple) and GP5 (green).
The start and stop codons of relevant ORFs are boxed. The “U” and “g” nucleotides
represent the mutations introduced to knockout ORF5a in the mutant Δ5a-2 viruses. The
TRS (grey box) for sg RNA5 synthesis is located far upstream and includes the ORF5a
start codon and thus, the ORF5a is possibly expressed from the same sg mRNA as GP5
by leaky ribosomal scanning. Modified from Firth et al. [81]

In vitro-transcribed full-length RNAs were electroporated into both BHK-21 and
equine pulmonary artery endothelial cells (EECs). Immunofluorescence staining with
monoclonal antibody to nsp1 protein was performed to verify transfection efficiency at
the early phase of virus replication (data not shown). Virus titers in the medium of
transfected cells were determined by plaque assay (Figure 7.2). ORF5a knockout mutants
showed a reduction in virus titer of at least two logs and a tiny plaque size indicating the
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progeny viruses of ORF5a knockout mutants had severely crippled phenotypes compared
to the wild-type virus. Therefore, this comparative study confirmed that the expression
of ORF5a is critical for efficient EAV amplification irrespective of virus strain where the
molecular clones are derived and cell lines used for analysis.

Figure 7.2.

Comparison of plaque morphology of wild-type EAV and ORF5a

knockout mutants. (A) Plaque morpohology on BHK-21 cells and (B) on equine
endothelial (EEC) cells. In both molecular clones, Δ5a-2 plaque sizes and titers are
severely reduced compared to those of the corresponding parental virus. Modified from
Firth et al. [81]

7.4. DISCUSSION
In this study, we described evidence for the presence, conservation and biological
significance of a novel short coding sequence in the 3’-proximal end of all arterivirus
genomes. The ORF5a and the overlapping GP5 gene are likely to be expressed from a
bicistronic sg mRNA. The mutational inactivation of ORF5a in EAV has shown that
ORF5a mutant has severely impaired replication indicating that its expression is
important for virus life cycle. To independently confirm the effect of the ORF5a knock
out, we used two molecular clones derived from EAV strains with different virulence.
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EAV strains can differ significantly in the severity of the disease they induce [15,328].
The EAV515 was based on an EAV isolate that was extensively passaged in cell culture
while the pEAVrVBS was based on EAV isolate, VBS, that causes severe disease in
horses.

Regardless of the virus backbones used to inactivate ORF5a expression, the

Δ5a-2 mutants had a severely crippled phenotype with tiny plaque sizes and lower virus
titers. In addition to BHK-21 cells, EECs of equine origin were also used to evaluate the
replication of the mutant viruses in a more natural host cell. In conclusion, these assays
have independently confirmed that the expression of ORF5a is required for efficient EAV
amplification, regardless of the background of the molecular clone and cell type used for
analysis.
Discovery of the new ORF5a protein drives arterivirus researchers to question
whether any previous attempts to engineer EAV-based vectors could have been affected,
inadvertently, by the presence of ORF5a. For example, in a construct created by de Vries
et al. [325] the overlap between ORF4 and ORF5 was removed and 24 nt were inserted to
create an insertion site for foreign sequences. Fortunately, the insertion site is in-frame
with ORF5a and the change appears to be tolerated. Similarly, spontaneous insertion of
12 nt into ORF5a of PRRSV-NA after passaging in cell culture 70 times seems to be
tolerated [438]. In contrast, attempts to insert any other foreign sequences encoding GFP
[439] or ectodomain of GP5 protein of other arteriviruses [147] into EAV-based vectors
failed, possibly due to the disruption of ORF5a.

Therefore, the reason for crippled or

non-viable phenotypes of some of previously reported constructs could be, at least
partially, attributed to the disruption of ORF5a protein expression.

Thus, it would be

important to engineer any arterivirus-based vector with care not to disrupt the expression
of functional ORF5a protein.
Unfortunately, the function of the ORF5a protein could not been determined in
this study.

Several attempts to raise polyclonal antisera against the ORF5a using

synthetic peptides containing the non-hydrophobic domain of this protein were
unsuccessful. Therefore, it was not possible either to confirm the presence of the ORF5a
protein in virus particles or to perform a subcellular localization study in the infected
cells. However, in a parallel but independent study performed by Johnson et al. [440],
the expression of the novel protein in cells infected with PRRSV was confirmed using
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proteomic analysis. This paper also described the production of antibodies recognizing
the PRRSV ORF5a protein in infected pigs [440]. Therefore, both PRRSV-NA and EAV
studies together strongly suggest that the ORF5a protein is the eighth structural protein of
the arteriviruses, although further studies are needed to obtain more detailed information
into its yet unknown function.
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CHAPTER EIGHT

Development of a fluorescent-microsphere immunoassay for detection of antibodies
specific to equine arteritis virus and comparison with the virus neutralization test
Clin Vaccine Immunol. 2008, 15(1): 76-87
Reprinted with permission.

8.1. SUMMARY
The development and validation of a microsphere immunoassay (MIA) to detect
equine antibodies to the major structural proteins of equine arteritis virus (EAV) is
described. This was based on cloning and expression of full-length individual major
structural proteins (GP51-255; M1-162; and N1-110) as well as the partial sequence of each
structural protein (GP51-116; GP575-112; GP555-98; M88-162; and N1-69) that comprise putative
antigenic regions of these proteins. Purified recombinant viral proteins expressed in E.
coli were covalently bound to fluorescent polystyrene microspheres and analyzed with
the Luminex xMap 100 instrument. Of the eight recombinant proteins, the highest
concordance with the virus neutralization test (VNT) results was obtained with the partial
GP555-98 protein. The latter assay was validated by testing a total of 2,500 equine serum
samples previously characterized in the VNT. With use of an optimal cutoff value of 992
mean fluorescence intensity (MFI), the sensitivity and specificity of the assay were 92.6%
and 92.9%, respectively. The GP555-98 MIA and VNT test outcomes correlated
significantly (r = 0.84; p-value<0.0001). Although the GP555-98 MIA is less sensitive than
the standard VNT, it has the potential to provide a rapid, convenient, and more
economical test for screening equine sera for the presence of antibodies to EAV, with the
VNT then being used as a confirmatory assay.
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8.2. INTRODUCTION
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA),
a respiratory and reproductive disease of horses [77]. EAV is a small enveloped virus
with a positive-sense, single-stranded RNA genome of 12.7 kb and belongs to the family
Arteriviridae (genus Arterivirus, order Nidovirales), which also includes porcine
reproductive and respiratory syndrome virus, simian hemorrhagic fever virus, and lactate
dehydrogenase-elevating virus of mice [7,34]. The EAV genome includes nine functional
open reading frames [34,56]. Open reading frames (ORF) 1a and 1b encode two replicase
polyproteins (pp1a and pp1ab) [34,56,100], and the remaining seven ORFs (2a, 2b and 37) encode structural proteins of the virus. These include four membrane glycoproteins
GP2 (25 kDa), GP3 (36-42 kDa), GP4 (28 kDa) and GP5 (30-44 kDa), respectively
encoded by ORFs 2b, 3, 4, and 5, two unglycosylated membrane proteins E (8 kDa) and
M (17 kDa) encoded by ORFs 2a and 6, and the phosphorylated nucleocapsid protein N
(14 kDa) encoded by ORF7 [57,58,137]. The major envelope glycoprotein GP5 expresses
the known neutralization determinants of EAV. The two major envelope proteins, GP5 and
M, form a disulfide-linked heterodimer in the virus particle, and this association is critical
for their maturation and for the expression of some of the neutralization epitopes in
authentic form [67,68,73].
Serological and clinical studies indicate that EAV is widely distributed in equine
populations around the world [173,175,176]. Although there is considerable variation in
the sequence of the GP5 protein of field strains of the virus, there is only one known
serotype of EAV, and all strains evaluated thus far are neutralized by polyclonal antiserum
raised against the prototype Bucyrus strain of EAV [69,70,71,72,74,75,76,158]. Both
natural and experimental infections of horses with either virulent or avirulent strains of
EAV result in long-lasting immunity against all strains of the virus [264,265,266]. Equine
arteritis virus infection in horses induces antibodies against the three major viral
structural proteins, GP5, M, and N [76,221,268]. Virus neutralizing (VN) antibodies are
detectable between 1 to 2 weeks after primary infection, and their appearance usually
coincides with the onset of clearance of virus from the circulation [240,441]. However,
virus does persist in the male reproductive tract of certain stallions for long periods of
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time despite the presence of high titers of virus-specific neutralizing antibodies in their
serum.
Serologic diagnosis of acute EAV infection of horses is based on demonstration of
seroconversion or a ≥ 4 -fold increase in neutralizing antibody titer to the virus in paired
(acute and convalescent) serum samples using the virus neutralization test (VNT). The VNT
is the principal serological assay used to detect evidence of EAV infection by most
laboratories around the world, and it continues to be the current World Organisation for
Animal Health (OIE) prescribed standard test for EVA [77,292,442,443,444]. The assay is
used for diagnostic, epidemiological surveillance, international trade, and vaccination
monitoring purposes. The number of equine sera tested annually by a diagnostic laboratory
can vary considerably, from several hundred to thousands of samples per year [443,444,445].
Although the VNT is currently the most highly sensitive and specific serodiagnostic test
for this infection, it is expensive, labor-intensive, and time-consuming to perform. In
addition, results tend to vary among laboratories, when adequate attention is not paid to
standardization of both test reagents and procedure. Moreover, serum cytotoxicity caused
by anti-cellular antibodies directed against rabbit kidney-13 (RK-13) cells can be
mistaken for viral cytopathic effect and can give rise to difficulties in test interpretation at
lower serum dilutions. To overcome these disadvantages, several laboratories have
developed and evaluated enzyme-linked immunosorbent assays (ELISAs) to detect
antibodies to EAV using whole virus, synthetic peptides, or recombinant viral proteins
(e.g., GP5, M, and N) as antigens [70,75,254,274,275,304,305,306,446]. The various
studies have shown that the source of antigen as well as the sera evaluated can markedly
influence the results obtained with EAV protein specific ELISAs and competitive ELISA
[76,80]. None of these ELISAs has yet been shown to be of equivalent sensitivity and
specificity to the VNT.
Recent developments in particle array technology have made it possible to perform
immunoassays using microspheres (microbeads). The best-established microsphere assay
system is the Luminex xMap system (Luminex Corp., Austin, TX), which incorporates
three well-developed technologies: bioassays, solution phase microspheres, and flow
cytometry. The microsphere assay technology developed by Luminex is ideally suited to
a wide range of applications in drug discovery and diagnostics, as well as basic research.
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Immunoassays based on this particle array technology can overcome the problems
associated with the traditional VNT and ELISAs. Some of the distinct advantages of
microsphere immunoassay (MIA) over traditional ELISAs include accuracy; high
sensitivity, specificity, and reproducibility; high-throughput sample analysis; and
multiplexing capability. MIAs are becoming increasingly popular for the serologic
diagnosis

of

autoimmune

and

infectious

diseases

of

humans

and

animals

[447,448,449,450,451]. The primary objective of the present study was to develop a
reliable immunological assay to detect antibodies to EAV in horses, using Luminex
xMap technology, and to compare its performance with that of the VNT. The MIA could
be suitable to detect antibodies to EAV in equine sera and the specificity and sensitivity
of this assay should be equivalent to that of the standard VNT.

8.3. MATERIALS AND METHODS
Cells
High-passage (P399 to P409) rabbit kidney-13 (RK-13) cells were propagated and
maintained in Eagle’s minimum essential medium (EMEM; Mediatech, Herndon, VA)
supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT), 100U/ml penicillin,
100μg/ml streptomycin, 1μg/ml amphotericin B and 0.06% sodium bicarbonate at 37°C
[452].

Equine sera
A total of 2,500 diagnostic equine serum samples were evaluated for the presence
of anti-EAV antibodies by the MIA and VNT. The sera used in the study were selected
randomly from those submitted for serological testing to the OIE EVA Reference
Laboratory, Gluck Equine Research Center (n = 1,500) and the Livestock Disease
Diagnostic Center (n = 1,000), University of Kentucky, Lexington, Kentucky. Panels of
EAV antibody-positive and antibody-negative sera from the Gluck Equine Research
Center were selected and used to establish normal MIA ranges for negative and positive
samples. In addition to these sera, archived sequential serum samples collected from 18
experimentally infected horses were evaluated with respect to the EAV specific antibody
response by both VNT and MIA. The horses were divided into four groups and each
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group was inoculated with a different strain of EAV (rVBS: n = 4; 030H: n = 2; KY84: n
= 7; and CA95G: n = 5) [154,224,327,453]. Blood samples were collected at 0, 2, 4, 6, 8,
10, 12, 14, 21, 28, 35, and at 42 days post infection (dpi) for the EAV rVBS-inoculated
horses; at 0, 2, 4, 6, 8, 10, 12, 14, and 21 dpi for the EAV 030H-inoculated horses; at 0, 2,
4, 6, 8, 10, 12, 14, 21, and 28 dpi for the EAV KY84-inoculated horses, and at 0, 2, 4, 7,
9, 14, 21, 28, and 35 dpi for the EAV CA95G-inoculated horses. Sera were aliquoted and
stored at -20°C.

PCR amplification, cloning, and sequencing of full-length and truncated versions of
ORFs 5, 6, and 7 of EAV
The oligonucleotide primers for amplification of the coding sequences of the GP5,
M, and N proteins (ORFs 5, 6, and 7, respectively) as well as the corresponding partiallength proteins were designed according to the published sequence of the EAV VBS
(GenBank accession number: DQ846750) [453]. The nucleotides 5’-CACC-3’ were
added at the 5’ end of each primer for directional cloning into the pET TOPO® vector
(Invitrogen, Carlsbad, CA; Table 8.1). The full-length ORFs 5, 6, and 7 (that respectively
encode full-length GP5, M, and N proteins), as well as the coding region for the aminoterminal ectodomain (aa 1-116) and two antigenic regions (aa 55-98 and aa 75-112) of
the GP5 protein [70,274,446], the antigenic carboxyl terminal (aa 88-162) of the M
protein [280], and the antigenic amino terminal (aa 1-69) region of the N protein [275],
were PCR-amplified from the plasmid containing the complete genomic sequence of the
EAV VBS strain (pEAVrVBS; GenBank accession number DQ846751) [453] using Pfu
DNA polymerase enzyme (La Jolla, Stratagene, CA). PCR amplification was performed
according to the manufacturer’s instructions. The individual PCR products were
concentrated using a Centricon (Ultracel YM-30; Millipore, Billerica, MA) and purified
using a commercial kit (Qiagen, Valencia, CA). The individually amplified cDNA
fragments encoding EAV ORFs 5, 6, 7 and their respective truncated forms were then
directly cloned into the pET100 Directional TOPO® vector according to the
manufacturer’s instructions (ChampionTM pET100/D-TOPO® Expression kit; Invitrogen,
Carlsbad,

CA).

The

pET100/D-TOPO
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Table 8.1. Primer pairs used for PCR amplification of full-length and partial-length segments of ORFs 5, 6, and 7.
ORF

Protein

GP51-255

GP51-116
5
GP555-98
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GP575-112

M1-162
6
M88-162

N1-110
7
N1-69
a

Sense

Sequencea

Nucleotide

Size

Recombinant

position

(bp)

plasmid

772

pET-GP51-255

355

pET-GP51-116

139

pET-GP555-98

121

pET-GP575-112

493

pET-M1-162

232

pET-M88-162

337

pET-N1-110

211

pET-N1-69

+

5'-CACCATGTTATCTATGATTGTATTG-3'

11146-11166

-

5'-CTATGGCTCCCATACCTCAG-3'

11913-11894

+

5'-CACCATGTTATCTATGATTGTATTG-3'

11146-11166

-

5'-CTAGAATTCACGGCCATAGTAA-3'

11493-11475

+

5'-CACCTACAATTGTTCCGCCAGTAAAAC-3'

11308-11330

-

5'-CTACGGTCCATGCGCCTGTTCC-3'

11439-11421

+

5'-CACCACGTTTGGAACCGATTG-3'

11368-11384

-

5'-CTAATAGTAAATAAAAGGGGGCATGTC-3'

11481-11458

+

5'-CACCATGGGAGCCATAGATTC-3'

11901-11917

-

5'-TCATTGTAGCTTGTAGGCTGTCG-3

12389-12367

+

5'-CACCATGCCTCGTCTTCGGTCC-3'

12162-12179

-

5'-CTATTGTAGCTTGTAGGCTGTCGCCG-3'

12386-12364

+

5'-CACCATGGCGTCAAGACGATCACG-3'

12313-12332

-

5'-TTACGGCCCTGCTGGAGGCGC-3'

12645-12625

+

5'-CACCATGGCGTCAAGACGATCACG-3'

12313-12332

-

5'-CTAGTTCGACGAAAGGGTGGCGCG-3'

12519-12499

Underline indicates the overhang sequence to enable directional cloning to pET TOPO® vector

recombinant protein with an XpressTM epitope and a polyhistidine (6×His)-tag at the
amino terminus of each recombinant protein. Plasmids containing individual ORFs were
transformed into One Shot® competent E. coli (Invitrogen, Carlsbad, CA). Following
transformation and purification, individual plasmids were identified and characterized by
restriction enzyme analysis for correct orientation of the insert. The authenticity of each
ORF and of each truncated version was confirmed by automatic sequencing as previously
described [80].

Expression and purification of full length GP5, M, N and their respective partiallength recombinant proteins
Plasmids pET-GP51-255, pET-GP51-116, pET-GP575-112, pET-GP555-98, pET-M1-162,
pET-M88-162, pET-N1-110 and pET-N1-69 were purified and used to transform the BL21
StarTM (DE3) strain of E. coli for expression of the recombinant proteins. The E. coli
strain BL21 StarTM (DE3) is especially designed for expression of genes regulated by the
T7 promoter. Following transformation with each expression plasmid, a single colony
was grown for approximately 3 h at 37°C in 2 ml of Luria-Bertani liquid medium
supplemented with 200 μg/ml of carbenicillin (LBC). Thereafter, 50 μl of the culture was
plated out on a LBC agar plate and incubated overnight at 37°C. On the next day,
bacterial colonies on the agar plate were scraped off with a sterile tissue culture scraper
and added to a 2-L flask containing 500 ml of LBC medium. Cultures were grown to a
density of 0.5-0.7 at OD600. Protein expression was induced with 0.5mM isopropyl-β-Dthiogalactopyranoside (IPTG). Bacterial cells were harvested 5 h after induction, by
centrifugation at 3000 ×g for 15 min at 4°C. Cell pellets were either stored at -80°C or
immediately used for further processing.
The recombinant GP51-255, GP51-116, GP575-112 and GP555-98 proteins were
purified using a Ni-NTA purification system (Invitrogen, Carlsbad, CA) under hybrid
conditions. Briefly, individual cell pellets were resuspended in guanidinium lysis buffer
(6M guanidine HCl, 20mM sodium phosphate, 500mM NaCl; pH7.8) containing
lysozyme (1mg/ml) and proteinase inhibitors (Halt Proteinase Inhibitor Cocktail kit,
Pierce, Rockford, IL) and slowly mixed on a rocker for 10 min at room temperature.
After incubation, cell pellets were lysed by sonication with shortwave pulses of 10 sec at
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high intensity (output 5). Subsequently, the crude lysates were centrifuged at 3000 ×g for
15 min at 4°C to remove bacterial cellular debris. The supernatant was loaded onto a NiNTA agarose column and allowed to bind for 1 h at room temperature. After binding, the
agarose containing column was washed twice with denaturing binding buffer (8M urea,
20mM sodium phosphate, 500mM NaCl; pH7.8) and twice with denaturing wash buffer
(8M urea, 20mM sodium phosphate, 500mM NaCl; pH6.0), to wash off non-specifically
bound proteins. Subsequently, protein-bound agarose was washed four times with native
wash buffer (50mM NaH2PO4, 0.5M NaCl, 10mM imidazole; pH8.0). Finally, each
recombinant protein was eluted from the column with 2-ml fractions of native elution
buffer pH8.0 (50mM NaH2PO4, 0.5M NaCl, 250mM imidazole; pH8.0).
Unlike the GP5 recombinant proteins, the recombinant full-length M1-162, M88-162,
full-length N1-110, and N1-69 proteins were purified under native conditions. Briefly,
individual cell pellets were resuspended in native binding buffer (50mM NaH2PO4, 0.5M
NaCl; pH8.0) containing lysozyme (1mg/ml) and proteinase inhibitors (Halt Proteinase
Inhibitor Cocktail kit, Pierce, Rockford, IL) and incubated on ice for 30 min. After
incubation, cell pellets were lysed by sonication with shortwave pulses of 10 sec at high
intensity (output 5). Subsequently, the crude sonicates were centrifuged at 3000 ×g for 15
min at 4°C to remove cellular debris. The supernatant was loaded onto a Ni-NTA agarose
column and allowed to bind for 2 h at 4°C. The recombinant proteins were eluted in
native elution buffer (pH8.0) as described above.
Fractions containing the same recombinant protein were pooled together and
centrifuged at 3,000 ×g for 45 min, with an Amicon® Ultra 5K (Millipore, Billerica, MA)
centrifugal filter device used to increase recombinant protein concentration. After
concentration, individual proteins were dialyzed against phosphate-buffered saline (PBS;
pH=7.4) overnight at 4°C. Final protein concentration was determined using a BCA
protein assay (Pierce, Rockford, IL), and the proteins were stored at -80°C.

Western immunoblotting assay
The authenticity of the purified recombinant proteins was confirmed by Western
immunoblotting assay as previously described [75,151]. Briefly, proteins were mixed
with an equal volume of 2X Laemmli sample buffer (Bio-Rad, Hercules, CA) containing
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62.5 mM Tris-HCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue, and
200mM of dithiothreitol (Pierce, Rockford, IL) and incubated for 15 min at room
temperature. Denatured samples were loaded onto sodium dodecyl sulfate-12%
polyacrylamide resolving gels and a 5% stacking gel. Following electrophoresis,
recombinant proteins were transferred onto a PVDF membrane (Bio-Rad, Hercules, CA).
Immunoblotting was performed by using 5% nonfat dried milk powder in Tris-buffered
saline with 0.05% Tween 20 (pH7.6) as the blocking solution. Expression and
authenticity of each recombinant protein were confirmed using antibodies against the Nterminal 6×His tag as well as individual EAV protein-specific monoclonal antibodies
MAb 6D10 for GP5 [75]; MAb 3E2 for N [213] and rabbit anti-EAV M #7888 for M
protein [268]. Bound antibodies were detected by enhanced chemiluminescence, as
previously described [75].

Virus neutralization test (VNT)
The neutralizing antibody titers of the test sera were determined as described by
Senne et al. [292,337]. Briefly, serial two-fold dilutions of each sample from 1:2 to 1:256
were made in MEM (Invitrogen, Carlsbad, CA) containing 10% guinea pig complement
(Rockland Immunochemicals, Gilbertsville, PA). Each serum sample was tested in
duplicate in 96-well plates. An equal volume of a working dilution of virus containing an
estimated 200 TCID50 of the modified live virus strain of EAV (ARVAC®, Ft. Dodge
Animal Health) was added to each well, except the serum controls. The plates were
shaken to ensure mixing of the well contents and then incubated for 1h at 37°C. A
suspension of high passage (P399 to P409) RK-13 cells was added to each well in a
volume equivalent to that of the serum-virus mixtures and incubated for 72 h at 37°C,
until viral cytopathic effect had fully developed in the virus control wells. The titer of a
sample was recorded as the reciprocal of the highest serum dilution that provided at least
50% neutralization of the reference virus.

Coupling of recombinant proteins to microspheres
Approximately 50 μg of each recombinant protein were covalently conjugated to
carboxyl groups on the surface of xMap Multi-Analyte COOH Microspheres according
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to the manufacturer’s protocol (Luminex Corp, Austin, TX). Each recombinant protein
was attached to 6.25 X 106 microspheres, and the microspheres were counted with a
hemocytometer so that equivalent quantities of each specific bead set were incorporated
into the assay.

Development of microsphere immunoassay
A 96-well 1.2 μm filter plate was blocked for 2 min with 100 μl of PBS (pH7.4)
with 1% bovine serum albumin and 0.02% sodium azide (PBN buffer) and then washed
once with 190 μl of PBS (pH7.4) with 0.05% Tween 20 (PBS-T buffer). Wells were kept
moist by addition of 20 μl of PBN buffer. Equine sera (50 μl, diluted 1:100 in PBN
buffer) were added to each well of the filter plate. Approximately 2,500 recombinant
antigen-conjugated microspheres per protein were added to each well in 50 μl of PBN
buffer. The plate was incubated on a shaker in the dark for 30 min at 37°C and then
washed three times with PBS-T using a vacuum manifold. Affinity-purified biotinlabeled goat anti-equine IgG (50 μl of a 1:1000 dilution in PBN) was added, and the plate
was incubated on a shaker in the dark for 30 min at 37°C and then washed twice with
PBS-T. Streptavidin-conjugated with R-phycoerythrin (50 μl of a 1:100 dilution in PBN
buffer) was added, and the plate was incubated on a shaker in the dark for 30 min at 37°C
and then washed twice with PBS-T using a vacuum manifold. The microspheres were
then resuspended in 125 μl of PBN per well, and 75 μl of suspension were transferred to
a clear polystyrene 96-well plate. Microspheres were aspirated through the flow cell of a
dual-laser Luminex 100 instrument. The median fluorescence intensity (MFI) of 100
microspheres of each specific protein was recorded for each well.

Statistical analysis
A comparison of the diagnostic performance of the tests, VNT and MIA based on
the GP555-98 and N1-110 proteins, was conducted using nonparametric density estimation
and receiver operating characteristic (ROC) analysis. An ROC curve provides a graphical
measure of the accuracy of a continuous diagnostic test. It represents a plot of the true
positive fraction (TPF) versus the false positive fraction (FPF) across all possible cutoff
values that can be used to dichotomize the data into positive or negative outcomes. In
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addition to the ROC curve, a related parameter of interest is the area under the curve
(AUC). For continuous tests, the AUC equals the probability that a randomly selected
diseased individual has a test score that is greater than that for a randomly selected nondiseased individual. A diagnostic test that perfectly discriminates between non-diseased
and diseased individuals has an ROC curve that is expressed by the horizontal line
TPF=1 with the corresponding AUC=1. Diagnostic tests that are purely random, and
hence are worthless, have a ROC curve expressed by the 45 degree angle line with a
corresponding AUC=0.5 [454].
Cross-sectional data were obtained from a dual test study design in which both
tests were carried out on sera from 2,500 horses, and where the true infection status of
each horse was determined using the definitive gold-standard test, the VNT. The
Pearson’s correlation coefficient was estimated for the GP555-98 based MIA and VNT. A
Bayesian bivariate normal analysis of the log transformed joint (GP555-98, N1-110)
outcomes was used to estimate ROC curves and area under the curve (AUC) based on
methods developed by Choi et al. [455]. Specifically, data derived using sera from
infected horses were modeled as a bivariate normal with unknown mean vector, (μGP555-98,
μN1-110), and an unknown covariance matrix that contained three parameters, namely, the
(marginal) variances for the GP555-98 test and for the N1-110 test, and the correlation
between GP555-98 and N1-110 test values. Independent diffuse normal prior distributions
with a mean of 0 and variance of 100 were placed on μGP555-98 and

μN1-110, and

independent inverse gamma priors with a mean of 1 and a variance of 1000 were used for
the variances. The correlation was assigned a uniform prior ranging from -1 to 1. A
bivariate normal distribution was also used to model the data for non-infected horses,
with the same prior specification as used for infected horses.
Results from the ROC analysis were used to determine an optimal cutoff value for
the purpose of classifying horses as EAV antibody-positive or –negative, based on the
outcome of the GP555-98 MIA test. The sensitivity and specificity of the GP555-98 MIA test
were then estimated at this cutoff value using Bayesian methods. The analysis was
performed in S-Plus (Insightful Corp., Seattle, WA) and WinBUGS [456].
The sensitivity for each recombinant EAV structural protein-based MIA was
calculated with: (number of true positives/[number of true positives + number of false

181

negatives]) × 100. Test specificities were calculated using the following equation:
(number of true negatives/[number of true negatives + number of false positives]) × 100.

8.4. RESULTS
Cloning, expression, and purification of recombinant proteins
Following PCR amplification, all major structural protein genes and their
corresponding partial-length ORFs were individually cloned into the pET100/D-TOPO
vector. The recombinant protein from each construct was expressed as a bacterial fusion
protein with an N-terminal tag containing the Xpress epitope and a 6×His tag (Figure 8.1
A). Various temperatures and IPTG concentrations were evaluated, to optimize the
conditions for protein expression. With the exception of recombinant GP51-255 and its
partial-length proteins (GP51-116, GP575-112 and GP555-98), all expressed recombinant
proteins were present in the soluble fraction of the E. coli lysate. The insoluble GP5
recombinant proteins had to be purified under hybrid conditions instead of native
conditions, which were successful for the soluble recombinant proteins (M1-162, M88-162,
N1-110, and N1-69).
The expression and authenticity of the recombinant proteins were confirmed by
Western immunoblotting assays. EAV structural protein-specific antibodies strongly
reacted with their respective recombinant proteins (Figure 8.1.B). In addition, the
attachment of a 6×His tag to the expressed proteins was demonstrated by Western
immunoblotting with HRP-labeled anti-HisG antibody (data not shown).
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Figure 8.1.

Recombinant EAV structural proteins expressed in E. coli.

(A)

Schematic representation of various EAV structural proteins expressed in E. coli. The
recombinant full-length proteins derived from EAV ORFs 5, 6, 7 and their respective
truncated versions are depicted. The black bars denote full-length proteins and the open
bars denote partial-length proteins. The putative major neutralization sites A (aa 49), B
(aa 61), C (aa 67-90) and D (aa 99-106) located in the N-terminal ectodomain of GP5
protein are indicated by hatched boxes. (B) Western blot analysis of purified bacterial
recombinant proteins with EAV protein-specific MAbs and rabbit antisera. Monoclonal
or rabbit EAV-specific antibodies used to detect each recombinant protein are indicated
at the bottom of the figure. The MW marker is indicated on the right. The molecular
masses of recombinant GP51-255, GP51-116, GP575-112, GP555-98, N1-110, N1-69, M1-162 and
M88-162 proteins were 32, 17, 7, 8, 15.3, 10.6, 20.6 and 11kDa, respectively.
183

Virus neutralization test
Of the 2,500 equine serum samples tested, 1,750 were negative for VN antibodies
to EAV (titers <1:4). A total of 750 sera were positive for antibodies to EAV, with titers
ranging from 1:4 to ≥1:512.
In addition to the diagnostic samples, a panel of 192 archived sequential sera from
18 horses experimentally infected with different strains of EAV was evaluated using the
VNT. The horses experimentally inoculated with EAV rVBS, 030H and KY84 strains
developed VN antibodies to EAV after 7-10 days post-exposure (Figure 8.2.A, B, and C).
Sera from horses inoculated with EAV rVBS and KY84 had VN antibody titers ranging
from 1:128 to 1:1024. The majority of horses in these two groups of horses maintained a
titer of ≥1:512 throughout the study. Horses infected with EAV 030H laboratory strain
developed lower antibody titers ranging from 1:32 to 1:64. In contrast, horses inoculated
with the avirulent CA95G strain developed detectable serum antibody titers from 14 dpi
to 35 dpi (Figure 8.2.D). Neutralizing antibody titers in sera from the CA95G inoculated
horses were generally lower than those in horses inoculated with the other 3 virus strains,
ranging only from 1:4 to 1:16. Only one horse in this group developed a high antibody
titer (1:256).
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Figure 8.2. Comparison of antibody response to EAV as determined by GP555-98
MIA and VNT using sequential serum samples from experimentally infected horses.
The reciprocal VN titers and MFI values of horses inoculated with different EAV strains,
EAV rVBS (A, E), EAV 030H (B, F), EAV KY84 (C, G), and CA95G (D, H) are plotted
against days post inoculation (dpi). Virus neutralizing antibody response in horse
experimentally infected with EAV rVBS (n = 4), EAV 030H (n = 2), EAV KY84 (n = 7),
and EAV CA95G (n = 5) measured by standard VNT (A, B, C and D). Virus antibody
response in horsed experimentally infected with EAV rVBS (4), EAV 030H (n = 2),
EAV KY84 (n = 7), and EAV CA95G (n = 5) measured by GP555-98 MIA (E, F, G and
H).
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Development of EAV recombinant structural proteins-based MIAs
Eight expressed recombinant proteins were used to coat polystyrene microbeads
in development of the MIAs. The optimal dilution of the test sera to be used in the MIAs
was predetermined by the use of known strong positive titer (≥1:512) and negative (<1:4)
equine sera. The optimal working dilution was considered the serum dilution with lowest
background activity from non-specific reactions. At a serum dilution of 1:100, the
maximal dynamic range was attained for all the recombinant proteins; this was defined as
the optimal serum dilution in the case of each protein (Figure 8.3).

Figure 8.3. GP555-98 and N1-110 MIA analyses of serially diluted serum samples. Sera
from horses with EAV neutralizing antibodies and negative control equine serum were
serially diluted and evaluated in the GP555-98 and N1-110 MIAs. The median fluorescent
intensity (MFI) for each dilution of standard was determined. Results are reported as MFI
per 100 microspheres.

To establish cutoff levels for the MIAs specific for each EAV recombinant
protein, 20 equine sera from known EAV-seronegative horses were used. The MIA
positive cutoff for each protein was established at three standard deviations above the
mean microsphere MFI of the known VNT negative sera. The mean MFI for GP51-255
was 279.5 (SD, 345) with an assay cutoff of 1315; the mean MFI for GP51-116 was 237.9
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(SD, 321) with a cutoff of 1202; the mean MFI for GP575-112 was 220.8 (SD, 160.4) with
a cutoff of 702; the mean MFI for GP555-98 was 263.1 (SD, 245) with a cutoff of 998; the
mean MFI for M1-162 was 344.7 (SD, 209.4) with a cutoff of 973; the mean MFI for M88162

was 377.3 (SD, 228.4) with a cutoff of 1063; the mean MFI for N1-110 was 432.1 (SD,

161.7) with a cutoff of 917; and the mean MFI for N1-69 was 216.6 (SD, 166.5) with a
cutoff of 716. Samples with MFI values above the cutoff value were designated as
positive, and those below that value were considered negative. Subsequent analysis of
125 positive (VNT titers ranging from 1:4 to >1:512) and 125 neutralizing antibody
negative sera tested in parallel in the VNT allowed evaluation of the performance of each
recombinant protein (n = 250) in the MIA. MIAs based on recombinant GP5 proteins had
high specificity. The specificity of GP51-255, GP51-116, and GP575-112 based-MIAs was
98.4%, with only two false positive results out of 125 VNT antibody-negative samples.
The GP555-98-based MIA had a slightly lower specificity, 97.6%, than did the other GP5based MIAs. The sensitivities of the GP51-255 and GP5 1-116 based MIAs were the lowest
among all of the proteins (3.2% and 5.6%, respectively), detecting only 4/125 and 7/125
VNT-positive samples. The sensitivities of the recombinant GP575-112 and GP555-98 based
MIAs were higher (41.6% and 77.6%, respectively) and with detection of 52/125 and
97/125 VNT-positive sera, respectively. Both M protein-based MIAs, (M1-162 and partial
M88-162), had a high specificity (97.6% and 98.4% respectively), and correctly detected
122/125 and 123/125 VNT seronegative samples. However, both had very low sensitivity
(6.4%) and only detected anti-EAV antibodies in 8/125 VNT-positive sera. The
sensitivity of the recombinant N1-69 based MIA was also very poor; it only detected antiEAV antibodies in 10/125 (8.0%) VNT-positive sera. In contrast, full-length N1-110
detected anti-EAV antibodies in 77/125 VNT-positive sera resulting in a significantly
higher sensitivity (61.6%). In summary, these results confirm that MIAs based on GP51255,

GP51-116, GP575-112, N1-69, M1-162 and M88-162 were markedly less sensitive than the N1-

110

and GP555-98 MIAs (61.6% and 77.6%, respectively) in detecting anti-EAV antibodies

in equine sera, as compared to the VNT (Table 8.2). Accordingly, the MIAs based on
recombinant proteins that showed poor sensitivity were excluded from further study, and
only GP555-98 and N1-110 protein-based MIAs were selected for further development and
validation.
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Table 8.2. Sensitivities and specificities of MIAs using individual recombinant EAV
structural proteins
Recombinant EAV structural

Sensitivity (%)a

Specificity (%)b

GP51-255

3.2

98.4

GP51-116

5.6

98.4

GP575-112

41.6

98.4

GP555-98

77.6

97.6

M1-162

6.4

97.6

M88-162

6.4

98.4

N1-110

61.6

91.2

N1-69

8

97.6

protein

ab

, Based on testing of 125 VNT-positive and 125 VNT-negative serum samples

Validation of the GP555-98 and N1-110 based MIAs
The same panel of 2,500 diagnostic equine sera evaluated in the VNT was
analyzed for the presence of EAV-specific antibodies using GP555-98 and N1-110-based
MIAs. Of the 750 VNT-positive sera, only 698 were determined to be positive by the
GP555-98 MIA. The GP555-98 MIA failed to detect anti-EAV antibodies in 52 serum
samples that were confirmed to be seropositive in the VNT (52 false negatives).
Furthermore, only 1644 of the 1,750 VNT-negative sera gave negative results with the
GP555-98 MIA assay. This indicated that GP555-98 gave 106 false positive results compared
to the VNT. The overall sensitivity and specificity of the GP555-98 MIA were 93.1% and
93.9%, respectively. Similarly, the N1-110 MIA gave 256 false negatives (only 494/750
were positive) and 374 false positive (1376/1750 were negative) results, as compared to
the VNT. The sensitivity and specificity of the N1-110 MIA were 65.9% and 78.6%,
respectively.
As mentioned previously, the cutoff values were assigned on the basis of three
standard deviations above the mean MFI of 20 EAV antibody-negative equine sera.
However, the cutoff value calculated according to this method varied slightly for each of
the protein-coated bead sets; this could be a factor contributing to the differences in
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sensitivity observed between the MIA and standard VNT. Moreover, a statistical
approach using the negative reference population assumes a normal distribution of the
test variable and does not consider the sensitivity of the assay [457]. Both sensitivity and
specificity are important parameters when a diagnostic test is applied to a given
population and an alternative approach to determination of the cutoff value is to consider
both the negative and positive reference populations [458,459,460]. Such an approach
was adopted in this study by using nonparametric ROC analysis to define the cutoff value
with the entire equine serum data set derived from the study. Such an approach to
tabulation of results is recommended in comparative studies of this type, in order to
eliminate variability in the day-to-day performance of the assay [461]. By using the ROC
analysis, a recalculated optimal cutoff value to classify sera as positive or negative was
992 MFI. With this cutoff, the sensitivity and specificity of GP555-98 MIA were 92.6%
and 92.9% respectively, as compared to the VNT (Table 8.3). The cutoff value that
maximizes the tradeoff between sensitivity and specificity of the N

1-110

based MIA was

1261.43. At this cutoff, the estimated sensitivity and specificity were 88.3% and 54.7%,
respectively.

Table 8.3. Sensitivity and specificity of VNT and GP555-98 MIA for determination of
antibodies to EAV
VNT

Total
no. of
samples
2500

GP555-98

Negative Positive

1750

750

a

a

Negative

Positive

1694

806

Sensitivityb %

Specificityb %

(95% CI)c

(95% CI)c

92.6

92.9

(90.1-94.3)

(91.7-94.1)

a

Determined according to the optimal cutoff 992 MFI

b

Sensitivity and specificity calculated using Bayesian analysis.

c

CI, credible interval

The results from both recombinant protein-based MIAs were subjected to
Bayesian analysis. The area under the ROC curve for both GP555-98 and N1-110 MIAs was
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compared to that for the VNT. The area under curve (AUC) for the GP555-98 MIA was
higher (AUC=0.983 with a 95% credible interval, the Bayesian analog of a confidence
interval, of 0.979 to 0.986) than the AUC for the N1-110 MIA (AUC=0.772 with a 95%
credible interval of 0.751 to 0.793; Fig. 8.4.). This result confirms that the diagnostic
accuracy of the GP555-98 based MIA is significantly higher than the N1-110 based MIA; it
can reliably detect anti-EAV antibodies in equine sera.

Figure 8.4. ROC curves depicting the sensitivity and specificity of the GP555-98 and
N1-110 MIAs compared to the VNT. An ROC curve represents a plot of the true positive
fraction (TPF) versus the false positive fraction (FPF) across all possible cutoff values
that can be used to dichotomize the data into positive or negative outcomes. In addition to
the ROC curve, a related parameter of interest is the area under the curve (AUC).
Estimated ROC curves (solid lines) with pointwise 95% credible bands (dashed lines) for
the GP555-98 MIA and N1-110 MIA are indicated.
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A correlation analysis was performed between the GP555-98 MIA and the VNT.
This indicated that there was a significant correlation between the outcomes of the GP55598

MIA and the standard VNT (r = 0.84; p-value<0.0001; Figure 8.5).

Figure 8.5. Analysis of the correlation analysis between the GP555-98 MIA and the
VNT for detection of anti-EAV antibodies in equine sera. GP555-98 MIA scatter plot
versus VNT using 2,500 equine sera is depicted on the log2 scale. The VNT data were
plotted on the X-axis and the MIA data were plotted on the Y-axis.

Comparison of the sensitivity of the GP555-98 MIA and VNT using sequential serum
samples from experimentally inoculated horses
A panel of 192 archived sequential serum samples from 18 horses comprising
four groups, each inoculated with a different strain of EAV, was used to compare the
antibody response detected by the GP555-98 MIA and the VNT [154,327,453].
Analysis of sera collected from EAV rVBS (n = 4) and EAV 030H (n = 2)
inoculated horses gave a reactive signal in the GP555-98 MIA from day 8 pi. The MFI
values for sera collected from day 8 to 42 were positive, with values ranging respectively
for the two strains from 2,541 to 27,736 (Figure 8.2.E) and from 1,295 to 21,874 (Figure
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8.2.F). Seroconversions detected by the GP555-98 MIA were in full agreement with the
VNT results, where neutralizing antibodies were also detected from day 8 (Figure 8.2.A
and 8.2.B). Similarly, reactive signals were detected in sera from horses inoculated with
EAV KY84 (n = 7) from dpi 7 (two horses) and dpi 10 (other horses). The MFI values in
sera from horses inoculated with EAV rVBS, 030H and KY84 ranged from 1,648 to
27,142. The only discrepancy between the results of the GP555-98 MIA and the VNT
involved serum from one horse (SD7925), which had a threshold neutralizing antibody
titer (1:4) on day 7 (Figure 8.2.C); this sample was not positive in the MIA (Figure 8.2.G).
In general, the pattern of antibody development determined with the GP555-98 MIA
correlated very well with the pattern found using the standard VNT. Both assays detected
EAV-specific antibodies in samples collected after 10 dpi. If consideration is given to the
fact that the two tests measure antibodies on different scales, there was greater variability
in results using the MIA than the VNT. Despite this, the sensitivity of the MIA was not
affected by this variability.
In contrast, when 44 sequential serum samples from 5 horses inoculated with the
highly attenuated EAV CA95G strain were used to compare the GP555-98 MIA and the
VNT, the GP555-98 MIA failed to give consistent positive reactive signals (Figure 8.2.H).
The earliest reactive signal detected by the GP555-98 MIA was on 28 dpi for horse 9624,
whereas the latter had detectable low levels of neutralizing antibodies from 14 dpi when
tested by the VNT (Figure 8.2.D). Similarly, horse number 5582 had a threshold
neutralizing antibody titer (1:4) on day 28 in the VNT; this was not detected by the
GP555-98 MIA which only had reactive signals from 35 dpi. Horse number 9131
developed a low neutralizing antibody titer (1:8) by 35 dpi which was detected by the
GP555-98 MIA. Horses number 9715 and 9649 did not show reactive signals at all whereas
VN antibodies were detected at low levels from 14 dpi. The MFI values of the antibodypositive sera from CA95G inoculated horses ranged from 1,055 to 4,688.

8.5. DISCUSSION
This study evaluated a newly developed MIA based on GP555-98 as an alternative
diagnostic procedure for the detection of antibodies to EAV. Evaluation of various forms
of recombinant viral structural proteins (e.g., full-length proteins, and partial-length
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proteins containing the antigenic regions) allowed identification of the best recombinant
protein antigen for use in the MIA. Previous reports have shown that two bacterial fusion
proteins (aa 1-116 and 55-98) and a synthetic peptide (aa 81-106), both based on GP5 of
EAV, can be used as effective diagnostic antigens in ELISAs [274,446]. It has been
previously demonstrated that horses immunized with portions of GP5 expressed either in
bacteria (aa 55-98) or as a synthetic oligopeptide (aa 75-97) developed EAV-neutralizing
antibodies [70,446]. Chirnside et al. (1995) used a series of recombinant bacterial fusion
proteins derived from EAV ORF7 to define the immunoreactive region of the viral
nucleocapsid (N) protein [275]. These studies indicated that the major N-protein epitope
that reacts with anti-EAV equine sera is located within the aa residue segment 1-69 in the
terminal region of the protein. Similarly, it has been demonstrated that only the carboxyl
terminal sequence (aa 88-162) of the M-protein is necessary to identify equine serum
antibodies specific to the EAV M protein; it was further suggested that this region should
be useful for the serodetection of EAV infected horses [280]. On the basis of the
foregoing, it was decided to express the full-length GP51-255, M1-162 and N1-110 and various
antigenic regions of the GP5 (aa 1-116, 75-112 and 55-98), M88-162 and N1-69 proteins as
bacterial fusion proteins to be used in MIAs to detect antibodies to EAV. When the
sensitivity and specificity of these different MIAs and the VNT were compared, all of the
MIAs with the exception of the MIA based on GP555-98 bacterial fusion protein, were of a
very low specificity and sensitivity; accordingly, they were considered unsuitable as serodiagnostic assays for EVA.
The low immunoreactivity of MIAs incorporating three of the GP5 proteins,
(GP51-255, N-terminal ectodomain GP51-116, and GP575-112), as well as M (M1-162 and M88162),

and N (N1-110 and N1-69) proteins may result from misfolding and aggregation of the

E.coli-expressed recombinant proteins. Despite the fact that the GP5 N-terminal
ectodomain contains the major neutralization epitopes of EAV, the three MIAs
incorporating GP5, the full-length GP51-255, the N-terminal ectodomain GP51-116, and
GP575-112 had markedly low sensitivity. It has been reported that in the absence of the M
protein, the recombinant GP5 protein tends to form large protein aggregates that are
neither immunogenic nor immunoreactive [76,221]. Similarly, it has been shown that the
GP5 protein, when expressed by baculovirus or mammalian expression systems, is not
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processed properly and is easily misfolded [154]. As the length of the recombinant GP5
was reduced, the sensitivity of the MIA increased significantly; this would indicate that a
reduction in length allows exposure of some of linear epitopes present in the antigenic
region of the recombinant GP5 protein.
There was very good agreement between the results of the GP555-98 based MIA
and the VNT. However, the GP555-98 MIA was found to have lower sensitivity and
specificity than the VNT. Many factors could adversely affect the sensitivity of the
GP555-98 MIA. (i) The short length of the GP5 protein incorporated into the assay could
have targeted antibodies that are only specific for linear epitopes present in the region of
aa 55-98, but not for any conformational epitopes. In addition, failure of the GP555-98
MIA to detect some sera that possessed VN antibodies to EAV could be also due to the
lack of two major neutralization sites located outside of this region, neutralization sites A
(aa 49) and D (aa 99-106), and/or lack of conformational interaction of the four
neutralization sites (A-D) in the N-terminal ectodomain of GP5 as shown previously [69].
(ii) Recombinant proteins expressed in E. coli differ from the virion-associated GP5
protein, due to the lack of secondary structural folding and post translational
modifications. (iii) The VNT putatively detects antibodies to the GP5 major envelope
glycoprotein, which carries the known neutralization determinants of EAV [76].
Although there is only one known serotype of EAV, the GP5 protein has been shown to
be the most variable of the EAV structural proteins among field strains of the virus
[151,158]. Antigenic variation among EAV field strains could reduce sensitivity of the
assay. It should be noted that the cloned GP5 amino acid sequence (aa 55-98) was
derived from the EAV VBS, and field strains of EAV have been shown to differ
significantly in this region; this could result in significant differences in neutralization
phenotype among viral isolates using polyclonal equine sera. (iv) The lower sensitivity of
the GP555-98 MIA could also be associated with dilution of the test samples. Previously, it
has been documented that recombinant proteins expressed by bacteria can exhibit high
background reactivity with equine serum [274,275,446]. In the present study, we
determined 1:100 to be the optimal serum dilution for minimization of the non-specific
binding of antibodies to the bacterial recombinant proteins. At this dilution, the majority
of sera with low antibody titers (1:4 to 1:8) in the VNT gave false negative results in the
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GP555-98 MIA (Table 8.4). It should be emphasized, therefore, that the MIA can only
reliably detect sera with moderate to high antibody titers (≥ 1:16) to EAV.
Table 8.4. Distribution of numbers of samples giving false negative results in
GP555-98 MIA (n=750)
Virus
Neutralizing titer

No. of false negative in MIA /
Total no. of VNT positive (%)

1:4

5 / 7 (71.4)

1:8

4 / 10 (40.0)

1:16

6 / 21 (28.6)

1:32

10 / 34 (29.4)

1:64

11 / 58 (18.9)

1:128

4 / 76 (5.3)

1:256

5 / 162 (3.1)

≥1:512

6 / 382 (1.6)

On testing sera from horses experimentally exposed to rVBS, 030H and KY84
strains of EAV, there was excellent concordance between the GP555-98 MIA and the VNT
for detection of the antibody response to the virus. While the EAV 030H and KY84
strains of EAV had one and four substitutions, respectively, between aa 55 and 98
compared to the cloned GP555-98, sera from horses exposed to these virus strains did not
give any false negative reactions in the GP555-98 MIA. In contrast, sera from the EAV
CA95G strain-inoculated horses failed to give a consistent positive signal in the GP555-98
MIA. On comparative amino-acid sequence analysis, EAV CA95G virus strain had six aa
substitutions in this region, five of which were located between aa 79 and 90 (Figure 8.6).
This would indicate that amino-acid substitutions located in the region of aa 79-90 could
have a significant effect on the sensitivity of the GP555-98 MIA. Furthermore, comparative
amino-acid analysis of GP5 showed that some other field strains of EAV (e.g., WA97
and IL93) had multiple amino acid substitutions between aa 79 and 90 (Figure 8.6).
Accordingly, horses exposed to EAV strains that have significant number of amino acid
substitutions in this region may well give false negative results in the GP555-98 MIA. To
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maximize sensitivity of a GP5-based MIA, it may be necessary to include a cocktail of
GP555-98 amino acid sequences comprising multiple sequences representative of known
phenotypically different strains of EAV rather than depend on a single GP555-98 sequence
from one strain.

Figure 8.6. Aligned deduced amino acid sequences of GP5 55-98 proteins from
various laboratory (rVBS and 030H) and field (KY84, CA95G, WA97 and IL93)
strains of EAV. Dots indicate the same amino acid as that in the sequence at the top.
Letters indicate the amino acid substitution at each site.

The predicted N-linked

glycosylation sites are underlined. The respective conserved and variable glycosylation
sites are indicated by * and .Neut., neutralization.

ELISA assays targeting whole virus or recombinant GP5, M, and N proteins have
been

investigated

for

the

serological

[221,254,268,274,275,304,305,306,446].

An

diagnosis
ELISA

of

procedure

EAV

infection

incorporating

an

ovalbumin-conjugated synthetic peptide representing aa 81-106 of GP5 has been
previously described for the detection of anti-EAV antibodies in equine sera [446]. That
ELISA had a slightly higher sensitivity and specificity (96.75% and 95.6% respectively)
than the MIA based on GP555-98 used in this study. Similarly, an ELISA based on a
cocktail of three major structural proteins (GP5, M, and N) expressed by baculovirus was
able to detect antibodies in most equine sera that were positive in the VNT following
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natural or experimental infection (92.3% sensitivity and 100% specificity) [221]. It
should be stressed that the latter two studies [221,446] were undertaken using a limited
number of EAV VNT antibody-positive (n = 400 and n = 73 respectively) and antibodynegative (n = 400 and n = 111 respectively) equine sera. By comparison, the sensitivity
(92.6%) and specificity (92.9%) of the GP555-98 MIA were evaluated based on testing
2,500 diagnostic equine sera.
The MIA based on GP555-98 has several advantages over the VNT as well as over
various ELISAs. ELISAs that utilize whole viral antigen preparations can give rise to a
large number of false-positive reactions, when sera are derived from horses vaccinated
with tissue culture-derived vaccines. Such animals can develop antibodies to cell culture
proteins remaining in the EAV whole-virus antigen preparation [462]. Furthermore, these
cell protein-specific antibodies cause cytotoxicity at the lower serum dilutions that in turn
can interfere with interpretation of the VNT results [463]. The GP555-98 MIA circumvents
both of these problems, since it utilizes a recombinant protein that represents the
immunodominant GP5 protein of EAV. Furthermore, the GP555-98 MIA is not subjective
in interpretation, is less time-consuming, is less expensive, and uses a smaller sample
volume. Accordingly, the GP555-98 MIA can be considered a more convenient and rapid
serologic testing procedure for EAV infection, especially for screening large numbers of
sera. The MIA can be completed within a few hours; in comparison the VNT takes 72 h.
The MIA does not require the use of live virus and so does not require virus containment
facilities.
In summary, we have developed and validated several MIAs that use recombinant
EAV structural proteins to detect antibodies to EAV in equine serum. Among eight
recombinant proteins, the highest concordance with the VNT results using selected equine
sera was obtained with the partial GP5 protein, GP555-98. The GP555-98 MIA and the VNT
outcomes correlated significantly (r = 0.84; p-value<0.0001). Although the GP555-98 MIA is
less sensitive than the VNT, it has the potential to provide an accurate, rapid, convenient and
more economical test for screening equine sera for the presence of antibodies to EAV with
the VNT used as a confirmatory assay.
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CHAPTER NINE

Characterization of Equine Humoral Antibody Response to the Nonstructural
Proteins of Equine Arteritis Virus
Clin Vaccine Immunol. 2011, 18(2): 268-79
Reprinted with permission

9.1. SUMMARY
Equine arteritis virus (EAV) replicase consists of two polyproteins (pp1a and
pp1ab) that are encoded by open reading frames (ORFs) 1a and 1b of the viral genome.
These two replicase polyproteins are post-translationally processed by three ORF1aencoded proteinases to yield at least 13 nonstructural proteins (nsp 1-12, including nsp7α
and 7β).

These nsps are expressed in EAV-infected cells but the equine immune

response they induce has not been studied. Therefore, the primary purpose of this study
was to evaluate the humoral immune response of horses to each of the nsps following
EAV infection.

Individual nsp-coding regions were cloned and expressed in both

mammalian and bacterial expression systems. Each recombinant protein was used in an
immunoprecipitation assay using equine serum samples from horses (n=3) that were
experimentally infected with three different EAV strains (VB, KY77 and KY84),
stallions (n=4) that were persistently infected with EAV, and horses (n=4) that were
vaccinated with the modified live virus (MLV) vaccine strain. Subsequently, proteinantibody complexes were subjected to Western immunoblotting analysis with individual
nsp-specific rabbit antisera, mouse anti-His antibody, or anti-FLAG-tagged antibody.
Nsp2, nsp4, nsp5 and nsp12 were immunoprecipitated by most of the sera from
experimentally or persistently infected horses, while sera from vaccinated horses did not
react with nsp5 and reacted weakly with nsp4. However, serum samples from vaccinated
horses were able to immunoprecipitate nsp2 and nsp12 proteins consistently. Information
from this study will assist ongoing efforts to develop improved methods for the serologic
diagnosis of EAV infection in horses.
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9.2. INTRODUCTION
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA),
a respiratory and reproductive disease of horses [77]. EAV is a small (approximately 4060 nm in diameter) enveloped virus with a positive-sense, single-stranded RNA genome
of ~12.7 kb and belongs to the family Arteriviridae (genus Arterivirus, order Nidovirales),
which also includes porcine reproductive and respiratory syndrome virus, simian
hemorrhagic fever virus, and lactate dehydrogenase-elevating virus of mice [7,34]. The
EAV genome includes nine known functional open reading frames (ORFs 1a, 1b, 2-7)
[34,56]. ORFs 1a and 1b are located in the 5’-proximal three-quarters of the genome and
are translated to produce replicase polyproteins pp1a and pp1ab (1,727 and 3,175 amino
acids, respectively), with the latter being a C-terminally extended version of the former
[141]. ORF 1b translation depends on a -1 ribosomal frameshift just before termination
of ORF 1a translation [10]. The two replicase precursor polyproteins are cleaved by three
different ORF 1a-encoded proteinases (see below) yielding at least 13 end products named
nonstructural protein (nsp) 1 to 12 (including a recently described nsp7α and 7β; [113]).
The three EAV proteinase domains are located in nsp1, nsp2 and nsp4 [34,66]. The
remaining seven ORFs (2a, 2b and 3-7) are located in the 3’ quarter of the genome and
encode the structural proteins (GP2, E, GP3, GP4, GP5, M and N, respectively) of the
virus.
EAV infection in horses induces long-lasting immunity that protects against
reinfection with all strains of the virus [76,195,264,265,266]. Resistance to reinfection is
assumed to be mediated by neutralizing antibodies directed against glycoprotein 5 (GP5),
the major envelope protein of the virus [69,74,76,145,148,149,151,152,279,327]. The
serum neutralization test, which principally detects antibodies to GP5, remains the most
sensitive assay to detect EAV-specific antibodies in horse serum. The antibody response
of horses to individual EAV proteins differs markedly depending on the interval after
infection, the infecting virus strain, the individual horse, and the specific serological
assay used [76]. Until now, the characterization of the humoral antibody response of the
horse to EAV has been mainly based on the structural proteins of the virus
[143,150,221,254,268,274,275,276,280,304,305,306,462,464]. The serologic response of
horses to the individual structural proteins of EAV has been extensively characterized by
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Western immunoblotting, enzyme-linked immunosorbent (ELISA), competitive ELISA
(cELISA) assays, and microsphere immunoassay (Luminex) using recombinant GP5 and
membrane

(M)

proteins

and

the

nucleocapsid

[143,150,221,254,268,274,275,276,280,304,305,306,462,464].

(N)

protein

Immunoblotting studies

confirmed that infected horses respond to a number of viral structural proteins, and that
sera from horses other than carrier stallions most consistently recognized the conserved
carboxy-terminal region of the M protein [268]. However, little is known about the
equine humoral immune response to the non-structural proteins of EAV.

The nsps of

EAV are the first viral proteins synthesized in cells infected with EAV and are essential
to the viral replication cycle [26,93]. Thus, it is reasonable to predict the antibodies
directed against nsps might appear early in the course of EAV infection based on their
level of abundance and immunogenicity. Therefore, it is hypothesized that a distinct
antibody response, similar to the immune response to structural proteins of EAV, may be
generated to some of the nsps.

The current study aimed to determine the humoral

immune response of EAV-infected horses to each of the nsps encoded by the ORF 1a and
ORF 1ab region of the viral genome (the proteolytic cleavage products derived from pp1a
and pp1ab).

Specifically, in the present study the recombinant nsps expressed in

mammalian cells and E. coli were utilized in combined immunoprecipitation and Western
immunoblotting analyses to establish the specificity of the antibody response of EAVinfected or vaccinated horses to the nsps of EAV.

9.3. MATERIALS AND METHODS
Cells
High-passage (P399 to P409) rabbit kidney-13 (KY RK-13) and baby hamster
kidney-21 (BHK-21 [ATCC CCL-10]; P61-P80) cells were cultured and maintained in
Eagle’s minimum essential medium (EMEM; [Mediatech, Herndon, VA]) supplemented
with 10% fetal calf serum (FCS; Hyclone, Logan, UT), 100U/ml penicillin, 100μg/ml
streptomycin, 1μg/ml amphotericin B and 0.06% sodium bicarbonate at 37°C.

200

Antibodies
Monoclonal antibodies specific for nsp1 of EAV (12A4) have been previously
described [306]. Similarly, mono-specific polyclonal rabbit antisera recognizing EAV
nsp2 [110], nsp3 (rabbit 98.E3, [84]), nsp4 (a 1:1 mix of anti-nsp4M and anti-nsp4C;
[110]), nsp7-8 [110], and nsp10 [87] have been previously described. In addition, we
used previously unpublished antisera against nsp9 and nsp11 that were both raised by
immunizing rabbits with full-length expression products purified from E.coli (J.C.
Zevenhoven, D. D. Nedialkova and E. J. Snijder, unpublished data). Commercially
available anti-FLAG (Agilent Technologies, Santa Clara, CA) and anti-His (Invitrogen,
Carlsbad, CA) monoclonal antibodies were used to detect FLAG and His-tagged fusion
proteins in Western immunoblotting analyses, respectively.

Equine sera
Sera from 11 horses that were seropositive for antibodies to EAV by virus
neutralization assay were used to characterize the equine humoral immune response to
the EAV nsps (Table 9.1). The panel consists of three serum samples from horses that
were experimentally inoculated with virulent Bucyrus (VB) strain or the KY77 and KY84
strains of EAV, four serum samples from stallions confirmed to be persistently infected
carriers of EAV (stallions D, E, G and R; [80,224,327]) and four serum samples from
horses vaccinated with the modified live virus vaccine strain of EAV (ARVAC®;
formerly Fort Dodge Animal Health Laboratories [now Pfizer Animal Health, New York,
NY]). Two equine serum samples negative for neutralizing antibodies to EAV were
included as controls.
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Table 9.1. Serologic response of horses to EAV nsps following experimental infection, vaccination, and in cases of persistent virus
infection.
Horse No.

§

Breed

Status/
PI

SN⌘
titer

nsp1

nsp2

nsp3

nsp4

Proteins
nsp5 nsp7 nsp8

nsp9

nsp10 nsp11 nsp12
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Acutely infected horses
1462 (VB,KY53)
TB
2 mo PI ≥1:1024
+
+w
+
77E853 (KY77)
TB
2 mo PI
1:1024
+
+
+
198/199 (KY84)
42 DPI
1:1024
+
+
+
Persistently infected stallions
D
Shedder
1:512
+w
+w
E
Shedder
1:256
+
+
+
R
DWB Shedder
≥1:512
+
+
+w
G
STB
Shedder
1:256
+
+
Vaccinated horses
SR-10258 (#800)
TB
≥1:512
+w
+w
94-593
TB
128 DPV
1:512
+w
+w
508
STB 8 mo PV
1:256
+w
+w
478
STB 8 mo PV
1:128
+w
+w
§
TB=Thoroughbred; DWB=Dutch Warmblood; STB=Standardbred
⌘
SN=Serum neutralization
+w Immunoprecipitation protein signal was weaker compared to other positive sera in Western immunoblotting analysis
+* Protein expressed in both mammalian and bacterial cells were immunoprecipitated with equine sera

-

+
+*
+w

-

+w
+
+w
+w

-

+
+
+
+

Virus neutralization (VN) test
The neutralizing antibody titers of the test sera were determined as described by
Senne et al. [292,337]. Briefly, serial two-fold dilutions of each sample from 1:4 to
1:512 were made in MEM (Invitrogen, Carlsbad, CA) containing 10% guinea pig
complement (Rockland Immunochemicals, Gilbertsville, PA). Each serum sample was
tested in duplicate in 96-well plates. An equal volume of a virus dilution containing an
estimated 200 TCID50 of the modified live virus vaccine strain of EAV (ARVAC®, Ft.
Dodge Animal Health) was added to each well, except the serum controls. The plates
were shaken to ensure mixing of the well contents and then incubated for 1h at 37°C. A
suspension of high passage (P399 to P409) RK-13 cells was added to each well in a
volume double that of the serum-virus mixtures and the plates were incubated for 72 h at
37°C, until viral cytopathic effect had fully developed in the virus control wells. The titer
of a sample was recorded as the reciprocal of the highest serum dilution that provided at
least 50% neutralization of the reference virus.

Construction of plasmids for expression of recombinant EAV nsp1 to 12 in
mammalian cells and E. coli
The twelve nonstructural proteins (nsp1 to nsp12) of EAV were PCR-amplified
from the EAV rVBS full-length infectious cDNA clone containing plasmid (pEAVrVBS;
GenBank accession number DQ846751; [328]) using the primer pairs listed in Table 9.2.
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Table 9.2. Primers used to for PCR amplification of individual nsps for cloning into pCAGGS vector

nsp1 (260)

Nucleotide
locationc
255-1004

nsp2 (571)

1005-2717

nsp3 (233)

2718-3416

nsp4 (204)

3417-4028

nsp5 (162)

4029-4514

nsp6 (22)

4515-4580

nsp7 (225)

4581-5255

nsp8 (50)

5256-5405

nsp9 (693)

5256-7333

nsp10 (467)

7334-8734

nsp11 (219)

8735-9391

nsp12 (119)

9392-9748

Protein(aa)
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a

Primer sequences (5’-3’)a,b
F
R
F
R
F

ttcGAATTCaccATGGCAACCTTCTCCGCTACTGG
ttcCTCGAGttaGCCGTAGTTGCCAGCAGGCAA
ttcGAATTCaccATGGGCTACAATCCACCAGGGGAC
ttcCTCGAGttaACCTATCAGCCGGAACCCCGGA
ttcGAATTCaccATGGGATGGATTTATGGGATATGC

R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R

ttcCTCGAGttaTTCAAACACCATCCCGCCCTC
ttcGAATTCaccATGGGGCTATTCAGGTCACCGAAGG
ttcCTCGAGttaCTCTCTATTGGATAAGCCATC
ttcGAATTCaccATGAGCAGCCTTTCTGGACCTCAG
ttcCTCGAGttaCTTATCGTCGTCATCCTTGTAATCCTCCAGGAAGTATTTCATCATG
ttcGAATTCaccATGGGAGGAGTGAAAGAGAGTGTCACC
ttcCTCGAGttaCTTATCGTCGTCATCCTTGTAATCCTCCTGGGTAATTGGTTTGC
ttcGAATTCaccATGAGTCTCACTGCAACATTAGC
ttcCTCGAGttaTTCATAGCTCCCCTTGCCCAGC
ttcGAATTCaccATGGGCCTAGATCAGGACAAAGTG
ttcCTCGAGtcaGTTTAACTGATTCACTGCCTC
ttcGAATTCaccATGGGCCTAGATCAGGACAAAGTG
ttcCTCGAGttaCTCATACTGCTTGGTGCGGAAG
ttcGAATTCaccATGAGTGCCGTGTGCACAGTTTGTGG
ttcCTCGAGttaCTTATCGTCGTCATCCTTGTAATCTTGCTTTTCCCAGCCACAG
ttcGAATTCaccATGTCCAACAAAATTTCGTGCCTC
ttcCTCGAGttaCTCTTGGACATAAAAGGTCGC
ttcGAATTCaccATGGGTGTTGATGCAGTTACATCAGC
ttcCTCGAGttaCTTATCGTCGTCATCCTTGTAATCCACGGGCCCAATGACTGAACC

The restriction enzyme sites used for cloning are underlined (EcoRI –GAATTC; XhoI-CTCGAG).
The C-terminal FLAG tag in the nsp5, nsp6, nsp10, nsp12 reverse primers are indicated in bold face.
c
The nucleotide positions for the primers are based on GeneBank accession number DQ846751
b

pCAGGS-nsp1

Predicted
MW(kDa)
28.6 (28.6)

pCAGGS-nsp2

61.4 (61.5)

pCAGGS-nsp3

25 (25.1)

pCAGGS-nsp4

21 (21.2)

pCAGGS-nsp5-FLAG

18.1 (19.3)

pCAGGS-nsp6-FLAG

2.3 (3.4)

pCAGGS-nsp7

25.2 (25.4)

pCAGGS-nsp8

5.5 (5.6)

pCAGGS-nsp9

76.8 (76.9)

pCAGGS-nsp10-FLAG

50.5 (51.6)

pCAGGS-nsp11

24.2 (24.3)

pCAGGS-nsp12-FLAG

12.5 (13.6)

Recombinant plasmid

The PCR amplification was performed with high fidelity Pfu DNA polymerase
enzyme (Agilent; Santa Clara, CA) according to the manufacturer’s protocol. The nsp5-,
nsp6-, nsp10-, and nsp12-coding regions were amplified using reverse primers with the
FLAG-tag coding sequence followed by a downstream stop codon. Subsequently, the
individual PCR products were gel purified, digested with restriction enzymes EcoRI and
XhoI, and cloned into the pCAGGS eukaryotic expression vector (generously donated by
Dr. Brenda Hogue, Arizona State University, Tempe, AZ [421]).

To remove the

ORF1a/ORF1b ribosomal frameshift site in the nsp9-coding sequence and allow fulllength nsp9 expression, mutations were introduced into the pCAGGS-nsp9 construct with
site-directed PCR mutagenesis using the Quick Change® II XL Site-Directed
Mutagenesis kit (Agilent, Santa Clara, CA) following manufacturer’s instructions.
Specifically, the ORF1a/ORF1b ribosomal frameshift site had been removed by mutating
nucleotide A-5404 to C and inserting a C between G-5399 and T-5400 ([65]; numbered
according to GenBank accession # DQ846751). Plasmids containing individual nspcoding sequences were transformed into E. coli (DH5α) and grown at 37°C overnight.
Plasmids were purified from overnight cultures of E. coli using the QIAprep Spin
Miniprep plasmid extraction kit (Qiagen, Valencia, CA).

Following purification,

individual plasmids were identified and characterized by restriction enzyme analysis for
correct orientation of the insert. The nucleotide identity of each construct was confirmed
by automatic BigDye terminator cycle sequencing (Eurofins MWG-Operon, Huntsville,
AL). The plasmids containing individual nsps 1-12 were identified as pCAGGS-nsp1 to
pCAGGS-nsp12, respectively.
For generating bacterial expression plasmids for EAV nsp1 to nsp12, each nspcoding sequence was amplified from pEAVrVBS using the primers listed in Table 9.3.
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Table 9.3. Primers used for PCR amplification of individual nsps for cloning into pQE-TriSystem His-Strep 2 vector.
Protein (aa)

Nucleotide
locationb
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nsp1 (260)

225-1004

nsp3 (233)

2718-3416

nsp4 (204)

3417-4028

nsp6 (22)

4515-4580

nsp7 (225)

4581-5255

nsp8 (50)

5256-5405

nsp10 (467)

7334-8734

nsp12 (119)

9392-9748

a
b

Primer sequences (5' - 3')a
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R

ttcGAATTCtATGGCAACCTTCTCCGCTACTGG
ttcCTCGAGGCCGTAGTTGCCAGCAGG
ttcGAATTCtGGATGGATTTATGGGATATGC
ttcCTCGAGTTCAAACACCATCCCGCCCTC
ttcGAATTCtGGGCTATTCAGGTCACCGAAGG
ttcCTCGAGCTCTCTATTGGATAAGCCATC
ttcGAATTCtGGAGGAGTGAAAGAGAGTGTCACC
ttcCTCGAGCTCCTGGGTAATTGGTTTGC
ttcGAATTCtAGTCTCACTGCAACATTAGC
ttcCTCGAGTTCATAGCTCCCCTTGCCCAGC
ttcGAATTCtGGCCTAGATCAGGACAAAGTG
ttcCTCGAGGTTTAACTGATTCACTGCCTC
ttcGAATTCtAGTGCCGTGTGCACAGTTTGTGG
ttcCTCGAGTTGCTTTTCCCAGCCACAG
ttcGAATTCtGGTGTTGATGCAGTTACATCAGC
ttcCTCGAGCACGGGCCCAATGACTGAACC

The restriction enzyme sites used for cloning are underlined (EcoRI - GAATTC; XhoI - CTCGAG).
The nucleotide positions for the primers are based on GenBank accession number DQ846751.

Recombinant
plasmid

Predicted MW
(kDa)

pQE-rVBSnsp1

28.6 (32.5)

pQE-rVBSnsp3

25 (28.8)

pQE-rVBSnsp4

21 (24.9)

pQE-rVBSnsp6

2.3 (6.1)

pQE-rVBSnsp7

25.2 (29.1)

pQE-rVBSnsp8

5.5 (9.6)

pQE-rVBSnsp10

50.5 (54.4)

pQE-rVBSnsp12

12.5 (16.4)

Subsequently, PCR products were gel purified, digested with EcoRI and XhoI, and cloned
into the pQE-TriSystem His·Strep 2 vector (Qiagen, Valencia, CA) which has promoters
for expression in E. coli, insect cells and mammalian cells, allowing expression of
His·Strep-tagged proteins from a single vector. Each construct containing nsp1-12 was
designated as pQE-rVBSnsp1 through pQE-rVBSnsp12. Following transformation and
purification, individual plasmids were identified and characterized by restriction enzyme
analysis for correct orientation of the insert. The nucleotide identity of each construct
was confirmed by automatic BigDye terminator cycle sequencing (Eurofins MWGOperon, Huntsville, AL).

Expression of recombinant nsp1 to nsp12 in mammalian cells
Expression of recombinant EAV nsps was performed in BHK-21 cells transfected
with individual plasmids containing nsp1-12 coding regions using Fugene® HD (Promega)
according to manufacturer’s instructions. Briefly, BHK-21 cells were plated the day
before transfection at a density of 5 × 105 cells into a 100 mm cell culture dish in 17 ml of
complete growth medium. A total of 19 µg of each plasmid was mixed with Fugene® HD
reagent (Promega) and the complex was incubated for 10 min at room temperature (RT).
Subsequently, each mixture was added onto confluent monolayers of BHK-21 cells and
incubated at 37°C in a 5% CO2 incubator. At 24 h post-transfection, cells were lysed in
NP40 cell lysis buffer (50mM Tris, [pH 7.4], 250mM NaCl, 5mM EDTA, 50mM NaF,
1mM Na3VO4, 1% Nonidet P40 [NP40] and 0.02% NaN3) supplemented with 1X
proteinase inhibitor cocktail (Pierce) and 1mM phenylmethanesulphonyl fluoride (PMSF).
Insoluble materials were removed by centrifugation at 4°C for 10 min at 13,000 ×g in a
microcentrifuge.

Cleared cell lysates were stored at -80°C for further use.

The

expression and validity of each recombinant protein were confirmed by indirect
immunofluorescence and Western immunoblotting analyses.

Expression and purification of recombinant EAV nsp1 to nsp12 expressed in
bacterial cells
Plasmids pQE-rVBSnsp1, nsp3, nsp4, nsp6, nsp7, nsp8, nsp10 and nsp12 were
transformed in an expression strain of E. coli, M15[pREP4], and a single colony was
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used to inoculate 10 ml of Luria-Bertani (LB) medium containing both ampicillin (100
µg/ml) and kanamycin (25 µg/ml). The culture was grown overnight, diluted 1:20 in
fresh LB medium with ampicillin and kanamycin, and subsequently grown at 37°C until
an OD600 of 0.6 was reached. Recombinant protein expression was induced by addition of
1mM of isopropyl-β-D-thiogalactopyranoside (IPTG). Bacterial cells were harvested 4 h
after induction by centrifugation at 4000 ×g for 20 min at 4°C and stored at -20°C.
Individual recombinant fusion proteins containing 8× His-tag were purified with the NiNTA (Qiagen, Valencia, CA) agarose-affinity isolation procedure.

Briefly, induced

bacterial cell pellets were resuspended in buffer B (100mM NaH2PO4, 10mM Tris base
and 8M urea, pH 8.0) and incubated for 1 h at RT with gentle mixing. The lysates were
clarified at 10,000 ×g for 30 min at RT. The supernatant containing recombinant protein
was decanted into 50% Ni-NTA slurry and rotated gently for 1 h at RT. After binding,
the agarose containing column was washed twice with buffer C (100mM NaH2PO4,
10mM Tris base and 8M urea, pH 6.3). Elution was performed in 0.5-ml fractions of
buffer D (100mM NaH2PO4, 10mM Tris base and 8M urea, pH 5.9) four times followed
by elution in 0.5-ml fractions of buffer E (100mM NaH2PO4, 10mM Tris base and 8M
urea, pH 4.5) four times. Fractions containing the same recombinant protein were pooled
together and stored at -80°C for further use.

Immunofluorescence assays
For the indirect immunoflurorescence assay (IFA), BHK-21 cells grown on glass
cover-slips in 24-well plates were transfected with 0.55 µg of each nsp expression
plasmid (nsp1 to nsp12) using Fugene® HD (Promega, Madison, WI) according to the
manufacturer’s instructions.

At 18 h post-transfection, cells were fixed in 4%

paraformaldehyde in phosphate-buffered saline (PBS; pH7.4) for 30 min at RT and
washed three times with PBS (pH 7.4) containing 10mM glycine (glycine/PBS). After
permeabilization with 0.2% Triton X-100 in PBS (pH 7.4) for 10 min, cover-slips were
incubated with the appropriate nsp-specific monoclonal or polyclonal antibody, or with
anti-FLAG tag MAb (1:200), in PBS containing 5% fetal bovine serum (FBS). After
three 10mM glycine/PBS washes, coverslips were incubated with FITC-conjugated goat
anti-mouse or anti-rabbit IgG (Southern Biotech, Birmingham, AL) for 1 h at RT. Cover-
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slips were washed and mounted in 4’, 6’-diamidino-2-phenylindole (DAPI) containing
aqueous mounting medium (Vector Laboratories, Burlingame, CA) and observed under
an inverted fluorescence microscope.

Western immunoblotting
The solubilized proteins were mixed with 5X reducing sample buffer containing
100mM dithiothreitol (DTT; Pierce, Rockford, IL) and incubated for 10 min at RT.
Samples were resolved in a SDS-12% polyacrylamide gel (PAGE).

The gel was

transferred to a PVDF membrane (Bio-Rad, Hercules, CA). Blocking was performed in 5%
skim milk powder dissolved in TBS-T (10mM Tris-HCl [pH 7.6], 150mM NaCl, 0.05%
Tween 20). Blots were incubated with primary antibody for 1 h at RT followed by
biotinylated goat anti-mouse or anti-rabbit antibodies (Invitrogen, Carlsbad, CA) for 1 h.
Subsequently, the blots were incubated with streptavidin-horseradish peroxidase tertiary
antibody (Invitrogen, Carlsbad, CA) and detected using an enhanced chemiluminescence
reaction (ECL, Amersham, Piscataway, NJ).

Immunoprecipitation
Immunoprecipitation of individual EAV nsps was performed using Dynabeads®
Protein G (Invitrogen, Carlsbad, CA) Immunoprecipitation kit following manufacturer’s
instructions. Briefly, 10 µl of equine antiserum was added to the Dynabeads® Protein G
and incubated with rotation for 10 min at RT allowing antibody binding to the beads via
their Fc region. The bead-bound antibody complex was washed with binding buffer.
EAV nsp-containing cell lysate was mixed with the bead-bound antisera complex and
incubated for 30 min at RT with constant rotation. Then, the bead-antibody-antigen
complex was washed 3 times with washing buffer.

The immunoprecipitated target

antigen was eluted in elution buffer and mixed with 5X reducing sample buffer
containing DTT (Pierce, Rockford, IL) and heated for 5 min at 70°C. Subsequently,
denatured samples were resolved by SDS-12% PAGE and subjected to Western
immunoblotting analysis as described previously.
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9.4. RESULTS
Characterization of EAV nonstructural proteins expressed in mammalian cell
cDNA fragments corresponding to twelve nonstructural proteins (nsp1-nsp12) of
the VB strain of EAV were cloned and expressed in BHK-21 cells. Due to lack of
protein specific-antisera, recombinant proteins nsp5, nsp6, nsp10 and nsp12 were
expressed as C-terminal FLAG-tagged fusion proteins from each construct.

The

expression and validity of each recombinant protein was confirmed by indirect
immunofluorescence (IFA) and Western immunoblotting analyses with protein-specific
rabbit antisera and monoclonal anti-FLAG antibody (Figures 9.1.A and 9.1.B). All
twelve proteins, except for nsp6 (a very short peptide of 22 amino acids) which was
expressed only in few cells, were expressed at high levels and detected by IFA (Figure
9.1.A). Consistent with the IFA result, nsp6 could not be detected in the Western
immunoblotting assay indicating that expression of this protein is either insufficient or it
may be lost during SDS-PAGE and Western immunoblotting due to its extremely small
size (3.4 kDa after modification). As shown in Fig. 1B, all of the recombinant proteins
migrated according to their predicted sizes, listed in Table 9.2.

Figure 9.1. Expression of EAV nonstructural proteins in mammalian cells. (A)
Expression of EAV nonstructural proteins in BHK-21 cells as detected by
immunofluorescence assay.

For this purpose, BHK-21 cells were transfected with

plasmids encoding individual nsps and examined at 24 h post-transfection by IFA.
Protein-specific monoclonal antibody 12A4 (nsp1), protein-specific rabbit anti-peptide
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sera (nsp2, nsp3, nsp4, nsp7-8, nsp9, and nsp11) or anti-FLAG monoclonal antibody
(nsp5, nsp6, nsp10 and nsp12) and FITC-conjugated goat anti-mouse or rabbit IgG (H+L)
were used for detection of each protein. Each recombinant protein is identified at the
bottom of each panel. (B) Western immunoblotting analyses of recombinant EAV nsps
expressed in mammalian cells, performed with protein-specific monoclonal antibodies as
specified for panel (A). Sizes of the molecular weight markers are shown on the left
hand side of the figure and nsps are identified above each lane. Arrows indicate the
position of each recombinant protein.

Characterization of EAV nonstructural proteins expressed in E. coli
As an alternative to the use of a mammalian expression system, we employed a
bacterial expression system with a C-terminally 8× His-tagged vector as a
secondary/purification strategy. This system is more convenient for production of larger
amounts of protein, which could be used as antigen in future diagnostic tests. Segments
of the EAV genome containing the sequences of nsp1, nsp3, nsp4, nsp6, nsp7, nsp8,
nsp10, and nsp12 were successfully inserted into the pQE-TriSystem His·Strep 2
expression vector.

When E. coli were transformed with each plasmid expressing

individual nsp and induced with IPTG, bands migrating at a position corresponding to
nsp1, nsp4, nsp7, nsp8, nsp10 and nsp12 with a molecular size of approximately 32 kDa,
26 kDa, 29 kDa, 9 kDa, 55 kDa and 16 kDa respectively, as indicated in Table 9.3, were
observed on Western blots (Figure 9.2). Although the predicted molecular mass of nsp4
is 21 kDa, nsp4 was detected as an approximately 30 kDa product, as documented
previously [110]. Nsp1 and nsp12 were expressed at high concentrations in both soluble
and insoluble fractions of cell lysates. In contrast, larger amounts of nsp3, nsp4, nsp6,
nsp7, nsp8 and nsp10 could be recovered from insoluble fractions of cell lysates
compared to soluble fractions.

Therefore, proteins were purified under denaturing

conditions using an immobilized-metal affinity chromatography procedure with the NiNTA resin column. Although expression of nsp3 and nsp6 proteins was confirmed in a
Western immunoblotting analysis before purification, these proteins could not be
recovered after purification using Ni-NTA resin columns. Accordingly, bacterially
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expressed nsp3 and nsp6 could not be further evaluated in the study. Furthermore, nsps 2,
5, 9 and 11 were toxic and could not be expressed in M15[pREP4] E. coli using pQETriSystem His·Strep 2 vector.

Figure 9.2. Western immunoblotting analyses of recombinant nsp4, nsp7, nsp8,
nsp9 nsp10 and nsp12 of EAV expressed in E. coli. Samples were total lysates from
IPTG-induced cultures of E. coli M15[pREP4] cells transformed with pQE-TriSystem
Strep·His2. Total bacterial cell lysate was bound to Ni-NTA resin column. The bound
individual recombinant proteins were eluted in elution buffer and subjected to Western
immunoblotting analysis.

Recombinant proteins were detected using anti-His

monoclonal antibody. Sizes of the molecular weight markers are shown on the left hand
side of the figure and nsps are identified above each lane. Arrows indicate the position of
the protein.

Immunoprecipitation of EAV nsps 1 to 12 expressed in mammalian cells with
equine serum
To determine the equine antibody response to nonstructural proteins of EAV,
recombinant proteins nsp1 to nsp12 expressed in mammalian cells were subjected to
immunoprecipitation using 11 serum samples containing antibodies to EAV. The VN
antibody titers of these serum samples varied between 1:128 and ≥1:1024 (Table 9.1).
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Individual

recombinant

nsps

expressed

in

mammalian

cells

were

immunoprecipitated using well-characterized equine serum samples from experimentally
and persistently infected horses plus sera from horses vaccinated with the commercial
modified live virus vaccine (ARVAC®, Fort Dodge Animal Health Laboratories [now
Pfizer Animal Health Inc., New York, NY]). Briefly, total solubilized proteins derived
from nsp-transfected (nsp1 to nsp12) or pCAGGS-empty vector-transfected BHK-21
cells were immunoprecipitated with equine sera and the immunoprecipitated proteins
were subjected to SDS-polyacrylamide gel electrophoresis. As a control, two equine
serum samples negative for EAV antibodies were included in these assays. Individual
nsps in the immunoprecipitates were then identified with an nsp-specific monoclonal
antibody (nsp1), a specific rabbit antiserum (nsp2, nsp3, nsp4, nsp7, nsp8, nsp9, nsp11),
or an anti-FLAG monoclonal antibody (nsp5, nsp6, nsp10 and nsp12) by Western
immunoblotting analysis. All three sera from horses that were previously experimentally
infected with EAV strains VB, KY77, and KY84 precipitated recombinant nsp2
expressed in mammalian cells. Also three out of four serum samples from persistently
infected horses recognized nsp2, although serum from stallion G gave a weak
precipitation reaction as compared to the others. In contrast, all four serum samples from
vaccinated horses weakly immunoprecipitated nsp2 as detected by Western
immunoblotting assay (Figure 9.3.A).

Similarly, all three sera from horses

experimentally infected with different EAV strains reacted strongly with recombinant
nsp5 expressed in mammalian cells. Interestingly, sera from persistently infected horses
did not consistently immunoprecipitate nsp5.

Sera from stallion E gave a strong

immunoprecipitation reaction with nsp5 (comparable to sera from experimentally
infected horses) while sera from stallions D and R reacted very weakly and serum from
stallion G did not react at all. In contrast, none of sera from vaccinated horses were able
to immunoprecipitate nsp5 (Figure 9.3.B).
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Figure 9.3. Immunoprecipitation analyses of (A) nsp2 and (B) nsp5 using sera from
experimentally infected, vaccinated and persistently infected horses. Nsp2 and nsp5
expressed in mammalian cells were immunoprecipitated using equine sera and detected
by Western immunoblotting analysis with an anti-nsp2 rabbit serum and the anti-FLAG
tag monoclonal antibody, respectively. Sizes of the molecular weight markers are shown
on the left hand side of the figure and serum samples used for immunoprecipitation are
identified above each lane. Extreme right hand lanes contain corresponding recombinant
proteins expressed in mammalian cells as the control.

All of the sera from experimentally infected horses gave a very weak
immunoprecipitation reaction with nsp12 (Figure 9.4). Equine serum from the horse
experimentally inoculated with the KY77 strain strongly immunoprecipitated nsp12
compared to sera from two other horses experimentally inoculated with the VB and
KY84 strains of EAV.

None of the sera from persistently infected stallions and

vaccinated horses recognized nsp12 expressed in mammalian cells. Interestingly, none of
the 11 equine serum samples evaluated in this study were able to immunoprecipitate nsp1,
nsp3, nsp4, nsp7, nsp8, nsp9, nsp10, and nsp11 expressed in mammalian cells (Table 9.1).
Based on these results using recombinant proteins expressed in mammalian cells, only
nsp2 and nsp5 were consistently recognized by equine antiserum. As expected, none of
the proteins were immunoprecipitated by the two negative control sera, confirming the
specificity of EAV nsp recognition. Furthermore, none of the equine sera reacted with
the solubilized cellular proteins from pCAGGS-empty vector-transfected BHK-21 cells
(data not shown).

214

Figure 9.4. Immunoprecipitation analysis of nsp12 using sera from experimentally
infected, vaccinated and persistently infected horses. Nsp12 expressed in mammalian
cells was immunoprecipitated using equine sera and detected by Western blot analysis
with the anti-FLAG tag monoclonal antibody.

Immunoprecipitation of EAV nonstructural proteins expressed in E. coli with
equine serum
In order to verify whether equine serum from acutely (experimentally) infected,
persistently infected, and vaccinated horses can react with bacterially expressed antigens
similar to antigens expressed in mammalian cells, purified nsp1, nsp3, nsp4, nsp7, nsp8,
nsp10 and nsp12 proteins were subjected to immunoprecipitation analyses with equine
antisera. Consistent with the immunoprecipitation results using antigens expressed in
mammalian cells, none of tested sera recognized nsp1, nsp3, nsp7, nsp8, and nsp10
antigens. Interestingly, sera from horses used in this study immunoprecipitated nsp4 and
nsp12 expressed in bacterial cells although they did not previously immunoprecipitate the
same proteins expressed in mammalian cells (Figures 9.5.A and 9.5.B).

With the

exception of serum from one persistently infected stallion, other sera from persistently
infected

stallions

and

all

three

experimentally

infected

horses

strongly

immunoprecipitated nsp4 expressed in E. coli. Serum sample from the persistently
infected stallion D gave a weak immunoprecipitation reaction as compared to other
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samples (Figure 9.5.A). Interestingly, the serum samples from vaccinated horses were
only able to weakly immunoprecipitate nsp4. Previously, most tested sera did not react
or reacted weakly with nsp12 expressed in mammalian cells. In contrast, most sera
reacted strongly with bacterially-expressed nsp12 antigen (Figure 9.5.B). Sera from VBand KY77-inoculated horses and stallion E reacted strongly with the bacterially
expressed nsp12 antigen, while the rest of the sera (KY84, stallions D, R and G) only
reacted weakly with this antigen in immunoprecipitation assays. Additionally, all four
sera from vaccinated horses were also able to strongly immunoprecipitate nsp12. Based
on these results, horses consistently mount an immune response to EAV nsp4 and nsp12.
Equine antisera from experimentally infected and vaccinated horses, as well as
persistently infected stallions were unable to immunoprecipitate nsp1, nsp7, nsp8, and
nsp10 expressed in E. coli. As expected, none of the proteins were immunoprecipitated
with negative control sera, confirming the specificity of our approach.

Figure 9.5. Immunoprecipitation analyses of (A) nsp4 and (B) nsp12 using sera
from experimentally infected, vaccinated and persistently infected horses. Nsp4 and
nsp12 expressed in E. coli were immunoprecipitated using equine sera and detected by
Western immunoblotting analysis with the anti-His monoclonal antibody. For molecular
weight markers and controls, see the legend to Figure 9.3.
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9.5. DISCUSSION
In this study, we generated recombinant EAV nsp1 to nsp12 using mammalian
and E. coli expression systems. Most of the proteins migrated at the predicted molecular
size as indicated in Tables 9.2 and 9.3. However, several nsps expressed in mammalian
cells showed nonspecific protein bands on the membrane that were also recognized by
protein-specific rabbit antisera, e.g. nsp2, nsp3, nsp4, nsp9 and nsp11 (Figure 9.1.B).
This observation was just considered to be background bands or possible
instability/degradation of expressed proteins. Previous studies have shown that nsp2,
nsp3 and nsp5 contain predicted membrane-spanning domains which may serve to anchor
nsps to the modified intracellular membranes with which the viral replication complex is
presumed to be associated [87]. Incomplete disassociation of these nsps from cellular
proteins during SDS-PAGE could have caused some of these extra bands with higher
molecular weights. Consistent with previous reports, the recombinant nsp4 (predicted as
21 kDa and 25 kDa with modifications in mammalian and bacterial expression systems,
respectively) migrated as a protein of approximately 30 kDa, a phenomenon described as
aberrant migration of this protein during SDS-PAGE [114,465]. Additionally, the two
bands of nsp4 visible by Western immunoblotting analysis using nsp4-specific rabbit
antisera have been reported earlier [465].
The difficulties encountered during expression of recombinant nsp2, nsp5, nsp9
and nsp11 and purification of nsp3 and nsp6 in E. coli were likely related to the inherent
toxicity, codon-usage differences between bacterial and mammalian cells and/or
misfolding of these proteins when expressed from the pQE-TriSystem vector. Although
expression of nsp3 and nsp6 was confirmed in pilot experiments, these proteins could not
be recovered by Ni-NTA purification. It is plausible that misfolding of these proteins
masked their 8× His-tag and prevented binding to the Ni-NTA resin. Specifically, nsp2
and nsp5, which showed high immunoreactivity against equine sera when expressed in
mammalian cells, may need to be expressed using a different expression vector and E.
coli strain to generate recombinant proteins that could be used in diagnostic assays in the
future.
Previous studies on characterization of the equine humoral immune response to
EAV focused mainly on detection of antibodies to major viral structural proteins,
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especially GP5, M and N proteins [148,150,221,254,268,274,277,306,462]. To further
characterize the host immune response to EAV proteins, individual recombinant nsps
expressed in both mammalian and bacterial cells were immunoprecipitated with EAV
antibody positive and negative sera and identified with individual protein specific
monoclonal antibodies or protein-specific rabbit antisera by Western immunoblotting
analyses. These viral proteins synthesized during early phase of infection in host cells
are degraded in the cytoplasm by the proteasome, and the resulting peptides are
translocated into the endoplasmic reticulum, where they are loaded onto major
histocompatibilty complex (MHC) class molecules [281]. It has been suggested that
during antigen processing, antigenic sites buried in native form, such as hydrophobic
regions are exposed to the immune system and make them more immunogenic [466,467].
The data showed that nsp2, nsp4, nsp5, and nsp12 are the most immunogenic proteins
among all twelve nsps (Table 9.1) and that horses tend to mount an immune response to
these viral proteins. All three sera from experimentally infected horses consistently
recognized nsp2, nsp4, nsp5, and nsp12. In contrast, the antibody response to nsp2, nsp4,
and nsp12 in persistently infected stallions was somewhat variable. In addition, nsp5 was
the only protein which consistently reacted with sera from carrier stallions. These data
suggested that the serologic response of horses against nsps which clear the virus
following acute infection might be different from that of persistently infected horses. It is
possible that horses mount a strong immune response to viral nsps in the acute-phase
(when virus replication is active) which remains until late convalescent-phase but
decreases over time. In the presence of high titer neutralizing antibodies in the serum
during persistent infection, EAV is harbored in the ampulla of the reproductive tract of
the stallion [188].

Therefore, it could be postulated that virus replicates in

immunologically privileged cells in the stallion’s reproductive tract preventing (or
reducing) the exposure of nsps to the host immune system. However, some of the nsps
may still be able to induce a limited immune response during prolonged persistent
infection in the reproductive tract of the stallion. Moreover, all nsps may not be equally
immunogenic and this may also vary among different strains of EAV. This could explain
the difference between serologic response to nsps in vaccinated animals as compared to
the horses experimentally inoculated with more virulent field strains (VB, KY77, and
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KY84 strains).

The response of vaccinated horses with the MLV vaccine strain

(ARVAC®) was also different from that of experimentally and persistently infected
horses. Sera from vaccinated horses recognized nsp2 and nsp12 while nsp4 and nsp5
reacted very weakly or did not react at all. Furthermore, different horses may also
respond differently to EAV nsps during infection. It has been previously shown that
immune response to EAV structural proteins differ with the infecting virus strain and
duration of infection [268]. The M protein was most consistently recognized by various
serum samples, whereas the response to the N and GP5 proteins was variable [221,268].
Interestingly, the equine humoral immune response to nsp4 and nsp12 differed
depending on whether the protein was expressed in mammalian or bacterial cells. Most
sera, except for those from vaccinated horses, strongly reacted with nsp4 expressed in
bacteria.

However, none of the sera immunoprecipitated nsp4 when expressed in

mammalian cells. Similarly, the equine sera from experimentally infected horses or
persistently infected stallions were either only weakly immunoprecipitated or did not
precipitate the nsp12 expressed in mammalian cells while they strongly reacted and
immunoprecipitated the nsp12 expressed in E. coli. The reason for this difference in
recognition of the same antigen expressed in a different expression system might be due
to the failure of antigenic epitopes to be presented in their native form to be recognized
by the equine antibodies. It is also possible that nsp4 and nsp12 proteins, when expressed
in a mammalian expression system, are not processed properly or misfolded; this may
lead to obscuring both the conformational and linear epitopes recognized by equine
antibodies.

However, the proteins expressed in E.coli are denatured during the

purification process and this may well expose the linear epitopes recognized by equine
antibodies and facilitate immunoprecipitation of both nsp4 and nsp12 proteins.
In porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs,
nsp1, nsp2, and nsp7 were found to be the most immunogenic nsps of the virus
[468,469,470]. Subsequently, PRRSV nsp1 α/β and nsp7, and also nsp2, have been
explored as potential antigens for the development of serological diagnostic assays.
However, our data strongly suggest that horses do not mount a strong humoral antibody
response to EAV nsp1 and nsp7 as compared to pigs infected with PRRSV. In our hands,
it appears that EAV nsp1 is toxic in both mammalian and bacterial cells as expression of
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this protein was not highly efficient as compared to other nsps. Therefore, suboptimal
antigen concentration provided for immunoprecipitation assay could have adversely
affected the result. As in PRRSV, there is significant variation in EAV nsp2 [63,164].
However, unlike the PRRSV nsp2, until now, no B cell or T cell epitopes have been
identified in this protein in the case of EAV [469,471,472].
The virus neutralization (VN) test is the OIE (World Animal Health Organization)
prescribed regulatory test for serologic detection of EAV infection of the horse [292].
However, this assay is expensive, labor-intensive, and time-consuming to perform.
Results of the assay tend to vary among laboratories when insufficient attention is paid to
standardization of both test reagents and procedures.

To address this problem, we

previously developed a microsphere immunoassay (MIA) using recombinant structural
proteins of EAV. However, the sensitivity and specificity of the assay was 92.6% and
92.9%, respectively, compared to the VN test [464]. In this current study, we identified
the key EAV nsps recognized by horses during acute and persistent infection, as well as
following vaccination.

Thus, the recombinant nsps (nsp2, nsp4, nsp5, and nsp12)

identified in this study in combination with the structural proteins could be used in a new
MIA to further improve the specificity and sensitivity of the assay. Moreover, nsp5 could
be a potential candidate to be used as antigen in a companion differential diagnostic test
to distinguish horses vaccinated with current modified live virus vaccine (ARVAC®)
from naturally infected horses. Once we develop this new MIA, it will be used to further
characterize the antibody response to EAV by testing sequential serum samples from
experimentally inoculated and vaccinated horses [224,327,328,331]. We also plan to
evaluate this MIA with a large panel of equine sera determined to be positive and
negative for EAV antibody by VN test.
In summary, data presented in this study showed that the equine humoral immune
response to EAV nsps is directed against the nsp2, nsp4, nsp5, and nsp12. None of the
horse sera recognized nsp1, nsp3, and nsp6 through nsp12 when recombinant antigens
were used in immunoprecipitation assays. Among these proteins, nsp2 and nsp12 were
consistently recognized by either experimentally and persistently infected horses or
vaccinated horses. In contrast, nsp4 and nsp5 were recognized efficiently only by sera
from experimentally and persistently infected horses but not by vaccinated horses.
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Therefore, this study suggests that these antigens can be used for serodiagnostic testing of
EAV infection. Incorporation of the immunogenic nsps in a new MIA, along with
structural proteins as antigen, might greatly improve the sensitivity and specificity of the
previously developed MIA. An improved MIA assay is already under development in
our laboratory. Thus, a multiplex MIA including the most immunogenic structural and
nonstructural proteins of EAV could become a potential alternative to the standard VN
test.
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SUMMARY OF DISSERTATION
The nature of the interaction between the virus and the host is cirtical not only for
viral replication, but also in determining the virulence and pathogenesis of the pathogen
concerned. The goal of this study was to better understand how cellular proteins interact
with viral RNA or viral proteins, and the role they play in viral infection. Furthermore, it
was hoped to characterize more clearly the mechanisms of EAV pathogenesis and viral
persistence in stallions using contemporary molecular biology techniques and host
genomic analysis via a genome-wide association study (GWAS).
The viremia that is present in horses acutely infected with EAV is primarily
associated with the buffy coat cells in the blood (peripheral blood mononuclear cells
[PBMCs]).

Currently, detailed information of the target cells and the role of viral

proteins in infection of PBMCs is lacking. A specific objective was to characterize the
EAV target cell population in equine PBMCs and the interaction between the targe cell
population and the virus. This was accomplished using two strains of EAV, the virulent
Bucyrus (VB) strain and the attenuated modified live virus (MLV) vaccine strain of EAV.
The VB strain of EAV primarily infects CD14+ monocytes and a small subpopulation of
CD3+ T lymphocytes (predominantly CD4+ T) as determined by dual-color flow
cytometry. In contrast, the MLV vaccine strain of EAV has significantly reduced ability
to infect CD14+ monocytes and has lost its capability to infect CD3+ T lymphocytes.
Using infectious cDNA clones of EAV and reverse genetic systems, it was shown that
interactions between GP2, GP3, GP4, GP5 and M envelope proteins of the VB strain
play a major role in determining the CD14+ monocyte tropism while the tropism of
CD3+ T lymphocytes is determined by GP2, GP4, GP5 and M envelope proteins but
not the GP3 protein. This altered tropism correlated with amino acid variations mostly
located in the ectodomain of major and minor envelope proteins of the virus which
occurred during extensive cell culture passage of the Bucyrus strain of EAV; this resulted
in the highly attenuated MLV strain. This may have direct and/or indirect effects on
interaction with host cell receptor(s). Specifically, changes in the MLV genome could
potentially influence its attachment and entry properties, as well as reducing viral
replication and production of progeny virus in host lymphocytes. Infection of CD14+
monocytes with EAV is perhaps not surprising in view of the fact that members of the
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Arteriviridae family are monocyte/macrophage tropic; however, it provided the first
evidence that CD3+ T lymphocytes may play a role in the pathogenesis of EVA when
horses are infected with virulent strains of EAV. During the course of this study, we
found a clear difference among horses in terms of the susceptibility of their CD3+ T
lymphocytes to in vitro infection with the VB strain of EAV.

Horses could be

categorized into two groups, the first arbitrarily designated Group A were those in which
almost one third of the monocytes along with CD3+ T lymphocyte (mainly CD4+ T cells)
subpopulations were susceptible to infection with the VB strain of EAV. The second
group designated Group B, were those in which monocyte susceptibility was only half
that observed in Group A horses and all CD3+ T lymphocyte subpopulations were
resistant to EAV VB strain infection. Based on this finding, we had to presume that the
horse’s intrinsic genetic make-up may play a role in determining the clinical outcome of
infection with EAV.

To investigate the possible hereditary basis of this trait, we

conducted a genome-wide association study (GWAS) using the Illumina Equine SNP50
chip to compare horses of susceptible or resistant phenotypes. This study led to the
identification of a common, genetically dominant haplotype associated with the
putative equine susceptible phenotype in the region ECA11: 49572804-49643932.
The presence of a common haplotype indicates that the trait occurred in a common
ancestor of all four breeds that were studied, suggesting that it may be segregating
among other modern horse breeds.

Subsequently, biological pathway analysis

revealed several cellular genes within this region encoding proteins associated with virus
attachment and entry, cytoskeletal organization and NF-κB pathways that may be
associated with the trait responsible for the in vitro susceptibility/resistance of CD3+ T
lymphocytes to EAV infection.

However, further studies are needed to investigate

potential mechanisms that involve the roles of proteins encoded by genes located in this
region of ECA11 in the virus life cycle and the host response to EAV infection. The
findings from this study can help in developing working hypotheses to decipher novel
mechanisms of viral immune evasion, viral pathogenesis, and establishment of persistent
infection in stallions. Consistent with these findings, we hypothesized that the in vitro
susceptibility of CD3+ T lymphocytes to EAV infection correlates with the clinical
responsiveness of horses following exposure to the virus. To test this hypothesis, we
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selected horses that were either susceptible or resistant based on their in vitro CD3+ T cell
phenotype and challenged them with the recombinant VB strain of EAV. The study
findings revealed a difference between the two groups of horses in terms of cytokine
mRNA expression and evidence of possible increased frequency in clinical signs in
individuals possessing the in vitro CD3+ T cell resistant phenotype (Group B).

An

inverse correlation was found between the in vitro susceptibility or resistance
phenotype of CD3+ T lymphocytes and the different clinical/cytokine expression
responses observed in horses following infection with EAV. This was the first study
to provide direct evidence of a correlation between variation in host genotype and
phenotypic differences in terms of the extent of viral replication, nature of clinical
signs and cytokine gene expression following infection with a recombinat virulent
strain of EAV. Determining the basis for differences in outcome to virus infection and
cytokine gene expression in horses may be key in the animals’s control of infection. We
extended these studies by investigating the possible correlation between susceptibility of
CD3+ T lymphocytes to EAV infection and establishment of persistent infection in
stallions. Data from this study showed that stallions that possess the susceptible
CD3+ T lymphocyte phenotype to EAV infection may be at higher risk of becoming
persistently infected compared to stallions that do not possess this phenotype.
Identification of specific gene(s) or a chromosome region associated with establishment
of persistent infection is under investigation. Hopefully, findings from this study will
allow us to develop a genetic diagnostic tool to predict stallions at higher risk of EAV
persistence with the potential to reduce the reservoir of the virus and thereby restrict
spread of the virus.
Based on the findings of studies conducted to date, there is evidence that both
virus and host factors are likely to influence the clinical outcome of EAV infection. One
of the major shortcomings of these studies, however, is failure to identify the small
subpopulation(s) of CD3+ T lymphocytes that are susceptible to infection with VB strain
of EAV in PBMCs of Group A horses. Whether susceptibility of T lymphocytes to
infection with the VB strain of the virus has a determining role in the pathogenesis of
infection with this strain of EAV remains unknown at this time and warrants further
investigation.

224

The host immune response facilitates viral clearance and is a key determinant of
the outcome of infection. To investigate this in greater detail, a study was undertaken to
determine the precise effect of EAV on the immune system of horses, innate and humoral
immunities. Many viruses have evolved strategies to counteract key elements of the type
I interferon (IFN) response and successfully prevent development of an antiviral
environment in the host that would inhibit their persistence in their host. This strategy of
evading the host immune system is commonly seen in persistent viral infections. In vitro
investigations in an equine endothelial cell line provided evidence that EAV inhibits type
I IFN production in infected cells. Among EAV nonstructural (nsps), nsps 1, 2 and 11
had the capability to inhibit type I IFN activity. Of these three nsps, nsp1 appeared
to have the strongest inhibitory effect on IFN synthesis. Collectively, these data
demonstrated that failure to induce type I IFN in EAV infected cells may allow the
virus to subvert the equine innate immune response and facilitate establishment of
persistent infection in the stallion. Further studies are needed, however, to map the
exact step(s) at which EAV nsp1 protein acts on the IFN induction pathway.
It is a fundamental fact that the host immune system is capable of detecting
invading foreign pathogens.

Until now, research emphasis has mostly been on the

humoral immune response to the structural proteins of EAV. One of the final objectives
of these studies, therefore, was to evaluate the humoral immune response of horses to
each of the nsps following EAV infection. Among 12 nsps, nsp2, nsp4, nsp5 and
nsp12 were immunoprecipitated by most of the sera from experimentally or
persistently infected horses, while sera from vaccinated horses did not react with
nsp5 and only reacted weakly with nsp4. However, serum samples from vaccinated
horses were able to immunoprecipitate nsp2 and nsp12 proteins consistently.
Information from this study hopefully will assist ongoing efforts to develop
improved methods for the serologic diagnosis of EAV infection in horses.
The host-virus interaction is in a continuous process of evolution where both entities
develop strategies to overcome the effects of the other. The outcome of interaction between
EAV and the horse have evolved such that the virus can persist in the stallion’s reproductive
tract despite the presence of high neutralizing antibody titers in its bloodstream. In the range
of studies that were carried out, we tried to integrate aspects of the interaction of EAV with
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its host. Our focus was initially on the virus and then on those aspects of the host that are
important for the successful interaction of the virus with the host. Special attention was paid
to those aspects that are important for clearance of virus from the host. The data presented
in this dissertation suggest new directions for future EAV research using genomic and
proteomic approaches to study host cell factors involved in EAV attachment and entry and
establishment of persistent infection in the stallion.
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APPENDIX 1

List of Abreviations
aa

Amino acid

AMΦ

Alveolar macrophage

Asn

Asparagine

BHK-21

Baby hamster kidney-21

BMΦ

Blood macrophage

bp

base pair

CAVV

Cavally virus

CD

Cluster of differentiation

cDNA

Complementary deoxyribonucleic acid

CF

Complement fixation

CMI

Cell mediated immunity

CoV

Coronavirus

CPE

Cytopathic effect

CTL

Cytotoxic T lymphocyte

Cys

Cysteine

DMV

Double membrane vesicle

DNA

Deoxyribonucleic acid

Dpi

Days post infection

Ds

Double stranded

E

Envelope protein

EAV

Equine arteritis virus

ED

Equine dermal

EDTA

Ethylenediaminetetraacetic acid

EEC

Equine endothelial cells

eGFP

Enhanced green fluorescence protein

ELISA

Enzyme linked immunosorbent assay

EPAEC

Equine pulmonary artery endothelial cells

ER

Endoplasmic reticulum

ERGIC

ER-Golgi intermediate complex

EToV

Equine Torovirus

EU

European

EVA

Equine viral arteritis

GAV

Gill-associated virus
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GFP

Green fluorescent protein

GP

Glycoprotein

GWAS

Genome-wide association study

HEK

Human embryonic kidney

HK

Horse kidney

IFN

Interferon

Ig

Immunoglobulin

IMP

Immunoprecipitation

IVT

In vitro transcription

kDa

kilodalton

LDV

Lactase dehydrogenase-elevating virus

M

Membrane protein

MAb

Monoclonal antibody

MDBK

Madin-Darby bovine kidney

MGB

Minor-groove binding

MIA

Microsphere immunoassay

MLV

Modified live virus

Mn

Manganese

MOI

Multiplicity of infection

mRNA

Messenger RNA

MW

Molecular weight

N

Nucleocapsid protein

NA

North American

NC

Nucleocapsid

NF-κB

Nuclear factor-kappa B

NMR

Nuclear magnetic resonance

Nsp

Nonstructural protein

NTPase

Nucleoside triphosphatase

OIE

World Organisation for Animal Health

ORF

Open reading frame

PAM

Pulmonary alveolar macrophage

PBMC

Peripheral blood mononuclear cells

PCP

Papain-like cysteine protease

PCR

Polymerase chain reaction

PFU

Plaque forming unit

PMO

Phosphorodiamidate morpholino oligomers

pp

Polyprotein
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PPMO

Peptide-conjugated phosphorodiamidate morpholino oligomers

PRRS

Porcine reproductive respiratory syndrome

PRRSV

Porcine reproductive respiratory syndrome virus

qrRT-PCR

quantitative real-time reverse-transcription PCR

RdRp

RNA-dependent RNA polymerase

RFS

Ribosomal frameshift

RK

Rabbit kidney

RK-13

Rabbit kidney-13

rMLV

recombinant MLV

RNA

Ribonucleic acid

RT-PCR

Reverse transcription-polymerase chain reaction

rRT-PCR

Real time reverse transcription-polymerase chain reaction

rVBS

recombinant VB strain

SARS

Severe acute respiratory syndrome

SARS-CoV

Severe acute respiratory syndrome coronavirus

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

sg mRNA

Subgenomic mRNA

SHFV

Simian hemorrhagic fever virus

SNP

Single nucleotide polymorphism

ss

Single stranded

T reg

Regulatory T cells

TCF

Tissue culture fluid

TCID50

50% tissue culture infective dose

TRS

Transcription regulation sequence

UTR

Untranslated region

VB

Virulent Bucyrus

VBS

Virulent Bucyrus strain

VI

Virus isolation

VN

Virus neutralization

VNT

Virus neutralization test

VRP

Venezuelan equine encephalitis virus replicon particle

YHV

Yellow head virus

ZBD

Zinc-binding domain

ZF

Zinc finger
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APPENDIX 2

Experimental Methods

TISSUE CULTURE MEDIA RECIPES
EPAEC (EQUINE PULMONARY ARTERY ENDOTHELIAL CELLS):
DMEM (with high glucose [4.5 g/L], without L-glutamine; Cellgro 15-013-CM)
Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)
Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)
0.1 mM Non-essential amino acids (10 mM [100X] Gibco 11140-050)
2 mM L-glutamine (200 mM [100X] Gibco 25030)

1L
110mL
11mL
11mL
10 mL

HEK293T (HUMAN EMBRYONIC KIDNEY 293T CELLS):
DMEM (with high glucose [4.5 g/L], without L-glutamine; Cellgro 15-013-CM)
Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)
Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)
200 mM L-glutamine (200 mM [100X] Gibco 25030)

500 mL
50 mL
5 mL
5 mL

A594 (HUMAN ALVEOLAR BASAL EPITHELIAL CELLS: ATCC CAT. # CCL-185):
F-12 Kaighn’s modification (Hyclone SH30526.01)
Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)
Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)

500 mL
50 mL
5 mL

PBMC (PERIPHERAL BLOOD MONONUCLEAR CELLS):
RPMI 1640 (without L-glutamine; Gibco 21870)
Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)
Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)
200 mM L-glutamine (200 mM [100X] Gibco 25030)
55 μM 2-mercaptoethanol (55 mM [1000X]; Gibco 21985-023)

500 ml
50 mL
5 mL
5 mL
0.5 ml

RABBIT KIDNEY 13 HIGH PASSAGE AND LOW PASSAGE (P207) FROM BILL MCCOLLUM,
UKY:
Laboratory Designated Name: RK-13 HP# (High passage), RK-13 LP# (Low passage)
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080
Cosmic calf serum 10% (Hyclone SH30087.03)
Penicillin and Streptomycin (GIBCO 15140-122)

500 ml
50 ml
5 ml

RABBIT KIDNEY 13 (ATCC CATALOG NO. CCL-37):
Laboratory Designated Name: CCL-37-RK13
Minimum Essential Medium (EMEM;
With Earle’s salts and L-glutamine; GIBCO 11095-080
Fetal Bovine Serum 10% (Hyclone SH30396.03)
Penicillin and Streptomycin (GIBCO 15140-122)
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)
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500 ml
50 ml
5 ml
5 ml
5 ml

RABBIT KIDNEY 1 (ATCC CATALOG NO. CCL-106):
Laboratory Designated Name: LLC-RK1
Medium 199 (GIBCO 11150-059)
Horse serum 10% (Hyclone SH30074.03)
Penicillin and Streptomycin (GIBCO 15140-122)

500 ml
50 ml
5 ml

VERO 76 (ATCC CATALOG NO. CRL-1587):
Laboratory Designated Name: VERO 76
DMEM (With high glucose [4.5g/L] and L-glutamine; GIBCO 11965-092)
Fetal Bovine Serum 10% (Hyclone SH30396.03)
Penicillin and Streptomycin (GIBCO 15140-122)

500 ml
50 ml
5 ml

VERO C1008 (ATCC CATALOG NO. CRL-1586):
Laboratory Designated Name: VERO C1008
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080
Fetal Bovine Serum 10% (Hyclone SH30396.03)
Penicillin and Streptomycin (GIBCO 15140-122)
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)

500 ml
50 ml
5 ml
5 ml
5 ml

BHK-21 (C-13; ATCC CATALOG NO. CCL-10):
Laboratory Designated Name: BHK-21
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080
Fetal Bovine Serum 10% (Hyclone SH30396.03)
TPB (Tryptose phosphate broth)
Penicillin and Streptomycin (GIBCO 15140-122)

500 ml
50 ml
50 ml
5 ml

EQUINE DERM CELLS (NBL-6; ATCC CATALOG NO. CCL-57):
Laboratory Designated Name: ED (Equine derm)
Minimum Essential Medium (EMEM;
With Earle’s salts and L-glutamine; GIBCO 11095-080
Fetal Bovine Serum 10% (Hyclone SH30396.03)
Penicillin and Streptomycin (GIBCO 15140-122)
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)

500 ml
50 ml
5 ml
5 ml
5 ml

MDBK (BOVINE KIDNEY CELLS; ATCC CATALOG NO. CCL-22)
Laboratory Designated Name: MDBK
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080)
Horse Serum 10% (Hyclone SH30396.03)
Penicillin and Streptomycin (GIBCO 15140-122)
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)

500 ml
50 ml
5 ml
5 ml
5 ml

FETAL EQUINE KIDNEY PRIMARY CELLS (FEK-XX1) FROM BILL MCCOLLUM, UKY
Laboratory Designated Name: FEK
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080)
Fetal Bovine Serum 10% (Hyclone SH30396.03)
Penicillin and Streptomycin (GIBCO 15140-122)
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500 ml
50 ml
5 ml

EQUINE PULMONARY ARTERY ENDOTHELIAL CELL MEDIUM (ECMM)
Laboratory Designated Name: EPAEC
DMEM (With high glucose [4.5g/L], without L-glutamine; Cellgro 15-013-CM)
Fetal Bovine Serum 10% (Hyclone SH30396.03)
Penicillin and Streptomycin (GIBCO 15140-122)
L-glutamine (200 mM; GIBCO
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)

1L
110 ml
11 ml
10 ml
11 ml

CELL LINES GROWN WITH EMEM 10% FSCS IN INCUBATOR WITHOUT CO2
BHK-21 (Baby Hamster Kidney 21: C-13; ATCC Cat. # CCL-10); RK-13 (Rabbit Kidney 13 Low passage
[P194-P204] from Bill McCollum, KY); RK-13 (Rabbit Kidney 13 High passage [P399-P409] from Bill
McCollum, KY); Vero 76 (African Green Monkey Kidney: ATCC Cat. # CRL-1587); MDBK (Bovine
Kidney cells: ATCC Cat. # CCL-22); ED (Equine Dermal cells: NBL-6; ATCC Cat. # CCL-57)

LARGE SCALE (10 L) CELL CULTURE MEDIA, EMEM 10% FSCS:
Materials
1. EMEM (NEAA, L-glutamine; Mediatech #50-011-PB; 10L/bt)
2. Ferritin supplemented calf serum (FSCS; Hyclone SH30072.03)
3. Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)
4. Fungizone (Sigma A-9528, one vial)
Fungizone
50 mg
Sterile distilled water
50 ml
Dissolve fungizone in dH2O and dispense in 10 ml aliquots. Store at -20°C.
Unreconstituted vial should be stored at 4°C.
5.
6.
7.
8.

Sodium bicarbonate (NaHCO3; Sigma Cat. # S5761-500g)
Glass fiber prefilter (Millipore Cat. # AP2012450)
Durapore® membrane filters (045 μm; Millipore Cat. # HVLP14250)
12 L bottle and stir bar

10L/bottle
1000 mL
100 mL
10 mL

6g

Method
EMEM
NaHCO3
Penicillin/Streptomycin
Fungizone (Amphotericin 1,000μg/ml)
Serum –ferritin supplemented calf serum (FSCS)
dH2O (tissue culture grade water)
1.
2.
3.
4.
5.
6.
7.
8.

96.1g
6.0 g
100 ml
10 ml
1000 ml
q.s. to 10,000 ml

Add 8 L dH2O to 12 L bottle with stir bar.
Place on stirrer/hotplate and turn stirrer to setting #3.
Add EMEM bottle (rinse twice with water) and mix until dissolved, about 15 min.
Add sodium bicarbonate (color should change from yellow to red), penicillin/streptomycin (p/s),
fungizone (f), and serum (rinse each container twice with water).
Final concentration of penicillin/streptomycin 100 U/ml and 100μg/ml and fungizone 1 μg/ml.
Add water to 10 L and mix 5 min.
In cell culture room, filter through sterile Millipore filter unit using a prefilter. Dispense 1
L/sterile 1 L bottle.
Perform sterility check. Store at 4°C.
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CARBOXYMETHYLCELLULOSE (CMC) OVERLAY MEDIA (1.3X EMEM 10% FSCS):
Materials
1. Carboxymethylcellulose, medium viscosity (Sigma C-4888)
2. Distilled water

6.0 g
140 ml

Method
1. Add water to a 1 L bottle, swirl while adding 0.75% carboxymethylcellulose (CMC) and then
shake if necessary.
2. Let stand overnight at room temperature (shake occasionally).
3. Autoclave for 20 min at 121°C (liquid setting).
4. When cooled to approx. 40°C, add 1.3X EMEM 10% FSCS to the 800 ml mark.
1.3X EMEM 10% FSCS:
EMEM
NaHCO3
Penicillin/Streptomycin
Fungizone (Amphotericin 1,000μg/ml)
Serum –ferritin supplemented calf serum (FSCS)
dH2O (tissue culture grade water)

96.1g
6.0 g
100 ml
10 ml
1000 ml
q.s. to 7,800 ml

Prepare same as for EMEM 10% FSCS except start with 6 L dH2O and q.s. to 7.8 L.
5.
6.

Perform sterility check. Store at 4°C.
Before using, add 0.8 ml gentamicin/bottle (working concentration – 50 μg/ml).

VIRUS TRANSPORT MEDIUM:
Hanks's Balanced Salt Solution w/ Phenol Red 1X (Invitrogen; 14170112)
HEPES Buffer (final concentration 25 mM; Invitrogen; 15630080)
Bovine Serum Albumin V (final concetration 0.5%; Sigma: A9647)
Antibitic-Antimycotic (100X, Peniillin, Steptomycin & Amphotericin B; Invitrogen; 15240112)
Gentamicin Sulfate (final concentration 250 mg/L) Cellgro; 30-005-CR

500 ml
20 ml
2.5 g
5 ml
2.5 ml

NET BUFFER (PH 7.5) FOR RESUSPENSION OF VIRUS PELLET:
Materials
50 mM Tris hydrochloride (500 ml dH2O)
50 mM Tris base (500 ml dH2O)
5 mM EDTA
150 mM NaCl

3.938 g
3.029 g
0.95 g
4.383 g

Method
1.
2.
3.

Add Tris base to Tris-hydrochloride until the mixture reaches pH 7.5. (Add about 100ml of 50mM
Tris-Base to 500ml of 50mM Tris-HCl to get pH 7.5)
Add 5 mM EDTA and 150 mM NaCl to above 50 mM Tris-HCl pH 7.5
Filter and store at 4°C.
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DULBECCO’S PHOSPHATE-BUFFERED SALINE (PBS):
PBS (Gibco 21600-069)
Sterile distilled water
1.
2.
3.
4.

95.5 g (1 bottle)
q.s. to 10,000 ml

Add 9 L dH2O to 12 L bottle with stir bar. Place on stirrer/hotplate and turn stirrer to setting #3.
Add PBS bottle (rinse twice with water) and mix for 10 min.
Add 800 ml to each 1 L bottles. Autoclave for 20 min at 121°C (liquid setting).
Cool to room temperature before tightening caps and labeling. Perform sterility check. Store at
room temperature.

TRYPSIN EDTA SOLUTION:
PBS (sterile 1X)
Trypsin EDTA (no phenol red [10X]; Gibco 15400-054)

180 ml
20 ml

FREEZING MEDIA:
Dimethylsulfoxide (DMSO; Sigma D-2650)
EMEM 10% FSCS

10%
90%

Or
Recovery™ Cell Culture freezing medium (Gibco; 12648-010)
GUINEA PIG COMPLEMENT:
100 ml/bottle, (Rockland Cat # C300-0100). Thaw and dispense (on ice) into 1 or 2 ml volumes and store
at -70°C.
MISCELLANEOUS:
0.5% Trypsin EDTA (no phenol red [10X]; Gibco 15400-054)
Phosphate buffered saline (PBS, pH 7.4, without calcium chloride/magnesium chloride; Gibco 10010)
Dulbecco’s Phosphate buffered saline (PBS 10L/bottle, Gibco 10010)
HEPES buffer solution (1M; Gibco 15630)

ANTIBIOTICS FOR CELL CULTURE
Gentamicin:
Gentamicin sulfate, 50 mg/ml, 10 ml/vial (Mediatech 30-005-CR). Store at 4°C.
Pen-Strep:
Penicillin and streptomycin (10,000 U/ml and μg/ml; Gibco 15140-122)
Antibiotic-Antimycotic:
Anti-Anti (100X; Gibco 15240)
Fungizone:
Amphotericin B Solubilized (Sigma A-9528)
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BACTERIAL MEDIA RECIPES
LIQUID MEDIA
LB Medium (Luria-Bertani Medium; 500 ml):
Deionized water
500 ml
Bacto-tryptone
5g
Bacto-yeast extract
2.5 g
NaCl
5g
1. Stir until the solutes have dissolved. Adjust the pH to 7.0 with 5N NaOH.
2. Sterilize by autoclaving for 20 minutes on liquid cycle.
Psi Broth (500 ml):
Bacto-tryptone
Bacto-yeast extract
NaCl
4 mM MgSO4
10 mM KCl
dH2O
1. Autoclave liquid cycle 30 min.

5.0 g
2.5 g
2.5 g

to 500 ml

MEDIA CONTAINING AGAR
LB Agar Plates:
Deionized water
Bacto-tryptone
Bacto-yeast extract
NaCl

500 ml
5g
2.5 g
5g

1.

Prepare LB medium according to the above recipe. Just before autoclaving, add 7.5 g of Bacto
agar. Sterilized by autoclaving for 20 minutes on liquid cycle.
2. When the medium is removed from the autoclave, swirl it gently to distribute the melted agar
throughout the solution (need to be very careful, the media may boil over when swirled). Allow
the medium to cool to 45-500C before adding antibiotics*.
3. To avoid air bubbles, mix the medium by swirling. Pour 20-25 ml of medium in a petri dish (use
the tissue culture hood and fluorescent light should be off).
4. When medium has hardened completely, invert the plates and wrap in aluminum foil and store
them at 4°C until needed. The plates should be removed from storage 1-2 hours before they are
used and allow them to dry.
*Antibiotics solutions
Antibiotic
Working concentration
Ampicillin
50 µg / ml
Streptomycin
50 µg / ml
Tetracycline
50 µg / ml
Kanamycin
50 µg / ml
Carbenicillin
60 µg / ml
Chloramphenicol
170 µg / ml
Stock solutions should be stored at -200C. Avoid repeated freeze thawing and exposure to light.
Magnesium ions are antagonists of tetracycline. Use media without magnesium salts for selection of
bacteria resistant to tetracycline.
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STORAGE MEDIA FOR BACTERIA
Cultures Containing Glycerol:
1. Aliquot 0.85 ml of bacterial culture in to a freezing vial and add 0.15 ml of sterile glycerol
(sterilized by autoclaving for 20 minutes on liquid cycle). Vortex the culture to disperse glycerol
evenly. Freeze the culture in ethanol-dry ice or liquid nitrogen, and then transfer the tube to -70°C.
2. To recover the bacteria, scrape the frozen surface of the culture with a sterile inoculating needle,
and then immediately streak the bacteria that adhere to the needle onto the surface of an LB agar
plate containing the appropriate antibiotics. Incubate the plate at 37°C. Return the frozen culture
to storage at -70°C.
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COMMONLY USED SOLUTIONS AND BUFFERS FOR MOLECULAR BIOLOGY

0.5 M EDTA (pH 8.0)
Deionized water
115 ml
EDTA (di-sodium)
27.918 g
5N NaOH
15,825 µl
Bring the volume to 150 mls with deionized water
5.0 M Sodium chloride
29.22 g of NaCl in 100 mls of distilled water
10% SDS
10 g in of SDS in 100 mls of deionized water
3.0 M Sodium acetate (pH 5.2)
Dissolve 24.609 g of sodium acetate in 60 mls of deionized water. Adjust the pH to 5.2 with
glacial acetic acid (approximately 25.6 mls). Bring the volume to 100 mls with deionized water.
10 M Ammonium Acetate (50 ml)
Ammonium acetate
Deionized water to

38.5 g
50 ml

1 M MgCl2 (100 ml):
MgCl2 6H20
Deionized water to

20.3 g
100 ml

1 M Dithiothreitol (DTT; 10 ml)
DTT
10 mM Sodium acetate (pH 5.2) to
Store at -200C
1M Tris HCl (pH 8.0)
Tris HCl
4.44 g / l
88.8 g / l
8.88 g / 100 mls
17.76 g / 200 mls

1.55 g
10 ml

Tris base
2.65 g / l
53.0 g / l
5.30 g / 100 mls 1.0 M
10.6 g / 200 mls 1.0 M

1M Tris HCl (per liter)
Tris Base
Add deionized water to 800 ml
Desired pH
pH 7.4
pH 7.6
pH 8.0
Add deionized water to 1 liter

Molarity
0.05 M
1.0 M

121.1g
Volume of HCl
70 ml
60 ml
42 ml

237

TE BUFFER
pH 8.0
10 mM Tris HCl (pH 8.0)
1 mM EDTA (pH 8.0)
pH 7.6
10 mM Tris HCl (pH 7.6)
1 mM EDTA (pH 8.0)
pH 7.4
10 mM Tris HCl (pH 7.4)
1 mM EDTA (pH 8.0)
TAE (Tris-acetate; 50X concentrated stock solution [per liter])
Tris base
242 g
Glacial acetic acid
57.1 ml 0.5
0.5 M EDTA (pH 8.0)
100 ml
Deionized water
q.s.
Working concentration 1X (dilute 10 ml in 490 ml of deionized water)

Proteinase K 2X Buffer
Reagent
Final concentration
Tris HCl (pH 8.0)
0.2 M
NaCl
0.3 M
EDTA (pH 8.0)
25 mM
SDS
2.0%
Deionized water

To make 100 mls of buffer
20 ml of 1.0 M Tris HCl (pH 8.0)
6.0 ml of 5.0 M NaCl
5.0 ml of 0.5 M EDTA (pH 8.0)
20 ml of 10% SDS
49 ml

Ethidium Bromide (EtBr; 10 mg/ml)
1.
2.
3.
4.

Add 1 g of EtBr to 100 ml of deionized water.
Stir on a magnetic stir for several hours to ensure that the dye has dissolved.
Wrap the container in aluminum foil or transfer the solution to a dark bottle and store at room
temperature.
Final concentration to be used: 0.5 μg/ml

Method
1.
2.

EtBr in agarose: 5.0 μl of EtBr (10 μg/μl) solution per 100 ml of agarose
EtBr staining solution (1× TAE with 0.5μg/ml EtBr): 25 μl of EtBr stock solution in 500 ml of× 1
TAE buffer

Gel Loading Buffer (6X)
0.25% bromophenol blue (MW 691.9)
30% glycerol
Dissolved in 1X TAE solution
To make 40 ml 6X loading buffer:
0.25% bromophenol blue (MW 691.9)
30% glycerol
1X TAE solution

0.1 g
12 ml
to 40 ml
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Preparation of 25 bp DNA ladder (Invitrogen Cat. # 10597-011)
100 bp DNA ladder (1 μg/μl)
50μl
6× loading buffer
100 μl
Nuclease free water
450 μl
Preparation of 100 bp DNA ladder (Invitrogen Cat. #)
100 bp DNA ladder (1 μg/μl)
50μl
6× loading buffer
100 μl
Nuclease free water
450 μl
Preparation of 1 kb plus DNA ladder (Invitrogen Cat. # 15615-024)
1 kb plus DNA ladder (1 μg/μl)
50 μl
6× loading buffer
100 μl
Nuclease free water
450 μl
Preparation of low DNA mass ladder (Invitrogen Cat. # 10068-013)
Low DNA mass ladder
100 μl
6× loading buffer
100 μl
Nuclease free water
400 μl
Preparation of PCR products
PCR products
6× loading buffer

10 μl
2 μl

Preparation of PCR products to estimate concentration
PCR products
2 μl
6× loading buffer
2 μl
Nuclease free water
8 μl
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BUFFERS AND REAGENTS FOR WESTERN IMMUNOBLOTTING
10X SDS-PAGE RUNNING BUFFER (4 LITERS)
Glycine
580 g
Tris base
120 g
SDS
40 g
Distilled water to
4 liters
TRANSFER BUFFER FOR WESTERN IIMMUNOBLOTTING (FOR PROTEINS <80,000 M.W)
1 Liter
4 Liters
Tris base 25 mM
2.9 g
11.6 g
Glycine 190 mM
14.5 g
58.0 g
Methanol 20%
200 ml
800 ml
Make up to 1 liter or 4 liters with distilled water (800 or 3200 mls)
WASHING BUFFER FOR WESTERN IMMUNOBLOTTING (TBS-T/ TRIS BUFFERED SALINE
WITH 0.05% TWEEN 20; pH 7.6)
1 Liter
4 Liters
Tris base
2.42 g (20 mM)
9.68 g
NaCl
8.0 g (137 mM)
32.0 g
6N HCl
3.8 ml
10.4 ml
Tween 20 (0.05%)
500 µl
2 ml
Deionized water to
1 liter
4 liters
ANTIBODY DILUTION BUFFER (ADB) FOR WESTERN IMMUNOBLOTTING
Nonfat dry milk
10 g
0.1 g
Sodium azide (NaN3)
NaCl
9.0 g
4.5 g
Na2HPO4
0.5 g
NaH2PO4
PBS (1X)
1L
AVIDIN-HRP CONJUGATE DILUTION BUFFER IN PBS FOR WESTERN
IMMUNOBLOTTING
PBS (1X)
500 ml
1% Nonfat dry milk
5g
0.05% Tween 20
250 µl

BLOCKING AGENT FOR WESTERN IMMUNOBLOTTING
5% Nonfat dry milk in TBS-T (25 g for 500 ml)
(Use nonfat dry milk for horse serum to reduce the high background. Generally BSA can be used as a
blocking agent for western immunoblotting).
MOLECULAR WEIGHT MARKERS AND SAMPLE BUFFER
BenchMark™ Pre-stained protein ladder (Invitrogen; Cat. #10748-010)
MagicMark™ XP Western protein standard (20-220kDa; Invitrogen; Cat. #LC5602)
Lane Marker Reducing sample buffer (5X) (Thermo Scientific Pierce; Cat. # 39000)
Laemmli sample buffer (2X) (BioRad; Cat. # 161-0737)
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SOLUTIONS AND REAGENTS
1.5 M Tris HCl, pH 8.8 (BioRad; Cat. # 161-0798)
0.5 M Tris HCl, pH 6.8 (BioRad; Cat. # 161-0799)
SDS solution 10% w/v (BioRad; Cat. # 161-0416)
TEMED (N, N, N’, N’-Tetra-methylethylenediamine) (BioRad; Cat. # 161-0801)
Blocking grade blocker non-fat dry milk (BioRad; Cat. # 170-6404)
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COMMONLY USED STAINS
Crystal violet stain (stock solution):
Crystal violet (Mallinckrodt 8839)
Methanol (Fisher A412-20)

12g
600 ml

Crystal violet stain (working solution):
1 part of above stock solution
9 parts 10% buffered formalin (Fisher 23-245-685)
Coomassie Blue R protein stain
Brilliant blue R
Glacial acetic acid
95% Ethanol
Distilled water

0.41 g
50 ml
225 ml
225 ml

0.2% Trypan Blue for cell counting
Trypan blue
PBS
Sterile filter.

0.2 g
100 ml
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ANTIBODIES
EAV SPECIFIC ANTIBODIES
Specificity
EAV GP5
EAV GP5
EAV M
EAV N
GP2
GP3
GP4
EAV nsp1
EAV nsp2
EAV nsp3
EAV nsp4
Nsp7 and 8
α-EAV antibody†

Clone
6D10
FP55
8887
3E2
4033
3509
7466
12A4
L3
98E
T1
D (M1)
11412

Species Origin
Mouse (MAb)
Rabbit
Rabbit
Mouse (MAb)
Rabbit
Rabbit
Rabbit
Mouse (MAb)
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit

Specifity
EAV GP5
EAV GP5
EAV M
EAV N
EAV GP2
EAV GP3
EAV GP4
EAV nsp1
EAV nsp2
EAV nsp3
EAV nsp4
EAV nsp7 and nsp8
EAV

CONJUGATED-EAV SPECIFIC ANTIBODIES
Specificity
Rabbit 8887 PB IgG
EHV-1
EAV anti-nsp1
EAV anti-N

Clone
Rabbit polyclonal
Monoclonal
12A4
3E2

Species Origin
Rabbit
Mouse (MAb)
Mouse (MAb)
Mouse (MAb)

Conjugated Form
Alexa Fluor 488
Alexa Fluor 488
Alexa Fluor 488
Alexa Fluor 488

Specifity
Prebleed
EHV-1
EAV nsp1
EAV N

CELL SURFACE ANTIGEN
Specificity

Clone

Company

Catalog #

E18A

Species
Origin
Mouse

VMRD

E18A

Species
Specifity
Horse

B cells
B cells

6Dw19

Mouse

Cornell

N/A

Horse

CD11a/CD18
CD13
CD14

CVS9
CVS19
Big10

Mouse
Mouse
Mouse

Serotec
Serotec
Alexis

MCA1081
MCA1084
ALX-804496

DH59B

Mouse
Mouse

Cornell
VMRD

N/A
DH59B

Mac288
UC F6G

Rat
Mouse

Serotec
UCD

MCA1278
N/A

Horse
Horse
Human,
pig, dog,
horse
Horse
Many
species
Horse
Horse

CD4
CD4

CVS4
BH2

Mouse
Mouse

Serotec
UCD

MCA1078
N/A

Horse
Horse

CD44
CD5
CD8
CD8

CVS18
CVS5
CVS8
KH8

Mouse
Mouse
Mouse
Mouse

Serotec
Serotec
Serotec
UCD

MCA1082
MCA1079
MCA2385
N/A

Horse
Horse
Horse
Horse

CD8α

73/6.9.1

Mouse

VMRD

73/6.9.1

Horse

CD14-105
CD172a
(SWC3)
CD2
CD3
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Working
Dilution
50 μl at 15
μg/ml
50 μl/ 5×105
cells
1:10
1:10
1:10

Isoty
pe
IgG2a

1:4
50 μl at 15
μg/ml
1:200
1:20 (1×106
cells/tube)
1:10
1:25 to 1:50
(2×106 cells)
1:10
1:10
1:10
1:25 to 1:50
(2×106 cells)
50 μl at 15

IgG1
IgG1

IgG1
IgG1
IgG1
IgG1

IgG2a
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG3

μg/ml
MHC I
MHC II
(HLA-DP)
CD163

N/A

Mouse
Mouse

VMRD
VMRD

H58A
H42A

Horse
Horse

IgG2a
IgG2a

CELL SURFACE ANTIGEN- CONJUGATED ANTIBODIES
Specificity

Clone

Species
Origin
Rat
Mouse

Company

Catalog #

Isotype

CD3-FITC
CD3-DyLight 649

CD3-12

Serotec
UCD

IgG1
N/A

IT2.2

Mouse

BD

MCA1477F
UC-F6GDyLight
555665

CD86 (B70/B7-2)R-PE
CD206 (MMR)-PE
CD83-PE
CD21-PE

3.29B1.10
HB15a
N/A

Mouse
Mouse
Mouse

Beckman
Beckman
BD
Pharmingen

PN IM2741
PN IM2218U
555422

IgG1
IgG2b
N/A

IgG2b, κ

ISOTYPE CONTROL ANTIBODIES
Specificity

Clone

IgG1
IgG
IgG2a
IgG3
PE-IgG1, κ
IgG2a, κ
Rabbit Ig
Fraction

MOPC-21
Polyclonal
G155-178
A112-3
MOPC-21
RTK275
N/A

Species
Origin
Mouse
Rabbit
Mouse
Mouse
Mouse
Rat
Rabbit

Company

Catalog #

Sigma
BD
BD
BD
BD
Biolegend
Dako

M5284
550875
553454
553486
556650
400501
X0936

Species
Specifity
Mouse
Rabbit
Mouse
Mouse
Mouse
Rabbit

Isotype
IgG1
IgGl
IgG2a, κ
IgG3, κ
IgG1, κ
IgG2a, κ
N/A

SECONDARY CONJUGATED ANTIBODIES
Specificity
Goat F(ab’)2 Anti-mouse IgG1
Goat F(ab’)2 Anti-mouse IgG1
Goat Anti-mouse IgG (H+L chain
specific)
Goat F(ab’)2 Anti-rat IgG (H+L chain
specific)
Goat Anti-horse IgG (H+L chain specific)

Conjugate Form
FITC
R-PE
Texas Red®
(TXRD)
FITC

Company
SouthernBiotech
SouthernBiotech
SouthernBiotech

Catalog #
1072-02
1072-09
1031-07

SouthernBiotech

3052-02

FITC

Goat Anit-guinea Pig IgG (H+L)

FITC

108-096003
FI-7000

Goat Anti-rabbit IgG (H+L)

Texas Red®

Goat Anti-horse IgG (H+L)

Biotin

Goat Anti-horse IgG (H+L)

Peroxidase

Donkey F(ab’)2 Anti-goat IgG (H+L
chain specific)

Allophycocyanin

Jackson
ImmunoResearch
Vector
Laboratories
Vector
Laboratories
Vector
Laboratories
Jackson
ImmunoResearch
Jackson
ImmunoResearch

244

TI-1000
BA-8000
108-035003
705-136147

Goat Anti-mouse IgG
Goat Anti-rabbit IgG (H+L)

Alexa Fluor 488
DyLight 549

Invitrogen
KPL

Goat F(ab’)2 Anti-mouse IgG (H+L
chain specific)
Goat F(ab’)2 Anti-mouse IgG (H+L
chain specific)
Goat F(ab’)2 Anti-rabbit IgG (H+L chain
specific)
Goat F(ab’)2 IgG
Goat F(ab’)2 Anti-mouse IgG (H+L
chain specific)
Goat F(ab’)2 Anti-mouse IgG (H+L
chain specific)
Goat α-rabbit IgG (H+L)
Goat α-mouse IgG (H+L)
Goat α-rabbit IgG (H+L)
Goat α-mouse IgG (H+L)

PE-Cy5.5

Unlabeled (UNLB)
Alexa Fluor 488

Caltag
(Invitrogen)
Caltag
(Invitrogen)
Caltag
(Invitrogen)
Southern Biotech
Invitrogen

R-PE

Invitrogen

A10543

Biotin-XX
Biotin-XX
HRP
HRP

Invitrogen
Invitrogen
Southern Biotech
Southern Biotech

B2770
B2763
4050-05
1031-05

R-PE
R-PE

A31561
072-04-1516
M35018
M35004-1
L43001
0110-01
A11017

ANTIBODIES FOR INTERFERON PATHWAY ANALYSIS
Specificity

Clone

Anti-human interferon alpha
Anti-human interferon beta

MMHA-2
MMHB-3

Species
Origin
Mouse
Mouse

Anti-human interferon gamma

MMHG-2

Mouse

Anti-STAT1α p91

c-111

Mouse

Anti-phospho-STAT1 (Tyr701)
Anti-STAT2

A-7

Mouse

Anti-phospho-STAT2 (Tyr689)
Anti-NF-κB p65

F-6

Rabbit
Mouse

Company

Catalog #
21100-1
21400-1

Anti-phospho-IRF3 (Ser398)
Anti-human IL-2 Rα (CD25)

Rabbit
Goat

PBL InterferonSource
PBL Biomedical
Laboratories
PBL Biomedical
Laboratories
Santa Cruz
Biotechnology
Cell Signaling
Santa Cruz
Biotechnology
Upstate (Millipore)
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Upstate (Millipore)
R&D

Anti-FLAG M2
Anti-His antibody
β-actin

Mouse
Mouse
Rabbit

Agilent
Invitrogen
Cell Signaling

Anti-phospho-NF-κB p65
(Ser276)
Anti-IRF3

Rabbit
FL-425

Rabbit
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21550-1
Sc-417
9171S
Sc-1668
07-224
Sc-8008
Sc-101749
Sc-9082
07-581
AF-223NA
200472-21
372900
4967

MITOGENS AND RECOMBINANT CYTOKINES
MITOGENS
Name
ConA
LPS
PWM
PHA-P
PMA
IL-2

Description
Concanavalin A
Lipopolysaccharide
Pokeweed mitogen
Phytohemagglutinin
Phorbol 12-myristate 13-acetate
Human Interleukin-2

Company
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma

Catalog #
C5275
L2630
L8777
L1168
P1585
I2644

Description
Recombinant IL-2
Human tumor necrosis factor-α
Equine interferon-α1

Company
R&D
Cell Signaling
KingFisher Biotech

Catalog #
1613-IL
8902SF
RP0142E-005

CYTOKINES
Name
reIL-2 (Cys141Ser)
Human TNF-α
Equine IFN-α1

REAGENTS FOR INTRACELLULAR CYTOKINE STAINING USED FOR FLOW
CYTOMETRY
Name
7-AAD
PI
Ionomycin
Brefeldin A

Description
7-Aminoactinomycin D
Propidium Iodide
Ionomycin calcium salt
Brefeldin A
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Company
Invitrogen
BD Pharmingen
Sigma
Sigma

Catalog #
A1310
51-66211E
I3909
B5936

TISSUE CULTURE TECHNIQUES

PROPAGATION OF CONTINUOUS CELL LINES (RK-13, BHK-21 AND VERO CELLS)
Materials
1. Trypsin EDTA (keep in the water bath for few minutes, at 370C)
2. Confluent T-75 flask of cells
3. Appropriate cell culture medium
Method
1.
2.
3.
4.

Cells must be confluent (3-7 days old).
Pour off media.
Rinse cells 2-3 times with PBS (pH 7.4)
Add 1 ml (25 cm2 flask), 2 ml (75 cm2 flask), 4 ml (150 cm2 flask) trypsin-EDTA, and rock gently
for 30 seconds, then let the flask(s) sit at RT for 1 min
5. Pour off trypsin-EDTA (optional) and incubate the flask(s) another 7-8 minutes at 37°C.
6. Add appropriate amount of media EMEM + 10% FSCS + p/s/f for 1:5 split.
Once a week split cells: 1-150 cm2 flask with confluent RK-13 cells is made up to approx. 300335 ml EMEM 10% FSCS.
10 ml is added to 25 cm2 flask,
30 ml to 75 cm2 flask,
60 ml to 150 cm2 flask

Note
To get a confluent monolayer within 24-36 hours transfer 2 ml of cell suspension into a T-75 flask and add
20 ml of complete medium to the flask (1:5 split).
Generally one T-75 flask is sufficient to seed five 96 well plates for neutralization or microtitration assays.
For specific cell lines:
One T-75 flask of BHK-21 cells (confluent) is sufficient for 5-10, 96 well plates.
One T-75 flask of Vero cells (confluent) is sufficient for 3-4, 96 well plates.
One T-75 flask of RK-13 cells (confluent) is sufficient for 3-4, 96 well plates.
COUNTING OF CELLS
Manual method
1. Trypsinize the cells and add 10 ml of complete medium.
2. Centrifuge and resuspend the cells in 10 ml of complete medium.
3. Make a 1:10 dilution of cell suspension (100 µl in 900 µl of complete medium). Take 0.5 ml of diluted
cell suspension into a snap cap tube and add 0.5 ml of 0.2% Trypan blue (1:2 dilution). Load the
hemocytometer and count the cells in each of the four large squares. Some cells will be touching the
outside borders. Count only those cells touching two of the outside borders (e.g., the upper and left).
Determine the average number of cells per 10-4 ml (cells / ml = average number of cells per large
square × 104 / ml × dilution factor).
Automated method using cell viability analyzer, ViCell XR (Beckman Coulter)
Materials
ViCell XR Quad reagent pak (Beckman Coulter Cat. # 383722)
4 ml sample cup 120/bag (Beckman Coulter Cat. # 383721)
1.
2.

Make 1 ml of 1:10 dilution of cell suspension (100 µl in 900 µl of complete medium)
Place 1 ml in a 4 ml sample cup (Beckman Coulter Cat. # 723908)
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3.
4.
5.
6.

Place the sample cup in the machine (position 1-10)
Log in sample: position, sample ID, cell type, dilution factor. OK or next sample when done.
Start queue
“Camera image” provides cell image while counting and “Autosample queue” provides average of
number of counted cells and viability

FREEZING CELLS
Materials
1. Freezing medium
2. Cells in log phase of growth
0
3. Trypsin EDTA (keep in the water bath for few minutes, at 37 C)
4. Nalgene™ Cryo 1°C freezing container (Nalgene Cat. # 5100-0001)
Method
1. Pour off the media.
2. Add 3-4 ml of trypsin EDTA solution and rinse the cells (this is to remove the fetal bovine serum).
3. Add 3-4 ml of fresh trypsin EDTA solution and leave it for 3-4 min. (preferably at 370C) and bang
on the flask to detach the cells from the surface.
4. Add 10-12 mls of complete medium (the medium contain 10% fetal bovine serum and this will
inhibit trypsin) and pour into a 50 ml conical tube.
5. Centrifuge at 1100 or 1300 rpm (200 ×g) in a table top centrifuge for 5 minutes at 250C.
6. Aspirate the supernatant and resuspend the cell pellet in freezing medium at approx. 107 cells / ml.
Freeze in 2 ml vials (1 ml per vial).
7. Freeze cells first in Nalgene™ Cryo 1°C freezing container with isopropanol at -80°C for 1 day
8. Transfer frozen cell vials to liquid nitrogen container
RECOVERY OF FROZEN CELLS
Material
1. Frozen cells (-70°C) in aliquots.
2. Growth medium
Method:
1. Rapid thawing of the cells is necessary. Thaw the cells in the water bath at 37°C, by swirling the
tube (do not submerge the lid to avoid contamination of the cells).
2. Resuspend in 15 ml of growth medium and centrifuge at 1200 or 1300 rpm (200 ×g) in a table top
centrifuge for 5 minutes at 25°C.
3. Aspirate the supernatant and resuspend the cells in 10 ml of growth medium. Transfer the cell
suspension into a T-75 flask and add 10 ml of medium. Incubate at 37°C for 2-3 days.
ISOLATION OF EQUINE DERMAL FIBROBLASTS
Materials
Skin biopsy punches (5mm; Miltex Cat. # 33-35)
Hanks’ balanced salt solution (HBSS; Gibco 14175)
PBS (pH 7.4)
Petri dishes and coverslips
Methods (modified from “Isolation and characterization of fibroblasts from diabetic patient with chronic
vascular disease by Megan Francis, Illinois Institute of Technology [IIT])
1.
2.

Skin biopsy is harversted from chest area of horse
Place tissue in a sterile PBS and gentamicin (200 g/ml)
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3.

4.

5.
6.
7.
8.

Each specimen is washed 3X with sterile HBSS (10mM) in Petri dishes and then turn with the skin
side to the glass bottom for careful dissection. Small pieces of dermal connective tissue is harvested
from the tissue.
The pieces are rinsed with HBSS and transferred to Petri dishes (65 mm × 15 mm). 4-5 pieces per dish.
A smaller Petri dish (35 mm × 10 mm) is placed on the tissue pieces to keep the tissue in place during
medium changes. To avoid floating of tissue, place a sterile coverslip on to each piece of tissue until
fibroblasts get attached on the plate.
Wells are filled with pre-warmed DMEM containing 10% (v/v) FBS, 200 g/ml gentamicin, 1.25 g/ml
fungizone and 2 mM gluctamine and incubated at 37°C, 5% CO2.
After 2 days of culturing, the medium is replaced DMEM containing 10% (v/v) FBS, 50 g/ml
gentamicin, and 2 mM glutamine.
Regular medium changes are performed every 2 days.
Cell growth is monitored with an inverted microscope.

ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM EQUINE BLOOD
Isolation of PBMCs
1.
2.
3.

4.
5.

6.
7.
8.
9.

Collect blood via venipuncture into tubes with EDTA. Invert several times to mix and keep on ice at
farm. Need one 15 ml conical tube w/Ficoll-Paque Plus for two 10 ml EDTA tubes.
Wait approximately 20~30 min. until RBC has settled down, leaving cloudy, yellow plasma layer on
top of RBC layer.
Using a pipet, carefully aspirate plasma from EDTA tube, stopping aspiration when reach the RBC
layer. Layer plasma on to 4ml Ficoll-Paque Plus in 15 ml conical tube. Cap tube when finished. Keep
at room temperature and harvest all plasma layers from tubes collected from same horse.
Centrifuge at 500 g, 30 min, 20°C
Aspirate plasma layer above gradient down to cloudy band of PBMC. Discard into sterile beaker. With
same pipet, aspirate PBMC at interface and place into 50 ml conical tube. Combine PBMC from 4
gradient (15 ml conical) tubes into one 50 ml tube for washing.
(For platelets removal) Add at least 3 volumes of PBS to the lymphocytes in the tube. Mix by pipetting.
Centrifuge at 100 g for 10 min at 20°C. Remove the supernatant.
Repeat same washing procedure once more.
Resuspend the pellet in adequate quantity of 10% cRPMI and count cells (Approx. ten of 10 ml EDTA
tubes give about 3 – 4 × 107 cells per ml)

Separation of adherent and non-adherent PBMCs
1.
2.

3.
4.
5.

6.
7.

Count the cells and resuspend them at 1 × 107/ml in complete RPMI (cRPMI). The objective is to get
at least 2 × 108 PBMC to plate out into one of 150mm culture dish.
Place 20ml PBMC preparation into 1 × 150mm diameter, treated tissue culture dishes (1 × 107
PBMC/ml; total volume 25ml). Avoid over crowding of the plate to give enough space for the adherent
cells to attach.
Incubate for 4h at 37°C/ 5% CO2
Gently tilt the dish and aspirate off the supernatant containing non-adherent cells. Pellet non-adherent
cells by centrifuging at 1900 rpm 15 min.
Wash adherent cells twice with 20ml of PBS (pH7.4). Rinse down the dish in 4 different angles
(5ml/angle). Aspirate and save the PBS after each wash in a tube and pellet them down for cell
counting.
Resuspend the cell pellets (non-adherent cells and PBS wash) in 10 ml of plain RPMI for each pellet
and count cells.
To calculate approx. number of adherent cells, subtract the number of non-adherent cells and cells
from PBS wash.
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GENERATION OF MONOCYTE-DERIVED DENDRITIC CELLS
Materials
1.
2.
3.
4.
5.
6.
7.
8.
a.
9.
10.

EDTA (purple top, 15% EDTA liquid, Kendall Cat. #8881 311743) vacutainer tubes
Ficoll-Paque Plus (GE Health Care, Cat. #17-1440-02)
15ml centrifuge tubes (Corning, Cat. #430052)
Complete RPMI 1640 (Gibco, Cat. #21870)
Plain RPMI 1640 (Gibco, Cat. #21870)
1× PBS (pH 7.4, Gibco, Cat. #10010)
Corning® treated tissue culture dishes (Corning, 100 mm Cat. # 430167, 150 mm Cat. # 430599)
Differentiation medium
Complete RPMI with GM-CSF (Sigma, Cat. #G5035) and IL-4 (R&D Cat. #1809-EL); see below
Nycoprep (Accurate Chemical, Cat. #AN-223510)
6-well tissue culture plate (Costar, Cat. #3506)

Collection and processing of blood
1.

Collect 300ml of horse blood in 30 EDTA containing vacutainer tubes (10ml × 30). Isolate PBMC by
layering plasma onto Ficoll-Paque Plus. Plasma from 20ml of blood (2 × 10mls tubes) can be layered
onto one 15 ml conical tube containing 4 ml of Ficoll.
-

2.

This gives approx. 5 × 107/ml viable PBMCs (Total number of cells 1.5 × 109 cells/300ml)
It is known that generally 100 ml of blood give 2 × 108 PBMC. Out of these cells 1-2% will be
monocytes

Count the cells and resuspend them at 1 × 107/ml in complete RPMI (cRPMI). The objective is to get
at least 2 × 108 PBMC to plate out into one of 150mm culture dish. Expect yield of 1.5% DC:PBMC.

Separating blood derived monocytes
8.

9.
10.
11.
12.
13.


Place 20ml PBMC preparation into 1 × 150mm diameter, treated tissue culture dishes (1 × 107
PBMC/ml; total volume 25ml). Avoid over crowding of the plate to give enough space for the adherent
cells to attach.
Incubate for 4h at 37°C/ 5% CO2
Gently tilt the dish and aspirate off the supernatant containing non-adherent cells
Wash adherent cells twice with 20ml of PBS (pH7.4). Rinse down the dish in 4 different angles
(5ml/angle).
Aspirate and discard the PBS after each wash.
Add 25ml of differentiation medium to the dish.
Preparation of stock and working GM-CSF (Sigma; Cat # G5035, Lot 027K1018)
- Vial contains 5μg of lyophilized GM-CSF
- Reconstitute with 5ml of sterile pyrogen-free distilled water which will give a stock
concentration of 1μg/ml. Aliquot in 50μl each tube and store at -20°C.
- Recommended working concentration is 0.1ng/ml of cRPMI
Working conc.
0.1ng
1ng
10ng



Working vol./ ml
0.1 μl
1 μl
10 μl

20ml media
2 μl
20 μl
200 μl

Preparation of stock and working IL-4 (R&D; Cat #1809-EL, Lot MFM016021)
- Vial contains 20 μg of lyophilized rEqIL-4
- Reconstitute with 2 ml of sterile distilled water which will give a stock concentration of 10
μg/ml. Aliquot in 200μl each tube and store at -20°C.
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-

Working concentration is 100ng/ml
Working conc.
Working vol./ ml
100ng
10 μl
200ng
20 μl

20ml media
200 μl
400 μl

14. Incubate the culture dishes in differentiation medium for 4 days at 37°/ 5% CO2.
Collection of cultured cells
1.
2.
3.
4.
5.
6.

During differentiation the cells round up and detach, so they are no longer adherent. Harvest the cells
with a pipette and transfer the entire volume into centrifuge tubes.
Pellet the cells (150 ×g , 10min) and resuspend each pellet in 10ml plain RPMI
Overlay each 10ml aliquot onto 4ml Nycoprep (1.068g/ml) in separate 15 ml centrifuge tubes
Spin at 500 ×g for 15 min with no brake
Harvest and pool the interfaces and wash once with PBS
Count the cells
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CLASSICAL VIROLOGY TECHNIQUES
PROCESSING OF NASAL SWABS FOR VIRUS ISOLATION
Materials
10 ml syringes
Autoclaved plastic forceps
0.45 µm syringe filter (Corning Cat. # 431220 or Millipore, Millex™ Cat. # SLHA033SB)
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.996 [color cap], #72.694.006 [clear cap])
15 ml conical tubes
Methods
1.
2.

3.
4.
5.

6.
7.
8.
9.

Thoroughly swab the nasopharyngeal area with a sterile rayon swabs (1/2” x 1”) with plastic shafts
(16”).
After collection, the rayon tip of each swab is cut off into 7 ml of virus transport medium (Hank’s
balanced salt solution with penicillin, streptomycin, gentamicin sulfate and amphotericin B; all from
Life Technologies, Carlsbad, CA).
Squeeze the swab to recover maximum amount of media and centrifuge at 300 ×g for 10 min to
remove debris.
Transfer individual nasal swabs in transport medium to the barrel of a 12 ml disposable syringe and
express through 0.45 µm syringe filter (Millipore).
Collect the filtrate into a 15 ml conical tube. Bring up the sample volume to 7 ml with plain MEM to
normalize samples (e.g. after filtration usually approx. 6 ml is recovered). Leave approximately 2.0 ml
for virus isolation and aliquot the remaining filtrate (approximately 1 ml × 2) into tubes. Freeze at 70°C until tested.
Aspirate off media from confluent RK-13 cells in 6-well plates and inoculate 500 μl specimen/well in
duplicate.
Incubate plates at 37°C in presence of 5% CO2 for 1-2 hours.
Add 10ml CMC overlay to each flask and incubate at 37°C in the presence of 5% CO2 for 5 days.
Do second passage on day 4 using the same cells. Stain cells on day 5 with crystal violet. Archive the
TCF at -80°C.

SERUM PROCESSING
Materials
Vacutainer needles
Vacutainer adapters (Termuno, Venoject II Cat. # P-1316R)
15 ml BD Vacutainer tubes (Kendall Monoject [no additive] Cat. # 8881 301819)
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.006)
Transfer disposable pipets for serology (Samco scientific Cat. # 202-1S)
Methods
1.
2.

3.
4.
5.

Collect blood into vacutainer tubes via jugular venipuncture (about 15 ml blood).
Transport blood tubes to the lab. Spray tubes with diluted Roccal-D (1:200). Rinse tubes and dry
with paper towel. Let stand at room temperature for 4-5 hours or for 1 hour at 37°C (water bath
works faster).
Sediment blood cells at 2000 rpm (300 ×g) for 10 min.
Collect serum and aliquot into tubes (1.4 ml × 4). Freeze at -20°C until tested for virus or
antibody.
Proceed as in steps 5-8 above for virus isolation.
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BUFFY COAT PROCESSING FOR VIRUS ISOLATION (WITHOUT GRADIENT
PURIFICATION)
Methods
1. Draw blood by venipuncture into vacutainer tubes containing sodium citrate or EDTA and mix
thoroughly.
2. Allow blood to stand for 1-2 hours or sediment at 600-700 rpm (100 ×g) for 10 min. Remove plasma
layer and sediment at 2000 rpm for 10 min. The few red blood cells in pellet cause no apparent
concern.
3. Aspirate off supernatant; resuspend pellet in 5 ml EMEM 10% FSCS and vortex thoroughly. (If
desired, pellet can be washed with PBS before resuspending in EMEM media). Freeze or inoculate.
4. Proceed as in steps 5-8 above.
PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) PROCESSING FOR VIRUS
ISOLATION
Materials
15 ml BD vacutainer tubes w/ACD (Citrate-dextrose solution; Sigma C3821- 50ML)
Ficoll-Paque Plus (GE Healthcare Cat#17-1440-03)
15 ml conical tubes
50 ml conical tubes
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.006)
Preparation of Vacutainer tubes with Acid Citrate Dextrose (ACD)
Using a small gauge needle and a 10 ml syringe, add 1.5 ml ACD to each 15 ml vacutainer tube. Mark
tubes to identify that they contain ACD. Store at 4°C.
Preparation of Ficoll-Paque Plus gradients in 15 ml conical bottom polypropylene tubes
Place 4.0 ml Ficoll-Paque Plus in each tube (will need 15 ml tube per 20 ml vacutainer of collected
blood). Centrifuge briefly to pull all of Ficoll-Paque Plus to bottom of the tube. Store at 4°C but warm
to room temperature before use.
Methods
1. Collect blood via venipuncture into tubes with ACD (about 13.5 ml blood and the final volume is
about 15 ml per tube). Invert several times to mix. Keep on ice at farm.
2. Transport blood tubes to the lab. Spray tubes with dilute Roccal. Rinse tubes and dry with paper
towel. Invert tubes several times to re-mix blood (prevents PBMC from settling on top of RBC
too much). Keep at room temperature.
3. Wait approximately 20-30 min until RBC has settled again, leaving cloudy, yellow plasma layer
on top of RBC layer.
4. Layering plasma onto Ficoll-Paque Plus using transfer disposable pipet.
5. Using serological pipet, carefully aspirate plasma of one Vacutainer tube, stopping aspiration as
reach the RBC layer (a few RBCs are OK but try not to pull lost of RBCs into pipet). Layer
plasma onto Ficoll-Paque Plus in conical tube. Plasma from one 20 ml vacutainer of blood should
approximately fill the Ficoll-Paque Plus tube to 14-15 ml height in tube. Cap tube when finished.
Keep at room temperature. Continue, using the same pipet, and harvest all plasma layers from the
vacutainers collected from one horse.
6. Centrifuge at 500 ×g (2800 rpm), 30 min, 25°C.
7. Harvesting PBMC from gradient:
 Aspirate plasma layer above gradient down to cloudy band of PBMC. Discard into
sterile beaker. With same pipet, aspirate PBMC at interface (approx. 2-3 ml/15 ml tube)
and place into 50 ml polypropylene centrifuge tube. Continue removing plasma,
harvesting interfaces. Combine PBMC from 4 gradient (15 ml conical) tubes into a 50 ml
tube for washing.
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8.

Cell washing steps:
 Add sterile PBS (pH 7.4) to bring the volume to 40 ml. Cap tube and mix cells by
inverting tube 5 times (or tapping tube with the index finger).
 Centrifuge for 15 min at 500 ×g (2800 rpm), 4°C.
 Aspirate the supernatant without disturbing the cell pellet.
 Add sterile PBS to bring the volume to 40 ml and cap tube. Mix cells by tapping the tube
with the index finger or by vortexing.
 Centrifuge for 10 min at 500 ×g (2800 rpm), 4°C.
 Aspirate the supernatant without disturbing the cell pellet.
 Resuspend the pellet in 8.0 ml of 10% EMEM (this gives about 1.5 × 107 – 3.0 × 107 cells
per ml). Leave 2.0 ml of buffy coat cells in the conical tube for virus isolation and
aliquot the remaining cells (approximately 1.2 ml × 5) into tubes.
 Freeze the remaining cells at -80°C.

ISOLATION OF EAV FROM SEMEN
1.
2.

3.

4.
5.

6.
7.
8.

9.
10.
11.

12.
13.
14.

Thaw 15 ml tube containing semen sample in warm tap water, then place on ice.
Label 8 flasks (25cm2) [4 RK-14 (KY) “high pass” and 4 RK-13 (ATCC-CCL37) “low
pass”]/semen, 2 ✕10-1, 1 ✕10-2, 1✕10-3 for high pass, 2 ✕10-1, 1 ✕10-2, 1✕10-3 for low
pass.
Sonicate (output 20, #4.5 on dial) samples on ice 3 ✕15 sec.; let set on ice for 15 sec. 1 min
between sonications (dilute small volumes to 5 ml). Clean sonicator probe with 95% EtOH 2X
between each sample. Spin 300 ×g (1900 rpm) for 10 min to remove sperm and debris, save and
use supernatant (SSP).
Set up 3 tubes (10-1 to 10-3) for each sample, 4.5 ml EMEM 10% FSCS per tube.
Aspirate off media from 25 cm2 (3-6 day old RK-13 monolayers). Do not rinse! Make 10-1 (0.5 ml
sample in 4.5 ml diluent), vortex; with new pipet add 0.5 ml of 10-1 to tube #2 (10-2) and 1 ml to
each of 4 flasks marked 10-1. Continue the same way with dilutions 10-2 and 10-3 (2 flasks each).
Incubate all flasks at 37°C in air incubator (incubator without CO2) with caps closed for 1 hour (2
hours maximum).
Add 10 ml of CMC overlay to each flask and incubate at 37°C in air incubator (incubator without
CO2) with caps closed.
Check for CPE on day 4.
If bacterial contamination occurs, redo after bacteriological examination and sensitivity testing to
find out which antibiotics to used in the TC media. Repeat test as above and also note
contamination. Specimen may be filtered through a 0.45 μm filter using a 5 or 10 cc syringe, if
necessary.
If negative, a second passage is performed on day 4. (See 2nd passage)
If sample is toxic this material is passages as is (2nd passage).
If positive, supernatant is usually harvested from a 10-2 flask showing viral activity (store at 20°C) and a reverse SN-test is performed against known positive and negative sera (See reverse
SN-test).
After 5 days harvest supernatant from flasks and stain flasks with crystal violet using 2 ml crystal
violet in buffered formalin. Stain 1-24 hours, remove stain, rinse flasks with tap water and read.
All semen samples are placed in freezer zip lock storage bags and stored at -70°C.
Permanently store negative SSP at -20°C and positive SSP at -70°C.

Second passage
1.
2.

Aspirate media from 2 “high pass” and 2 “low pass” confluent 3-5 day old RK-13 cells in 25 cm2
flasks for each negative semen sample.
From 2 flasks of 10-1 passage #1 take up 0.5 ml from each with same pipet (1ml) and add 1 ml to 1
new flask for each high and low pass. Do the same for 10-2 passage #1, taking up 1 ml from each.
Do 10-1 and 10-2 only. Close caps and incubate at 37°C for 1-2 hours (minimum 1 hour) in air
incubator.
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3.
4.
5.

Add 10 ml of CMC overlay to all flasks, close caps, and incubate at 37°C in air incubator (without
CO2).
Read after 3-4 days.
After 4 days, harvest media and stain flasks (See passage #1).

MAKING WORKING VIRUS STOCKS
Materials
1. EAV
2. Five confluent monolayers of RK-13 cells in T-150 flasks
3. EMEM
4. RK-13 medium
5. 50 ml conical centrifuge tubes
6. Freezing vials
Method
1. Inoculate monolayers with EAV at an m.o.i. of 1. Resuspend the virus in approximately 50 ml of
serum free MEM and add 10 ml per T-150 flask.
2. At the same time mock infect one T-75 flask of RK-13 cells.
3. Adsorb for 1 hour at 37°C. .
4. Add 40 ml of complete RK -13 medium / T-150 flask. Incubate at 37°C for 48 hours or until 95% 100% CPE.
5. Centrifuge at 5000 g (or 3000 rpm in the table top centrifuge) at 4°C for 15 minutes.
6. Make 1.8 ml and 0.5 ml aliquots of supernatant and store at -70°C.
7. Use one 0.5 ml frozen vial to titrate the virus.
PREPARATION OF HIGH TITER VIRUS STOCKS
Methods
1. Seed cells into 3, triple-deck flasks and grow until confluency.
2. Remove the medium and leave approx. 50 ml of complete medium containing 10% fetal bovine
serum. Add 500 µl-1 ml of virus per flask. If the titer of the virus is known use an m.o.i of 1
(higher m.o.i will may produce deletion mutant).
Adsorb
for 1 hour at room temperature on the orbital shaker.
3.
4. Add 20-40 ml of complete medium containing 10% fetal bovine serum and incubate at 37°C for 3-4
days. Check for signs of infection 2 days after the start of infection.
5. Pellet down the cellular debris (3000 rpm / 4°C / 15 minutes) and aliquot into freezing vials and
store at 4°C (stable for up to 6 months) and / or -70°C (for long term storage). Virus should be
stored away from the fluorescent lights since the virus titer appears to decrease when exposed to
fluorescent light for prolonged period of time.
6. Determine the virus titer using the plaque assay procedure.
CONCENTRATION OF EQUINE ARTERITIS VIRUS BY USING A 20% SUCROSE CUSHION
Materials
1. 20% sucrose in NET buffer
2. SF-MEM
3. RK-13 Medium
4. NET buffer
Method
1.
2.
3.

Five T-150 flasks with 3 days old confluent monolayers of RK-13 cells.
Inoculate EAV PP3 P3 at an m.o.i. of 5. Use approximately 2 vials (1 ml / vial) / T-150 flask. 10 vials
of virus for five T-150 flasks.
Dissolve the virus in SF-MEM.
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1.
2.
3.
4.
5.
6.

10 mls / T-150 × 5 = 50 mls
Take 40 mls of SF-MEM and add 10 ml of virus
Add 10 mls / T-150 flask
At the same time mock infect one T-75 flask of RK-13 cells.
Adsorb for 1 hour at 370C. .
Add 20 ml of complete RK -13 medium / T-150 flask. Incubate at 370C for 48 hours or until 95% 100% CPE.
7. Collect the supernatant and centrifuge at 5000 g (or 3000 rpm) / 4°C / 15 minutes to remove cellular
debris.
8. Filter the supernatant through 4.5μm bottle-top filter (optional) and overlay on to approx. 3-5 ml of 20%
sucrose cushion placed in ultracentrifuge clear tubes. Place each tube into ultracentrifuge bucket and
balance to equal weight.
9. Pellet the virus by ultra-centrifugation [36,000 rpm (155,300 g) / 4°C / 4 hours in AH 650 rotor].
Remove brake.
10. Aspirate the supernatant and resuspend the virus pellet in 300-500 μl PBS (pH 7.4). Sonicate for 15/15
sec on and off for three times
11. Store at -80°C.
12. It is better to collect following samples for micro-titration assay to determine the efficiency of
purification.
MICROTITRATION ASSAY TO ESTIMATE EQUINE ARTERITIS VIRUS TITERS
Materials:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

96 Wells microtitration plates (Falcon 3072)
Sterile snap cap tubes (Fisher or Falcon 2054)
Multi channel pipette (8 or 12 channels)
Antiserum or ascitic fluid (Monoclonal antibodies)
Negative control serum or control ascitic fluid
EMEM (BioWhittaker)
Complete RK-13 medium
Confluent RK-13 cells (one T-75 flask is sufficient for 5 ninety six well plates)
Equine arteritis virus stock to be titrated
Crystal violet staining / fix solution

Method:
1.
2.
3.
4.

5.
6.
7.
8.

Each test virus is done in triplicate. Label the 96 well plates with cell controls.
Dilute the test virus from 10-1 to 10-8 in EMEM (ten fold serial dilution). Use 200 µl of virus +
1800 µl of EMEM.
Add 50 µl of EMEM to all the wells except to control wells (column 10, 11 and 12) where 100 µl
of EMEM should be added.
Trypsinize a confluent T -75 flask of RK-13 cells and resuspend the pellet in 10 ml of RK-13
medium. Take 2 ml of the cell suspension and resuspend in 10 ml (1:5) of RK-13 medium (or 4
ml in 20 ml would be better. This gives enough volume to work).
Add 50 µl of diluted virus to test wells in triplicate. Start with the highest dilution (10-8) and go to
the lowest dilution (10-1; therefore, can use the same pipet tip)
Add 100µl of resuspended RK-13 cells to each well. Incubate at 37°C for four days.
Feed the plates with 50 µl of growth media on day 2 and day 3 (if necessary) to maintain
monolayers.
When CPE occurs (usually 4 days), dump out the media in sink and stain with 1% crystal violet
solution/fix for 20-30 minutes (it is easy to leave the plate(s) in a bucket containing 1% crystal
violet/fix solution because the 1% crystal violet/fix solution can be reused.) and then wash gently
with tap water to remove excess Crystal violet (three times). Air dry plates and determine EAV
titer by Reed and Munch method.
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9.

50% end point values, by Read and Munch Method: Under lined numbers indicate logarithmic
characteristic of end point dilution. Triplicates;
3 - 2 - 0 - 0 = 0.25
3 - 1 - 2 - 0 = 0.5
3 - 2 - 1 - 0 = 0.5
3 - 1 - 3 - 0 = 0.2
3 - 2 - 2 - 0 = 0.0
3 - 0 - 0 - 0 = 0.5
3 - 2 - 3 - 0 = 0.3
3 - 0 - 1 - 0 = 0.7
3 - 1 - 0 - 0 = 0.75
3 - 0 - 2 - 0 = 0.8
3 - 1 - 1 - 0 = 0.0
3 - 0 - 3 - 0 = 0.0
10. Report virus titers as TCID50 per 50 µl.

PLAQUE ASSAY
Materials:
6 well plates
RK-13 cells
Carboxymethylcellulose (CMC) overlay media (1.3X EMEM 10% FSCS)
Virus for titration
METHOD:

1. Prepare RK-13 in 6-well plates.
2. Make virus dilution (10-1 to 10-8) in complete 10% EMEM growth media.
3. Aspirate the medium and add 200 µl of diluted virus to each well in duplicate(Start from 10-8 and go to
10-1). Mix gently by rocking the plate.

4. Incubate the plate at 37°C for 1 hour to allow virus particles to adsorb into cells.
5. Following 1 hour incubation period, overlay cells with 4 ml (per well) of CMC overlay media adding
to the side of the plate.

6.
7.
8.
9.

Allow plates to sit undisturbed on a leveled surface for 4 days until visible plaques develop.
After 4 days, discard supernatant and stain with crystal violet staining solution.
Count >10 to <100 plaques per well.
PFU/ml = (# of plaques in each well [duplicate]/2) × (highest dilution that gives # of plaques) ×
(dilution factor)

10. e.g. [(25 + 30)/2] × 10-5 × 5 (200 μl) = 137.5 × 10-5 = 1.37 × 10-7 pfu/ml
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SEROLOGY
VIRUS NEUTRALIZATION TEST (VNT)
Methods
1.
2.
3.
4.
5.
6.
7.

Inactivate sera at 56°C for 30 minutes
Put 25μl of serum diluent (10% GP complement in EMEM 10% FSCS [keep on ice until used]) in all
wells.
Put 25μl of test serum to the first well of two rows (No row for checking toxicity*). Dilute with 25 μl
multichannel pipettor.
Add 25 μl of virus (200 TCID50) diluted in EMEM 10% FSCS to all wells except controls (“See
controls”).
Incubate plates at 37°C (5% CO2 incubator) for one hour.
Add 125 μl of trypsinized cells (prepared as directed below) to every well.
Seal plates and incubate at 37°C (5% CO2 incubator). Read after 48, read and final at 72 hours.
Controls: cell controls, known positive and negative sera, and virus titration controls.
Cell controls: add 50 μl serum diluent to 2 wells.
Serum controls: add 25 μl serum diluent to 1 well/each test serum, add 25 μl test serum.
Known positive serum and known negative serum are set up the same way as test sera.
Virus titration: Add 25 μl serum diluent into each of 4 wells for cell controls (Row #1).
Add 25 μl of working virus dilution to each of 4 wells (Row #2).
Add 25 μl of 1:10 dilution of working virus in EMEM 10% FSCS to each of 4 wells
(Row #3).
Add 25 μl of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4 wells
(Row #4).
Add 25 μl of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4 wells
(Row #5).
Add 125 μl of trypsinized cells to all 20 wells.
*If serum is toxic in serum control well (1:4 dilution), then repeat test with a row to check for toxicity.

REVERSE SN-TEST FOR EAV VERIFICATION – confirmation test
Materials
1.
2.
3.
4.

Known positive serum, inactivated and diluted 1:4 in PBS (should come from field sample(s), not from
vaccinated horses).
Known negative serum inactivated and diluted 1:4 in PBS.
Stock virus (Bucyrus)
Unknown virus isolate

Methods
1.
2.
3.
4.
5.
6.

Add 0.3 ml of known negative serum to 4 tubes for each virus sample to be tested (including stock
virus).
Add 0.3 ml of known positive serum to 3 tubes for each virus sample to be tested (including stock
virus).
Make up 1:10 dilution of guinea pig complement in EMEM + 10% FSCS + antibiotics (10 ml for each
sample).
Make up 10-1 to 10-5 dilutions of all virus samples to be tested using 1.8 ml of media in #3 and 0.2 ml
of virus (It may be necessary to dilute stock virus to 10-3 before starting these dilutions).
To positive serum (3 tubes) add 0.3 ml of 10-1, 10-2 and 10-3 virus dilutions.
To negative serum (4 tubes) add 0.3 ml of 10-2, 10-3, 10-4 and 10-5 virus dilutions.
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7.
8.

Incubate serum-virus mixture for 1 hour at 37°C.
14 flasks 25 cm2 [7 RK-13 (KY) “high pass”, 7 RK-13 (ATCC-CCL37) “low pass”] are used for each
virus to be tested. Aspirate off media from 3-5 day RK-13 flasks and add 0.25 ml of above serumvirus mixture to 2 flasks/dilution.
9. Incubate for 2 hours at 37°C (closed caps, no CO2), rock flasks after 1hour.
10. Add 10 ml of CMC overlay/flask. Incubate for 4-5 days according to development of CPE, remove
media, and stain with crystal violet plaque stain.

TREATMENT OF SERUM WITH TOXICITY DUE TO (DUVAXYN) ANTIBODIES TO RK-13
CELLS
This procedure has been used successfully to eliminate (or reduce to readable at 1:4) toxicity from serum
samples demonstrating the vaccine-induced “European” toxicity at 1:4 and greater in the EAV SNT. These
horses have been vaccinated with Duvaxyn EHV 1,4 (the EHV-1 component is made in RK-13 cells).
Always treat a known negative and a known positive serum whenever this treatment is performed on toxic
serum specimens. Preferably, use serum that has not been previously inactivated. Use sterile technique for
the following steps:
Methods
1.

2.
3.
4.
5.
6.

Decant growth media from as flask of 7-10 day old RK-13 (KY) cells (P399-409). Wash flask 3X
with 10 ml Dulbecco’s PBS. Add 1 ml trypsin EDTA/flask, rotate to spread over cell monolayer, then
incubate approximately 6-8 min at 37°C.
When cells have detached, add 2 ml EMEM with 10% FSCS/flask. Mix well with 5 ml pipet, then
divide between three 1.5 ml microcentrifuge tubes.
Spin tubes at 2,0000 rpm for 15 sec in microcentrifuge. Use a Pasteur pipet to remove and discard all
supernatant.
Add 0.5 ml of toxic serum or control serum per tube; mix with pipet until cells are resuspended; label
tube appropriately. Incubate for 1 hour at 37°C. Flick tubes after 30 min to resuspend.
Spin 2,500 rpm for 15 sec. Use a Pasteur pipet to transfer each serum to a new, labeled 1.5 ml
microcentrifuge tube.
Inactivate at 56°C for 30 min if serum has not been inactivated previously. Proceed with EAV SNT
test, running sera (toxic, negative, positive) as usual and in pre-seeded (planted 18-24 hours prior)
plates.

ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
Materials
1. Microtiter plates for ELISA
2. Coating buffer
3. ELISA wash buffer
4. Biotinylated anti-mouse IgG
5. Enzyme substrate
6. Substrate stopping solution
7. Blocking solution
8. Antibody dilution buffer (ADB)
9. Conjugate dilution buffer
10. Substrate (e.g., OPD)
11. 1% SDS
12. Test serum or culture supernatant
13. Positive control serum
14. Negative control serum
15. Multichannel pipette
16. Wash bottle
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Method
1. Coat the ELISA plates with the antigen as previously described (see antigen preparation for coating
ELISA plates) and store the plates overnight at 40C. It is advisable to include negative control antigen
(e.g., 1% BSA in coating buffer) in the plate.
2. Aspirate coating antigen solution and block unbound sites on the plastic by incubation with 150 µl
blocking solution (1% BSA, gelatin, ovalbumin, casein, milk powder) or with antibody dilution buffer
(ADB) per well for 30 minutes
3. Wash off unbound protein three times with 150 µl ELISA wash buffer (PBS-Tween [0.05%] also
known as TPBS; add 0.5 ml of Tween 20 to 1 liter of PBS, pH 7.5) per well.
4. Add 50 µl of primary antibody diluted in ADB (need to titrate the antibody to find out the best dilution
to be used). If tissue culture supernatant is used add 50-100 µl straight. Include some wells with
known positive antibody and known negative antibody. Incubate for one hour at room temperature.
5. Wash off unbound antibody three times with 150 µl ELISA wash buffer per well.
6. Add 50 µl of Biotinylated secondary antibody (Biotinylated anti mouse IgG 1:2000 dilution in ADB).
Incubate for one hour at room temperature.
7. Wash off unbound secondary antibody three times with 150 µl ELISA wash buffer per well.
8. Add 50 µl of 1:2000 dilution of Avidin-HRP in conjugate dilution buffer (PBS pH 7.5, 0.5% BSA,
0.05% Tween 20). Incubate for 15 minutes at room temperature.
9. Wash off unbound Avidin-HRP three times with 150 µl ELISA wash buffer per well.
10. Add 100 µl of substrate and let react until BSA control just becomes visible, 1 to 20 minutes (10 mls
substrate per plate - 0.1M Citrate pH 4.5, 3.3 µl of H2O2, 10 mg OPD substrate). If needed terminate
reaction with 50 µl of 1% SDS.
11. Assess the color intensity visually or quantitatively in a spectrophotometer designed to read microtitre
plates (ELISA) reader.
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MOLECULAR BIOLOGY/ RECOMBINANT DNA TECHNIQUES
DESIGNING OF PRIMERS
The approach for designing of specific and efficient primers remains somewhat empirical; there are no hard
and fast rules. With experience and by using a good primer designing program (e.g., MacDNASIS v3.5;
Hitachi) the majority of the primers can be made to work. Following are some guidelines to design specific
and efficient primers.
1. Where possible, select primers with an average G+C content of around 50%.
2. Where possible, select primers with a random base distribution. Try to avoid primers with stretches of
polypurines, polypyrimidines, or other unusual sequences.
3. Melting temperature (Tm) should be between 55-75°C.
against
4. Increasing the Tm, therefore, the annealing temperature enhances discrimination
incorrectly annealed primers and reduces misextension of incorrect nucleotides at the 3’ end of the
primers. Therefore, increasing the annealing temperature will help to increase the specificity. An
applicable annealing temperature is 5°C below the true Tm of the amplification primer. The best
annealing temperatures is in the range of 55-72°C. Quick way to calculate annealing temperature is:
5. Annealing temp. (°C) = (# of A and T [A+T] × 2 + # of G and C [G+C] × 4) - 5°C.
6. Try to design both positive and negative primers with same Tm (1-20C difference will not matter).
7. Make sure the primer ends (3’) with a G or C.
8. Primer length should be between 19 and 30 bases (19 to 22 bases are preferred).
9. If possible select a unique area of the genome to design the primer.
10. Avoid sequences with significant secondary structure (computer programs are very useful for this).
11. Check the primers against each other for complementarily. Avoiding primers with 3’ overlaps will
reduce the incidence of “primer-dimer” artifacts.
12. If possible do a simple homology matching (compare the primers with the whole genome using a
computer program) and see whether primer(s) have <50% homology in the area closer to be amplified
(or to the desired area). This will reduce the number of nonspecific products of same size.

AGAROSE GEL ELECTROPHORESIS
Materials
1. Agarose (SEAKEM LE agarose; FMC Bio Products).
2. 50X TAE buffer (Tris Acetate EDTA, pH 8.0).
3. Gel casting plate.
4. Gel sealing tape
5. Buffer tank.
Method
1. Make 1000 ml of 1X TAE, by measuring 20 ml of 50X stock into a 1000 ml graduated cylinder and q.s.
to 1000 ml mark with deionized distilled water.
2. Weigh 1.0 g of agarose (for 1% gel) and dissolve it in 100 ml of 1X TAE. Melt agarose solution in
microwave until completely dissolved. Let stand at room temperature (or at 45°C in a water bath) to
remove air bubbles but not enough to solidify.
3. Prepare gel-casting plate by taping the ends with gel sealing tape. Place the sample comb in the proper
position on the plate.
4. Pour 100 ml of 1% agarose on to the gel casting plate slowly and allow it to solidify (volume of
agarose needed depends on the size of the gel casting plate). The gel should be between 0.3 and 0.5
cm thick. After gel has set, final gelling carried out at 4°C for 30 minutes. There should not be any air
bubbles in the gel.
5. Remove the tapes and keep the gel plate in the buffer tank. Add 1X TAE buffer into the reservoirs
until it covers the surface of gel at a depth of 3-4 mm.
6. Slowly remove the sample comb and load the samples into the wells (Mix 1-20µl of RNA or DNA
with 6X gel loading buffer; loading volume depends on the sample and make sure gel loading buffer
get diluted to 1X with sample).
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7.

Voltage 70V for 2-3 hours (95V for 45-60 minutes) or until the first band has migrated at least 2.5
inches away from the wells. The voltage must never exceed 100V. For low melt Agarose use low
voltage (70V). Always run the gel in constant voltage.
8. Stain gel in ethidium bromide, letting it sit for 5-10 min. Destain gel by placing in deionized distilled
water for 5 min.
9. Transfer the gel onto a UV light source. Usually a trans illuminator is used to facilitate this step. Place
a piece of plastic wrap between the gel and surface of the illuminator. Use a face shield, gloves, and
body shield to minimize the UV exposure. Take a picture for records.
10. Locate the DNA or RNA bands and excise by using a sharp scalpel blade (e.g. to obtain the desired
band)
Note: Range of separation in gels containing different concentrations of agarose.
% of agarose (%[w/v])
0.3
0.6
0.7
0.9
1.2
1.5
2.0

Efficient range of separation of linear DNA molecules (Kb)
5-60
1-20
0.8-10
0.5-7
0.4-6
0.2-3
0.1-2

REAL TIME RT-PCR MEASURING EQUINE CYTOKINE GENE EXPRESSION
Materials
A.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.

Total RNA extraction
MagMAX 96™ Total RNA isolation kit (Applied Biosystems [ABI]; Cat# 1830)
Isopropanol (Sigma; I9516-500 ml)
Absolute ethanol (Decon Labs Inc.; Cat #2716)
Sterile round bottom 96-well plate (Corning; #3799)
96-well Magnetic-Ring Stand (ABI; AM10050)
1.5ml sterile microcentrifuge tubes
AluminaSeal™ (Diversified Biotech; Cat #ALUM-1000)
MagMAX™ Express-96, 96-well Deep Well volume (ABI; Cat# 4400077)
MagMAX Express 96 deep well tip combs (ABI; Cat #4388487)
MagMAX Express 96 standard plates, 200 µl (ABI; Cat #4388475)
MagMAX Express 96 deep well plates (ABI; Cat #4388476)

B. Reverse Transcription
1. High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor, 200 reactions (Applied
Biosystems [ABI] Cat# 4374966)
2. Twin.tec PCR plate 96, skirted (96 × 150 µl [Eppendorf; Cat# 0030 128.656])
3. PCR film (Eppendorf; Cat# 0030 127.480)
4. Epgradient Master Cycler (Eppendorf thermal cycler)
5. Nuclease free water (Ambion; Cat #AM9937)
C.
1.
2.
3.
4.
5.
6.
7.

Real Time PCR
TaqMan® Gene Expression Master Mix (Applied Biosystems [ABI], Cat# 4369016)
20X Gene Expression Assays (Custom designed primers and probe, see below for Order #)
Automated Liquid Handling System (Corbett; CAS-1200)
50 µl tips, filtered, liquid sensing (Qiagen; Cat #990512)
MicroAmp® Fast Optical 96-Well Reaction Plate with Barcode, 0.1 ml (ABI, Cat# 4346906)
MicroAmp® Optical Adhesive Film (ABI, Cat# 4311971)
Applied Biosystems 7500 Fast Real-Time PCR System
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Methods
A. RNA extraction
1. Extract RNA using MagMAX™-96 Total RNA Isolation Kit. It lyses up to 2 × 106 cells. Cells can be
stored in 140μl of Lysis/Binding Solution at -80C until RNA extraction.
Note: If you stored RNA at -80C, prior to RT heat the sample to 70C for 2 min in a thermal cycler and
put on ice to denature RNA.
2. Measure RNA concentration using NanoDrop and adjust to 0.5 µg or 1 µg (in 19.8 µl [final 30 µl
reaction] or 26.4 µl [final 40 µl reaction]) depending on samples of the study.
B. Reverse Transcription
1. Prepare 2X reverse transcription master mix, mix and centrifuge briefly.
Final total volume =30 µl
Components

10X RT buffer
25X dNTP Mix
(100mM)
10X RT Random
primers
MultiScribe RTase
RNase inhibitor
Total
(Optional) Water
2.
3.
4.
5.
6.
7.

Volume (µl)
n=1
30 µl
40 µl
3
4
1.2
1.6

Volume (µl)
(32 samples + 3 extra)
30 µl
40 µl
105
140
42
56

Volume (µl)
(28 samples + 3 extra)
30 µl
40 µl
93
124
37.2
49.6

3

4

105

140

93

124

1.5
1.5
10.2

2
2
13.6

52.5
52.5
357

70
70
476

46.5
46.5
316.2

62
62
421.6

Pipette 10.2 µl of 2X RT master mix into each tube or 96-well plate. Keep on ice.
Pipette 19.8 µl of RNA (0.5 µg) sample into each well pipetting up and down two times to mix
(NOTE: volume can be adjusted with H20 based on the RNA conc.).
Seal plates with PCR film.
Centrifuge briefly to remove bubbles and spin down the contents.
Place the place on ice until ready to load on to the thermal cycler.
Load the reactions into the thermal cycler and start the reverse transcription run (under Yun Young’s
folder - High Capacity RT)
Step
1
2
3
4

Temp (°C)
25
37
85
4

8.
9.

Time
10 min
120 min
5 min
∞

Store at -20 or use immediately for PCR amplification.
If you are using -20C/80C frozen cDNA, immediately after thawing, heat the samples to 70C for 2 min
in a thermal cycler to denature the cDNA and cool on ice.
10. For real time PCR, dilute cDNA samples 1:1 with RNase free water (pool duplicate cDNA samples in
one tube and add 60 µl of RNase free water).

263

C. Real Time PCR
Components
TaqMan® Gene Expression Master Mix
20X Gene Expression Assays
1:1 diluted cDNA template
Total
1.
2.
3.
4.
5.

6.
7.
8.
9.
10.
11.
12.
13.

Volume (µl)
5
0.5
4.5
10

Use automated pipettor (Corbett) to dispense both reaction mix and cDNA samples.
Turn on the robot and open “1-06-10 YYG.CAS4” program (see Real time plate plan)
Prepare reaction mix in 1.5 ml eppendorf tube.
Mix 70 µl of TaqMan Gene Expression Mix + 7 µl of 20X Gene Expression Assays
For a 96-well plate I am running 7 cytokines + B-GUS (8 eppendorf tubes)
The program is setup to load 5.5 µl of each reagent mix into corresponding well
Place the reagent mix containing tube in the reagent rack and place a new 96-well real time PCR plate
in the robot.
Press Run (10 minutes).
NOTE: If cannot proceed to sample loading immediately, wrap the plate with parafilm and store at 4C
until sample loading.
Meanwhile prepare cDNA samples in a 1.5 ml eppendorf tube for sample loading.
Transfer 97 µl of 1:1 diluted cDNA into 1.5 ml eppendorf tube
For a 96-well plate, I am running 3 samples + NTC + Positive control
When reaction mix loading is complete, open “1-06-2010 sample load YYG.CAS4”
Place sample tubes on the reagent rack.
Program is setup to load 4.5 µl of cDNA sample into corresponding well and mix twice.
Press Run (20 minutes)
Seal the plate with optical adhesive film
Centrifuge the plate briefly to remove air and bubbles.
Load the plate into the ABI 7500 Fast PCR Cycler (RQ plate – standard mode – 1:30h duration)
Step
1
2
3
4

Temp (°C)
50
95
95
60

Time
2 min
10 min
15 sec
1 min

Applied Biosystems 20X Gene Expression Assay Order Number:
Order Number Order Name*
1749300
EQIL-1B-JN2
1918058
EquineIL-2-JN2
1798106
EQIL4IS-JN2
50414323
EQIL-6
1833786
EQIL-8IS-JN1
50442836
EQIL10IS-JN2
1649196
IL-12
1947516
EQIFNA-4-SITER
1947516
EQIFNBETA-SITER
50442836
EQIFNGIS-JN3
1787254
EQTNFAIS-JN2
1725506 GUS
*Probe labeled with 5’-FAM and 3’-NFQ

Order Number Order Name

3065515

EqIL-4

3065515
3053604
3053604

EqIL-12p40
EqIFNAlpha
EqIFNBeta
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Cycle
1
2
40

PREPARATION OF COMPETENT BACTERIA CELLS - DH5α
Materials
1.
2.
3.
4.
5.
6.

Large, autoclave tray with ice for the ice/water bath.
40 sterile microcentrifuge tubes.
Glycerol
LB agar plates without ampicillin.
Autoclave centrifuge bottles, microcentrifuge tubes. Dry cycle. 30 min.
Chill these: centrifuge bottle, 15 ml conical tube, 0.1 M MgCl2 and CaCl2 solutions.

Perform all procedures using sterile plasticware and solutions.
Solutions
1.
2.
3.
4.

100 ml of 0.1 M MgCl2 prepared from 1 M MgCl2 stock.
100 ml of 0.1 M CaCl2 prepared from 1 M CaCl2 stock.
Stock solutions can be sterilized by autoclaving and stored at room temperature. 0.1M solutions should
be prepared fresh.
LB (10g Bacto-tryptone, 5g yeast extract, 5g NaCl for 1000 ml LB) supplemented with 1 g/L glucose.
Autoclave.

Preparation of solutions
1. Glucose-supplemented LB medium (500 ml)
Bacto-tryptone
5.0 g
2.5 g
Bacto-yeast extract
2.5 g
NaCl
Glucose
0.5 g
dH2O
to 500 ml
Autoclave. Liquid cycle 30 min. Store at 4C.
2. Glycerol 100 ml
Autoclave. Liquid cycle 30 min. Store at 4C.
3. 1 M MgCl2 stock (100 ml)
MgCl2·6H2O (FW 203.30)
20.33 g
dH2O
to 100 ml
Autoclave. Liquid cycle 30 min. Store at Room temperature.
4. 1 M CaCl2 stock (100 ml)
CaCl2·2H2O (FW 47.02)
14.70 g
dH2O
to 100 ml
Autoclave. Liquid cycle 30 min. Store at Room temperature.
5. 0.1 M MgCl2 working solution (100 ml) and 0.1 M CaCl2 working solution (100 ml)
Method
1.

Streak out bacteria (DH5α or other strain) on an LB agar plate (without antibiotics). Allow to grow
overnight at 37°C.
2. The next day, pick a single colony and grow in 2 ml of LB medium (without antibiotics), shaking
(250 rpm) at 37°C overnight. Best to do this in the late afternoon.
3. Take 0.5 ml of the prepared LB medium to use as a blank for the OD. Transfer overnight bacterial
prep to a 2L flask containing 500 ml of glucose-supplemented LB medium. Incubate at 37°C with
vigorous shaking. During this time chill all solutions and centrifuge bottles on ice and turn on
spectrophotometer, set wavelength at 550. After several hours (2.5-3 h), remove 0.5 ml of bacteria

265

4.

5.
6.

7.

using a sterile pipet and check OD550 (use LB/glucose as blank). Continue to check the culture until
the OD550 reaches 0.5 (bacteria double about every 20 min). As soon as the correct OD is achieved
immediately transfer the culture flask from the shaker to an ice/water bath. Constantly swirl flask for
5 min until the whole sample is uniformly chilled. Pour the bacteria into the chilled centrifuge bottle
and spin at 4000 rpm, 4°C for 20 min.
Decant supernatant and place bottle with bacteria pellet on ice. Resuspend in 10 ml of ice cold 0.1 M
MgCl2 using sterile 10 ml pipet. Once resuspended, add the remaining 90 ml of chilled 0.1 M
MgCl2. Sit on ice for 5 min and spin for 20 min at 4000 rpm 4°C.
While spinning, transfer 8.6 ml of 0.1 M CaCl2 to a 15 ml conical tube. Add 1.4 ml glycerol. Mix
well and let sit on ice.
Decant supernatant and place bottle on ice. Resuspend in 10 ml of ice cold 0.1 M CaCl2 using
sterile 10 ml pipet. Once resuspended, add the remaining 81.4 ml of ice cold 0.1 M CaCl2. Sit on
ice for 20 min and spin in the centrifuge for 20 min at 4000 rpm 4°C.
Decant supernatant well and place bottle on ice. Resuspend bacteria in a chilled solution of 8.6 ml
0.1 M CaCl2 /1.4 ml glycerol. Mix well and transfer 0.25 ml aliquots to microcentrifuge tubes that
have been placed in dry ice or drop tubes into liquid nitrogen. Quick freeze and store bacteria at 80°C until use. Once thawed, the cells should not be frozen

TRANSFORMATION OF DH5α
Materials
1.
2.
3.
4.

Water bath at 42°C
Warm SOC medium to RT
Warm 3 LB plates w/ampicillin
Thaw on ice 1 vial of competent cells (DH5α) for each transformation

Methods
1.
2.
3.
4.
5.
6.
7.
8.
9.

Thaw on ice, one vial of competent cells per transformation.
Add all ligated product to 100ul of competent cell and mix by stirring gently with the pipette. Do not
mix by pipetting up and down.
Incubate on ice for 30 min
Heat-shock the cells for 45 seconds at 42°C without shaking
Immediately transfer the tubes on ice 2min
Add 900ul of RT SOC medium
Cap the tube tightly and shake the tube horizontally at 37°C for 1 h (240rpm)
After incubation at 37C for 1h. Transfer the culture to microcentrifuge tube. Decant the supernatant
leaving about 100ul of media. Resuspend the bacterial pellet.
Spread 100ul from each transformation on a prewarmed LB agar plate (w/ampicillin) and incubate
overnight at 37°

PREPARATION OF COMPETENT BACTERIA CELLS - M15 [pREP4]
Materials
1.
2.
3.
4.
5.
6.
7.
8.

M15[pREP4] cells (Qiagen)
LB medium-kanamycin (25 µg/ml)
LB agar-kanamycin (25 µg/ml)
TFB1
TFB2
Kanamycin stock solution (25 mg/ml in H2O, sterile filter, store in aliquots at -20°C)
Large, autoclave tray with ice for ice/water bath
40 sterile microcentrifuge tubes (Label them and place at -80°C at the beginning of the day)
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9.

Autoclave centrifuge bottles. Dry cycle 30 min. Chill centrifuge bottle and 15 ml conical tube and
TFB1, TFB2 buffers.
10. Dry ice
Buffers
TFB1 (500ml)
100 mM Rubidium Chloride (RbCl)
50 mM Manganese Chloride (MnCl2)
30 mM Potassium acetate
10 mM Calcium Chloride (CaCl2)
15% (w/v) Glycerol
Adjust pH to 5.8. Sterilize by filtration.
TFB2 (100ml)
10 mM MOPS
10 mM Rubidium Chloride (RbCl)
75 mM Calcium Chloride (CaCl2)
15% (w/v) Glycerol
Adjust pH to 6.8 with KOH. Sterilize by filtration.

MW
120.9
197.9
98.14
147.0

500 ml
6.05 g
4.95 g
1.47 g
0.735 g
75 ml

MW
209.3
120.9
147.0

100 ml
0.21 g
0.12 g
1.10
15 ml

LB Medium-kanamycin (final concentration 25 µg/ml)
Method
1.

Streak out a trace of M15 [pREP4] cells from the vial with a sterile inoculating loop on LB-kanamycin
agar plate.
2. Incubate at 37°C overnight.
3. Pick a single colony and inoculate 10 ml of LB-kanamycin (25 µg/ml). Grow overnight at 37°C.
4. Add 2 ml overnight culture to 200 ml prewarmed LB-kan medium in a 500 ml flask, and shake at 37°C
until an OD600 of 0.5 is reached (approximately 90-120 min). Use LB-kan media as blank. Turn on the
centrifuge and keep it cool (4°C).
5. Cool the culture on ice for 5 min. Constantly swirl the flask for 5 min until the whole sample is
uniformly chilled. Transfer the culture to a sterile, centrifuge bottle.
6. Collect the cells by centrifugation at low speed (5 min, 4000x g, 4°C).
7. Discard the supernatant carefully. Always keep the cells on ice.
8. Resuspend the cells gently in cold (4°C) TFB1 buffer (30 ml for a 100 ml culture) and keep the
suspension on ice for an additional 90 min.
9. Collect the cells by centrifugation (5 min, 4000 x g, 4°C).
10. Discard the supernatant carefully. Always keep the cells on ice.
11. Resuspend the cells carefully in 4 ml ice-cold TFB2 buffer.
12. Prepare aliquots of 220 µl in sterile microcentrifuge tubes and freeze in liquid nitrogen or a dry-ice.
Store the competent cells at -80°C.
TRANSFORMATION OF COMPETENT M15 CELLS
Materials
1.
2.
3.

Water bath at 42°C
Psi broth (LB medium, 4 mM MgSO4, 10 mM KCl)
LB-agar plates containing 100 µg/ml ampicillin and 25 µg/ml kanamycin

Method
1.
2.

Transfer an aliquot of the ligation mix or plasmid (10 µl or less) into a cold sterile 15 ml Falcon tube.
Thaw an aliquot of frozen competent M15[pREP4] cells on ice.
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3.
4.
5.
6.

Gently resuspend the cells and transfer 100 µl of the cell suspension into the tube with the ligation mix
(or plasmid).
Transfer the tube to a 42°C water bath for 90 sec.
Add 500 µl Psi broth to the cells and incubate for 60-90 min at 37°C in a shaking incubator.
Plate out 100 µl on LB-agar plates containing 25 µg/ml kanamycin and 100 µg/ml ampicillin.
Incubate the plates at 37°C overnight.

RAPID SCREENING OF SMALL EXPRESSION CULTURES
Method
1.

2.
3.
4.
5.

Pick single colonies of transformants into 1.5 ml of culture media containing both ampicillin (100
µg/ml) and kanamycin (µg/ml). Inoculate one extra culture to serve as a noninduced control. Grow
the cultures overnight.
Inoculate 10 ml of prewarmed medium (including antibiotics) with 500 µl of the overnight cultures,
and grow at 37°C for 30 min, with vigorous shaking, until the OD600 is 0.5-0.7.
Induce expression by adding IPTG to a final concentration of 1 mM (do not add IPTG to the culture to
be used as a noninduced control).
Grow the cultures for an additional 4-5h, and transfer to microcentrifuge tubes. Harvest the cells by
centrifugation for 1 min at 15,000 x g, and discard supernatants.
Resuspend cells in Lysis buffer (Use B-PER from Pierce).

Ni-NTA BASED RECOMBINANT PROTEIN PURIFICATION
A. UNDER NATIVE CONDITIONS
Materials
Ni-NTA purification system (Invitrogen, K950-01)
Method
I.

Preparing cell lysates under native conditions

1.

Harvest cells from a 50 ml culture by centrifugation (5,000 rpm for 5 min). Resuspend the cells in 8
ml of Native binding buffer.
Add 8 mg lysozyme and 1X proteinase inhibitors (Pierce) and incubate on ice for 30 min.
Using a sonicator, sonicate the solution on ice using six 10-sec bursts at high intensity with a 10-sec
cooling period between each burst.
Centrifuge the lysate at 3,000 × g for 15 min to pellet the cellular debris. Transfer the supernatant to a
fresh tube.
Remove 5 µl of the lysate for SDS-PAGE analysis. Store the remaining lysate on ice or freeze at 20°C.

2.
3.
4.
5.

II. Preparing Ni-NTA column and purification under native conditions
1.
2.
3.
4.
5.
6.

Resuspend the Ni-NTA agarose in its bottle by inverting and gently tapping the bottle repeatedly.
Pipet 1.5 ml of the resin into a 10 ml purification column.
Allow the resin to settle completely (5-10 min). Gently aspirate the supernatant.
Add 6 ml sterile, distilled water and resuspend the resin by alternately inverting and gently tapping the
column.
Allow the resin to settle using gravity and aspirate the supernatant.
For purification under Native conditions, add 6 ml Native binding buffer.
Resuspend the resin by alternately inverting and gently tapping the column.
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7.
8.
9.
10.
11.
12.
13.
14.

Allow the resin to settle using gravity and gently aspirate the supernatant. Repeat this step one more
time.
Add 8 ml lysate prepared under native conditions to a prepared purification column.
Bind for 2h at 4°C using gentle agitation to keep the resin suspended in the lysate solution.
Settle the resin by gravity and carefully aspirate the supernatant. Save supernatant at 4°C for SDSPAGE analysis.
Wash with 8 ml Native wash buffer. Settle the resin by gravity and carefully aspirate the supernatant.
Save supernatant at 4C for SDS-PAGE analysis.
Repeat step 11 three more times.
Clamp the column in a vertical position and snap off the cap on the lower end. Elute the protein with
8-12 ml Native elution buffer. Collect 1 ml fractions and analyze with SDS-PAGE.
Store the eluted fractions at 4C.

B. UNDER HYBRID CONDITIONS
Method
I. Preparing cell lysates under denaturing conditions
1.
2.
3.
4.
5.
6.
7.

Equilibrate the Guanidium Lysis Buffer, pH 7.8 to 37°C
Harvest cells from a 50 ml culture by centrifugation (5,000 rpm for 5 min)
Resuspend the cell pellet in 8 ml of Guanidium Lysis Buffer from step 1. Add 8mg of lysozyme and
1X proteinase inhibitor cocktail.
Slowly rock the cells for 10 min at RT to ensure thorough cell lysis
Sonicate the cell lysate on ice with three 5-sec pulses at high intensity
Centrifuge the lysate at 3,000 × g for 15 min to pellet the cellular debris. Transfer the supernatant to a
fresh tube.
Remove 5 µl of the lysate for SDS-PAGE analysis. Store the remaining lysate on ice or at -20°C.
When ready to use, proceed to the hybrid protocol.

II. Preparing Ni-NTA column and purification under hybrid conditions
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

11.

12.

13.

Resuspend the Ni-NTA agarose in its bottle by inverting and gently tapping the bottle repeatedly.
Pipet 2 ml of the resin into a 10 ml purification column supplied with the kit. Allow the resin to settle
completely by gravity (5-10 min). Gently aspirate the supernatant.
Add 6 ml of sterile, distilled water and resuspend the resin by alternately inverting and gently tapping
the column.
Allow the resin to settle using gravity and aspirate the supernatant.
For purification under Denaturing conditions, add 6 ml of Denaturing binding buffer.
Resuspend the resin by alternately inverting and gently tapping the column.
Allow the resin to settle using gravity and gently aspirate the supernatant. Repeat the step one more
time.
Add 8 ml lysate to a prepared purification column.
Bind for 1h at RT using gentle agitation to keep the resin msuspended in the lysate solution. Settle the
resin by gravity or low speed centrifugation and carefully aspirate the supernatant.
Wash the column with 4 ml Denaturing binding buffer by resuspending the resin and rocking for two
min. Settle the resin by gravity and carefully aspirate the supernatant. Save supernatant at 4°C for
SDS-PAGE analysis. Repeat this step one more time.
Wash the column with 4 ml Denaturing wash buffer (pH 6.0) by resuspending the resin and rocking for
2 minutes. Settle the resin by gravity and aspirate the supernatant. Save supernatant at 4°C for SDSPAGE analysis. Repeat this step one more time.
Wash the column with 8 ml Native wash buffer by resuspending the resin and rocking for 2 min.
Settle the resin by gravity and aspirate the supernatant. Save supernatant at 4°C for SDS-PAGE
analysis. Repeat this step 3 more times for a total of 4 native washes.
Clamp the column in a vertical position and snap off the cap on the lower end. Elute the protein with 8
ml Native elution buffer. Collect 2 ml fractions and analyze with SDS-PAGE.
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PURIFICATION OF RECOMBINANT PROTEINS (pQE-TriSystem - QIAGEN)
PROTEINS UNDER DENATURING CONDITIONS
Methods
I.
1.

3.
4.
5.
6.
7.

Growth of E. coli expression culture (100 ml)
Inoculate 10 ml of culture medium containing both ampicillin (100 ug/ml) and kanamycin (25 ug/ml)
in a 50 ml flask. Grow the cultures at 37°C overnight.
Inoculate 100 ml of prewarmed media (with antibiotics) with 5 ml of the overnight cultures and grow
at 37°C with vigorous shaking until an OD600 of 0.6 is reached (30-60 min).
Take a 1 ml sample immediately before induction.
Induce expression by adding IPTG to a final concentration of 1 mM.
Incubate the cultures for an additional 4-5 h. Collect a second 1 ml sample.
Harvest the cells by centrifugation at 4000 ×g for 20 min.
Freeze the cells overnight at -20°C.

II.

Preparation of cleared E.coli lyasates under denaturing conditions

1.
2.

Thaw the cell pellet for 15 min on ice and resuspend in buffer B at 5 ml per gram wet weight.
Stir cells for 15-60 min at RT or lyse them by gently vortexing, taking care to avoid foaming. Lysis is
complete when the solution becomes translucent.
Centrifuge lysate at 10,000 ×g for 20-30 min at RT to pellet the cellular debris. Save supernatant
(cleared lysate).

2.

3.

III. Batch purification of 6xHis-tagged proteins from E. coli under denaturing conditions
Materials
1.
2.
3.
4.

Cleared lysate
Ni-NTA resin
Empty columns
Buffers B-E

Methods
1.
2.
3.
4.
5.

Add 1 ml of the 50% Ni-NTA slurry to 4 ml lysate and mix gently by shaking (on a rotary shaker) for
15-60 min at RT.
Load-lysate-resin mixture carefully into an empty column with the bottom cap still attached.
Remove the bottom cap and collect the flow-through.
Wash twice with 4 ml buffer C.
Elute the recombinant protein 4 times with 0.5 ml buffer D, followed by 4 times with 0.5 ml buffer E.
Collect fractions and analyze by SDS-PAGE.

Buffers for purification under denaturing conditions (Use molecular grade water)
Buffer B (Lysis Buffer)
Components
MW
1L
500 ml
100 mM NaH2PO4
119.96 g/mol
11.9 g
5.99 g
10 mM Tris Base
121.1 g/mol
1.2 g
0.6 g
8 M Urea
60.06 g/mol
480.5 g
240.25 g
Adjust pH to 8.0 using NaOH

Buffer C (Wash Buffer)
Components
100 mM NaH2PO4

MW
119.96 g/mol
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1L
11.9 g

500 ml
5.99 g

100 ml
1.19 g
0.12 g
48.05 g

100 ml
1.19 g

10 mM Tris Base
8 M Urea
Adjust pH to 6.3 using HCl

121.1 g/mol
60.06 g/mol

1.2 g
480.5 g

0.6 g
240.25 g

0.12 g
48.05 g

Buffer D (Elution Buffer)
Components
100 mM NaH2PO4
10 mM Tris Base
8 M Urea
Adjust pH to 5.9 using HCl

MW
119.96 g/mol
121.1 g/mol
60.06 g/mol

1L
11.9 g
1.2 g
480.5 g

500 ml
5.99 g
0.6 g
240.25 g

100 ml
1.19 g
0.12 g
48.05 g

Buffer E (Elution Buffer)
Components
100 mM NaH2PO4
10 mM Tris Base
8 M Urea
Adjust pH to 4.5 using HOH

MW
119.96 g/mol
121.1 g/mol
60.06 g/mol

1L
11.9 g
1.2 g
480.5 g

500 ml
5.99 g
0.6 g
240.25 g

100 ml
1.19 g
0.12 g
48.05 g

Important Note: Due to the dissociation of urea, the pH of Buffers B, C, D, and E should be adjusted
immediately prior to use. Do not autoclave.

PROTEIN ANTIGEN DIALYSIS
Materials
1.

Slide-A-Lyzer MW 3.5K (Pierce; Cat# 66333)

Methods
1. Hydrate Membrane
- Remove the cassette from its pouch and slip into the groove of the buoy
- Immerse cassette in dialysis buffer
- Hydrate the 3.5K cassettes for 30sec
- Remove cassette from buffer and remove excess liquid by tapping the edge of the cassette gently on
paper towels.
2. Add sample * Do NOT allow the needle to contact the membrane
- Fill the syringe with the sample, leaving a small amount of air in the syringe
- Insert the tip of the needle through one of the syringe ports located at a top corner of the cassette
- Inject sample slowly (Avoid foaming)
- Withdraw air by pulling up on the syringe piston
- Remove the syringe needle from the cassette while remaining air in the syringe
3. Dialysis
- Slip the cassette into the groove of a buoy and float this assembly in the dialysis buffer (Use the
dialysis buffer at 500 times the volume of the sample
- Dialyze for 2 hours at 4°C
- Change the dialysis buffer and dialyze for another 2 hours
- Change the dialysis buffer and dialyze O/N at 4°C
4. Sample Removal
- Fill syringe with a volume of air at least equal to the sample size ( For low volume samples, fill syringe
with a volume of air approximately equal to two times the sample volume)
- Penetrate the gasket with the needle through a top, unused syringe guide port.
- Discharge air into cassette cavity to separate membranes
- Turn the unit so that needle is on the bottom and allow the sample to collect near the port
- Withdraw the sample into the syringe
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BCA PROTEIN ASSAY (adapted for Nanodrop use)
The BCA Assay requires a standard curve to be generated each time it is run
Materials
BCA protein assay (Pierce; Cat# 23225)
Method
1. Prepare diluted albumin (BSA) standards.
- Dilute the contents of one BSA ampule into several clean vials. Preferably use the same diluent as the
sample(s). Each 1 ml ampule of 2.0 mg/ml BSA is sufficient to prepare a set of diluted standards.
Working range = 20-2,000 ug/ml
Vial
Volume of Diluent
Volume and Source of BSA
Final BSA concentration
A
0
300ul of Stock
2,000 ug/ml *
B
125ul
375ul of Stock
1,500 ug/ml *
C
325ul
325ul of Stock
1,000 ug/ml *
D
175ul
175ul of vial B dilution
750 ug/ml
E
325ul
325ul of vial C dilution
500 ug/ml *
F
325ul
325ul of vial E dilution
250 ug/ml
G
325ul
325ul of vial F dilution
125 ug/ml *
H
400ul
100ul of vial G dilution
25 ug/ml
I
400ul
0
0ug/ml= Blank
If nanodrop allows only 5 standard points use these concentrations (*) to make the standard curve
2. Prepare the BCA Working Reagent (WR)
- Use the following formula to determine the total volume of WR required:
(# standards + # unknowns) × (# replicates) × (volume of WR per sample) = total volume WR required
3. Prepare WR
- Mix 50 parts of BCA reagent A with 1 part of BCA reagent B (50:1, Reagent A:B)
4. Regular assay (using a 20:1 reagent/sample volume ratio).
- Pipet 4 ul of sample in 80 ul of BCA reagent into a 1.7 ml centrifuge tube and mix well.
- Incubate tubes at 37°C for 30 minutes (working range = 20- 2,000 ug/ml). It is better to use water bath.
- Cool all tubes to RT.
5. Measure protein concentration using Nanodrop.
- A blank must be measured before the standard curve may be generated.
- Step 1: Measure the blank (BCA reagent – a “0” standard)
- Step 2: Up to 5 standards can be measured
- Step 3: Measure samples

ANTIBODY PURIFICATION FROM ASCITES
Materials
1.
2.
3.
4.
5.
6.
7.

Zeba Desalt Spin Columns (2ml, Thermo Scientific #89889; 5ml #89891)
Melon Gel IgG Spin Purification Kit (Thermo Scientific # 45206)
Ascites Conditioning Reagent (Thermo Scientific #45219)
Variable-speed centrifuge
15 ml conical tubes
Buffer for exchange
Serum samples
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8.

Pipettes and tips

Methods
A. Ascites Conditioning
1. Measure the volume of the sample and transfer to a centrifuge tube
2. Place one half the sample volume of 1 X Gel Purification Buffer into a tube and add 40 μl of the
Ascites Conditioning Reagent for every 1 ml of original sample volume. Pulse vortex for 10 sec.
3. While mixing the sample, slowly add the buffer containing the Ascites Conditioning Reagent.
4. Rock or rotate sample for 10 min at RT. (Mixture appears opaque after conditioning)
5. Centrifuge sample at 5,000 ×g for 10 min. Take the supernatant and discard the pellet.
6. Desalt sample using Zeba Desalt Spin Columns pre-equilibrated with 1X Melon Gel Purification
Buffer. (For best results, use a sample volume less than 10% of the total Zeba Column volume) Follow
the manufacter’s instructions about “Procedure for Protein Desalting”.
B. IgG Purification from Ascites
1. Equilibrate the Melon Gel IgG Purification Support and Buffer to RT
2. Swirl bottle containing the Purification Support (don’t vortex) to obtain an even suspension. Dispense
500μl of slurry into a Spin Column placed in a microcentrifuge tube. Swirl the bottle of gel slurry
before pipetting each sample to maintain the gel suspension.
3. Centrifuge the uncapped column/tube for 1 min at 2,000-6,000 × g, then remove the spin column and
discard flow-through.
4. Add 10 μl of 5X Regenerant per 1 ml of sample to the conditioned ascites and mix. Add 100 μl of the
mixture to the gel, cap column, and incubate for 5 min at RT with end-over-end mixing.
5. Remove the bottom cap from the column, loosen top cap and re-insert spin column in the collection
tube.
6. Centrifuge for 1 min to collect the purified antibody in the microcentrifuge tube. Repeat steps 5-7 for
the second batch.
7. The antibody may be directly used or stored at -20°C
NOTE: Discard or regenerate the gel. For gel regeneration, perform the following steps:
1.
2.
3.

Add 1.5 times the gel-bed volume of Melon Gel 1X Regenerant, mix for 5 min with end-over-end
mixing, centrifuge and discard flow-through. Repeat this process a total of three times.
Wash gel with 10 times the gel-bed volume of water.
For storage, wash column with 10 times the gel-bed volume of 1X Melon Gel Purification Buffer.
For storage longer than 1 week, add a final concentration of 0.02% sodium azide to the buffer used
to wash the column.

IgG ANTIBODY PURIFICATION FROM SERUM
Materials
1.
2.
3.
4.
5.
6.
7.

Zeba Desalt Spin Columns (2ml, Thermo Scientific #89889; 5ml #89891)
Melon Gel IgG Spin Purification Kit (Thermo Scientific # 45206)
Variable-speed centrifuge
15 ml conical tubes
Buffer for exchange
Serum samples
Pipettes and tips

Methods
A. Procedure for buffer exchange
1. Twist off the column’s bottom closure and loosen cap. Place column in a collection tube.
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2.

3.
4.
5.
6.
7.

Centrifuge column at 1,000 × g for 2 min to remove storage solution. Place a mark on the side of the
column where the compacted resin is slanted upward. Place column in centrifuge with the mark facing
outward in all subsequent centrifugation step.
Add 1ml of Melon Gel Purification Buffer to the column. Centrifuge at 1,000 × g for 2 min to remove
buffer.
Repeat step 3 two additional times, discarding buffer from the collection tube.
Place column in a new collection tube, remove cap and slowly apply 200-700 μl sample to the center
of the compact resin bed.
To ensure maximal protein recovery from low-volume samples, apply a stacker of ultrapure water or
buffer to the resin bed after the sample has fully absorbed (40 μl stacker for samples <350μl)
Centrifuge at 1,000 × g for 2 min to collect the sample. Discard column after use.

B. Spin-column procedure for antibody purification
1. Equilibrate the Melon Gel IgG Purification Support and Purification Buffer to RT (~ 15 min)
2. Swirl bottle containing the Purification Support (don’t vortex) to obtain an even suspension. Dispense
500μl of slurry into a Spin Column placed in a microcentrifuge tube. Swirl the bottle of gel slurry
before pipetting each sample to maintain the gel suspension.
3. Centrifuge the uncapped column/tube for 1 min at 2,000-6,000 × g, then remove the spin column and
discard flow-through.
4. Add 300 μl of Purification Buffer to the column, pulse centrifuge for 10 sec and discard flow-through.
Repeat this wash once. Place the bottom cap on the column.
5. Add 10-100 μl of buffer exchanged serum to the column. Cap column and incubate for 5 min at RT
with end-over-end mixing.
6. Remove the bottom cap from the column, loosen top cap and re-insert spin column in the collection
tube.
7. Centrifuge for 1 min to collect the purified antibody in the microcentrifuge tube. Repeat steps 5-7 for
the second batch.
8. The antibody may be directly used or stored at -20°C.
NOTE: Discard the used gel support. If the gel must be used again, it can be regenerated by adding 500μl
of 5M NaCl or 0.5N NaOH, mix for 5 min, centrifuge, and discard flow-through. Wash gel five times by
adding 500μl Purification Buffer, centrifuge and discard flow-through. Add 500μl Purification Buffer and
store at 4°C. The gel may be regenerated three times without significant loss of selectivity.

MONOCLONAL ANTIBODY ISOTYPING
Antigen-Independent Protocol
For each antibody sample to be tested, this method uses a set of 10 microplate wells corresponding to one
negative control, one positive control, and the eight different class/subclass-specific specific primary
antibodies (rabbit anti-mouse) supplied in the kit.
In the antigen-independent protocol, the first step is coating the microplate with anti-mouse Ig (G+A+M)
polyclonal antibody; therefore, only the mouse IgG, IgA and IgM subclasses that are recognized by this
coated antibody are detected.
Materials
1. Monoclonal antibody Isotying kit (Thermo Scientific #37501)
2. Flat-bottom high binding 96-well ELISA plate
3. PBS
4. Coating buffer (10mM sodium bicarbonate, pH 9.4; Cat. #28382)
5. Coating Antibody working solution: add 1 drop (~50 μl) of Coating Antibody (supplied) to 5 ml of
Coating Buffer (prepare immediately before use in step 1).
6. 1X Blocking Solution: add 1 drop (~50 μl) of 50X Blocking Solution (supplied) to 2.5 ml of PBS
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7. Wash Buffer: add 1 drop (~50 μl) of 50% Tween 20 (supplied) to 50 ml of PBS
8. HRP-GAR IgG (secondary antibody): add 1 drop (~50 μl) of HRP-Conjugated Goat Anti-Rabbit IgG
(supplied) to 2.5 ml of wash buffer (prepared immediated before use in step 8)
9. 1X ABTS Substrate Buffer: add 5 drops (~250 μl) of the 10X ABTS Substrate Buffer concentrate
(supplied to 2.5 ml of ultrapure water)
10. 1X ABTS Substrate Solution: add 1 drop (~50 μl) of 50X of ABTS Substrate (supplied) to 2.5 ml of 1X
ABTS Substrate Buffer (prepare immediately before to use in step 10 of procedure)
Methods
Coat wells of a microplate with Coating Antibdoy by adding 50 μl of Coating Antibody Working
Solution into 10 wells for each antibody sample to be assayed. Cover and incubate plate at 4°C
overnight or at RT for 2 hr.
2. Empty the wells; add 125 μl of 1X Blocking Solution to coated wells; cover and incubate microplate at
37°C for 1 hr.
3. Empty wells and wash four times with 125 μl of Wash Buffer.
4. Add 50 μl of each antibody sample to wells #1 - #9 of each coated plate 10-well set; add 1 drop (50 μl)
of Positive Control (supplied) to well #10 of each 10-well set; cover and incubate microplate at 37°C
for 1 hr.
5. Empty wells and wash four times with 125 μl of Wash Buffer.
6. Add 1 drop (50 μl) of each specific anti-mouse antibody (8 total) to corresponding wells #1- #8 or each
10-well set.
Add 1 drop (50 μl) of Normal Rabbit Serum (negative control) to well #9 of each 10-well set.
Add 1 drop (50 μl) of the Anti-Mouse IgG1 Antibody to well #10 of each 10-well set.
Record pattern of these primary antibody additions using the data template.
Cover and incubate microplate at 37°C for 1hr.
7. Empty wells and wash four times with 125 μl of Wash Buffer.
8. Add 50 μl of HRP-GAR IgG (secondary antibody) to each well; cover and incubate microplate at 37°C
for 1 hr.
9. Empty wells and wash four times with 125 μl of Wash Buffer.
10. Add 100 μl of 1X ABTS Substrate Solution to each well; cover and incubate microplate at RT for
approximately 30 min. until color development is sufficiently complete.
11. Evaluate results qualitatively by spectrophotometry at 405nm. Positive wells typically have absorbance
ranging from 0.8 to 1.2.
1.

ALEXA FLUOR 488 PROTEIN LABELING (Molecular Probe)
Materials
1.
2.
3.
4.
5.

0.5ml of IgG solution at 2mg/ml
Handheld UV lamp
Ringstand
Alexa Fluor 488 Protein Labeling Kit (Molecular Probe #A10235) – 3 labelings
Autoclaved deionized water

Methods
A. Labeling the protein
1. Prepare a 1M solution of sodium bicarbonate by adding 1mL of dH20 to the provided vial of sodium
bicarbonate (component B). Vortex until fully dissolved. It can be stored at 4°C for up to 2 weeks.
2. If the protein concentration if greater than 2mg/ml, dilute the protein to 2mg/ml in PBS.
3. To 0.5mL of the 2mg/ml protein solution, add 50μl of 1M bicarbonate.
4. Allow a vial of reactive dye to warm to RT. Transfer the protein solution from step 3 to the vial of
reactive dye. This vial contains a magnetic stir bar. Cap the vial and invert a few times to fully dissolve
the dye. Stir the reaction mixture for 1 hr at RT.
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B. Purifying the Labeled Protein
1. Assemble the column and position it upright: attach a funnel to the top of a column. Gently insert the
column through the X-cut in one of the provided foam holders to avoid damaging the column. Using
the foam holder, secure the column with a clamp to a ringstand. Carefully remove the cap from the
bottom of the column.
2. Prepare the elution buffer by diluting the RT 10X stock (component D) 10-fold in dH2O. Typically,
less than 10 ml is required for each purification.
3. Using one of the provided pipets, stir the purification resin (component C) thoroughly to ensure a
homogeneous suspension. Pipet the resin into the column, allowing excess buffer to drain away into a
small beaker or other container. Resin should be packed into the column until the resin is ~3cm from
the top of the column.
4. Allow the excess buffer to drain into the column bed. Do not worry about the column drying out, since
the matrix will remain hydrated. Make certain the buffer elutes through the column with a consistently
even flow prior to adding the reaction mixture. If the flow of buffer is slow or stalled, repack the
column. Carefully load the reaction mixture from Part A onto the column. Allow the mixture to enter
the column resin. Rinse the reaction vial with ~100 μl of elution buffer and apply to the column. Allow
this solution to enter the column.
5. Slowly add elution buffer, taking care not to disturb the column bed. Continue adding elution buffer
until the labeled protein has been eluted (about 50 min).
6. As the column runs, periodically illuminate the column with a handheld UV lamp. You should observe
two colored bands, which represent the separation of labeled protein from unincorporated dye. Collect
the first band, which contains the labeled protein, into one of the provided collection tubes. Add
elution buffer to the column as necessary. Do not collect the slower moving band, which consists of
unincorporated dye.
7. Store the labeled protein – which will be in PBS, pH 7.2, containing ~2mM sodium azide- at 2-6°C,
protected from light. If the final concentration of purified protein conjugate is less than 1mg/ml, add
BSA or other stabilizing protein to 1-10mg/ml. The conjugate should be stable at 4°C for several
months. For long-term storage, divide the solution into small aliquots and freeze at ≤ -20°C.
It is good practice to centrifuge solutions of conjugates in a microcentrifuge before use; only the
supernatant should then be used in the experiment. This step will remove any aggregates that may have
formed during storage.

BIOTINYLATION OF EAV RECOMBINANT VIRUSES
Materials
1.
2.
3.
4.
5.

Amersham ECL Protein Biotinylation Module (RPN2203)
Orbital shaker
PBS, pH 7.5
PBS containing 1% BSA
Distilled water

Methods
1.
2.
3.
4.

5.

Determine the concentration of protein to be biotinylated (see BCA method using nanodrop)
Prepare a 40 mM working concentration of bicarbonate buffer (BB) by diluting 1:20 in distilled water.
(prepare always fresh)
Place the biotinylation reagent at RT and ensure the vial has equilibrated to RT prior to opening.
Dilute the protein to 1mg/ml in the diluted bicarbonate buffer. The maximum volume suitable for
loading on to the column is 2.5 ml (the minimum volume is 2.0 ml). Add 40ul of biotinylation reagent
for each mg of protein.
Incubate at RT for 1 h with constant agitation.
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6.

Discard the buffer at the top of the Sephadex G25 column, and cut 1-2 mm off the tip seal. Equilibrate
the column with 5 ml of PBS-1% BSA (pH 7.5) followed by 20 ml of PBS. Discard the column
washings. Do not allow the column to run dry.
7. Allow the buffer level in the top of the column to fall to the level of the plastic sinter at the top of the
gel bed.
8. Apply the protein sample (in 2.0-2.5 ml) to the column. Allow the sample volume to enter the column
before eluting with PBS and collecting fractions.
9. Elute the sample in 5 ml of PBS (use 2-3 mls of PBS to wash the tubes containing virus). Collect 1 ml
fractions (total 5 fractions). Measure protein concentration of 1-5 fractions to determine the eluted
protein containing fractions.
10. Measure either protein concentration or UV absorbance at 280nm to verify the fraction number
containing the eluted protein.
11. Aliquot in 0.5ml/tube. Make one tube with 110 μl of biotinylated EAV for titration. Store at -80C
VIRUS BINDING ASSAY
Keep everything at 4°C during the whole experiment
1. See EEC in 6 well plates and wait to grow 100% confluent.
2. Place cells at 4°C for 30 min to cool down.
3. Wash cells with cold PBS-2%FBS (PBS-F) 3 times before adding biotinylated VBS into each well.
4. Incubate the virus and cell mixtures at 4°C on a shaker for 60 min.
5. Remove the inocula and wash the unbound cells extensively (3X) with cold PBS-F
6. Add the non-enzymatic cell dissociation solution (Sigma, #C-5914, 1X, 1 ml/25cm2 flask),
400ul/well and mix on a shaker.
7. Incubate at 4°C until cells are dissociated form the plates.
8. Add 1ml PBS-F to each well to the cells and pipet repeatedly to dissociate clumps. Transfer the
cell suspension in 1.5ml eppendorf tube. Spin at 1000xg for 5 min (in real time PCR room, cool
centrifuge at 4C prior to the experiment) and wash with 1ml PBS-F once to remove non-enzymatic
buffer.
9. Incubate the washed cell pellets with 200ul 1:100 diluted streptavidin-FITC conjugated
(Amersham, #RPN 1232) in PBS F for 60 min at 4C on a shaker
10. Wash cells once with ice cold PBS, and resuspend in 500 ul PBS F for immediate flow cytometric
analysis.
Modified protocol for PBMC (EEC for control)
1. Prepare PBMC as for conventional flow cytometry staining. Process AD and NAD cells separately.
Incubate on ice to keep it at 4C. Also resuspend EEC cells to use as control. Count the cells and
place 106 cells into each well or tube.
2. Wash cells twice with ice cold PBS-2% FBS (PBS-F) at 4C
3. Incubate cells with anti-equine CD3 MAb (100ul) and biot-EAV (10ug protein, m.o.i. of 100? I
am not sure how much difference is between these or which one will work better yet) in facs
buffer (1% NGS; prepare newly and keep it sterile) for 45 min on ice.
4. Wash once with PBS-F
5. Incubate and anti-mouse IgG PE and streptavidin-FITC (total volume 100ul) for 45 min on ice
6. Wash twice with ice cold PBS-F followed by one wash with ice-cold PBS
7. Resuspend in 300ul of 2% paraformaldehyde.

INDIRECT IMMUNOFLUORESCENT ASSAY
Materials:
1.
2.
3.
4.

Chamber slides (Lab-Tek [Chamber Slide™]; Nunc, Inc.) or coverslips for 24-well plate
Cover slips (large).
Confluent monolayer of cells (BHK21, RK13 etc.)
Cell medium (10% BCS-EMEM)
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5.
6.
7.
8.
9.
10.
11.

Fixative: 4% paraformaldehyde
Wash buffer: 10mM glycine in PBS
Permeabilization buffer: PBS w/ 0.2% Triton-X 100
Primary antibody dilution: PBS w/ 5% FBS
Secondary antibody dilution buffer: PBS w/ 5% FBS or 0.02% evans blue in PBS
FITC-conjugated goat anti-mouse IgG F(ab’)2 (Caltag)
Mounting medium (Vector, Vectashield H-1000)

Method:
1.

2.

3.
4.
5.
6.
7.
8.
9.

10.
11.
12.

13.
14.
15.

Trypsinize cells (T-75 flask) and resuspend into 60 mls of growth media. Plate 0.3 ml per well on to 8well chamber slides (in this case, usually cells in chamber slides will be ready for infection in 24
hours). Incubate at 37°C. OR T-25 flask of cells were resuspended into 12 ml of growth medium. Plate
300µl cells per well on to eight chamber slides. Incubate at 37°C
Twenty four hours later or when cells are subconfluent aspirate media and infect with EAV at a m.o.i.
of 5 (100 µl of diluted VBS53 EAV). Adsorb for 1 hour at 37°C. Add 0.3 ml of fresh medium and
incubate for 24 hours.
Aspirate cell media.
Wash one time with cold PBS (0.6 ml per well).
Fix with 4% paraformaldehyde in PBS for at least 30 min at room temperature.
Rinse 3X in PBS/10mM glycine. 0.5-0.6ml/well. Leave the cells in your last PBS-glycine wash and store
them at 4°C until labeling
Permeablize with PBS containing 0.2% Triton-X 100, leave at RT 5-10min.
Wash 3X with PBS/10mM glycine with slides on a shaker.
Dilute mouse MAb 12A4 against EAV nsp1
Make 1:250 dilutions for unconjugated 12A4 (3.5µg/ml)
Make 1:100 dilutions for AF488 conjugated 12A4 (1mg/ml)
Place 100μl drops of diluted Ab to each well. Incubate at RT for 1 hour. Leave slides on a shaker.
Wash 3X with PBS/10mM glycine 3 times with slides on a shaker.
Dilute secondary Ab [FITC-conjugated goat anti-mouse IgG F(ab’)2 (Cat # 31543, Pierce
Biotechnology) and FITC-conjugated goat anti-rabbit IgG(H+L) F(ab’)2 (Cat # 31573, Pierce
Biotechnology)]
Make 1:100 dilutions
Incubate in dark for 1h at RT with slides on a shaker.
Wash 3X with PBS/10mM glycine with slides on a shaker.
Remove gaskets. Peel off the plastic stickers. Add a drop of mounting medium with DAPI (Vector,
Vectashield H-1500) on each well of the chamber slides. Then place a coverslip over the stained slide.
Store at 4°C in dark.

FLOW PROTOCOL FOR SURFACE AND INTRACELLULAR LABELING of AD and NAD
PBMCs
Materials
1.
2.
3.
4.
5.
6.

4% paraformaldehyde fixation
FACS buffer (DPBS with 0.1% (w/v) sodium azide. Filter 0.2 μm pore membrane. Store at 4°C.
Add 1% NGS when needed)
Permeabilization buffer: DPBS, 1% heat-inactivated NGS, 0.1% (w/v) sodium azide, 0.1%
saponin (w/v) and sterile filter (0.2 μm pore membrane)
Antibodies with appropriate dilution (All intracellular antibody dilutions will be performed in
permeabilization buffer/ surface marker Abs are diluted in FACS buffer)
Secondary antibodies
Blocking solution (Flow buffer with 10% FBS)
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Methods
Virus infection
1.

2.
3.
4.

5.

Plate cells in each 150 mm culture dish and infect with virus at m.o.i. of 5. Dilute the virus in
minimum volume of plain media (7 ml of plain RPMI is enough to cover 150 mm dish) Note:
Include control cells (e.g. equine endothelial cells T-75 has approx. 1.5 × 107 cells)
Adsorb virus for 1 h and add 18 ml of 10% cRPMI media into each dish. Incubate for 12, 18, 36 h.
Cell collection.
Non-adherent cells: collect TCF. Wash twice with PBS (10 ml each time) and pull them together
with TCF.
Adherent cells: discard TCF and wash with PBS (10 ml each time) and discard the washed fluid.
After washing, collect adherent cells using a scrapper and wash the dish with PBS and collect the
PBS wash.
Pellet cells and count them.

Surface staining
1.
2.
3.
4.
5.

Dilute the surface markers in facs buffer. Dilute cell pellet in facs buffer and equally aliquot ~1.0 x106
cells into each of V-bottomed 96 well plate.
Label cells with 100ul of cell surface marker. Mix by pipetting and incubate for 30 minutes at 4°C
(ice-bucket).
Wash once with 200ul facs buffer, centrifuge at 500 g for 5 minutes.
Label cells with 100ul of 2° Ab (goat anti-mouse IgG-PE conjugated diluted 1:200 in facs buffer).
Incubate for 30 minutes at 4°C covered with aluminum foil
Wash once with 200ul facs buffer, centrifuge at 500 g for 5 min. Flick off excess

E. INTRACELLULAR EAV STAINING
6. Fix the cells with 200µl 4% paraformaldehyde for 30 minutes at RT in dark. Centrifuge at 500 g for 5
minutes.
7. Wash once with 200ul facs buffer.
8. Permeabilize membrane with permeabilization buffer (200 µl /tube) for 5 minutes.
9. Centrifuge at 500 g for 5 minutes.
10. Block Fc receptors with 10% FBS in FACS buffer for 30 minutes at RT in dark.
11. Dilute the intracellular labeling antibody in permeabilization buffer.
12. Label with fluorochrome- conjugated intracellular antibody for 30 minutes at RT in dark.
13. Wash 1X with 200 ul FACS buffer.
14. Resuspend in 200 ul of 0.5% paraformaldehyde/PBS and store at 4°C for next day acquisition.

SDS-PAGE and WESTERN BLOTTING
A. SDS-PAGE
Materials
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

BIO-RAD minigel apparatus
Glass plates with 1.5 mm spacers (Bio-Rad Cat #1653312)
Glass plates (short plates; Bio-Rad Cat#1653308)
1.5 mm combs, 10 lanes (Bio-Rad Cat #1653365) or 15 lanes (Bio-Rad Cat#1653366)
Gaskets (Bio-Rad Cat #1653305)
Casting frames (Bio-Rad Cat#1653304)
1.5 M Tris HCl pH 8.8, ml (Bio-Rad #161-0798)
0.5 M Tris HCl pH 6.8, ml (Bio-Rad #161-0799)
Acrylamide/Bis, 30%/0.8% (Bio-Rad Cat #161-0158)
10% SDS, µl (Bio-Rad Cat #161-0416)
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11.
12.
13.
14.
15.
16.
17.
18.
19.

TEMED, µl (Bio-Rad Cat #161-0801)
10% Ammonium persulfate (APS; Bio-Rad Cat #161-0700)
Dissolve 1g of APS in 10ml of DW
Prepare 1 ml aliquots and store at -20°C
Laemmli sample buffer (Bio-Rad Cat #161-0737)
No-Weigh™ Dithiothreitol (DTT; Pierce Cat # 20291)
BenchMark Pre-stained protein ladder (Invitrogen, Cat #10748-010)
MagicMark XP (Invitrogen, Cat #LC5602)
Molecular grade water
<Gel Recipes: to make 2 mini-gels of 1.5mm thickness>
Resolving (lower) gel
Stacking (upper) gel
10%
12%
4%
30% AA
4.9
6 ml
0.675 ml
1.5 M Tris HCl pH 8.8
3.75
3.75 ml
0.5 M Tris HCl pH 6.8
1.25 ml
dH2O
6
4.95 ml
3 ml
10% SDS
150 μl
150 ul
50 μl
10% AP
75 μl
75 μl
30 μl
TEMED
15 μl
15 μl
5.5 μl

Buffers (See below for buffer recipe)
1. 1X TGS Running Buffer
Methods
1.

Assemble the minigel apparatus: Wash glass plates and spacers with distilled water and detergent.
Air-dry in a rack. The glass plates must be absolutely clean. Just before assembly wipe the glass
plates with 70% ethanol.
2. Preparation of gel solutions using following table: Make up 12% resolving gels for viral proteins.
Make up 10% resolving gel if looking for heavy (50,000 kDa) and light (25,000 kDa) of purified
immunoglobulins. This will give best separation and resolution of heavy and light chains. Make up 5%
stacking gel at the same time.
3. Prepare both gel solutions according to the recipe. Do not add TEMED until just before pouring the gel
into the apparatus.
4. Pour the gel solution between the glass plates. Leave enough space for the stacking gel (comb depth +
1 cm approx). Overlay the gel with dH2O.
5. Let the gel to polymerize (approx. 30 min), pour off the overlay and wash the top of gel several times
with dH2O. Remove any remaining H2O with the edge of a paper towel.
6. Add TEMED to the prepared stacking gel solution, mix and immediately pour over top of resolving gel.
Add close to the top. Place combs (before placing the combs should be washed with warm water and
dried) in to the stacking gel (stop 3-5 mm above the inter phase of stacking and resolving gels). Avoid
air bubbles. Allow 15 minutes for polymerization (during this time get the samples ready). Remove
combs. Air bubbles should run in to replace combs.
7. Make up one liter of 1X SDS-PAGE running buffer (4X = 232 g glycine, 48 g Tris base, 16 g SDS
made up to 4 liters) and pour 500 ml into the buffer tank.
8. Remove the gels (molds with the plexiglass holders) from the casting stand and lock into the central
unit with thumbs pushing from the bottom. Small glass plate goes against the rubber gasket. Bottom
clicks into place on base pate of the central unit.
9. Drop assemble unit into the buffer tank. Add running buffer to center compartment until gels get
submerged. Do not allow inside buffer and buffer in the tank to communicate (not imperative). Flush
out each well with pipette before loading the samples.
10. Preparation of Samples and Running the Gel: Denature protein in sample buffer (with the appropriate
concentrations of DTT Pierce #20291) for 1-3 minutes. Can store the samples at -200C or -700C. Mix
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11.

12.
13.
14.

15.

1 tube of DTT (500mM) with 250ul of sample buffer. Mix with sample 1:1 dilution (e.g. 15ul of DTT
in sample buffer + 15ul of sample)
Load 30-35 µl (10 lane combs) or 15 µl (15 lane combs) per lane. Use long slender pipette tips. Slip
into space between two glass plates gently eject the sample into the well made by the comb. Load 1X
sample buffer into lane 1 and 10 (or 15; do not load samples into these lanes and this will avoid the
smiling effect). Load appropriate molecular weight markers to the second lane.
Add running buffer to the buffer tank until the level of the top of the gels.
Cover minigel unit (fits only one way) and fix red to red (positive), black to black (negative). Proteins
are negatively charged and they migrate to the anode at the bottom. Run at 200 V, 30~40 min.
Stop when the dye front reaches the bottom. Turn off the power, pull off top and remove central gel
unit and mark the left side of the glass plates with a “Sharpie” pen (this will indicate the lane one).
Take apart the plates and cut the corner of the gel with a blade for identification (e.g. top left corner for
gel).
Gels are ready for transfer (for western immunoblotting), autoradiography (for immunoprecipitation),
or staining with Coomassie or silver stains. Proceed to appropriate protocol.

B. Gel transfer to PVDF membrane
Materials
1. Immun-Blot® PVDF membrane (7×8.4 cm; Bio-Rad Cat #162-0174)
2. Extra thick blot paper (cut to same size as blot membranes; Bio-Rad Cat#1703969)
3. Methanol (Fisher Cat#A412-4)
4. Clean forceps
Buffers (See below for buffer recipe)
1. Transfer buffer
2. TBS-T
Methods
1. Soak 2 filter papers for each gel in transfer buffer.
2. Pre-wet PVDF membrane in 100% methanol for 1-2 min and equilibrate the membrane in DW for 2
min and let it in transfer buffer.
3. Equilibrate the gel for 10 min in transfer buffer
4. For transfer, place one filter paper, PVDF membrane, SDS-PAGE and on top the second filter paper.
5. Assemble the transfer unit. Run at 15V for 1hr.
6. Rinse the transferred membrane in TBS-T buffer and proceed to western blotting step.
C. Western Blotting
Materials
1. Skim milk (Bio-Rad Cat#170-6404)
2. Antibody saver trays (Scienceware, small size)
3. Primary antibody (e.g. anti-EAV nsp1 [12A4] purified IgG)
4. Biotinylated goat anti-mouse IgG (Zymed Cat #81-6540) or biotinylated goat anti-rabbit IgG (Zymed
Cat #81-6140)
5. Streptavidin-HRP (Zymed Cat #43-8323)
6. ECL™ Western blotting analysis system (GE Healthcare Cat #RPN2109)
7. Rad Tape (Midsci Cat #RAD-10)
Buffers (See below for buffer recipe)
1. TBS-T
2. Antibody dilution buffer (ADB)
3. 5% nonfat dry milk/PBS blocking buffer
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Methods
1. Block the membrane in blocking buffer at 4°C O/N on a shaker or 1-2 hr at RT.
2. Wash the membrane with TBS-T once.
3. Incubate with primary antibody (most of MAb work at 1µg/ml) 1 hr at RT.
4. Wash 3 times with TBS-T (10 min/each)
5. Incubate with 1:5,000 diluted secondary antibody (Biotin-conjugated anti-Ms or anti-Rb) in ADB 1hr
at RT.
6. Wash 3 times with TBS-T (10 min/each)
7. Incubate with 1:2,000 diluted Stv-HRP in Stv-HRP dilution buffer 1hr at RT.
8. Wash 3 times with TBS-T (10 min/each)
9. Mix 1:1 components of ECL to develop the membrane.

COOMASSIE BLUE R PROTEIN STAINING FOR DETECTION OF PROTEIN IN SDS-PAGE
GELS
1.
2.

3.

Place the gels on a glass dish and add 100 ml of Coomassie blue stain and leave on the rocker for 4
hours or more (can stain over night) to allow staining.
Remove the Coomassie blue stain (save can reuse) and add 200-250 ml of gel destaining buffer (40%
methanol, 10% acetic acid in distilled water). Leave on the rocker for 8 hours. Keep a sponge or
kimwipes in the glass dish to absorb stain.
Dry the gels on cellophane/perspex frames. Get two 12’’ x 10’’ cellophane sheets and wet with
distilled water (wet one at a time). Lay one wet cellophane sheet on the bottom frame (with center in
place to support cellophane) and place the gels over that. Overlay with second wet cellophane, avoid
air bubbles, make good contact between gels and the cellophane sheets. Place the top frame (no center
needed). Clamp edges together with bulldog clips while pulling cellophane tight. Make small hole for
drainage in bottom corner and leave upright. Allow to dry 8-12 hours and remove the frames and store
the gels.

NORTHERN BLOT
Materials
Before starting Northern Blot, check availability of following reagents
Gel Running
1.
2.
3.
4.

10X Denaturing Gel buffer (Ambion #8676; 4°C)
1X MOPS Gel Running Buffer (Ambion #8671; 4°C)
Formaldehyde Load Dye (Ambion #8551; -20°C)
Water bath or heat block 65°C

Transfer RNA to the membrane and hybridization steps (made in the lab)
1. Depurination solution:
0.25M HCl
2. Denaturation solution:
1.5M NaCl (43.8g for 500 ml or 87.6g for 1L)
0.5 M NaOH (10g for 500 ml or 20g for 1L)
Add molecular biology grade distilled water to a final volume of 500 ml or 1 L and filter through a 0.45 um
membrane.
3. Neutralization solution (pH 7.5):
1.0M Tris Base (60.55g for 500 ml or 121.1g for 1L)
1.5M NaCl (43.5g for 500 ml or 87g for 1L)
Add molecular biology grade distilled water to a volume 400 ml or 800 ml.
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Adjust to pH 7.5 with HCl. Make up to a final volume of 500 ml or 1L with distilled water and filter
through a 0.45um membrane.
4. Transfer solution 20X SSC [(pH 7.0-7.2)]
NaCl
175g
Trisodium citrate (Na3C6H5O7.H20)
88.2g
Add distilled molecular biology grade distilled water to a final volume 1L.
If necessary, adjust to pH 7.0-7.2 with concentrated citric acid. Filter through a 0.45um membrane.
or
20X SSC ready packs form Ambion (Cat # 9762)
Dissolve in 1 liter of molecular biology grade water and make it alkaline by adding NaOH to a 10 mM
concentration (0.4 gram per liter). This works well for transfer.
5. DIG Easy Hyb (Roche Biochemicals # 1 603 558)
6. Water bath 68°C
7. Hybridization oven 68°C
8. Boiling water or heat block >95°C
After hybridization
Low Stringency Buffer (2X SSC containing 0.1% SDS)
High Stringency Buffer (0.1X SSC containing 0.1% SDS) preheat to 68°C

GENERATION RECOMBINANT VIRUS FROM IN VITRO TRANSCRIBED RNA
A. PURIFICATION OF LINEARIZED PLASMID
1.

Linearization of plasmid EAV infectious cDNA clone. Digestion of each plasmid DNA with Xho I to
linearize the plasmid DNA.
Plasmid DNA
35.0 µl
Xho I (40U/μl, Roche)
1.0 µl
Buffer H (10x) (Roche)
4.0 µl
Total:
40.0 µl
Prepare 1 digestion reaction for each plasmid DNA. Incubate at 37°C for 2 hours.

2.

Run 1 µl digested plasmid DNA on 1% agarose gel to make sure that the plasmid DNA is linearized.
Digested plasmid DNA
1.0 µl
6x loading buffer
2.0 µl
nuclease free water
9.0 µl
Total:
12.0 µl---------loading amount per well
Run 12 µl 1 kb DNA ladder (Invitrogen)

3.

Add 2 µl of 20 mg/ml Proteinase K (Ambion) and bring the volume to 200 µl with nuclease free water
and incubate at 37°C for 30 min.

4.

2× phenol chloroform extract and precipitate the DNA with 100% ethanol.
- add 200 µl of phenol : chloroform : isoamyl alcohol (25:24:1) (Cat # P3803, Sigma) and mix until an
emulsion is formed
- centrifuge at 13,000 rpm for 4 min at room temperature
- remove 180 µl of the upper aqueous phase into a new tube
- add 180 µl of phenol : chloroform : isoamyl alcohol (25:24:1) and repeat the extraction
- remove 160 µl of the upper aqueous phase into a new tube
- add 500 µl of 100% ethanol and 16 µl of 3M sodium acetate to the DNA sample
- mix and centrifuge at 13,000 rpm for 10 min
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5.

Wash with 140 µl of 70% ethanol. Spin at 13,000 rpm for 4 min. Aspirate the 70% ethanol and dry on
the bench for 4-5 min.

6.

Resuspend the pellet in 32 µl of nuclease free water and run 1 µl on gel.
Phenol chloroform extracted linearized plasmid DNA 1.0 µl
6x loading buffer
2.0 µl
nuclease free water
9.0 µl
Total
12.0 µl---------loading amount per well

B. IN VITRO TRANSCRIPTION
1. Prepare in vitro transcription reactions as follows. For linear DNA, rNTPs, BSA, DTT, 5 x
transcription buffers, and cap analog, thaw them out at room temperature. Mix well before use. Always
leave RNA guard RNase inhibitor and T7 RNA polymerase on ice. Use XhoI-linearized and phenolchloroform purified plasmid DNA
Master mix for in vitro transcription
Linear DNA
15.0 µl
rNTPs mix (10mM each)
5.0 µl
BSA (1mg/ml)
5.0 µl
100 mM DTT
2.5 µl
5X T7 Transcription buffer
10.0 µl
Cap analog (10mM)
5.0 µl
RNA guard RNase Inhibitor
2.5 µl
T7 RNA polymerase
2.5 µl
Nuclease free water
2.5 µl
50.0 µl
Incubate at 37ºC for 2 hours.
2.

3.
4.

Wash electrophoresis unit (electrophoresis tank, gel cast and running trays, comb) thoroughly with
detergent. Then rinse thoroughly with dH2O. Spray electrophoresis unit with RNaseZap, then rinse
thoroughly with dH2O. Let it air dry.
Prepare 1x TAE buffer. Cast 0.8% agarose gel.
After 1 h of in vitro transcription at 37ºC, run 2 µl of in vitro transcribed RNA on a 0.8% agarose gel.
TE Buffer (pH=7.2)
8.0 µl
10%SDS
1.0 µl
0.5M EDTA (pH=8.0)
0.25 µl
RNA
2.0 µl
- place mix at 70ºC for 2 minutes and then place on ice for 2 minutes
- add 2.25 µl of 6X gel loading buffer
- load 13.5 µl mixtures to each well of the gel. Run the gel at 90V.

5.
6.
7.

Check the gel under UV light.
Measure RNA concentration with spectrophotometry.
Dilute 2 μl in vitro transcribed RNA into 198 μl nuclease-free water and measure A260. Use nucleasefree water as blank control.
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C. TRANSFECTION OF BHK21 CELLS WITH ELECTROPORATION
Preparation of cells
1.

Make sure to use cells that are not confluent. Typically a flask of BHK21 cells were split 1:4 two days
before planning to do the electroporation. One T-150 cm2 flask of BHK21 cells will be used for 2
electroporations.

2.

Aspirate the medium from T-150 flasks of subconfluent BHK21 (P67) cells. Wash cells twice with
PBS. Add 4 ml ATV to each T-150 flask. Shake for 30 sec. Let it sit at room temperature for 1 min.
Then remove the ATV and put the flasks at 37ºC for a few minutes.
3. After cells slough off, add 10 ml EMEM to each T-150 flask.
4. Use a pipet with a wide bore to transfer cells to 50 ml conical centrifuge tube. Place immediately on
ice.
5. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice.
6. Remove medium and add 25 ml sterile ice cold PBS. Resuspend cell pellet by gentle shaking of tube.
If you need to use a pipet to resuspend cells, use a wide bore pipet and pipet gently.
7. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice.
8. Remove media and wash cells by the addition of 25 ml sterile ice cold PBS. At this time take a small
sample of cells for counting with a hemocytometer.
9. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice.
10. Remove PBS with a pipet and resuspend cell pellet in ice cold PBS to a final concentration of 1 x 107
cells/ml.
Electroporation of cells
1.
2.
3.

4.
5.
6.

7.

Place 25 μl of freshly thawed in vitro transcribed into each microcentrifuge tube. Set up one tube
without RNA as negative control.
Add 500 μl of BHK21 cells (5× 106 cells) into microcentrifuge tube containing in vitro transcribed
RNA and mix gently.
Transfer RNA-cells mixture into each electroporation cuvette (0.4 cm electrode gap). Place the cuvette
into the cuvette holder and pulse cells twice. The following settings are used: 850 volts, capacitance set
at 25 μF, and the pulse controller set at infinite ohms. When doing pulses, push the two buttons
together until you hear the beep, then immediately push them again until you hear the second beep.
After electroporation is complete, set cells aside (room temperature) for a 10 min ‘recovery period’.
Do the next sample.
After the recovery period is complete, transfer the cells from the cuvette into 15 ml of room
temperature growth medium (EMEM) in a T-75 flask. Aliquot 0.15 ml of cells to each well of 8-well
chamber slides for immunofluorescence assay (2 wells-mock transfected and 2 wells transfected).
Place cells at 37ºC CO2 incubator. Check the development of CPE. When CPE is complete (usually 7296 h post transfection), tissue culture fluids were harvested and centrifuged at 1900 rpm for 10 min at
4ºC. The tissue culture fluids were titrated in RK13 cells.

ELECTROPORATION USING BTXPRESS ELECTROPORATOR AND ELECTROPORATION
SOLUTION
Method
A. PREPARE THE CELLS
Divide the cells 18-24 hours prior to electroporation as needed and culture overnight.
B. PREPARE FOR ELECTROPORATION
1. Warm all solutions to RT before use.
2. Harvest cells for electroporation, and count cells to determine cells/ml.
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3.

4.
5.

Determine the total volume needed for all the electroporations. Multiply the number of
electroporations needed by 0.1 ml (for 0.2 cm cuvettes) OR by 0.25 ml (for 0.4 cm cuvettes) and add
10% more for pipetting errors. Total volume needed= ________ ml.
Determine the volume of cells required for each electroporation according to the formula:
Volume needed (ml) = (#cells needed/ml [5 x 106 cells/ml]/# counted cells/ml) × Total volume of
BTXpress Solution from step C

6.
7.

Enter the calculated volume needed = ______________ml
Pipette the volume of cells determined in step d into a new tube and centrifuge at 1000 ×g for 5
minutes. Aspirate the supernatant.
8. Prepare a culture vessel with pre-warmed complete medium.
9. Immediately transfer to 60mm petri dish (21 cm2 surface area) containing growth
medium. (Each well of 6 well-plate is 10 cm2) I decide to put everything in 6 well plate with 4
ml growth medium. Then take 500 ul into chamber slides for IFA.
10. Resuspend the centrifuged cells from step e in ____ ml BTXpress Solution according to the volume
determined in step c.
C. Add ______ μl IVT RNA (use 20 μg/ml of cells= 5 μg) to the cells. Mix gently.
i) pEAV-GFP IVT RNA (total 49 μl RNA)
ii) mock infection
b) Aliquot 100 μl (0.25 cm cuvette) or 250 ul (0.4 cm cuvette) DNA/cell mix to each cuvette.
c) Eletroporate at RT. Using a square wave system set the voltage and pulse length given for your
cells as described in Table1. If using an exponential decay set the capacitance to 950 μF and
resistance to “None”. Use the voltage given for your cells from Table 1&2 for complete protocol.
Voltage=____260 V____
D. Electroporation settings:
Choose Mode:
T
500 V/Capacitance & Resistance (LV)
Capacitance:
C
950F
Set Resistance:
R
R1 (13ohm)
Chamber Gap: BTX Disposable Cuvette P/N 640 (4mm gap)
Set Charging Voltage:
S
260V
Desired Field Strength: E 650 V/cm
Desired Pulse Length:
t
Approximately 9 msec (Reality: 10 msec)
a) Immediately mix the cells gently and transfer to the dish prepared in step B-f.
b) Incubate in complete medium for 12-72 hours or as required.
c) Harvest cells and perform assay as required.
MAMMALIAN CELL TRANSFECTION USING LIPID-BASED TRANSFECTION REAGENT
Materials
1.
2.

Lipofectamine™ 2000 (Invitrogen, Cat# 11668-027)
Fugene HD (Roche, Cat# E2311)

Method
1.
2.

Place sterile glass cover slips onto wells to be used for IFA staining.
Trypsinize T-75 flask of Vero 76 (ATCC #CRL-1587) cells and count the cells (One confluent T-75
contains approx. 1 × 107 Vero cells).
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3.
4.

5.
6.

One day before transfection, plate 2 × 105 cells/well in 500 µl of growth medium so that cells will be
90-95% confluent at the time of transfection.
For each transfection sample, prepare complexes as follows:
a. Dilute 0.8 µg of plasmid DNA in 50 µl of Opti-MEM I. Mix gently.
b. Mix Lipofectamine™ 2000 gently before use, then dilute 2.0 µl of Lipofectamine in 50 µl of OptiMEM I medium. Incubate for 5 min at RT.
c. After the 5 min incubation, combine the diluted DNA with diluted Lipofectamine™ 2000 (total
volume = 100 µl). Mix gently and incubate for 20 min at RT.
Add the 100 µl of transfection mix to each well containing cells and medium. Mix gently by rocking
the plate back and forth.
Incubate cells at 37°C in a CO2 incubator for 4 hr.
After incubation for 4 hr with the transfection mix, replace the mix with 500 µl of growth media
(containing FBS). Incubate at 37°C for 18-48 hours prior to testing for transgene expression.

DETECTION OF EAV SUBGENOMIC RNA IN INFECTED CELLS
Method
A. TOTAL RNA EXTRACTION FROM EAV INFECTED CELLS
1.
2.
3.
4.
5.

Prepare 2 T-25 for infected cells and 2-T25 for uninfected cells. Final number of tubes for each group
will be 4 (total 8 tubes)
Infect confluent monolayer of EECs in a T-25 flask at an m.o.i of 2 (diluted in 1ml of plain MEM) and
incubate for 1 h. Add 9 ml of growth media and incubate for 18 h.
Decant the excess media and wash with ice-cold PBS (Gibco) 3 times. Scrape the cells and pellet
down in a microcentrifuge tube at 3000g for 15 minutes.
Aspirate the medium and wash 1X in PBS.
Extract RNA using MagMAX™-96 Total RNA Isolation Kit (Ambion, AM1830). According to the
protocol, it lyses up to 2 × 106 cells in 140μl of Lysis/Binding Solution. So a pellet from 1 T-25 flask
can be divided into two and extract RNA simultaneously as two different samples. Elute RNA in 50 μl
of elution buffer. Store RNA at -80°C.

B. REVERSE TRANSCRIPTION
Material
1. SuperScript III First-Strand synthesis System for RT-PCR (Invitrogen; Cat# 18080-051)
Method
3.

2.
3.
4.
5.

Prepare the following mixture:
RNA
2.0 μl
Reverse primer (20 μM)
1.0 μl
dNTP mix (10 mM each)
1.0 μl
RNase-free water
6.0 μl
Mix and briefly centrifuge each component before use.
Prepare RNA/primer mixtures in sterile 0.2 ml tubes as above.
Incubate each sample at 65C for 5 min, then place on ice for at least 1 min.
Prepare the following cDNA Synthesis Mix, adding each component in the indicated order:
10X RT buffer
25mM MgCl2
0.1M DTT
Rnase OUT Rnase Inhibitor
Superscript III RT

2 μl
4 μl
2 μl
1μl
1μl
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6.

Add 10ul of cDNA Synthesis Mix to each RNA/primer mixture, mix gently, and collect by brief
centrifugation.
7. Incubate at 50C for 60 min.
8. Terminate the reactions at 85C for 5 min. Chill on ice.
9. Collect the reactions by brief centrifugation. Add 1 ul of Rnase H (2 units/ul) to each tube and incubate
for 20 min at 37C.
10. The final volume of the product is 21ul. cDNA synthesis reaction can be stored at -20C or used for
PCR immediately.
11. For long-term storage, place the reactions at -20C.
C. PCR USING PFU TURBO DNA POLYMERASE (STRATAGENE)
cDNA template
Forward primer (20 μM)
Reverse primer (20 μM)
dNTP mix (25 mM each)
10X Pfu Turbo PCR buffer
Pfu Turbo DNA polymerase
RNase-free water

2.0 μl
0.5 μl
0.5 μl
0.2 μl
2.5 μl
0.5 μl
18.8 μl

Cycles
1
35

Duration
2 min
45 sec
45 sec
3 min
10 min

D. PCR CONDITION

1

Temp
95C
95C
48C
72C
72C

D. PRODUCT SIZE
Product
gmRNA
sgmRNA2
sgmRNA3
sgmRNA4
sgmRNA5
sgmRNA6
sgmRNA7

Size (bp)
12704
3200
2684
2251
1883
1041
659
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